NZ789986A - Antibodies against tim3 and uses thereof - Google Patents
Antibodies against tim3 and uses thereof Download PDFInfo
- Publication number
- NZ789986A NZ789986A NZ789986A NZ78998617A NZ789986A NZ 789986 A NZ789986 A NZ 789986A NZ 789986 A NZ789986 A NZ 789986A NZ 78998617 A NZ78998617 A NZ 78998617A NZ 789986 A NZ789986 A NZ 789986A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- tim3
- nos
- amino acid
- antibody
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title abstract description 830
- 108090001123 antibodies Proteins 0.000 title abstract description 830
- 102100016384 HAVCR2 Human genes 0.000 title description 9
- 101710004393 HAVCR2 Proteins 0.000 title description 9
- 101700008936 Tim8 Proteins 0.000 title 1
- 230000027455 binding Effects 0.000 abstract description 387
- 210000004027 cells Anatomy 0.000 abstract description 211
- 239000000427 antigen Substances 0.000 abstract description 138
- 108091007172 antigens Proteins 0.000 abstract description 135
- 102000038129 antigens Human genes 0.000 abstract description 135
- 210000001744 T-Lymphocytes Anatomy 0.000 abstract description 62
- 102000018358 Immunoglobulins Human genes 0.000 abstract description 49
- 108060003951 Immunoglobulins Proteins 0.000 abstract description 49
- 102000004169 proteins and genes Human genes 0.000 abstract description 40
- 108090000623 proteins and genes Proteins 0.000 abstract description 40
- 201000011510 cancer Diseases 0.000 abstract description 24
- 229920000023 polynucleotide Polymers 0.000 abstract description 6
- 239000002157 polynucleotide Substances 0.000 abstract description 6
- 230000001225 therapeutic Effects 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 description 418
- 125000003275 alpha amino acid group Chemical group 0.000 description 287
- 235000001014 amino acid Nutrition 0.000 description 279
- 150000001413 amino acids Chemical class 0.000 description 231
- 101700073818 CDR1 Proteins 0.000 description 188
- 102100002977 CDR1 Human genes 0.000 description 188
- 108060001277 CDR2 Proteins 0.000 description 181
- 102100008744 CDR2 Human genes 0.000 description 181
- 101700027814 CDR3 Proteins 0.000 description 178
- 125000000539 amino acid group Chemical group 0.000 description 77
- 150000007523 nucleic acids Chemical class 0.000 description 75
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 70
- 238000004166 bioassay Methods 0.000 description 70
- 238000006467 substitution reaction Methods 0.000 description 69
- 229920001850 Nucleic acid sequence Polymers 0.000 description 61
- 108020004707 nucleic acids Proteins 0.000 description 59
- 108010045030 monoclonal antibodies Proteins 0.000 description 57
- 210000004602 germ cell Anatomy 0.000 description 56
- 102000005614 monoclonal antibodies Human genes 0.000 description 56
- 230000004048 modification Effects 0.000 description 47
- 238000006011 modification reaction Methods 0.000 description 47
- 101700043375 sing Proteins 0.000 description 47
- 230000002829 reduced Effects 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 42
- 210000004379 Membranes Anatomy 0.000 description 40
- 239000012528 membrane Substances 0.000 description 40
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 210000000447 Th1 Cells Anatomy 0.000 description 33
- 108090001095 Immunoglobulin G Proteins 0.000 description 32
- 102000004851 Immunoglobulin G Human genes 0.000 description 32
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 32
- 230000000694 effects Effects 0.000 description 32
- 238000000034 method Methods 0.000 description 32
- 230000000903 blocking Effects 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 28
- 238000000684 flow cytometry Methods 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 230000028993 immune response Effects 0.000 description 27
- 230000001965 increased Effects 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 230000035772 mutation Effects 0.000 description 26
- 210000004408 Hybridomas Anatomy 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 24
- 229910052727 yttrium Inorganic materials 0.000 description 24
- 102100016020 IFNG Human genes 0.000 description 23
- 101700086956 IFNG Proteins 0.000 description 23
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 23
- 229960000060 monoclonal antibodies Drugs 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000003899 glycosylation Effects 0.000 description 21
- 238000006206 glycosylation reaction Methods 0.000 description 21
- 230000004936 stimulating Effects 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 230000002708 enhancing Effects 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 229910052717 sulfur Inorganic materials 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 108010027440 Immunoconjugates Proteins 0.000 description 16
- 102000018748 Immunoconjugates Human genes 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 108010087819 Fc receptors Proteins 0.000 description 15
- 102000009109 Fc receptors Human genes 0.000 description 15
- 101000240409 HAVCR2 Proteins 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 15
- 102000030091 human HAVCR2 protein Human genes 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 15
- 238000007799 mixed lymphocyte reaction Methods 0.000 description 15
- 230000001404 mediated Effects 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102100015541 FCGR3A Human genes 0.000 description 13
- 101710044656 FCGR3A Proteins 0.000 description 13
- 230000035693 Fab Effects 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 230000000051 modifying Effects 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 210000000987 Immune System Anatomy 0.000 description 12
- -1 X12 is L Inorganic materials 0.000 description 12
- 230000000295 complement Effects 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 12
- 230000001603 reducing Effects 0.000 description 12
- 230000001105 regulatory Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 230000020411 cell activation Effects 0.000 description 11
- 230000000875 corresponding Effects 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000002424 x-ray crystallography Methods 0.000 description 11
- 101710008209 FBLIM1 Proteins 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229940035295 Ting Drugs 0.000 description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 101700072735 lys-1 Proteins 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 102100015543 FCGR2B Human genes 0.000 description 9
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 9
- 108090001096 Immunoglobulin M Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002703 mutagenesis Methods 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 8
- 102100019764 PDCD1 Human genes 0.000 description 8
- 108060007796 SPATA2 Proteins 0.000 description 8
- 230000001413 cellular Effects 0.000 description 8
- 108091006028 chimera Proteins 0.000 description 8
- 230000002222 downregulating Effects 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
- 229920002676 Complementary DNA Polymers 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 229960002433 Cysteine Drugs 0.000 description 6
- 101710044657 FCGR3B Proteins 0.000 description 6
- 101700009480 Fcgr3 Proteins 0.000 description 6
- 230000036499 Half live Effects 0.000 description 6
- 102000007346 Hepatitis A Virus Cellular Receptor 2 Human genes 0.000 description 6
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 6
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 230000003213 activating Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 210000003162 effector T lymphocyte Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 238000003259 recombinant expression Methods 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 210000003719 B-Lymphocytes Anatomy 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101710003435 FCGRT Proteins 0.000 description 5
- 102100014838 FCGRT Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 230000001808 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 230000001737 promoting Effects 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000003612 virological Effects 0.000 description 5
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 210000000170 Cell Membrane Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010043156 Immunoglobulin D Proteins 0.000 description 4
- 108090001124 Immunoglobulin E Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 206010024324 Leukaemias Diseases 0.000 description 4
- 210000004698 Lymphocytes Anatomy 0.000 description 4
- 210000002540 Macrophages Anatomy 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000001472 cytotoxic Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002519 immonomodulatory Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229960001230 Asparagine Drugs 0.000 description 3
- 210000004443 Dendritic Cells Anatomy 0.000 description 3
- 230000036947 Dissociation constant Effects 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000282619 Hylobates lar Species 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108090001122 Immunoglobulin A Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 210000001165 Lymph Nodes Anatomy 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 210000001616 Monocytes Anatomy 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 239000004698 Polyethylene (PE) Substances 0.000 description 3
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 102200163729 SELL N60Q Human genes 0.000 description 3
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000011091 antibody purification Methods 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000002860 competitive Effects 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 3
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 229940121354 immunomodulators Drugs 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 230000003278 mimic Effects 0.000 description 3
- 230000000869 mutational Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 210000004899 C-terminal region Anatomy 0.000 description 2
- 102100016449 CCL5 Human genes 0.000 description 2
- 101700063377 CCL5 Proteins 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 108091006004 Fc-tagged proteins Proteins 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100009498 HMGB1 Human genes 0.000 description 2
- 108010014739 HMGB1 Protein Proteins 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100004651 LGALS9 Human genes 0.000 description 2
- 101710015837 LGALS9 Proteins 0.000 description 2
- 102100010013 LILRB2 Human genes 0.000 description 2
- 101710002780 LILRB2 Proteins 0.000 description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 2
- 210000000138 Mast Cells Anatomy 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 210000004693 NK cell Anatomy 0.000 description 2
- 108010019706 Nivolumab Proteins 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 108010093001 anti-IgG Proteins 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal Effects 0.000 description 2
- 238000007374 clinical diagnostic method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 230000001461 cytolytic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003308 immunostimulating Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 239000004311 natamycin Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- XDLMVUHYZWKMMD-UHFFFAOYSA-N 3-trimethoxysilylpropyl 2-methylprop-2-enoate Chemical compound CO[Si](OC)(OC)CCCOC(=O)C(C)=C XDLMVUHYZWKMMD-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-Bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101710038256 ABAT Proteins 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 241001253206 Andrias Species 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 206010002449 Angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 108091008154 B cell receptors Proteins 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100007290 CD274 Human genes 0.000 description 1
- 101710012053 CD274 Proteins 0.000 description 1
- 210000001233 CDP Anatomy 0.000 description 1
- 101700008564 CHIC2 Proteins 0.000 description 1
- 210000003229 CMP Anatomy 0.000 description 1
- 101700054183 CTLA4 Proteins 0.000 description 1
- 102100005310 CTLA4 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000036640 Cullin Ring E3 Ligases Human genes 0.000 description 1
- ZWIADYZPOWUWEW-XVFCMESISA-N Cytidine diphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710002377 FLG Proteins 0.000 description 1
- 101700044513 FUT8 Proteins 0.000 description 1
- 102100012684 FUT8 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 102200017188 GRK3 N60S Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- 108060005986 Granzymes Proteins 0.000 description 1
- 102000001398 Granzymes Human genes 0.000 description 1
- 102100019126 HBB Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 102200091137 IGHG1 K97R Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101700048185 LAMP1 Proteins 0.000 description 1
- 102100005918 LAMP1 Human genes 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 208000006116 Lymphomatoid Granulomatosis Diseases 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 101710028361 MARVELD2 Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 108091005503 Nucleic proteins Chemical group 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102200049175 PPA2 S61P Human genes 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000186704 Pinales Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010065857 Primary effusion lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229960002429 Proline Drugs 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 102100001285 SEMA4A Human genes 0.000 description 1
- 101710023759 SEMA4A Proteins 0.000 description 1
- 229910003667 SRa Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010065789 Secretory Immunoglobulin A Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- 206010062113 Splenic marginal zone lymphoma Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 1
- 102200024171 TPST1 N60A Human genes 0.000 description 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N Temefos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 108091005908 Type I transmembrane proteins Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 101700041002 ant Proteins 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LNBHUCHAFZUEGJ-UHFFFAOYSA-N europium(3+) Chemical compound [Eu+3] LNBHUCHAFZUEGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 210000002443 helper T lymphocyte Anatomy 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002318 immunoblotting Methods 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 200000000010 kidney injury Diseases 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010017378 prolyl aminopeptidase Proteins 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- HKCRVXUAKWXBLE-UHFFFAOYSA-N terbium(3+) Chemical compound [Tb+3] HKCRVXUAKWXBLE-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Abstract
Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof. vided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
Description
ANTIBODIES AGAINST TIM3 AND USES THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional application of New Zealand patent application 750284, filed 13
July 2017, which is the national phase entry in New Zealand of PCT international application
, filed 13 July 2017 (published as WO2018/013818), and claims the priority benefit of
U.S. ional Application Nos. ,541, filed July 14, 2016, and 62/459,499, filed February 15, 2017,
each of which is hereby incorporated by nce in its entirety.
REFERENCE TO SEQUENCE G SUBMITTED ELECTRONICALLY VIA EFS-WEB
The content of the electronically submitted sequence listing in ASCII text file (Name:
3338_052PC02_SeqListing.txt; Size: 779,837 bytes; and Date of Creation: July 10, 2017) filed with the
application is herein incorporated by reference in its ty.
BACKGROUND OF THE DISCLOSURE
T-cell immunoglobulin and mucin-domain ning-3 (TIM3), also known as hepatitis A virus
cellular receptor 2 (HAVCR2), is a type-I transmembrane protein that functions as a key regulator of immune
responses. TIM3 was initially identified on ted IFN-γ producing T cells (e.g., type 1 helper CD4+ T cells
and cytotoxic CD8+ T cells) and shown to induce T cell death or exhaustion after binding to in-9. More
recent studies have indicated that TIM3 expression is also important in regulating the activities of many innate
immune cells (e.g., macrophages, monocytes, dendritic cells, mast cells, and natural killer cells). See Han G et
al., Front Immunol. 4: 449 (2013).
Like many inhibitory receptors (e.g., PD-1 and CTLA-4), TIM3 expression has been associated
with many types of chronic diseases, including cancer. TIM3+ T cells have been detected in patients with
advanced melanoma, non-small cell lung cancer, or follicular B-cell non-Hodgkin lymphoma. And the presence
of TIM3+ regulatory T cells have been described as an effective indicator of lung cancer progression. See
Anderson AC. Cancer l Res. 2: 393-8 (2014).
Several potential ligands for TIM3 have been identified: Galectin-9, HMGB1, orin-4A,
-1, ILT-4 and phosphatidylserine (PtdSer or PS). PS is an important cell ne component, and
is normally localized to the inner leaflet of cell membranes. But as a cell undergoes apoptosis, PS is
redistributed and exposed to the outer membrane. This redistribution is also ed in many tumor cell lines.
See Riedl S et al., Biochim Biophys Acta. 1808: 2638-2645 (2011). Binding of TIM3 to PS may be critical for
phagocytosis and presentation. See Nakayama M et al., Blood. 113: 3821-30 (2009).
Studies have shown a close relationship between TIM3 and the inhibitory or PD-1. For
example, many tumor-specific T cells express both PD-1 and TIM3, and these T cells have been shown to be
more dysfunctional compared to T cells that express only PD-1 or TIM3. See Fourcade J et al., J Exp Med. 207:
2175-2186 (2010).
Accordingly, agents that target TIM3, and methods of using such agents, are highly desirable for
designing new cancer immunotherapies and improving traditional cancer immunotherapies.
SUMMARY OF THE DISCLOSURE
Provided herein are ed antibodies, such as monoclonal antibodies, in particular human (e.g.,
monoclonal) antibodies, that specifically bind TIM3 and have desirable functional properties. These properties
include, e.g., high affinity binding to human TIM3, g to monkey TIM3 (e.g., cynomolgus TIM3), and the
ability to stimulate immune ses, e.g., antigen-specific T cell responses, such as in a tumor-bearing or
virus-bearing (virus-infected) subject, and to detect TIM3 protein in a sample.
In one aspect, the isolated antibodies, or antigen binding portions f, which bind to TIM3,
exhibit at least one of the following properties:
(a) binding to soluble and/or membrane bound human TIM3;
(b) binding to soluble and/or membrane bound cyno TIM3;
(c) ng or stimulating an immune response;
(d) inducing or stimulating T cell tion, e.g., Th1 cell activation, (as evidenced, e.g., by enhanced cytokine
secretion and/or eration);
(e) inducing or stimulating T cell proliferation (e.g., CD4+, CD8+ T cells, Th1 cells or TILs), e.g., in a coculture
assay, such as described in the Examples;
(f) ng or stimulating IFN-γ production by T cells, e.g., Th1 cells or tumor infiltrating lymphocytes (TILs),
such as TILs from human renal, lung, pancreatic or breast cancer tumors, as determined, e.g., in the assay
described in the Examples;
(g) ng or inhibiting the binding of human TIM3 to PtdSer, as determined, e.g., in the assay described in
the Examples;
(h) not internalizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(i) binding to human TIM3 extracellular domain (a) CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID
NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ ID NOs: 296 and 298, respectively); or (d)
LNGDFR (SEQ ID NO: 297);
(j) competing with, or blocking, the binding to human TIM3 of an antibody binding to TIM3 described
herein (e.g., 13A3, 3G4, 17C3, 17C8, 9F6, or any of TIM3.2 to TIM3.18), as determined, e.g., in the assay
described in the Examples;
(k) binding to human TIM3, but not to human TIM3 having an amino acid substitution of one or more of the
following amino acid residues: L48, C58, P59, V60, F61, E62, C63, G64, W78, S80, R81, W83, L84, G86, D87,
R89, D104, R111, Q113, G116, M118, and D120, as ed in SEQ ID NO: 286 ();
(l) binding to human TIM3 s 49VPVCWGKGACPVFE62 (SEQ ID NO: 367),
111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368), and 119NDEKFNLKL127 (SEQ ID NO: 373) as determined
by HDX-MS;
(m) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography; and/or
(n) competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
described in the Examples.
In certain embodiments, the anti-TIM3 antibodies, or antigen binding portion thereof, stimulate an
umor immune response, e.g., an antigen-specific T cell se. In other ments, the anti-TIM3
antibodies, or antigen binding portions thereof, increase cytokine production (e.g., IFN-γ) in TIM3-expressing T
cells and/or increase T cell proliferation. In some embodiments, the anti-TIM3 antibodies, or antigen binding
portions thereof, do not bind to Fc receptors.
In certain embodiments, the anti-TIM3 antibodies, or n binding ns thereof, bind to
soluble human TIM3 with a KD of 10 nM or less as measured by Biacore, bind to membrane bound human
TIM3 with a KD of 1 nM or less as measured by Scatchard, bind to soluble cynomolgus TIM3 with a KD of 100
nM or less as measured by Biacore, bind to membrane bound human TIM3 with an EC50 of 1 μg/mL or less as
measured by flow cytometry, bind to membrane bound human TIM3 with an EC50 of 0.1 μg/mL or less as
measured by flow cytometry, bind to membrane bound cynomolgus TIM3 with an EC50 of 1 μg/mL or less as
measured by flow cytometry, bind to membrane bound cyno TIM-3 with a KD of 1 nM or less as measured by
Scatchard.
Provided herein are isolated dies, or antigen g portions thereof, which bind to human
TIM3 and comprise heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3, wherein
the heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:
53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ
ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, and SEQ ID NO: 129.
In certain embodiments, the heavy chain CDR1 comprises X1, X2, X3, X4, Y, X5, and X6, and
wherein X1 is S or none, X2 is R or none, X3 is S, R, or D, X4 is Y or H, X5 is W or M, and X6 is G, N, S, or
H. In other embodiments, the heavy chain CDR1 comprises X1, Y, Y, M, and X2, and wherein X1 is S or D and
X2 is H or S. In some embodiments, the heavy chain CDR1 comprises R, X1, Y, W, and X2, and wherein X1 is
H or Y and X2 is N or S.
In one embodiment, the heavy chain CDR2 comprises X1, I, X2, X3, X4, G, X5, X6, X7, X8, Y,
X9, X10, X11, X12, X13, and X14, and wherein X1 is S, Y, I, or F, X2 is Y, H, N, or S, X3 is Y, P, G, T, or S,
X4 is S, T, R, or G, X5 is F, S, or D, X6 is S, T, or I, X7 is I or none, X8 is Y, N, or I, X9 is N, Q, S, or A, X10
is P, S, Q, or D, X11 is S or K, X12 is L, F, or V, X13 is K or Q, and X14 is S or G. In another ment, the
heavy chain CDR2 comprises Y, I, H, Y, X1, G, S, T, N, Y, N, X2, S, L, K, and S, and wherein X1 is S or T and
X2 is S or P. In some ments, the heavy chain CDR2 comprises F, I, S, X1, X2, G, S, X3, I, Y, Y, A, D,
S, V, K, and G, and wherein X1 is G, T or S, X2 is G or S, and X3 is T or I. In other embodiments, the heavy
chain CDR2 comprises I, I, N, P, R, G, D, S, I, I, Y, A, Q, K, F, Q, and G.
In certain embodiments, the anti-TIM3 antibodies, or antigen binding ns thereof, comprise a
light chain CDR1 comprising SEQ ID NO: 64 or SEQ ID NO: 65, a light chain CDR2 comprising SEQ ID NO:
66 or SEQ ID NO: 67, and/or a light chain CDR3 comprising SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO:
70, or SEQ ID NO: 71.
Provided herein are isolated antibodies, or antigen binding portions thereof, which bind human
TIM3 and comprise heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2, and CDR3, wherein
(a) the heavy chain CDR1 is ed from the group consisting of SEQ ID NO: 41, SEQ ID NO: 42; SEQ ID
NO: 43; SEQ ID NO: 44; and SEQ ID NO: 45;
(b) the heavy chain CDR2 is selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47; SEQ ID
NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 122; SEQ ID NO:
123; SEQ ID NO: 124 and SEQ ID NO: 125;
(c) the heavy chain CDR3 is selected from the group consisting of SEQ ID NO: 53, SEQ ID NO: 54; SEQ ID
NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 126; SEQ ID NO:
127; SEQ ID NO:128 and SEQ ID NO: 129;
(d) the light chain CDR1 comprises SEQ ID NO: 64 or SEQ ID NO: 65;
(e) the light chain CDR2 comprises SEQ ID NO: 66 or SEQ ID NO: 67; and
(f) the light chain CDR3 comprises SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71.
Provided herein are isolated dies, or antigen binding portions thereof, which bind to human
TIM3 and comprise:
(a1) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 41, 46, 53, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, respectively;
(a2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a3) the heavy chain le region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 123, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a4) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 124, 53,
respectively, and the light chain le region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 68,
respectively;
(a5) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a6) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 127,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a7) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(a8) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 129,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(a9) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a10) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(b1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 47, 54, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(b2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 125, 54,
tively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69,
respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 43, 48, and 55, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 44, 49, and 56, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, tively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 64, 66, and 69, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 71, tively;
(g) heavy chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 67, and 70, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 51, and 58, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 52, and 59, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
Provided herein are isolated antibodies, or antigen g portions thereof, which bind to human
TIM3 and comprise heavy and light chain le regions, wherein the heavy chain le region comprises
an amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%,
at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the
amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, 38, 39, 40, 112, 113,
114, 115, 116, 117, 118, 119, 120, 121, and 364 and/or n the light chain variable region comprises an
amino acid sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at
least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the
amino acid sequence selected from the group consisting of SEQ ID NOs: 60, 61, 62, and 63.
Provided herein are isolated antibodies, or antigen binding portions thereof, which bind to human
TIM3 and cross-compete for binding to human TIM3 with a reference antibody sing a VH and a VL,
wherein the VH and the VL are selected from the group consisting of:
(a) a VH comprising the amino acid sequence set forth in SEQ ID NO: 34 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(b) a VH comprising the amino acid sequence set forth in SEQ ID NO: 35 and a VL comprising the amino acid
ce set forth in SEQ ID NO: 61;
(c) a VH comprising the amino acid sequence set forth in SEQ ID NO: 36 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(d) a VH comprising the amino acid sequence set forth in SEQ ID NO: 37 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(e) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(f) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 62;
(g) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 63;
(h) a VH comprising the amino acid sequence set forth in SEQ ID NO: 39 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(i) a VH comprising the amino acid sequence set forth in SEQ ID NO: 40 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(j) a VH comprising the amino acid ce set forth in SEQ ID NOs: 121 and a VL comprising the amino acid
sequence set forth in 63, respectively;
(k) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 120 and a VL comprising the amino
acid ce set forth in 61, respectively;
(l) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 112 and a VL comprising the amino acid
sequence set forth in 60, tively;
(m) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 113 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(n) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 114 and a VL comprising the amino
acid sequence set forth in 60, tively;
(o) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 115 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(p) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 116 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(q) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 117 and a VL sing the amino
acid ce set forth in 60, respectively;
(r) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 118 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(s) a VH comprising the amino acid ce set forth in SEQ ID NOs: 119 and a VL comprising the amino
acid sequence set forth in 60, respectively; and
(t) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 364 and a VL comprising the amino acid
sequence set forth in 60, respectively.
In one embodiment, the isolated anti-TIM3 dies, or antigen binding portions thereof, bind to
TIM3 at the same epitope as the reference antibody.
In other embodiments, the isolated anti-TIM3 antibodies, or antigen binding portions thereof,
comprise a VH and a VL, selected from the group ting of:
(a) a VH sing the amino acid sequence set forth in SEQ ID NO: 34 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(b) a VH comprising the amino acid sequence set forth in SEQ ID NO: 35 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(c) a VH comprising the amino acid sequence set forth in SEQ ID NO: 36 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(d) a VH comprising the amino acid sequence set forth in SEQ ID NO: 37 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(e) a VH sing the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(f) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 62;
(g) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 63;
(h) a VH comprising the amino acid sequence set forth in SEQ ID NO: 39 and a VL comprising the amino acid
ce set forth in SEQ ID NO: 60;
(i) a VH comprising the amino acid sequence set forth in SEQ ID NO: 40 and a VL sing the amino acid
sequence set forth in SEQ ID NO: 61;
(j) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 121 and a VL comprising the amino acid
ce set forth in 63, respectively;
(k) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 120 and a VL comprising the amino
acid sequence set forth in 61, tively;
(l) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 112 and a VL comprising the amino acid
sequence set forth in 60, respectively;
(m) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 113 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(n) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 114 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(o) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 115 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(p) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 116 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(q) a VH sing the amino acid sequence set forth in SEQ ID NOs: 117 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(r) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 118 and a VL comprising the amino
acid ce set forth in 60, respectively;
(s) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 119 and a VL comprising the amino
acid sequence set forth in 60, respectively; and
(t) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 364 and a VL comprising the amino acid
sequence set forth in 60, tively.
In certain embodiments, the anti-TIM3 antibodies, or antigen binding portions thereof, are selected
from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4 or a variant thereof. In some embodiments, the
anti-TIM3 antibodies, or antigen binding portions thereof, comprise an effectorless IgG1 Fc that comprises the
following mutations: L234A, L235E, G237A, and optionally A330S and P331S. In other embodiments, the anti-
TIM3 antibodies, or antigen binding portions thereof, comprise a heavy chain constant region comprising an
amino acid ce selected from the group consisting of SEQ ID NOs: 130-133. In certain embodiments, the
anti-TIM3 antibodies, or n binding portions f, are human or humanized antibody.
In n embodiments, the anti-TIM3 antibodies, or antigen binding portions thereof, specifically
bind to human TIM3 and comprise
(a1) heavy and light chain sequences comprising SEQ ID NOs: 301 (or 302) and 29, respectively;
(a2) heavy and light chain sequences comprising SEQ ID NOs: 1 (or 8) and 29, respectively;
(a3) heavy and light chain sequences comprising SEQ ID NOs: 15 (or 22) and 29, respectively;
(a4) heavy and light chain sequences comprising SEQ ID NOs: 303 (or 304) and 29, respectively;
(a5) heavy and light chain sequences comprising SEQ ID NOs: 72 (or 82) and 29, respectively;
(a6) heavy and light chain sequences comprising SEQ ID NOs: 92 (or 102) and 29, respectively;
(a7) heavy and light chain sequences sing SEQ ID NOs: 305 (or 306) and 29, respectively;
(a8) heavy and light chain sequences comprising SEQ ID NOs: 73 (or 83) and 29, respectively;
(a9) heavy and light chain sequences comprising SEQ ID NOs: 93 (or 103) and 29, respectively;
(a10) heavy and light chain sequences comprising SEQ ID NOs: 307 (or 308) and 29, respectively;
(a11) heavy and light chain sequences comprising SEQ ID NOs: 74 (or 84) and 29, respectively;
(a12) heavy and light chain sequences comprising SEQ ID NOs: 94 (or 104) and 29, respectively;
(a13) heavy and light chain sequences comprising SEQ ID NOs: 309 (or 310) and 29, respectively;
(a14) heavy and light chain sequences comprising SEQ ID NOs: 75 (or 85) and 29, respectively;
(a15) heavy and light chain sequences comprising SEQ ID NOs: 95 (or 105) and 29, respectively;
(a16) heavy and light chain sequences comprising SEQ ID NOs: 311 (or 312) and 29, respectively;
(a17) heavy and light chain sequences sing SEQ ID NOs: 76 (or 86) and 29, tively;
(a18) heavy and light chain sequences sing SEQ ID NOs: 96 (or 106) and 29, respectively;
(a19) heavy and light chain sequences comprising SEQ ID NOs: 313 (or 314) and 29, respectively;
(a20) heavy and light chain sequences comprising SEQ ID NOs: 77 (or 87) and 29, respectively;
(a21) heavy and light chain sequences comprising SEQ ID NOs: 97 (or 107) and 29, respectively;
(a22) heavy and light chain sequences comprising SEQ ID NOs: 315 (or 316) and 29, respectively;
(a23) heavy and light chain sequences comprising SEQ ID NOs: 78 (or 88) and 29, tively;
(a24) heavy and light chain sequences sing SEQ ID NOs: 98 (or 108) and 29, respectively;
(a25) heavy and light chain sequences comprising SEQ ID NOs: 317 (or 318) and 29, respectively;
(a26) heavy and light chain sequences comprising SEQ ID NOs: 79 (or 89) and 29, respectively;
(a27) heavy and light chain sequences sing SEQ ID NOs: 99 (or 109) and 29, respectively;
(a28) heavy and light chain sequences comprising SEQ ID NOs: 319 (or 320) and 29, respectively;
(a29) heavy and light chain sequences comprising SEQ ID NOs: 349 (or 350) and 29, respectively;
(a30) heavy and light chain sequences comprising SEQ ID NOs: 351 (or 352) and 29, respectively;
(a31) heavy and light chain sequences comprising SEQ ID NOs: 353 (or 354) and 29, respectively;
(b1) heavy and light chain sequences comprising SEQ ID NOs: 321 (or 322) and 30, respectively;
(b2) heavy and light chain sequences comprising SEQ ID NOs: 2 (or 9) and 30, tively;
(b3) heavy and light chain sequences sing SEQ ID NOs: 16 (or 23) and 30, respectively;
(b4) heavy and light chain sequences comprising SEQ ID NOs: 323 (or 324) and 30, respectively;
(b5) heavy and light chain sequences comprising SEQ ID NOs: 80 (or 90) and 30, respectively;
(b6) heavy and light chain sequences comprising SEQ ID NOs: 100 (or 110) and 30, respectively;
(b7) heavy and light chain sequences comprising SEQ ID NOs: 325 (or 326) and 30, respectively;
(c1) heavy and light chain sequences comprising SEQ ID NOs: 327 (or 328) and 30, respectively;
(c2) heavy and light chain ces comprising SEQ ID NOs: 3 (or 10) and 30, respectively;
(c3) heavy and light chain sequences comprising SEQ ID NOs: 17 (or 24) and 30, respectively;
(c4) heavy and light chain sequences comprising SEQ ID NOs: 329 (or 330) and 30, respectively;
(d1) heavy and light chain sequences comprising SEQ ID NOs: 331 (or 332) and 29, respectively;
(d2) heavy and light chain sequences comprising SEQ ID NOs: 4 (or 11) and 29, respectively;
(d3) heavy and light chain sequences comprising SEQ ID NOs: 18 (or 25) and 29, tively;
(d4) heavy and light chain sequences comprising SEQ ID NOs: 333 (or 334) and 29, respectively;
(e11) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 32, respectively;
(e12) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 33, respectively;
(e13) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 33, respectively;
(e2) heavy and light chain sequences comprising SEQ ID NOs: 5 (or 12) and 33, respectively;
(e3) heavy and light chain sequences comprising SEQ ID NOs: 19 (or 26) and 33, respectively;
(e4) heavy and light chain sequences comprising SEQ ID NOs: 337 (or 338) and 33, respectively;
(e5) heavy and light chain sequences comprising SEQ ID NOs: 81 (or 91) and 33, tively;
(e6) heavy and light chain sequences comprising SEQ ID NOs: 101 (or 111) and 33, respectively;
(e7) heavy and light chain ces comprising SEQ ID NOs: 339 (or 340) and 33, tively;
(f1) heavy and light chain ces comprising SEQ ID NOs: 341 (or 342) and 29, respectively;
(f2) heavy and light chain sequences comprising SEQ ID NOs: 6 (or 13) and 29, tively;
(f3) heavy and light chain sequences comprising SEQ ID NOs: 20 (or 27) and 29, respectively;
(f4) heavy and light chain ces comprising SEQ ID NOs: 343 (or 344) and 29, respectively;
(g1) heavy and light chain sequences comprising SEQ ID NOs: 345 (or 346) and 30, respectively;
(g2) heavy and light chain sequences comprising SEQ ID NOs: 7 (or 14) and 30, respectively;
(g3) heavy and light chain sequences comprising SEQ ID NOs: 21 (or 28) and 30, respectively; or
(g4) heavy and light chain sequences comprising SEQ ID NOs: 347 (or 348) and 30, respectively.
In other embodiments, the anti-TIM3 antibodies, or antigen binding portions thereof, have one or
more of the following properties:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore, e.g., as described in the Examples;
(2) binding to e cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by e, e.g., as described in the Examples;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(4) binding to ne bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the Examples;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow try (e.g., as described in the Examples);
(6) binding to membrane bound lgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by ard analysis, e.g., as described in the es;
(7) inducing or enhancing T cell activation (e.g., by blocking or ng the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ tion in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs), e.g., as described in the Examples;
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay, e.g., as described in the
Examples;
(9) inhibiting the binding of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" blocking
assay, e.g., as described in the Examples;
(10) not internalizing or gulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following regions of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
G (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297), e.g., as described in the
Examples;
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wild-type
human TIM3, e.g., as described in the Examples;
(13) competing in either direction or both directions for g to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or TIM3.7, TIM3.8, TIM3.10,
TIM3.11, 2, TIM3.13, TIM3.14, TIM3.15, TIM3.16, TIM3.17, and TIM3.18, e.g., as described in the
Examples;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
IPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the es; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to g to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368), and
119NDEKFNLKL127 (SEQ ID NO: 373), as ined by HDX-MS, as described in the Examples; and/or (c)
competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
described in the Examples.
Provided herein are bispecific molecules comprising an anti-TIM3 antibody linked to a molecule
having a second binding specificity.
Provided herein are nucleic acids encoding the heavy and/or light chain variable regions of the
anti-TIM3 antibodies, or antigen binding portions thereof, sion vectors comprising the nucleic acid
molecules, and cells transformed with the sion vectors.
Provided herein are immunoconjugates comprising the anti-TIM3 antibodies described herein,
linked to an agent.
Provided herein are compositions comprising anti-TIM3 antibodies, or antigen binding portions
thereof, bispecific molecules, or immunoconjugates described herein, and a carrier. Also provided herein are
kits comprising the anti-TIM3 antibodies, or antigen binding portions f, bispecific molecules, or
immunoconjugates described herein, and instructions for use.
Provided herein is a method of preparing anti-TIM3 antibodies, or antigen binding portions
thereof, comprising expressing an anti-TIM3 antibody, or antigen binding portion thereof, in a cell and isolating
the antibody, or n g portion thereof, from the cell.
ed herein is a method of stimulating an antigen-specific T cell response comprising
contacting the T cell with an IM3 antibody, or n binding portion thereof, bispecific molecules, or
immunoconjugates described herein such that an antigen-specific T cell response is stimulated (e.g., by
ting the negative effect of TIM3 on cells, e.g., T cells).
Provided herein is a method of activating or co-stimulating a T cell, e.g., an effector T cell (e.g.,
Th1 cell), comprising contacting a cell, e.g., an or T cell, with an anti-TIM3 antibody, or n binding
portion thereof, bispecific molecules, or immunoconjugates described herein, and CD3, wherein the effector T
cell is activated or co-stimulated (e.g., by inhibiting the negative effect of TIM3 on cells, e.g., T cells).
Provided herein is a method of increasing IFN-γ production in and/or eration of a T cell, e.g.,
Th1 cell or TIL, comprising contacting the T cell with an effective amount of an anti-TIM3 antibody, or antigen
binding portion thereof, bispecific molecules, or immunoconjugates described herein.
Provided herein is a method of increasing IFN-γ production in T cells in a subject comprising
stering to the subject an effective amount of an anti-TIM3 dy, or antigen g portion thereof,
bispecific molecule, or immunoconjugate described herein to increase IFN-γ production from the T cells.
Provided herein a method of ating TIL activity in a subject comprising administering to the
t a therapeutically effective amount of an anti-TIM3 antibody, or antigen g portion thereof,
described herein, such that the TILs proliferate or secrete a cytokine, e.g., IFN-γ.
Provided herein are methods for stimulating NK cells (e.g., by increasing NK cell cytotoxic
activity) and/or macrophages or other n presenting cell in a subject, sing administering to the
subject an effective amount of an anti-TIM3 antibody, or antigen binding portion thereof, bispecific molecule,
or immunoconjugate described herein. For example, an anti-TIM3 antibody described herein can increase IL-12
secretion by antigen presenting cells contacted with the TIM3 antibody.
Provided herein is a method of ating an immune response in a subject comprising
administering to the subject an anti-TIM3 antibody, or n g n thereof, bispecific molecule or
immunoconjugate described herein, such that an immune response in the subject is stimulated. In certain
embodiments, the subject has a tumor and an immune response against the tumor is stimulated.
Provided herein is a method for inhibiting the growth of tumors or reducing the size of tumors in a
subject comprising administering to the t an anti-TIM3 antibody, or antigen binding portion thereof,
bispecific molecule, or conjugate described herein, such that growth of the tumor is inhibited in the
Provided herein is a method of treating cancer, e.g., by immunotherapy, comprising administering
to a subject in need thereof a therapeutically effective amount of an anti-TIM3 antibody, or antigen binding
portion thereof, bispecific molecule, or immunoconjugate described herein to treat the cancer. In certain
embodiments, the cancer is selected from the group consisting of: bladder cancer, breast cancer, uterine/cervical
cancer, ovarian cancer, prostate , testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic
cancer, colorectal , colon cancer, kidney cancer, head and neck cancer, lung cancer, stomach , germ
cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm of the l nervous system,
ma, leukemia, myeloma, sarcoma, virus-related cancer, and any combinations thereof. In some
embodiments, the cancer is a metastatic cancer, refractory cancer, or recurrent . In some embodiments,
the cancer is a cold tumor.
In certain embodiments, the methods described herein further comprise one or more additional
therapeutics with an anti-TIM3 antibody, e.g., an D-l dy, an anti-LAG-3 dy, an anti-CTLA-4
antibody, an anti-GITR antibody, and/or an anti-PD-L1 antibody.
Provided herein is a method of detecting the presence of a TIM3 protein in a sample comprising
contacting the sample with an anti-TIM3 antibody, or antigen binding portion thereof, under conditions that
allow for formation of a x between the antibody, or antigen binding portion f, and TIM3, and
detecting the formation of a complex.
EMBODIMENTS
Embodiment 1. An isolated antibody (e.g., a human antibody), or antigen binding n thereof,
which binds to human T-cell immunoglobulin and mucin-domain containing-3 (TIM3), n the antibody or
n binding portion thereof comprises heavy chain CDR1, CDR2, and CDR3 and light chain CDR1, CDR2,
and CDR3, wherein
(a) the heavy chain CDR1 is selected from the group consisting of SEQ ID NO: 41, SEQ ID NO: 42; SEQ ID
NO: 43; SEQ ID NO: 44; and SEQ ID NO: 45;
(b) the heavy chain CDR2 is selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47; SEQ ID
NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 122; SEQ ID NO:
123; SEQ ID NO: 124 and SEQ ID NO: 125;
(c) the heavy chain CDR3 is selected from the group consisting of SEQ ID NO: 53, SEQ ID NO: 54; SEQ ID
NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 126; SEQ ID NO:
127; SEQ ID NO:128 and SEQ ID NO: 129;
(d) the light chain CDR1 comprises SEQ ID NO: 64 or SEQ ID NO: 65;
(e) the light chain CDR2 comprises SEQ ID NO: 66 or SEQ ID NO: 67; and
(f) the light chain CDR3 comprises SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71.
Embodiment 2. An isolated antibody, or antigen binding portion thereof, which binds to human
TIM3, comprising:
(a1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 53, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, respectively;
(a2) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 41, 122, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(a3) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 123, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a4) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 124, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a5) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 68,
respectively;
(a6) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 127,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a7) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(a8) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 129,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a9) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a10) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 68,
respectively;
(b1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 47, 54, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(b2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 125, 54,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69,
respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 43, 48, and 55, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 44, 49, and 56, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 ces comprising SEQ ID NOs: 64, 66, and 71, respectively;
(g1) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 67, and 70, respectively;
(g2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 71, tively;
(g3) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 51, and 58, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 52, and 59, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, tively.
Embodiment 3. The antibody, or antigen binding portion thereof, of Embodiment 1 or 2, n
the heavy chain variable region comprises an amino acid sequence which is at least about 80%, at least about
85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least
about 99%, or about 100% identical to the amino acid sequence selected from the group consisting of SEQ ID
NOs: 34, 35, 36, 37, 38, 39, 40, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, and 364 and/or the light chain
variable region comprises an amino acid sequence which is at least about 80%, at least about 85%, at least about
90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about
100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 60, 61, 62, and
Embodiment 4. The antibody, or antigen binding n f, of any one of Embodiments 1 to
3, wherein the antibody, or antigen binding portion thereof, comprises an effectorless IgG1 Fc that comprises
the following mutations: L234A, L235E, G237A, and optionally A330S and P331S.
Embodiment 5. The antibody, or antigen binding portion thereof, of any of the preceding
Embodiments, comprising a heavy chain constant region comprising an amino acid sequence selected from the
group consisting of SEQ ID NOs: 263-266.
Embodiment 6. The antibody, or antigen binding portion thereof, of any of the preceding
Embodiments, wherein the antibody, or antigen binding n thereof, is a human or humanized antibody.
Embodiment 7. The antibody of any one of Embodiments 1-6, n the antibody comprises:
(a1) heavy and light chain sequences comprising SEQ ID NOs: 301 (or 302) and 29, respectively;
(a2) heavy and light chain sequences comprising SEQ ID NOs: 1 (or 8) and 29, respectively;
(a3) heavy and light chain sequences sing SEQ ID NOs: 15 (or 22) and 29, respectively;
(a4) heavy and light chain ces sing SEQ ID NOs: 303 (or 304) and 29, respectively;
(a5) heavy and light chain sequences comprising SEQ ID NOs: 72 (or 82) and 29, respectively;
(a6) heavy and light chain sequences comprising SEQ ID NOs: 92 (or 102) and 29, respectively;
(a7) heavy and light chain sequences comprising SEQ ID NOs: 305 (or 306) and 29, respectively;
(a8) heavy and light chain sequences sing SEQ ID NOs: 73 (or 83) and 29, respectively;
(a9) heavy and light chain sequences comprising SEQ ID NOs: 93 (or 103) and 29, tively;
(a10) heavy and light chain sequences comprising SEQ ID NOs: 307 (or 308) and 29, respectively;
(a11) heavy and light chain ces comprising SEQ ID NOs: 74 (or 84) and 29, tively;
(a12) heavy and light chain sequences comprising SEQ ID NOs: 94 (or 104) and 29, respectively;
(a13) heavy and light chain sequences comprising SEQ ID NOs: 309 (or 310) and 29, respectively;
(a14) heavy and light chain sequences comprising SEQ ID NOs: 75 (or 85) and 29, tively;
(a15) heavy and light chain sequences comprising SEQ ID NOs: 95 (or 105) and 29, respectively;
(a16) heavy and light chain sequences comprising SEQ ID NOs: 311 (or 312) and 29, respectively;
(a17) heavy and light chain sequences sing SEQ ID NOs: 76 (or 86) and 29, respectively;
(a18) heavy and light chain sequences comprising SEQ ID NOs: 96 (or 106) and 29, respectively;
(a19) heavy and light chain sequences comprising SEQ ID NOs: 313 (or 314) and 29, respectively;
(a20) heavy and light chain sequences comprising SEQ ID NOs: 77 (or 87) and 29, respectively;
(a21) heavy and light chain sequences sing SEQ ID NOs: 97 (or 107) and 29, respectively;
(a22) heavy and light chain sequences comprising SEQ ID NOs: 315 (or 316) and 29, respectively;
(a23) heavy and light chain sequences comprising SEQ ID NOs: 78 (or 88) and 29, respectively;
(a24) heavy and light chain sequences comprising SEQ ID NOs: 98 (or 108) and 29, respectively;
(a25) heavy and light chain sequences comprising SEQ ID NOs: 317 (or 318) and 29, respectively;
(a26) heavy and light chain sequences comprising SEQ ID NOs: 79 (or 89) and 29, respectively;
(a27) heavy and light chain sequences comprising SEQ ID NOs: 99 (or 109) and 29, respectively;
(a28) heavy and light chain sequences comprising SEQ ID NOs: 319 (or 320) and 29, tively;
(a29) heavy and light chain sequences comprising SEQ ID NOs: 349 (or 350) and 29, respectively;
(a30) heavy and light chain sequences comprising SEQ ID NOs: 351 (or 352) and 29, respectively;
(a31) heavy and light chain ces comprising SEQ ID NOs: 353 (or 354) and 29, respectively;
(b1) heavy and light chain sequences comprising SEQ ID NOs: 321 (or 322) and 30, respectively;
(b2) heavy and light chain sequences comprising SEQ ID NOs: 2 (or 9) and 30, respectively;
(b3) heavy and light chain sequences comprising SEQ ID NOs: 16 (or 23) and 30, respectively;
(b4) heavy and light chain sequences comprising SEQ ID NOs: 323 (or 324) and 30, tively;
(b5) heavy and light chain sequences comprising SEQ ID NOs: 80 (or 90) and 30, respectively;
(b6) heavy and light chain sequences sing SEQ ID NOs: 100 (or 110) and 30, respectively;
(b7) heavy and light chain sequences comprising SEQ ID NOs: 325 (or 326) and 30, respectively;
(c1) heavy and light chain sequences comprising SEQ ID NOs: 327 (or 328) and 30, respectively;
(c2) heavy and light chain ces sing SEQ ID NOs: 3 (or 10) and 30, tively;
(c3) heavy and light chain sequences comprising SEQ ID NOs: 17 (or 24) and 30, respectively;
(c4) heavy and light chain sequences comprising SEQ ID NOs: 329 (or 330) and 30, respectively;
(d1) heavy and light chain sequences sing SEQ ID NOs: 331 (or 332) and 29, respectively;
(d2) heavy and light chain sequences comprising SEQ ID NOs: 4 (or 11) and 29, respectively;
(d3) heavy and light chain sequences comprising SEQ ID NOs: 18 (or 25) and 29, tively;
(d4) heavy and light chain sequences comprising SEQ ID NOs: 333 (or 334) and 29, respectively;
(e1.1) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 32, respectively;
(e1.2) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 33, respectively;
(e1.3) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 31, respectively;
(e2) heavy and light chain sequences comprising SEQ ID NOs: 5 (or 12) and 33, respectively;
(e3) heavy and light chain sequences comprising SEQ ID NOs: 19 (or 26) and 33, respectively;
(e4) heavy and light chain sequences comprising SEQ ID NOs: 337 (or 338) and 33, respectively;
(e5) heavy and light chain sequences comprising SEQ ID NOs: 81 (or 91) and 33, tively;
(e6) heavy and light chain sequences comprising SEQ ID NOs: 101 (or 111) and 33, respectively;
(e7) heavy and light chain sequences comprising SEQ ID NOs: 339 (or 340) and 33, respectively;
(f1) heavy and light chain sequences sing SEQ ID NOs: 341 (or 342) and 29, respectively;
(f2) heavy and light chain sequences sing SEQ ID NOs: 6 (or 13) and 29, respectively;
(f3) heavy and light chain sequences comprising SEQ ID NOs: 20 (or 27) and 29, respectively;
(f4) heavy and light chain sequences comprising SEQ ID NOs: 343 (or 344) and 29, respectively;
(g1) heavy and light chain sequences comprising SEQ ID NOs: 345 (or 346) and 29, respectively;
(g2) heavy and light chain sequences comprising SEQ ID NOs: 7 (or 43) and 30, respectively;
(g3) heavy and light chain sequences comprising SEQ ID NOs: 21 (or 28) and 30, respectively; or
(g4) heavy and light chain sequences sing SEQ ID NOs: 347 (or 348) and 30, respectively;
wherein the antibody specifically binds to human TIM3.
Embodiment 8. The antibody or antigen binding portion thereof, of any of ments 1-7,
wherein the antibody or antigen binding portion thereof has one or more of the following properties:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as ed
by Biacore;
(2) binding to soluble lgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry;
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by ard is;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow cytometry;
(6) binding to membrane bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by Scatchard analysis;
(7) inducing or enhancing T cell activation (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs);
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay;
(9) inhibiting the binding of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" blocking
assay;
(10) not internalizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following regions of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297);
(12) having d binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 is
substituted with r amino acid relative to binding to wildtype human TIM3;
(13) competing in either direction or both directions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or , TIM3.8, TIM3.10,
TIM3.11, TIM3.12, TIM3.13, 4, TIM3.15, TIM3.16, TIM3.17, and TIM3.18;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
IPGIMNDEKFNLKL127 (SEQ ID NO: 368) as ined by HDX-MS
(15) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the Examples; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having d binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to binding to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the Examples; and/or (c)
competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3.
Embodiment 9. A bispecific molecule comprising the dy of any one of the preceding
Embodiments linked to a molecule having a second binding specificity.
Embodiment 10. A nucleic acid encoding the heavy and/or light chain variable region of the
antibody, or antigen g portion thereof, of any one of Embodiments 1 to 8.
Embodiment 11. A cell ormed with the nucleic acid of Embodiment 10.
Embodiment 12. An immunoconjugate comprising the antibody according to any one of
Embodiments 1 to 8, linked to an agent.
Embodiment 13. A composition sing the antibody, or antigen binding portion thereof,
bispecific molecule or immunoconjugate, of any one of Embodiments 1 to 9 and 12, and a r.
ment 14. A kit comprising the antibody, or n binding portion thereof, or bispecific
molecule, or immunoconjugate of any one of Embodiments 1 to 9 and 12 and instructions for use.
Embodiment 15. A method of stimulating, increasing or modulating an immune response in a
subject in need thereof or for treating cancer in a subject in need thereof, comprising administering the antibody,
or antigen binding portion thereof, bispecific molecule or immunoconjugate, of any one of Embodiments 1 to 9
and 12, wherein an antigen-specific T cell response is stimulated, wherein the effector T cell is activated or costimulated
, wherein IFN-γ production in a T cell is increased, wherein the number of T cells is increased,
wherein TIL activity is stimulated, wherein the size of a tumor in the subject is reduced, wherein growth of a
tumor in the subject is inhibited, or any combination f, after the administration.
Other features and ages of the instant disclosure will be apparent from the ing
detailed description and examples, which should be ued as limiting.
BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
shows the nucleotide sequence (SEQ ID NO: 167) and the amino acid sequence (SEQ ID
NO: 34) of the mature heavy chain variable (VH) region of the anti-TIM3 monoclonal antibody 13A3. The
CDR1 (SEQ ID NO: 41), CDR2 (SEQ ID NO: 46) and CDR3 (SEQ ID NO: 53) are delineated, and the V, D
and J germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 193) and the amino acid sequence (SEQ ID
NO: 60) of the mature light chain variable (VL) region of the anti-TIM3 onal antibody 13A3. The CDR1
(SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 68) are delineated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 167) and the amino acid sequence (SEQ ID
NO: 34) of the heavy chain VH region of the anti-TIM3 onal antibody 13A3 with a signal sequence
(SEQ ID NOs: 274 and 269, respectively), and the nucleotide sequence (SEQ ID NO: 193) and the amino acid
sequence (SEQ ID NO: 60) of the light chain VL region of the IM3 monoclonal antibody 13A3 with a
signal sequence (SEQ ID NOs: 273 and 268, respectively).
shows the tide sequence (SEQ ID NO: 168) and the amino acid sequence (SEQ ID
NO: 35) of the mature heavy chain variable (VH) region of the anti-TIM3 monoclonal antibody 8B9. The CDR1
(SEQ ID NO: 42), CDR2 (SEQ ID NO: 47) and CDR3 (SEQ ID NO: 54) are delineated, and the V, D and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 194) and the amino acid sequence (SEQ ID
NO: 61) of the mature light chain variable (VL) region of the anti-TIM3 monoclonal antibody 8B9. The CDR1
(SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 69) are delineated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 168) and the amino acid sequence (SEQ ID
NO: 35) of the heavy chain VH region of the anti-TIM3 monoclonal antibody 8B9 with a signal ce (SEQ
ID NOs: 274 and 269, respectively), and the nucleotide sequence (SEQ ID NO: 194) and the amino acid
sequence (SEQ ID NO: 61) of the light chain VL region of the anti-TIM3 monoclonal antibody 8B9 with a
signal sequence (SEQ ID NOs: .273 and 268, respectively).
shows the nucleotide sequence (SEQ ID NO: 169) and the amino acid sequence (SEQ ID
NO: 36) of the mature heavy chain variable (VH) region of the anti-TIM3 monoclonal antibody 8C4. The CDR1
(SEQ ID NO: 43), CDR2 (SEQ ID NO: 48) and CDR3 (SEQ ID NO: 55) are delineated, and the V, D and J
germline tions are indicated.
shows the tide sequence (SEQ ID NO: 194) and the amino acid sequence (SEQ ID
NO: 61) of the mature light chain variable (VL) region of the anti-TIM3 monoclonal dy 8C4. The CDR1
(SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 69) are delineated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 169) and the amino acid sequence (SEQ ID
NO: 36) of the heavy chain VH region of the anti-TIM3 monoclonal antibody 8C4 with a signal sequence (SEQ
ID NOs: 274 and 269, respectively), and the tide sequence (SEQ ID NO: 194) and the amino acid
sequence (SEQ ID NO: 61) of the light chain VL region of the IM3 monoclonal antibody 8C4 with a
signal sequence (SEQ ID NOs: 273 and 268, respectively).
shows the nucleotide sequence (SEQ ID NO: 170) and the amino acid sequence (SEQ ID
NO: 37) of the mature heavy chain variable (VH) region of the anti-TIM3 monoclonal antibody 17C3. The
CDR1 (SEQ ID NO: 44), CDR2 (SEQ ID NO: 49) and CDR3 (SEQ ID NO: 56) are delineated, and the V, D
and J germline derivations are ted.
shows the nucleotide sequence (SEQ ID NO: 193) and the amino acid sequence (SEQ ID
NO: 60) of the mature light chain variable (VL) region of the anti-TIM3 onal antibody 17C3. The CDR1
(SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 68) are ated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 170) and the amino acid sequence (SEQ ID
NO: 37) of the heavy chain VH region of the anti-TIM3 monoclonal antibody 17C3 with a signal sequence
(SEQ ID NOs: 272 and 267, respectively), and the nucleotide sequence (SEQ ID NO: 193) and the amino acid
ce (SEQ ID NO: 60) of the light chain VL region of the anti-TIM3 monoclonal antibody 17C3 with a
signal sequence (SEQ ID NOs: 273 and 268, respectively).
shows the nucleotide sequence (SEQ ID NO: 171) and the amino acid sequence (SEQ ID
NO: 38) of the mature heavy chain variable (VH) region of the anti-TIM3 monoclonal antibody 9F6. The CDR1
(SEQ ID NO: 45), CDR2 (SEQ ID NO: 50) and CDR3 (SEQ ID NO: 57) are delineated, and the V, D and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 195) and the amino acid sequence (SEQ ID
NO: 62) of the mature light chain le (VL) region of VK1 of the anti-TIM3 monoclonal antibody 9F6. The
CDR1 (SEQ ID NO: 65), CDR2 (SEQ ID NO: 67) and CDR3 (SEQ ID NO: 70) are delineated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 196) and the amino acid sequence (SEQ ID
NO: 63) of the mature light chain variable (VL) region of VK2 of the anti-TIM3 monoclonal antibody 9F6. The
CDR1 (SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 71) are delineated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 194) and the amino acid sequence (SEQ ID
NO: 61) of the mature light chain le (VL) region of VK3 of the anti-TIM3 monoclonal antibody 9F6. The
CDR1 (SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 69) are ated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 171) and the amino acid sequence (SEQ ID
NO: 38) of the heavy chain VH region of the anti-TIM3 monoclonal dy 9F6 with a signal sequence (SEQ
ID NOs: 275 and 270, respectively), and the nucleotide sequences (SEQ ID NO: 195, 196, and 194,
respectively) and the amino acid sequences (SEQ ID NO: 62, 63, and 61, respectively) of the light chain VL
region of VK1, VK2 and VK3 of the anti-TIM3 monoclonal dy 9F6 with a signal sequence (SEQ ID NOs:
276 and 271, respectively).
shows the nucleotide sequence (SEQ ID NO: 172) and the amino acid sequence (SEQ ID
NO: 39) of the mature heavy chain variable (VH) region of the anti-TIM3 monoclonal antibody 3G4. The CDR1
(SEQ ID NO: 45), CDR2 (SEQ ID NO: 51) and CDR3 (SEQ ID NO: 58) are delineated, and the V, D and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 193) and the amino acid sequence (SEQ ID
NO: 60) of the mature light chain le (VL) region of the anti-TIM3 monoclonal antibody 3G4. The CDR1
(SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 68) are ated, and the V and J
germline derivations are ted.
shows the nucleotide ce (SEQ ID NO: 172) and the amino acid sequence (SEQ ID
NO: 39) of the heavy chain VH region of the anti-TIM3 monoclonal dy 3G4 with a signal sequence (SEQ
ID NOs: 275 and 270, respectively), and the nucleotide sequence (SEQ ID NO: 193) and the amino acid
sequence (SEQ ID NO: 60) of the light chain VL region of the anti-TIM3 monoclonal antibody 3G4 with a
signal sequence (SEQ ID NOs: 273 and 268, respectively).
shows the nucleotide sequence (SEQ ID NO: 173) and the amino acid sequence (SEQ ID
NO: 40) of the mature heavy chain le (VH) region of the anti-TIM3 monoclonal antibody 17C8. The
CDR1 (SEQ ID NO: 45), CDR2 (SEQ ID NO: 52) and CDR3 (SEQ ID NO: 59) are delineated, and the V, D
and J germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 194) and the amino acid sequence (SEQ ID
NO: 61) of the mature light chain variable (VL) region of the anti-TIM3 monoclonal antibody 17C8. The CDR1
(SEQ ID NO: 64), CDR2 (SEQ ID NO: 66) and CDR3 (SEQ ID NO: 69) are delineated, and the V and J
germline derivations are indicated.
shows the nucleotide sequence (SEQ ID NO: 173) and the amino acid sequence (SEQ ID
NO: 40) of the heavy chain VH region of the anti-TIM3 monoclonal antibody 17C8 with a signal sequence
(SEQ ID NOs: 275 and 270, respectively), and the nucleotide sequence (SEQ ID NO: 194) and the amino acid
ce (SEQ ID NO: 61) of the light chain VL region of the IM3 monoclonal antibody 17C8 with a
signal sequence (SEQ ID NOs: 273 and 268, respectively).
shows a sequence alignment of the heavy chain variable (VH) region of monoclonal
antibodies 13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and 17C8. The complementarity determining regions (CDRs) are
boxed.
lists the SEQ ID NOs for the VH regions, each of the CDRs, and mutants thereof, of the
antibodies.
shows a sequence alignment of the light chain variable (VL) region of monoclonal
antibodies 13A3, 8B9, 8C4, 17C3, 9F6_VK1, 9F6_VK2, 9F6_VK3, 3G4, and 17C8. The complementarity
determining regions (CDRs) are boxed.
lists the SEQ ID NOs for the VL regions and each of the CDRs of the antibodies.
shows a sequence alignment of the mature full length heavy chain (HC) of monoclonal
antibody TIM3.5 (13A3) and exemplary variants thereof: TIM3.13 (D101E), TIM3.14 (P102V), TIM3.15
(P102Y), TIM3.16 (P102L), TIM3.17 P102Y), TIM3.18 (N60Q/D101E), 0 (N60Q), TIM3.11
(N60S), and TIM3.12 (N60A). The VH region of each of the heavy chains is underlined.
shows a sequence alignment of the mature full length HC of monoclonal antibody 9F6 and
an exemplary variant TIM3.7 (A108T) f. The VH region of each heavy chain is underlined.
shows a ce alignment of the mature full length HC of monoclonal 8B9 and an
exemplary t TIM3.8 (S61P) thereof. The VH region of each heavy chain is underlined.
lists the SEQ ID NOs of the full length heavy and light chains, variable regions and CDRs
of hybridoma derived antibodies (13A3, 8B9, 8C4, 17C3, 9F6, 3G4 and 17C8) and recombinant (TIM3.2-
TIM3.18) anti-human TIM3 antibodies. The isotype of the heavy and light chains is also indicated. "H.n." refers
to oma name. Heavy and light chains that are referred to in can be derived from its ts, e.g.,
variable and constant regions that are disclosed herein. Where a SEQ ID NO does not appear in a given column
on the second or third page of the table, it is provided in that column in the page preceding it or the page
preceding that one.
FIGs. 14A-14B show the binding curves and EC50s of anti-TIM3 antibodies to human TIM-3
transfected CHO cells (A) and activated human T cells (B).
FIGs. 15A-15B show the binding curves and EC50s of anti-TIM3 antibodies to a cyno TIM3-
ected CHO cell line (A) and ted cyno T cells (B).
shows anti-TIM3 activity (at various antibody concentrations) in promoting IFN-γ
tion from tumor infiltrating leukocytes (TILs) in renal cell carcinoma (RCC). The 8 bars for each
antibody represent different concentrations of antibody, as indicated.
FIGs. 17A-17B show IM3 activity (at various antibody concentrations) in promoting IFN-
γ production from lung cancer TILs (A, IFN-γ ELISA; B, intracellular IFN-γ staining). In A, the individual bar for each antibody represents different concentrations of antibody, as indicated. In B, the upper panel shows CD4+ cells and the lower panel shows CD8+ cells. The level of TIM3 was measured
with 8B9 (x-axis).
shows anti-TIM-3 antibodies (i.e., dies 13A3 and 3G4) in promoting IFN-γ
secretion from TILs isolated from various s in the presence of CHO-OKT3 cells.
shows anti-TIM-3 cross-blocking of TIM-3 antibodies on activated human T cells.
shows the amino acid residues that are necessary for binding of anti-TIM3 monoclonal
antibodies 13A3, 3G4, 17C3 and 8B9 to human TIM3. The signal sequence and the transmembrane domains are
ined.
FIGs. 21A-21B show that n anti-TIM3 antibodies block the interaction between human TIM3
and PS-liposome. A shows a schematic diagram of the phosphatidylserine (PS)-hTIM3 "in-tandem"
blocking assay. B shows blocking of binding of hTIM3-Fc to PS-liposome by certain anti-TIM3
antibodies, as measured via the M3 ndem" blocking assay shown in A.
shows a summary of the functional activity of various anti-TIM3 antibodies (e.g., TIM3.5,
TIM3.4, TIM3.2, TIM3.9, 9F6, TIM3.8, and TIM3.6). Data for the binding assay, T-cell assay, TIL assay, and
PS-TIM3 blocking assay are provided.
provides a listing of all SEQ ID Numbers with a description of the sequences represented
by the SEQ ID Numbers.
FIGs. 24A-24B show the anti-tumor activity of the combined administration of anti-PD1 and anti-
TIM3 antibodies in the CT26 colorectal tumor mouse model. A shows the tumor volume at various time
points post tumor implantation in mice (n=10/group) treated with the (i) control IgG (upper left panel), (ii)
RMT3-23 anti-TIM3 dy alone (upper right , (iii) RMP1-14 anti-PD1 antibody alone (bottom left
panel), and (iv) combination of the RMT3-23 anti-TIM3 and RMP1-14 anti-PD1 antibodies (bottom right
panel). B shows the e tumor volume as a function of time (days post tumor tation) in mice
d with (i) RMT3-23 anti-TIM3 antibody alone, (ii) AbM anti-TIM3 antibody alone, (iii) RMP1-14 anti-
PD1 antibody alone, (iv) combination of RMT3-23 anti-TIM3 and RMP1-14 anti-PD1 dies, (v)
combination of Ab M anti-TIM3 and RMP1-14 anti-PD1 antibodies, and (vi) isotype control antibody.
shows the list of common peptides of hTIM-3 that were used to map the epitopes of the
anti-TIM3 antibodies (13A3 and 3G4) using hydrogen/deuterium exchange mass spectrometry (HDX-MS).
Each bar tes a peptic peptide. The circled residues (i.e., N99, T145, and N172) indicate the glycosylation
sites.
shows the human TIM-3 binding regions of the anti-TIM3 antibodies (13A3 and 3G4)
identified using HDX-MX. The upper panel shows the binding region of the 13A3 anti-TIM3 dy. The
bottom panel shows the binding region of the 3G4 anti-TIM3 antibody.
FIGs. 27A-27B show the results of a Scatchard analysis of TIM3.18.IgG1.3 to CHO cells
ectopically expressing human or cyno TIM3. A shows a IM3 Ab standard curve. B shows
the amount of TIM3.18.IgG1.3 antibody bound to CHO cells expressing human (left panel) and cyno (right
panel) TIM3.
shows the results of a Scatchard analysis of TIM3.18.IgG1.3 to activated Th1 cells from
two donors (left and right panels).
FIGs. 29A and 29B show TIM3.18.IgG1.3 and TIM3.18.IgG1.3 Fab ed proliferation of Th1
T cells in the polarized Th1/irradiated CHO-OKT3 co-culture assay. A shows Th1 cell proliferation
observed with various concentrations of TIM3.18.IgG1.3, 13A3 ("13A3-g4") or with no antibody or e
l antibodies (hIgG1.1 and hIgG4). B shows Th1 cell proliferation observed with various
concentrations of TIM3.18.IgG1.3 Fab or with no antibody or isotype control antibody IgG1.3.
shows that anti-TIM3 antibody TIM3.18.IgG1.3 enhanced proliferation of Th1 T cells in
the polarized Th1/irradiated CHO-OKT3-PD-L1 co-culture assay in combination with nivolumab.
shows that anti-TIM3 antibody TIM3.18.IgG1.3 enhanced eron-γ secretion of renal
cell carcinoma tumor infiltrating lymphocytes (TILs) stimulated with irradiated CHO-OKT3 cells.
shows that anti-TIM3 antibody TIM3.18.IgG1.3 enhanced interferon-γ ion of breast
cancer TILs stimulated with irradiated CHO-OKT3 cells.
shows CD163, CD206 and TIM3 expression on the M0 macrophages that were used in an
AlloMLR (mixed lymphocyte on) assay, the results of which are shown in .
shows the proliferation of cells in an AlloMLR assay conducted in the presence of the
anti-TIM3 antibody TIM3.18.IgG1.3, an isotype control or in the e of antibody.
is a ribbon diagram of the structure of a TIM3:TIM3.18 Fab x, as ined by
crystallography. The Fab fragment is shown in light gray and TIM3 is shown in dark gray.
shows the structure of TIM3:TIM3.18 Fab complex, as determined by crystallography.
The Fab fragment is shown as a ribbon diagram. TIM3 is shown in white surface representation, with the Fab
t residues depicted in dark gray.
is a diagram of the assay that was used to measure ial internalization by anti-TIM3
dies.
shows that anti-TIM3 dies 13A3 (bottom left panel) and certain variants (D101E –
top left panel; N60Q – top right panel) thereof do not trigger receptor (i.e., TIM3) mediated internalization.
FIGs 39A and 39 B show a ribbon diagram depicting the epitopes of anti-TIM3 antibodies 13A3
(A) and 3G4 (B). The amino acid sequences of the epitopes for each of the antibodies are
provided below the ribbon diagram. The different patterns identify the specific s of the IM3
antibodies that correspond to the ic epitopes.
DETAILED DESCRIPTION OF DISCLOSURE
In order that the present description can be more readily understood, certain terms are first defined.
onal tions are set forth throughout the detailed description.
It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a
nucleotide sequence," is understood to represent one or more nucleotide ces. As such, the terms "a" (or
"an"), "one or more," and "at least one" can be used interchangeably herein.
Furthermore, r" where used herein is to be taken as specific disclosure of each of the two
specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as
"A and/or B" herein is ed to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term
"and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following aspects: A,
B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A ); B (alone); and C ).
It is understood that wherever aspects are described herein with the ge "comprising,"
otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also
provided.
Unless defined otherwise, all cal and scientific terms used herein have the same meaning as
commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the
Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The
Dictionary of Cell and lar Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of
Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a
general dictionary of many of the terms used in this disclosure.
Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted
form. Numeric ranges are inclusive of the numbers defining the range. Unless ise indicated, nucleotide
sequences are written left to right in 5' to 3' orientation. Amino acid sequences are written left to right in amino
to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure,
which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately
below are more fully defined by reference to the specification in its entirety.
The term "about" is used herein to mean approximately, roughly, around, or in the s of.
When the term "about" is used in conjunction with a cal range, it modifies that range by extending the
boundaries above and below the numerical values set forth. In general, the term "about" can modify a numerical
value above and below the stated value by a variance of, e.g., 10 percent, up or down (higher or lower).
The term "T-cell globulin and mucin-domain ning-3" or "TIM3" as used herein
refers to a receptor that is a member of the T cell immunoglobulin and mucin domain (TIM) family of proteins.
Primary ligand for TIM3 include phosphatidylserine (TIM3-L). TIM3 is also referred to as hepatitis A virus
cellular receptor 2 (HAVCR2), T-cell immunoglobulin mucin receptor 3, TIM-3, TIMD3, TIMD-3, Kidney
Injury Molecule-3, KIM-3, and CD366. The term "TIM3" includes any variants or isoforms of TIM3 which are
lly expressed by cells. Accordingly, antibodies described herein can cross-react with TIM3 from species
other than human (e.g., cynomolgus TIM3). Alternatively, the antibodies can be specific for human TIM3 and
do not exhibit any cross-reactivity with other species. TIM3 or any variants and isoforms thereof, can either be
isolated from cells or tissues which naturally express them or be inantly produced using well-known
techniques in the art and/or those described herein.
Two isoforms of human TIM3 have been fied. Isoform 1 (Accession No. NP_116171; SEQ
ID NO: 286) consists of 301 amino acids and represents the cal sequence. Isoform 2 (Accession No.
AAH20843; SEQ ID NO: 287) consists of 142 amino acids, and is e. It lacks amino acid residues 143-
301, which encode the transmembrane domain, the cytoplasmic domain, and part of the extracellular domain of
TIM3. The amino acid residues 132-142 also differ from the cal sequence described above.
Below are the amino acid sequences of the two known human TIM3 isoforms.
(A) Human TIM3 isoform 1 (Accession No. NP_116171; SEQ ID NO: 286; encoded by the nucleotide ce
having Accession No. NM_032782.4; SEQ ID NO: 288; ):
MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDV
NYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPR
MLTTRGHGPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRIGIYIGAGICAGLALALIFGALIFK
WYSHSKEKIQNLSLISLANLPPSGLANAVAEGIRSEENIYTIEENVYEVEEPNEYYCYVSSRQQPSQPLGCRFAM
(B) Human TIM3 isoform 2 (Accession No. AAH20843; SEQ ID NO: 287; d by the nucleotide sequence
having Accession No. BC020843.1; SEQ ID NO: 289):
MFSHLPFDCVLLLLLLLLTRSSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDV
NYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPGEWTFACHLYE
The signal ce of isoforms 1 and 2 ponds to amino acids 1-21 (underlined). Thus, the
mature isoforms 1 and 2 consist of amino acids 22 to 301 or 142, respectively. The extracellular domain of
mature human TIM3 consists of amino acids 22-202 of SEQ ID NO: 286 and has the amino acid sequence:
AEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLT
IENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDI
NLTQISTLANELRDSRLANDLRDSGATIRIG (SEQ ID NO: 290).
Cynomolgus TIM3 protein consists of the following amino acid sequence (including a signal
sequence):
MFSHLPFDCVLLLLLLLLTRSSEVEYIAEVGQNAYLPCSYTPAPPGNLVPVCWGKGACPVFDCSNVVLRTENRDV
NDRTSGRYWLKGDFHKGDVSLTIENVTLADSGVYCCRIQIPGIMNDEKHNLKLVVIKPAKVTPAPTLQRDLTSAF
PRMLTTGEHGPAETQTPGSLPDVNLTQIFTLTNELRDSGATIRTAIYIAAGISAGLALALIFGALIFKWYSHSKE
KTQNLSLISLANIPPSGLANAVAEGIRSEENIYTIEEDVYEVEEPNEYYCYVSSGQQPSQPLGCRFAMP (SEQ
ID NO: 360)
The term "antibody" refers, in one embodiment, to a protein comprising at least two heavy (H)
chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is sed of a heavy
chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH).
In certain antibodies, e.g., naturally occurring IgG antibodies, the heavy chain constant region is comprised of a
hinge and three s, CH1, CH2 and CH3. In certain antibodies, e.g., naturally occurring IgG antibodies,
each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain
constant region. The light chain constant region is comprised of one domain (abbreviated herein as CL). The VH
and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining
regions (CDR), persed with regions that are more conserved, termed framework regions (FR). Each VH
and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the
following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains
contain a binding domain that interacts with an n. The constant regions of the antibodies can mediate the
binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g.,
effector cells) and the first component (C1q) of the classical complement system. A heavy chain may have the
C-terminal lysine or not. Unless specified otherwise herein, the amino acids in the variable regions are
numbered using the Kabat numbering system and those in the constant regions are numbered using the EU
system.
An "IgG antibody", e.g., a human IgG1, IgG2, IgG3 and IgG4 antibody, as used herein has, in
certain embodiments, the structure of a naturally occurring IgG antibody, i.e., it has the same number of heavy
and light chains and disulfide bonds as a naturally occurring IgG antibody of the same subclass. For example, an
anti-TIM3 IgG1, IgG2, IgG3 or IgG4 dy consists of two heavy chains (HCs) and two light chains (LCs),
wherein the two heavy chains and light chains are linked by the same number and location of disulfide s
that occur in naturally occurring IgG1, IgG2, IgG3 and IgG4 antibodies, respectively (unless the antibody has
been mutated to modify the disulfide bridges).
dies typically bind specifically to their cognate antigen with high affinity, reflected by a
dissociation constant (KD) of 10-5 to 10-11 M or less. Any KD greater than about 10-4 M is generally considered to
indicate cific binding. As used , an antibody that "binds specifically" to an antigen refers to an
antibody that binds to the antigen and substantially identical antigens with high affinity, which means having a
KD of 10-7 M or less, 10-8 M or less, 5 x 10-9 M or less, or between 10-8 M and 10-10 M or less, but does not bind
with high affinity to unrelated antigens. An antigen is "substantially identical" to a given antigen if it exhibits a
high degree of sequence ty to the given n, for example, if it exhibits at least 80%, at least 90%, at
least 95%, at least 97%, or at least 99% sequence identity to the sequence of the given antigen. By way of
example, an antibody that binds specifically to human TIM3 can, in certain embodiments, also have crossreactivity
with TIM3 ns from certain primate species (e.g., cynomolgus TIM3), but cannot cross-react
with TIM3 antigens from other species or with an antigen other than TIM3.
An immunoglobulin can be from any of the commonly known isotypes, including but not limited
to IgA, secretory IgA, IgG and IgM. The IgG isotype is d in subclasses in certain species: IgG1, IgG2,
IgG3 and IgG4 in humans, and IgG1, IgG2a, IgG2b and IgG3 in mice. In certain embodiments, the anti-TIM3
antibodies described herein are of the IgG1 subtype. Immunoglobulins, e.g., IgG1, exist in several pes,
which differ from each other in at most a few amino acids. "Antibody" includes, by way of example, both
naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and
humanized dies; human and nonhuman antibodies and wholly synthetic antibodies.
The term "antigen-binding portion" of an antibody, as used herein, refers to one or more nts
of an antibody that retain the ability to specifically bind to an antigen (e.g., human TIM3). It has been shown
that the antigen-binding function of an antibody can be performed by fragments of a ength antibody.
Examples of binding fragments encompassed within the term "antigen-binding n" of an dy, e.g., an
anti-TIM3 antibody described herein, include (i) a Fab nt (fragment from papain cleavage) or a similar
monovalent fragment consisting of the VL, VH, LC and CH1 domains; (ii) a F(ab')2 fragment (fragment from
pepsin cleavage) or a similar bivalent fragment sing two Fab fragments linked by a disulfide bridge at the
hinge region; (iii) a Fd fragment ting of the VH and CH1 domains; (iv) a Fv fragment consisting of the
VL and VH domains of a single arm of an antibody, (v) a dAb nt (Ward et al., (1989) Nature 341:544-
546), which consists of a VH ; (vi) an isolated complementarity determining region (CDR) and (vii) a
combination of two or more isolated CDRs which can optionally be joined by a synthetic linker. Furthermore,
although the two domains of the Fv fragment, VL and VH, are coded for by te genes, they can be joined,
using recombinant s, by a synthetic linker that enables them to be made as a single protein chain in
which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g.,
Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).
Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of
an antibody. These antibody fragments are ed using conventional techniques known to those with skill in
the art, and the fragments are screened for utility in the same manner as are intact dies. Antigen-binding
portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact
immunoglobulins.
A cific" or "bifunctional antibody" is an artificial hybrid antibody having two different
heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of
s including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, Clin.
Exp. Immunol. 79:315-321 (1990); Kostelny et al., J. Immunol. 148, 1547-1553 (1992).
The term "monoclonal antibody," as used herein, refers to an antibody from a population of
substantially homogeneous antibodies, i.e., the individual antibodies comprised in the population are
substantially similar and bind the same epitope(s) (e.g., the antibodies display a single binding specificity and
affinity), except for possible variants that may arise during production of the monoclonal antibody, such variants
generally being present in minor amounts. The modifier "monoclonal" indicates the character of the antibody as
being obtained from a substantially homogeneous population of antibodies, and is not to be construed as
requiring production of the antibody by any ular method. The term "human monoclonal antibody" refers to
an antibody from a population of ntially homogeneous antibodies that display(s) a single binding
icity and which has variable and al constant regions derived from human germline immunoglobulin
sequences. In one embodiment, human monoclonal antibodies are produced by a hybridoma which includes a B
cell obtained from a transgenic non-human animal, e.g., a transgenic mouse, having a genome sing a
human heavy chain transgene and a light chain transgene fused to an immortalized cell.
The term "recombinant human antibody," as used herein, includes all human antibodies that are
prepared, expressed, created or isolated by recombinant means, such as (a) dies isolated from an animal
(e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma
prepared therefrom, (b) antibodies isolated from a host cell transformed to express the antibody, e.g., from a
transfectoma, (c) antibodies isolated from a inant, combinatorial human antibody library, and (d)
dies prepared, expressed, d or isolated by any other means that involve splicing of human
immunoglobulin gene sequences to other DNA sequences. Such inant human antibodies comprise
variable and constant regions that utilize particular human germline immunoglobulin ces are encoded by
the germline genes, but include subsequent rearrangements and mutations which occur, for example, during
antibody maturation. As known in the art (see, e.g., Lonberg (2005) Nature h. 23(9): 1117- 1125), the
variable region contains the antigen binding domain, which is encoded by various genes that rearrange to form
an antibody specific for a foreign antigen. In addition to rearrangement, the variable region can be further
modified by multiple single amino acid changes (referred to as somatic mutation or hypermutation) to increase
the ty of the antibody to the foreign antigen. The constant region will change in further response to an
antigen (i.e., isotype switch). Therefore, the nged and somatically mutated c acid molecules that
encode the light chain and heavy chain immunoglobulin polypeptides in response to an antigen cannot have
sequence identity with the original nucleic acid les, but instead will be substantially cal or similar
(i.e., have at least 80% ty).
A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the
framework and CDR s are derived from human germline immunoglobulin ces. Furthermore, if the
antibody contains a constant region, the constant region also is derived from human germline immunoglobulin
sequences. The anti-TIM3 antibodies described herein can include amino acid residues not encoded by human
germline globulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro
or by somatic mutation in vivo). However, the term "human antibody", as used herein, is not intended to include
antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse,
have been d onto human framework sequences. The terms "human" antibodies and "fully human"
antibodies are used synonymously.
A "humanized" antibody refers to an dy in which some, most or all of the amino acids
outside the CDR s of a non-human antibody are replaced with corresponding amino acids derived from
human immunoglobulins. In one embodiment of a humanized form of an antibody, some, most or all of the
amino acids outside the CDR domains have been ed with amino acids from human immunoglobulins,
whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions,
deletions, ions, substitutions or modifications of amino acids are permissible as long as they do not
abrogate the ability of the antibody to bind to a particular antigen. A "humanized" antibody retains an antigenic
specificity similar to that of the original antibody.
A "chimeric antibody" refers to an antibody in which the variable regions are derived from one
species and the constant regions are derived from another s, such as an antibody in which the variable
regions are derived from a mouse antibody and the constant regions are derived from a human dy.
As used , "isotype" refers to the antibody class (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgAl,
IgA2, IgD, and IgE antibody) that is encoded by the heavy chain constant region genes.
"Allotype" refers to naturally occurring ts within a specific isotype group, which variants
differ in a few amino acids (see, e.g., Jefferis et al. (2009) mAbs 1:1). Anti-TIM3 antibodies described herein
can be of any allotype. As used herein, antibodies referred to as ," "IgG1.1f," or "IgG1.3f" isotype are
IgG1, effectorless IgG1.1, and effectorless IgG1.3 antibodies, respectively, of the allotype "f," i.e., having 214R,
356E and 358M according to the EU index as in Kabat, as shown, e.g., in SEQ ID NO: 3.
The phrases "an antibody recognizing an antigen" and "an antibody specific for an n" are
used interchangeably herein with the term "an antibody which binds ically to an antigen."
An "isolated antibody," as used herein, is intended to refer to an antibody which is substantially
free of other proteins and cellular material.
As used herein, an dy that "inhibits binding of TIM3-L to TIM3" is intended to refer to an
antibody that inhibits the binding of TIM3 to its ligand, e.g., phosphatidylserine, e.g., in binding assays using
CHO cells transfected with human TIM3 or TIM3 expressing activated T cells, with an EC50 of about 1 μg/mL
or less, such as about 0.9 μg/mL or less, about 0.85 μg/mL or less, about 0.8 μg/mL or less, about 0.75 μg/mL or
less, about 0.7 μg/mL or less, about 0.65 μg/mL or less, about 0.6 μg/mL or less, about 0.55 μg/mL or less,
about 0.5 μg/mL or less, about 0.45 μg/mL or less, about 0.4 μg/mL or less, about 0.35 μg/mL or less, about 0.3
μg/mL or less, about 0.25 μg/mL or less, about 0.2 μg/mL or less, about 0.15 μg/mL or less, about 0.1 μg/mL or
less, or about 0.05 µg/mL or less, in art-recognized methods, e.g., the FACS-based binding assays described
herein.
An "effector on" refers to the interaction of an antibody Fc region with an Fc receptor or
ligand, or a biochemical event that results therefrom. Exemplary "effector functions" include C1q binding,
complement dependent cytotoxicity (CDC), Fc receptor g, FcγR-mediated effector functions such as
ADCC and antibody dependent cell-mediated phagocytosis (ADCP), and downregulation of a cell surface
or (e.g., the B cell receptor; BCR). Such effector functions generally require the Fc region to be combined
with a binding domain (e.g., an antibody le domain).
An "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs
that bind to an IgG antibody comprise receptors of the FcγR family, including allelic ts and alternatively
spliced forms of these receptors. The FcγR family consists of three activating (FcγRI, FcγRIII, and FcγRIV in
mice; FcγRIA, A, and FcγRIIIA in humans) and one inhibitory (FcγRIIB) receptor. Various properties of
human FcγRs are known in the art. The majority of innate effector cell types coexpress one or more ting
FcγR and the inhibitory FcγRIIB, s natural killer (NK) cells selectively express one activating Fc
receptor (FcγRIII in mice and FcγRIIIA in humans) but not the inhibitory FcγRIIB in mice and humans. Human
IgG1 binds to most human Fc receptors and is considered equivalent to murine IgG2a with respect to the types
of activating Fc receptors that it binds to.
An "Fc region" (fragment llizable region) or "Fc domain" or "Fc" refers to the C-terminal
region of the heavy chain of an antibody that mediates the binding of the immunoglobulin to host s or
factors, including binding to Fc receptors located on various cells of the immune system (e.g., or cells) or
to the first component (C1q) of the classical complement system. Thus, an Fc region ses the constant
region of an antibody excluding the first constant region immunoglobulin domain (e.g., CH1 or CL). In IgG,
IgA and IgD antibody isotypes, the Fc region comprises two identical protein fragments, derived from the
second (CH2) and third (CH3) constant domains of the antibody's two heavy chains; IgM and IgE Fc regions
comprise three heavy chain constant domains (CH domains 2-4) in each ptide chain. For IgG, the Fc
region ses immunoglobulin domains CH2 and CH3 and the hinge between CH1 and CH2 domains.
Although the definition of the boundaries of the Fc region of an immunoglobulin heavy chain might vary, as
defined herein, the human IgG heavy chain Fc region is defined to stretch from an amino acid residue D221 for
IgG1, V222 for IgG2, L221 for IgG3 and P224 for IgG4 to the carboxy-terminus of the heavy chain, wherein
the ing is according to the EU index as in Kabat. The CH2 domain of a human IgG Fc region extends
from amino acid 237 to amino acid 340, and the CH3 domain is positioned on C-terminal side of a CH2 domain
in an Fc region, i.e., it extends from amino acid 341 to amino acid 447 or 446 (if the C-terminal lysine residue is
) or 445 (if the C-terminal glycine and lysine residues are absent) of an IgG. As used herein, the Fc region
can be a native sequence Fc, including any allotypic variant, or a variant Fc (e.g., a non-naturally ing Fc).
Fc can also refer to this region in isolation or in the context of an Fc-comprising protein polypeptide such as a
"binding protein comprising an Fc region," also referred to as an "Fc fusion protein" (e.g., an antibody or
immunoadhesion).
A "native sequence Fc region" or "native sequence Fc" ses an amino acid sequence that is
identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc s include
a native sequence human IgG1 Fc region; native ce human IgG2 Fc region; native sequence human IgG3
Fc region; and native sequence human IgG4 Fc region as well as lly occurring ts thereof. Native
sequence Fc include the various allotypes of Fcs (see, e.g., Jefferis et al. (2009) mAbs 1: 1).
The term "epitope" or "antigenic determinant" refers to a site on an antigen (e.g., TIM3) to which
an immunoglobulin or antibody specifically binds, e.g., as defined by the specific method used to identify it.
Epitopes can be formed both from contiguous amino acids (usually a linear epitope) or noncontiguous amino
acids juxtaposed by tertiary folding of a protein (usually a conformational epitope). Epitopes formed from
contiguous amino acids are typically, but not always, retained on re to denaturing solvents, whereas
epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope lly
includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation.
Methods for determining what epitopes are bound by a given dy (i.e., epitope mapping) are well known in
the art and include, for e, immunoblotting and immunoprecipitation , n overlapping or
contiguous peptides from (e.g., from TIM3) are tested for reactivity with a given antibody (e.g., anti-TIM3
dy). Methods of determining spatial conformation of epitopes include techniques in the art and those
bed herein, for example, x-ray crystallography, antigen mutational analysis, 2-dimensional nuclear
magnetic resonance and HDX-MS (see, e.g., Epitope Mapping Protocols in Methods in lar Biology, Vol.
66, G. E. Morris, Ed. (1996)).
The term "epitope mapping" refers to the process of identification of the molecular determinants
for antibody-antigen recognition.
The term "binds to the same epitope" with reference to two or more antibodies means that the
antibodies bind to the same segment of amino acid residues, as determined by a given method. Techniques for
determining whether antibodies bind to the "same epitope on TIM3" with the antibodies described herein
include, for example, epitope mapping methods, such as, x-ray analyses of ls of antigen:antibody
complexes which provides atomic resolution of the epitope and hydrogen/deuterium ge mass
spectrometry (HDX-MS). Other methods monitor the binding of the antibody to antigen nts or mutated
variations of the antigen where loss of binding due to a modification of an amino acid residue within the antigen
sequence is often considered an indication of an e component. In addition, computational combinatorial
methods for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to
affinity isolate specific short peptides from combinatorial phage display peptide libraries. Antibodies having the
same VH and VL or the same CDR1, 2 and 3 sequences are expected to bind to the same epitope.
Antibodies that "compete with r antibody for binding to a target" refer to antibodies that
inhibit (partially or completely) the binding of the other antibody to the target. Whether two antibodies compete
with each other for g to a target, i.e., whether and to what extent one dy inhibits the binding of the
other antibody to a target, can be determined using known ition experiments, e.g., BIACORE® surface
plasmon resonance (SPR) analysis. In certain embodiments, an antibody competes with, and inhibits binding of
another antibody to a target by at least 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or
competition can be different depending on which antibody is the "blocking antibody" (i.e., the cold dy that
is incubated first with the ). Competition assays can be conducted as described, for example, in Ed Harlow
and David Lane, Cold Spring Harb Protoc ; 2006; doi: 10.1101/pdb.prot4277 or in r 11 of "Using
Antibodies" by Ed Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY,
USA 1999. Two antibodies "cross-compete" if antibodies block each other both ways by at least 50%, i.e.,
regardless of whether one or the other antibody is contacted first with the antigen in the competition experiment.
Competitive binding assays for determining whether two dies compete or cross-compete for
binding include: ition for binding to T cells expressing TIM3, e.g., by flow cytometry, such as described
in the Examples. Other methods include: SPR (e.g., BIACORE®), solid phase direct or indirect
mmunoassay (RIA), solid phase direct or ct enzyme immunoassay (EIA), sandwich ition
assay (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid phase direct -avidin EIA (see
Kirkland et al., J. Immunol. 137:3614 (1986)); solid phase direct labeled assay, solid phase direct labeled
sandwich assay (see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988));
solid phase direct label RIA using 1-125 label (see Morel et al., Mol. Immunol. 7 (1988)); solid phase
direct biotin-avidin EIA (Cheung et al., Virology 176:546 (1990)); and direct d RIA. (Moldenhauer et al.,
Scand. J. Immunol. 32:77 (1990)).
As used herein, the terms "specific binding," "selective binding," "selectively binds," and
"specifically binds," refer to antibody binding to an epitope on a predetermined antigen. Typically, the antibody
(i) binds with an equilibrium dissociation constant (KD) of approximately less than 10-7 M, such as
approximately less than 10-8 M, 10-9 M or 10-10 M or even lower when determined by, e.g., surface plasmon
resonance (SPR) technology in a BIACORE® 2000 instrument using the predetermined antigen, e.g.,
recombinant human TIM3, as the analyte and the antibody as the ligand, or Scatchard is of binding of the
antibody to antigen positive cells, and (ii) binds to the predetermined antigen with an ty that is at least twofold
greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the
predetermined antigen or a closely-related antigen. Accordingly, an antibody that "specifically binds to human
TIM3" refers to an antibody that binds to soluble or cell bound human TIM3 with a KD of 10-7 M or less, such as
approximately less than 10-8 M, 10-9 M or 10-10 M or even lower. An dy that "cross-reacts with
cynomolgus TIM3" refers to an antibody that binds to cynomolgus TIM3 with a KD of 10-7 M or less, such as
approximately less than 10-8 M, 10-9 M or 10-10 M or even lower. In certain embodiments, such antibodies that do
not cross-react with TIM3 from a non-human species exhibit essentially undetectable binding t these
proteins in standard binding assays.
The term "kassoc" or "ka", as used herein, is intended to refer to the association rate of a particular
antibody- antigen interaction, whereas the term "kdis" or "kd," as used herein, is intended to refer to the
iation rate of a particular antibody-antigen interaction. The term "KD", as used herein, is intended to refer
to the dissociation constant, which is obtained from the ratio of kd to ka (i.e,. kd/ka) and is expressed as a molar
tration (M). KD values for antibodies can be determined using methods well established in the art.
Available methods for determining the KD of an antibody include surface n resonance, a sor
system such as a BIACORE® system or flow cytometry and ard analysis.
As used herein, the term "high affinity" for an IgG antibody refers to an antibody having a KD of
-8 M or less, 10-9 M or less, or 10-10 M or less for a target antigen. However, "high affinity" binding can vary
for other antibody isotypes. For example, "high affinity" binding for an IgM isotype refers to an antibody having
a KD of 10-10 M or less, or 10-8 M or less.
The term "EC50" in the context of an in vitro or in vivo assay using an antibody or antigen binding
fragment thereof, refers to the concentration of an antibody or an antigen-binding portion thereof that induces a
response that is 50% of the maximal response, i.e., halfway between the maximal response and the baseline.
The term "naturally-occurring" as used herein as applied to an object refers to the fact that an
object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an
organism (including s) that can be isolated from a source in nature and which has not been intentionally
modified by man in the laboratory is lly- occurring.
A "polypeptide" refers to a chain comprising at least two consecutively linked amino acid residues,
with no upper limit on the length of the chain. One or more amino acid residues in the protein can contain a
modification such as, but not limited to, ylation, phosphorylation or disulfide bond formation. A in"
can comprise one or more polypeptides.
The term "nucleic acid molecule," as used herein, is intended to include DNA molecules and RNA
molecules. A nucleic acid molecule can be single- stranded or double- ed, and can be cDNA.
"Conservative amino acid substitutions" refer to substitutions of an amino acid residue with an
amino acid residue having a similar side chain. Families of amino acid residues having r side chains have
been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic acid), ged polar side chains (e.g., glycine,
gine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine,
, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine,
valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In certain
embodiments, a predicted nonessential amino acid residue in an anti-TIM3 antibody is replaced with another
amino acid e from the same side chain family. Methods of identifying nucleotide and amino acid
vative substitutions which do not eliminate antigen binding are well-known in the art (see, e.g., Brummell
et al., m. 32: 1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999); and Burks et al.
Proc. Natl. Acad. Sci. USA 94:412-417 (1997)).
For c acids, the term "substantial gy" indicates that two nucleic acids, or designated
sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or
deletions, in at least about 80% of the nucleotides, at least about 90% to 95%, or at least about 98% to 99.5% of
the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective
hybridization conditions, to the ment of the strand.
For polypeptides, the term "substantial homology" tes that two polypeptides, or designated
sequences thereof, when optimally aligned and compared, are cal, with appropriate amino acid insertions
or deletions, in at least about 80% of the amino acids, at least about 90% to 95%, or at least about 98% to 99.5%
of the amino acids.
The percent identity between two sequences is a function of the number of identical positions
shared by the ces (i.e., % homology = # of identical positions/total # of positions x 100), taking into
account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of
the two sequences. The comparison of sequences and determination of percent ty between two sequences
can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
The percent identity n two tide sequences can be determined using the GAP m
in the GCG software package (available at worldwideweb.gcg.com), using a NWSgapdna.CMP matrix and a
gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between two
nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller
(CABIOS, 4: 11-17 (1989)) which has been incorporated into the ALIGN m (version 2.0), using a
PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity
n two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 44-
453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package
(available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of
16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
The nucleic acid and protein sequences described herein can further be used as a "query sequence"
to perform a search against public databases to, for example, fy related sequences. Such searches can be
performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.
215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength
= 12 to obtain nucleotide ces homologous to the nucleic acid molecules described . BLAST protein
searches can be performed with the XBLAST m, score = 50, wordlength = 3 to obtain amino acid
sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison
purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res.
(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the
respective ms (e.g., XBLAST and NBLAST) can be used. See worldwideweb.ncbi.nlm.nih.gov.
The nucleic acids can be present in whole cells, in a cell lysate, or in a partially purified or
substantially pure form. A nucleic acid is "isolated" or "rendered substantially pure" when purified away from
other cellular components or other contaminants, e.g., other cellular nucleic acids (e.g., the other parts of the
chromosome) or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column
chromatography, e gel electrophoresis and others well known in the art. See, F. l, et al., ed.
t Protocols in Molecular Biology, Greene Publishing and Wiley cience, New York (1987).
Nucleic acids, e.g., cDNA, can be mutated, in accordance with standard techniques to provide gene
sequences. For coding sequences, these mutations, can affect amino acid sequence as desired. In particular,
DNA sequences substantially homologous to or d from native V, D, J, constant, switches and other such
sequences described herein are contemplated (where ed" indicates that a sequence is identical or modified
from another sequence).
The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of
transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid," which refers to a
circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector
is a viral vector, wherein onal DNA segments can be d into the viral genome. Certain vectors are
e of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a
bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g.,non-episomal mammalian
vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are
replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of
genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression
vectors" (or simply, ssion s") In general, expression vectors of utility in inant DNA
techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used
interchangeably as the plasmid is the most commonly used form of vector. r, also included are other
forms of sion vectors, such as viral s (e.g., replication defective retroviruses, adenoviruses and
adeno-associated viruses), which serve equivalent functions.
The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a
cell that comprises a nucleic acid that is not naturally present in the cell, and can be a cell into which a
recombinant expression vector has been introduced. It should be understood that such terms are intended to refer
not only to the particular subject cell but to the progeny of such a cell. Because certain modifications can occur
in succeeding generations due to either mutation or environmental influences, such progeny , in fact, be
identical to the parent cell, but are still included within the scope of the term "host cell" as used .
An "immune response" is as understood in the art, and generally refers to a biological response
within a vertebrate against foreign agents or abnormal, e.g., cancerous cells, which response protects the
organism against these agents and diseases caused by them. An immune response is mediated by the action of
one or more cells of the immune system (for example, a T lymphocyte, B lymphocyte, natural killer (NK) cell,
hage, eosinophil, mast cell, dendritic cell or neutrophil) and soluble macromolecules produced by any of
these cells or the liver (including antibodies, cytokines, and complement) that results in selective targeting,
binding to, damage to, destruction of, and/or elimination from the vertebrate's body of invading pathogens, cells
or tissues infected with ens, cancerous or other abnormal cells, or, in cases of munity or
pathological inflammation, normal human cells or tissues. An immune reaction includes, e.g., tion or
inhibition of a T cell, e.g., an effector T cell, a Th cell, a CD4+ cell, a CD8+ T cell, or a Treg cell, or activation
or inhibition of any other cell of the immune system, e.g., NK cell.
An "immunomodulator" or oregulator" refers to an agent, e.g., an agent targeting a
component of a signaling pathway that can be involved in modulating, regulating, or modifying an immune
response. "Modulating," "regulating," or "modifying" an immune se refers to any alteration in a cell of the
immune system or in the activity of such cell (e.g., an effector T cell, such as a Th1 cell). Such modulation
includes stimulation or suppression of the immune system which can be manifested by an increase or decrease
in the number of various cell types, an increase or decrease in the activity of these cells, or any other changes
which can occur within the immune system. Both inhibitory and stimulatory immunomodulators have been
identified, some of which can have enhanced function in a tumor nvironment. In some embodiments, the
immunomodulator targets a molecule on the surface of a T cell. An "immunomodulatory target" or
"immunoregulatory target" is a molecule, e.g., a cell surface molecule, that is targeted for binding by, and whose
activity is altered by the binding of, a substance, agent, moiety, nd or molecule. Immunomodulatory
targets include, for example, receptors on the surface of a cell nomodulatory ors") and receptor
ligands ("immunomodulatory ligands").
"Immunotherapy" refers to the treatment of a subject afflicted with, or at risk of contracting or
suffering a recurrence of, a disease by a method comprising inducing, enhancing, suppressing or otherwise
modifying the immune system or an immune response.
"Immuno stimulating therapy" or "immuno stimulatory y" refers to a therapy that results in
increasing ing or enhancing) an immune response in a subject for, e.g., treating cancer.
"Potentiating an endogenous immune response" means increasing the effectiveness or potency of
an existing immune response in a subject. This se in effectiveness and potency can be achieved, for
example, by overcoming mechanisms that suppress the endogenous host immune response or by stimulating
mechanisms that enhance the endogenous host immune response.
"T effector" ("Teff") cells refers to T cells (e.g., CD4+ and CD8+ T cells) with cytolytic activities
as well as T helper (Th) cells, e.g., Th1 cells, which cells secrete cytokines and activate and direct other immune
cells, but does not include regulatory T cells (Treg cells). Certain anti-TIM3 antibodies described herein activate
Teff cells, e.g., CD4+ and CD8+ Teff cells and Th1 cells.
An increased y to stimulate an immune response or the immune system, can result from an
enhanced agonist activity of T cell co-stimulatory receptors and/or an enhanced antagonist activity of inhibitory
receptors. An increased ability to stimulate an immune response or the immune system can be reflected by a fold
increase of the EC50 or l level of activity in an assay that measures an immune response, e.g., an assay
that measures changes in cytokine or chemokine release, cytolytic activity (determined directly on target cells or
indirectly via detecting CD107a or granzymes) and proliferation. The y to stimulate an immune response or
the immune system activity can be enhanced by at least 10%, 30%, 50%, 75%, 2 fold, 3 fold, 5 fold or more.
As used herein, the term "linked" refers to the association of two or more molecules. The e
can be covalent or non-covalent. The linkage also can be genetic (i.e., inantly fused). Such es can
be achieved using a wide variety of art recognized techniques, such as chemical ation and inant
protein production.
As used herein, istering" refers to the physical uction of a composition comprising a
therapeutic agent to a subject, using any of the various methods and delivery systems known to those skilled in
the art. Different routes of administration for the anti-TIM3 antibodies described herein e enous,
intraperitoneal, intramuscular, subcutaneous, spinal or other eral routes of administration, for example by
injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and includes, without limitation, enous,
intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital,
intracardiac, ermal, transtracheal, subcutaneous, subcuticular, rticular, subcapsular, subarachnoid,
pinal, epidural and ternal injection and infusion, as well as in vivo electroporation. Alternatively, an
antibody described herein can be administered via a non-parenteral route, such as a topical, epidermal or
mucosal route of stration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.
Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended
periods.
As used herein, the term "T cell-mediated response" refers to a response mediated by T cells,
including effector T cells (e.g., CD8+ cells) and helper T cells (e.g., CD4+ cells). T cell mediated responses
include, for example, T cell cytotoxicity and proliferation.
As used herein, the term "cytotoxic T lymphocyte (CTL) response" refers to an immune response
induced by cytotoxic T cells. CTL responses are mediated primarily by CD8+ T cells.
As used herein, the terms "inhibits" or "blocks" (e.g., referring to inhibition/blocking of binding of
TIM3-L to TIM3 on cells) are used interchangeably and encompass both partial and complete
inhibition/blocking. In some embodiments, the anti-TIM3 antibody ts binding of TIM3-L to TIM3 by at
least about 50%, for example, about 60%, 70%, 80%, 90%, 95%, 99%, or 100%, determined, e.g., as further
described herein. In some embodiments, the anti-TIM3 antibody inhibits binding of TIM3-L to TIM3 by no
more than 50%, for example, by about 40%, 30%, 20%, 10%, 5% or 1%, determined, e.g., as further bed
herein.
As used , the phrase "inhibits growth of a tumor" includes any measurable decrease in the
growth of a tumor, e.g., , the inhibition of growth of a tumor by at least about 10%, for example, at least about
%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least
about 80%, at least about 90%, at least about 99%, or 100%.
As used herein, "cancer" refers a broad group of diseases characterized by the uncontrolled growth
of abnormal cells in the body. Unregulated cell division can result in the formation of malignant tumors or cells
that invade neighboring tissues and can metastasize to distant parts of the body through the lymphatic system or
bloodstream.
The terms "treat," "treating," and "treatment," as used , refer to any type of intervention or
process performed on, or administering an active agent to, the subject with the objective of reversing,
alleviating, ameliorating, inhibiting, or slowing down or preventing the progression, pment, severity or
recurrence of a symptom, complication, condition or biochemical indicia ated with a disease or enhancing
overall al. ent can be of a subject having a disease or a subject who does not have a disease (e.g.,
for prophylaxis).
A "hematological malignancy" es a lymphoma, leukemia, myeloma or a lymphoid
malignancy, as well as a cancer of the spleen and the lymph nodes. Exemplary lymphomas include both B cell
mas (a B-cell hematological cancer) and T cell lymphomas. B-cell lymphomas include both Hodgkin's
lymphomas and most non-Hodgkin's lymphomas. Non-limiting examples of B cell mas include e
large B-cell lymphoma, follicular lymphoma, mucosa-associated tic tissue lymphoma, small cell
lymphocytic lymphoma aps with chronic lymphocytic leukemia), mantle cell lymphoma (MCL), Burkitt's
lymphoma, mediastinal large B cell lymphoma, Waldenstrom macroglobulinemia, nodal marginal zone B cell
lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion
lymphoma, lymphomatoid granulomatosis. Non-limiting examples of T cell mas include extranodal T
cell lymphoma, cutaneous T cell lymphomas, anaplastic large cell lymphoma, and angioimmunoblastic T cell
lymphoma. Hematological malignancies also e leukemia, such as, but not limited to, secondary leukemia,
chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and acute
lymphoblastic leukemia. Hematological malignancies further include myelomas, such as, but not limited to,
multiple a and smoldering multiple myeloma. Other hematological and/or B cell- or T-cell-associated
s are encompassed by the term hematological ancy.
The term "effective dose" or "effective dosage" is defined as an amount sufficient to achieve or at
least partially achieve a desired . A "therapeutically effective " or "therapeutically effective
dosage" of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with
r therapeutic agent, promotes disease regression evidenced by a decrease in severity of disease ms,
an increase in frequency and duration of disease m-free periods, or a prevention of impairment or
disability due to the disease affliction. A therapeutically effective amount or dosage of a drug includes a
"prophylactically ive amount" or a "prophylactically effective dosage", which is any amount of the drug
that, when stered alone or in combination with another therapeutic agent to a subject at risk of developing
a disease or of suffering a recurrence of disease, inhibits the development or recurrence of the disease. The
ability of a therapeutic agent to promote disease regression or inhibit the pment or recurrence of the
disease can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects
during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the ty of
the agent in in vitro assays.
By way of example, an anti-cancer agent is a drug that promotes cancer regression in a subject. In
some embodiments, a therapeutically effective amount of the drug promotes cancer regression to the point of
eliminating the cancer. "Promoting cancer regression" means that administering an effective amount of the drug,
alone or in combination with an antineoplastic agent, results in a reduction in tumor growth or size, necrosis of
the tumor, a decrease in severity of at least one disease symptom, an increase in ncy and duration of
disease symptom-free periods, a prevention of impairment or disability due to the disease affliction, or ise
ration of disease symptoms in the patient. In addition, the terms "effective" and "effectiveness" with
regard to a treatment includes both pharmacological effectiveness and physiological safety. Pharmacological
effectiveness refers to the ability of the drug to promote cancer regression in the t. Physiological safety
refers to the level of toxicity, or other adverse physiological s at the cellular, organ and/or organism level
(adverse s) resulting from administration of the drug.
By way of example for the treatment of tumors, a therapeutically effective amount or dosage of the
drug ts cell growth or tumor growth by at least about 20%, by at least about 40%, by at least about 60%, or
by at least about 80% relative to untreated subjects. In some embodiments, a therapeutically ive amount or
dosage of the drug completely inhibits cell growth or tumor growth, i.e., inhibits cell growth or tumor growth by
100%. The y of a compound to inhibit tumor growth can be evaluated using the assays described infra.
Alternatively, this property of a ition can be evaluated by examining the ability of the compound to
inhibit cell growth, such inhibition can be measured in vitro by assays known to the d practitioner. In other
embodiments described , tumor regression can be observed and continue for a period of at least about 20
days, at least about 40 days, or at least about 60 days.
The term "patient" includes human and other mammalian subjects that receive either prophylactic
or therapeutic treatment.
As used herein, the term "subject" includes any human or non-human animal. For e, the
methods and compositions described herein can be used to treat a subject having cancer. The term "non-human
animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog,
cow, chickens, amphibians, reptiles, etc.
The term "weight based" dose or dosing as referred to herein means that a dose that is administered
to a patient is calculated based on the weight of the patient. For example, when a patient with 60 kg body weight
requires 3 mg/kg of an IM3 antibody, one can calculate and use the appropriate amount of the anti-TIM3
antibody (i.e., 180 mg) for administration.
The use of the term "fixed dose" with regard to a method of the sure means that two or more
different antibodies in a single composition (e.g., anti-TIM3 antibody and a second antibody, e.g., a PD-1 or
PD-L1 antibody) are present in the composition in ular (fixed) ratios with each other. In some
ments, the fixed dose is based on the weight (e.g., mg) of the antibodies. In certain embodiments, the
fixed dose is based on the concentration (e.g., mg/ml) of the antibodies. In some embodiments, the ratio of the
two dies (e.g., anti-TIM3 and anti-PD1 or anti-PD-L1) is at least about 1:1, about 1:2, about 1:3, about
1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about
1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about
1:160, about 1:180, about 1:200, about 200:1, about 180:1, about 160:1, about 140:1, about 120:1, about 100:1,
about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about
:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, or about 2:1 mg first antibody
(e.g., anti-TIM3 antibody) to mg second antibody. For example, a 2:1 ratio of an anti-TIM3 antibody and a PD-1
antibody, such as nivolumab, can mean that a vial or an injection can contain about 480 mg of the anti-TIM3
antibody and 240 mg of the anti-PD-1 antibody, or about 2 mg/ml of the IM3 dy and 1 mg/ml of the
anti-PD-1 antibody.
The use of the term "flat dose" with regard to the methods and dosages described herein means a
dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient.
The flat dose is ore not provided as a mg/kg dose, but rather as an absolute amount of the agent (e.g., the
anti-TIM3 antibody). For example, a 60 kg person and a 100 kg person would e the same dose of an
antibody (e.g., 480 mg of an anti-TIM3 antibody).
As used herein, the terms "ug" and "uM" are used interchangeably with "μg" and "μΜ,"
respectively.
Various aspects described herein are described in r detail in the following subsections.
I. Anti-human TIM3 dies
Described herein are antibodies, e.g., fully human antibodies, which are characterized by particular
functional features or properties. For example, the antibodies specifically bind human TIM3, and more
specifically, a particular domain (e.g., a functional domain) within the extracellular domain of human TIM3. In
a particular embodiment, the antibodies specifically bind to the site on TIM3 to which TIM3-L binds. In n
ments, the antibodies are antagonist antibodies, i.e., they inhibit or suppress the T cell inhibitory activity
of TIM3 on cells, e.g., T cells. In certain embodiments, anti-TIM3 antibodies cross-react with TIM3 from one or
more non-human primates, such as cynomolgus TIM3. In certain embodiments, the antibodies specifically bind
to the extracellular region of human TIM3 and the extracellular region of cynomolgus TIM3. In one
embodiment, the antibodies bind to human TIM3 with high affinity.
Anti-TIM3 antibodies bed herein exhibit one or more of the following functional properties:
(a) binding to soluble and/or membrane bound human TIM3;
(b) binding to soluble and/or membrane bound cyno TIM3;
(c) inducing or stimulating an immune response;
(d) inducing or stimulating T cell activation, e.g., Th1 cell activation (as evidenced, e.g., by enhanced cytokine
ion and/or proliferation);
(e) inducing or stimulating T cell proliferation (e.g., CD4+, CD8+ T cells, Th1 cells, or TILs), e.g., in a
coculture assay, such as bed in the Examples;
(f) inducing or stimulating IFN-γ production by T cells, e.g., Th1 cells or tumor infiltrating lymphocytes (TILs),
such as TILs from human renal, lung, pancreatic, or breast cancer tumors, as determined, e.g., in the assay
described in the Examples;
(g) blocking or inhibiting the binding of human TIM3 to PtdSer, as determined, e.g., in the assay described in
the es;
(h) not internalizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(i) binding to human TIM3 extracellular domain (i) CPVFECG (SEQ ID NO: 296); (ii) RIQIPGIMND (SEQ ID
NO: 298); (iii) CPVFECG and RIQIPGIMND (SEQ ID NOs: 296 and 298, respectively); or (iv)
WTSRYWLNGDFR (SEQ ID NO: 297);
(j) competing with, or cross-blocking, the binding to human TIM3 of an antibody binding to TIM3 described
herein (e.g., 13A3, 3G4, 17C3, 17C8, 9F6, or any of TIM3.2 to TIM3.18), as determined, e.g., in the assay
described in the Examples;
(k) binding to human TIM3, but not to human TIM3 having an amino acid substitution of one or more of the
following amino acid residues: L48, C58, P59, V60, F61, E62, C63, G64, W78, S80, R81, W83, L84, G86, D87,
R89, D104, R111, Q113, G116, M118, and D120, as numbered in SEQ ID NO: 286 (); and
(l) binding to human TIM3 s 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
IPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS;
(m) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray llography; and/or
(n) competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
bed in the Examples.
In some embodiments, anti-TIM3 antibodies described herein bind to human TIM3 with high
affinity, for example, with a KD of 10-7 M or less, 10-8 M or less, 10-9 M or less, 10-10 M or less, 10-11 M or less,
-12 M or less, 10-12 M to 10-7 M, 10-11 M to 10-7 M, 10-10 M to 10-7 M, or 10-9 M to 10-7 M. In certain
ments, an anti-TIM3 antibody binds to soluble human TIM3, e.g., as determined by BIACORE™ (e.g.,
as described in the es), with a KD of 10-7 M or less, 10-8 M or less, 10-9 M (1 nM) or less, 10-10 M or less,
-12 M to 10-7 M, 10-11 M to 10-7 M, 10-10 M to 10-7 M, 10-9 M to 10-7 M, or 10-8 M to 10-7 M. In certain
embodiments, an anti-TIM3 antibody binds to bound (e.g., cell membrane bound) human TIM3, such as on
activated human T cells, e.g., as ined by flow cytometry and Scatchard plot, with a KD of 10-7 M or less,
-8 M or less, 10-9 M (1 nM) or less, 0 M or less, 10-10 M or less, 10-12 M to 10-7 M, 10-11 M to 10-8 M, 10-10
M to 10-8 M, 10-9 M to 10-8 M, 10-11 M to 10-9 M, or 10-10 M to 10-9 M. In certain embodiments, an anti-TIM3
antibody binds to bound (e.g., cell membrane bound) human TIM3, such as on activated human T cells, e.g., as
determined by flow cytometry, with an EC50 of 10 ug/mL or less, 5 ug/mL or less, 1 ug/mL or less, 0.9 ug/mL or
less, 0.8 ug/mL or less, 0.7 ug/mL or less, 0.6 ug/mL or less, 0.5 ug/mL or less, 0.4 ug/mL or less, 0.3 ug/mL or
less, 0.2 ug/mL or less, 0.1 ug/mL or less, 0.05 ug/mL or less, or 0.01 ug/mL or less. In some embodiments,
anti-TIM3 antibodies described herein bind to cyno TIM3, for example, with a KD of 10-7 M or less, 10-8 M or
less, 10-9 M or less, 10-10 M or less, 10-11 M or less, 10-12 M or less, 10-12 M to 10-7 M, 10-11 M to 10-7 M, 10-10M
to 10-7 M, or 10-9 M to 10-7 M. In n embodiments, an anti-TIM3 antibody binds to soluble cyno TIM3, e.g.,
as determined by BIACORE™ (e.g., as described in the Examples), with a KD of 10-7 M or less, 10-8 M or less,
-9 M (1 nM) or less, 10-10 M or less, 10-12 M to 10-7 M, 10-11 M to 10-7 M, 10-10 M to 10-7 M, 10-9 M to 10-7 M, or
-8 M to 10-7 M. Anti-TIM3 antibodies can bind to membrane bound cynomolgus TIM3, e.g., with an EC50 of
100 nM or less, 10 nM or less, 100 nM to 0.01 nM, 100 nM to 0.1 nM, 100 nM to 1 nM, or 10 nM to 1 nM, e.g.,
as measured by flow cytometry (e.g., as described in the Examples). In certain ments, an anti-TIM3
antibody binds to bound (e.g., cell membrane bound) cyno TIM3, such as on activated human T cells, e.g., as
determined by flow cytometry and ard plot, with a KD of 10-7 M or less, 10-8 M or less, 10-9 M (1 nM) or
less, 0 M or less, 10-10 M or less, 10-12 M to 10-7 M, 10-11 M to 10-8 M, 10-10 M to 10-8 M, 10-9 M to 10-8 M,
-11 M to 10-9 M, or 10-10 M to 10-9 M.
In certain embodiments, anti-TIM3 dies described herein stimulate or enhance an immune
response, e.g., by activating T cells, e.g., in the tumor. For example, the anti-TIM3 antibodies can activate or
costimulate cells, as evidenced, e.g., by enhanced cytokine (e.g., IFN-γ) secretion and/or enhanced proliferation,
which may result from the inhibition of TIM3 mediated T cell inhibitory activity. In certain embodiments, T cell
activation or mulation by a TIM3 antibody occurs in the presence of CD3 stimulation. In certain
embodiments, an anti-TIM3 antibody increases IFN-γ secretion by a factor of 50%, 100% (i.e., 2 fold), 3 fold, 4
fold, 5 fold or more, optionally with a maximum of up to 10 fold, 30 fold, 100 fold, as measured, e.g., on
primary human T cells and/or T cells expressing human TIM3, such as tumor infiltrating lymphocytes (TILs).
In certain embodiments, anti-TIM3 antibodies inhibit binding of phosphatidylserine to human
TIM3 on cells, e.g., CHO cells or activated T cells sing human TIM3, e.g., with an EC50 of 10 μg/ml or
less, 1 μg/ml or less, 0.01 μg/ml to 10 μg/ml, 0.1 μg/ml to 10 μg/ml, or 0.1 μg/ml to 1 μg/ml.
In certain embodiments, anti-TIM3 antibodies described herein bind to an epitope, e.g., a
conformational epitope, in the ellular portion of human TIM3, e.g., in the Ig like domain of the
extracellular region, i.e., amino acids 22 to 202 of SEQ ID NO: 286 (). In certain embodiments, an anti-
TIM3 antibody binds to an e located within amino acids 22 to 120 of human TIM3 extracellular domain
(SEQ ID NO: 286) or 1-99 of mature human TIM3 (SEQ ID NO: 290) (see Examples). In n embodiments,
an anti-TIM3 antibody binds to, or to an epitope , a region consisting of amino acids 58-64 of human
TIM3 having SEQ ID NO: 286, which corresponds to amino acid residues 37-43 of mature human TIM3
(CPVFECG, SEQ ID NO: 296; see ). In certain embodiments, an anti-TIM3 antibody binds to, or to an
epitope within, a region consisting of amino acids 111-120 of human TIM3 having SEQ ID NO: 286, which
corresponds to amino acid es 90-99 of mature human TIM3 (RIQIPGIMND, SEQ ID NO: 298; see ). In certain embodiments, an anti-TIM3 antibody binds to, or to an epitope within, a region consisting of a
region ting of amino acids 58-64 of human TIM3 having SEQ ID NO: 286 (CPVFECG, SEQ ID NO:
296) and to, or to an epitope within, a region consisting of amino acids 111-120 of human TIM3 having SEQ ID
NO: 286 (RIQIPGIMND, SEQ ID NO: 298; see ). In certain embodiments, an anti-TIM3 antibody binds
to, or to an epitope within, a region consisting of amino acids 78-89 of human TIM3 having SEQ ID NO: 286,
which corresponds to amino acid residues 57-83 of mature human TIM3 (WTSRYWLNGDFR, SEQ ID NO:
297; see ).
In one embodiment, an anti-TIM3 antibody binds to substantially the same epitope as that of 13A3,
i.e., an epitope (or region of human TIM3) comprising one or more of amino acid residues C58, P59, F61, E62,
C63, R111, and D120 of SEQ ID NO: 286 (). In some embodiments, an anti-TIM3 antibody binds to an
epitope (or region of human TIM3) comprising one or more of amino acid es C58, P59, F61, E62, C63,
D104, R111, Q113 and D120 of SEQ ID NO: 286 (). In n embodiments, an anti-TIM3 antibody
does not bind significantly, or only with significantly reduced binding affinity, to a human TIM3 protein in
which one or more of amino acid residues C58, P59, F61, E62, C63, R111, and D120 of SEQ ID NO: 286 is
changed to another amino acid, e.g., in a non-conservative amino acid substitution. In certain embodiments, an
anti-TIM3 antibody does not bind significantly, or only with significantly d binding affinity, to a human
TIM3 n in which one or more of amino acid residues C58, P59, F61, E62, C63, D104, R111, Q113 and
D120 of SEQ ID NO: 286 is changed to another amino acid, e.g., in a non-conservative amino acid substitution.
In some embodiments, an anti-TIM3 antibody binds to substantially the same e as that of
3G4, i.e., an epitope (or region of human TIM3) comprising one or more of amino acids residues C58, P59,
V60, F61, E62, C63, G116, and M118 of SEQ ID NO: 286 (). In some embodiments, an anti-TIM3
antibody binds to an epitope (or region of human TIM3) comprising one or more of amino acid residues C58,
P59, V60, F61, E62, C63, D104, G116, and M118 of SEQ ID NO: 286 (). In certain embodiments, an
anti-TIM3 antibody does not bind significantly, or only with significantly reduced binding affinity, to a human
TIM3 protein in which one or more of amino acid residues C58, P59, V60, F61, E62, C63, G116, and M118 of
SEQ ID NO: 286 is d to another amino acid, e.g., in a non-conservative amino acid substitution. In
n embodiments, an anti-TIM3 dy does not bind significantly, or only with icantly reduced
binding affinity, to a human TIM3 protein in which one or more of amino acid residues C58, P59, V60, F61,
E62, C63, D104, G116, and M118 of SEQ ID NO: 286 is changed to another amino acid, e.g., in a nonconservative
amino acid substitution.
In some embodiments, an anti-TIM3 dy binds to ntially the same epitope as that of
17C3, i.e., an epitope (or region of human TIM3) comprising one or more of amino acids es C58, P59,
V60, F61, E62, C63, G64, and G116 of SEQ ID NO: 286 (). In some embodiments, an anti-TIM3
antibody binds to an epitope (or region of human TIM3) comprising one or more of amino acid residues C58,
P59, V60, F61, E62, C63, G64, D104, and G116 of SEQ ID NO: 286 (). In certain embodiments, an
IM3 antibody does not bind significantly, or only with significantly reduced binding affinity, to a human
TIM3 protein in which one or more of amino acid residues C58, P59, V60, F61, E62, C63, G64, and G116 of
SEQ ID NO: 286 is changed to another amino acid, e.g., in a non-conservative amino acid substitution. In
n embodiments, an anti-TIM3 antibody does not bind significantly, or only with significantly reduced
binding affinity, to a human TIM3 protein in which one or more of amino acid residues C58, P59, V60, F61,
E62, C63, G64, D104, and G116 of SEQ ID NO: 286 is changed to another amino acid, e.g., in a nonconservative
amino acid substitution.
In some embodiments, an anti-TIM3 antibody binds to substantially the same epitope as that of
8B9, i.e., an epitope (or region of human TIM3) comprising one or more of amino acids residues L48, W78,
S80, R81, W83, G86, D87, and R89 of SEQ ID NO: 286 (). In some embodiments, an anti-TIM3
antibody binds to an epitope (or region of human TIM3) comprising one or more of amino acid residues L48,
W78, S80, R81, W83, L84, G86, D87, and R89 of SEQ ID NO: 286 (). In some ments, an anti-
TIM3 antibody binds to substantially the same epitope as that of 8B9, i.e., an epitope (or region of human
TIM3) comprising one or more of amino acids residues L48, W78, S80, R81, W83, G86, D87, R89, and D104
of SEQ ID NO: 286 (). In certain embodiments, an anti-TIM3 antibody does not bind icantly, or
only with significantly reduced binding affinity, to a human TIM3 n in which one or more of amino acid
residues L48, W78, S80, R81, W83, G86, D87, and R89 of SEQ ID NO: 286 () is changed to another
amino acid, e.g., in a non-conservative amino acid substitution. In certain embodiments, an anti-TIM3 antibody
does not bind significantly, or only with significantly reduced binding affinity, to a human TIM3 n in
which one or more of amino acid residues L48, W78, S80, R81, W83, L84, G86, D87, and R89 of SEQ ID NO:
286 () is changed to another amino acid, e.g., in a non-conservative amino acid substitution. In some
embodiments an anti-TIM3 antibody does not bind significantly, or only with significantly reduced g
affinity, to a human TIM3 protein in which one or more of amino acid residues L48, W78, S80, R81, W83, G86,
D87, R89, and D104 of SEQ ID NO: 286 () is changed to another amino acid, e.g., in a non-conservative
amino acid substitution.
In certain embodiments, anti-TIM3 dies e for g to human TIM3 with (or inhibit
binding of) IM3 antibodies comprising CDRs or variable regions described herein, e.g., those of
antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 and any of TIM3.2 to TIM3.18. In certain embodiments,
anti-TIM3 antibodies inhibit g of antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to
TIM3.18 to human TIM3 by at least 50%, 60%, 70%, 80%, 90% or by 100%. In certain embodiments, 13A3,
3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to TIM3.18 inhibit binding of anti-TIM3 dies to
human TIM3 by at least 50%, 60%, 70%, 80%, 90% or by 100%. In certain embodiments, anti-TIM3 antibodies
inhibit binding of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to TIM3.18 to human TIM3 by at
least 50%, 60%, 70%, 80%, 90% or by 100% and 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to
TIM3.18 inhibit binding of the anti-TIM3 antibodies to human TIM3 by at least 50%, 60%, 70%, 80%, 90% or
by 100% (e.g., compete in both directions).
In certain embodiments, anti-TIM3 dies have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or
all of the following features:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore, e.g., as described in the Examples;
(2) g to soluble cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore, e.g., as described in the Examples;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the Examples;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(6) binding to ne bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as ed by Scatchard analysis, e.g., as described in the Examples;
(7) inducing or enhancing T cell tion (e.g., by blocking or reducing the inhibitory effects of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM-3 expressing T cells (e.g., Th1 cells or TILs), e.g., as described in the Examples;
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay, e.g., as described in the
(9) inhibiting the binding of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" blocking
assay, e.g., as described in the Examples;
(10) not internalizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following s of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
G (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and IMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297), e.g., as described in the
Examples;
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wildtype
human TIM3, e.g., as described in the Examples;
(13) competing in either direction or both directions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or TIM3.7, TIM3.8, TIM3.10,
TIM3.11, TIM3.12, TIM3.13, TIM3.14, TIM3.15, TIM3.16, TIM3.18, e.g., as described in the es;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
IPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain variable s interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the Examples; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to binding to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the Examples; and/or (c)
competing with or blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
described in the Examples.
Accordingly, an dy that ts one or more of these functional properties (e.g.,
biochemical, immunochemical, ar, physiological or other biological ties, or the like) as determined
according to methodologies known to the art and described , will be understood to exhibit a statistically
significant difference in the particular activity relative to that seen in the absence of the antibody (e.g., or when a
control antibody of irrelevant icity is present). In some embodiments, anti-TIM3 antibody-induced
increases in a measured parameter (e.g., T cell proliferation, cytokine production) in a given assay effects a
statistically significant increase by at least 10% of the measured parameter, e.g., by at least 20%, 30%, 40%,
50%, 60%, 70%, 80%, 90%, 95%, 100% (i.e., 2 fold), 3 fold, 5 fold or 10 fold, and in n embodiments, an
antibody described herein can increase the measured parameter, e.g., by greater than 92%, 94%, 95%, 97%,
98%, 99%, 100% (i.e, 2 fold), 3 fold, 5 fold or 10 fold, relative to the same assay conducted in the absence of
the antibody. Conversely, anti-TIM3 antibody-induced ses in a measured parameter (e.g., tumor volume,
TIM3-L binding to human TIM3) in a given assay effects a statistically significant decrease by at least 10% of
the measured ter, e.g., by at least 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%, and in certain
ments, an antibody bed herein can se the ed parameter, e.g., by greater than 92%,
94%, 95%, 97%, 98% or 99%, relative to the same assay conducted in the absence of the antibody.
Standard assays to evaluate the g ability of the antibodies toward TIM3 of various species
are known in the art, including for example, ELISAs, Western blots, and RIAs. Suitable assays are described in
detail in the Examples. The binding kinetics (e.g., binding affinity) of the antibodies can also be assessed by
standard assays known in the art, such as by Biacore analysis. Assays to evaluate the effects of the antibodies on
onal properties of TIM3 (e.g., ligand binding, T cell proliferation, cytokine production) are described in
further detail infra and in the Examples.
In certain ments, anti-TIM3 antibodies are not native antibodies or are not naturallyoccurring
antibodies. For example, anti-TIM3 antibodies have post-translational modifications that are ent
from those of antibodies that are naturally occurring, such as by having more, less or a different type of posttranslational
modification.
In certain embodiments, anti-TIM3 antibodies do not have agonist activity, as determined, e.g., in
cross-linking of anti-TIM3 antibodies in CHO-OKT3-CD32:T cell co-culture experiments, in which such
antibodies do not enhance activity beyond anti-TIM3 alone. In certain embodiments, anti-TIM3 antibodies
block the interaction of TIM3 with its ligand without promoting agonist activity.
In certain embodiments, anti-TIM3 dies enhance IL-12 production from monocytes or
dendritic cells treated with LPS.
In certain embodiments, anti-TIM3 antibodies revive tumor infiltrating CD8+ T cells that ess
PD-1 and TIM3 by combined treatment, hence ng depletion of CD8+ T cells.
II. Exemplary Anti-TIM3 Antibodies
Particular anti-TIM3 antibodies described herein are antibodies, e.g., monoclonal, recombinant,
and/or human antibodies, having the CDR and/or variable region sequences of antibodies 13A3, 3G4, 17C3,
17C8, 9F6, 8B9, 8C4 or any one of TIM3.2 to TIM3.18, ed and urally characterized as described
herein, as well as antibodies having at least 80% identity (e.g., at least 85%, at least 90%, at least 95%, or at
least 99% identity) to their variable region or CDR sequences. The VH amino acid sequences of 13A3, 8B9,
8C4, 17C3, 9F6, 3G4, and 17C8 are set forth in SEQ ID NOs: 34-40, respectively. The VH amino acid
sequences of mutated versions of 13A3, 8B9 and 9F6 are set forth in SEQ ID NOs: 112-121, and 364. The VL
amino acid sequences of 13A3, 17C3, and 3G4 are set forth in SEQ ID NO: 60. The VL amino acid sequences
of 8B9, 8C4, and 17C8 are set forth in SEQ ID NO: 61. The VL amino acid sequence of 9F6 are set forth in
SEQ ID NOs: 61, 62, and 63. The VL amino acid sequences of the mutated versions of 13A3, 8B9 and 9F6 are
those of the corresponding nonmutated antibodies. A summary of the identity of SEQ ID NOs is provided in
.
Accordingly, provided herein are isolated antibodies, or antigen binding portion thereof,
comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises an amino
acid sequence selected from the group consisting of SEQ ID NOs: 34-40, 112-121 and 364.
Also provided are isolated antibodies, or antigen binding portions thereof, comprising heavy and
light chain variable regions, wherein the light chain le region comprises an amino acid sequence selected
from the group consisting of SEQ ID NOs: 60-63.
Provided herein are isolated anti-human TIM3 antibodies, or antigen-binding portion thereof,
comprising:
(a) heavy and light chain variable region sequences comprising SEQ ID NOs: 34 and 60, respectively;
(b) heavy and light chain variable region sequences comprising SEQ ID NOs: 35 and 61, tively;
(c) heavy and light chain le region sequences comprising SEQ ID NOs: 36 and 61, respectively;
(d) heavy and light chain variable region sequences comprising SEQ ID NOs: 37 and 60, respectively;
(e) heavy and light chain variable region sequences comprising SEQ ID NOs: 38 and 61, respectively;
(f) heavy and light chain variable region sequences comprising SEQ ID NOs: 38 and 62, tively;
(g) heavy and light chain le region ces comprising SEQ ID NOs: 38 and 63, respectively;
(h) heavy and light chain variable region sequences comprising SEQ ID NOs: 39 and 60, respectively;
(i) heavy and light chain variable region sequences comprising SEQ ID NOs: 40 and 61, respectively;
(j) heavy and light chain variable region sequences comprising SEQ ID NOs: 121 and 63, respectively;
(k) heavy and light chain le region sequences comprising SEQ ID NOs: 120 and 61, respectively;
(l) heavy and light chain variable region sequences sing SEQ ID NOs: 112 and 60, respectively;
(m) heavy and light chain variable region sequences sing SEQ ID NOs: 113 and 60, tively;
(n) heavy and light chain variable region sequences comprising SEQ ID NOs: 114 and 60, respectively;
(o) heavy and light chain variable region sequences comprising SEQ ID NOs: 115 and 60, respectively;
(p) heavy and light chain variable region sequences comprising SEQ ID NOs: 116 and 60, respectively;
(q) heavy and light chain variable region sequences comprising SEQ ID NOs: 117 and 60, respectively;
(r) heavy and light chain variable region ces comprising SEQ ID NOs: 118 and 60, respectively;
(s) heavy and light chain variable region sequences comprising SEQ ID NOs: 119 and 60, respectively; or
(t) heavy and light chain variable region sequences comprising SEQ ID NOs: 364 and 60, respectively.
Anti-TIM3 antibodies can comprise the heavy and light chain CDR1s, CDR2s and CDR3s of
13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and 17C8 or any one of TIM3.2 to TIM3.18, or combinations thereof. The
amino acid sequences of the VH CDR1s of 13A3, 8B9, 8C4, and 17C3 are set forth in SEQ ID NOs: 41-44,
respectively. The amino acid ces of the VH CDR1s of 9F6, 3G4, and 17C8 are set forth in SEQ ID NO
45. The amino acid sequence of the VH CDR1 of the mutated 13A3 antibodies (i.e., TIM3.10-TIM3.18) is the
same as that of the nonmutated 13A3 antibody, i.e., SEQ ID NO: 41. The amino acid sequence of the VH CDR1
of the mutated 8B9 antibody (i.e., TIM3.8) is the same as that of the nonmutated 8B9 antibody, i.e., SEQ ID
NO: 42. The amino acid sequence of the VH CDR1 of the mutated 9F6 dy (i.e., TIM3.7) is the same as
that of the nonmutated 9F6 antibody, i.e., SEQ ID NO: 45. The amino acid sequences of the VH CDR2s of
13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and 17C8 are set forth in SEQ ID NOs: 46-52, respectively. The amino acid
sequence of the VH CDR2s of the d 13A3 antibodies TIM3.10, 7, and TIM3.18 is set forth in
SEQ ID NO: 122. The amino acid sequence of the VH CDR2s of the mutated 13A3 antibodies TIM3.11 and
TIM3.12 are set forth in SEQ ID NOs: 123 and 124, respectively. The amino acid sequence of the VH CDR2 of
the mutated 13A3 antibodies TIM3.13 and TIM3.16 is that of the nonmutated 13A3 antibody, i.e., SEQ ID NO:
46. The amino acid sequence of the VH CDR2 of the mutated 8B9 antibody (i.e., TIM3.8) is set forth in SEQ ID
NO: 125. The amino acid sequence of the VH CDR2 of the mutated 9F6 antibody (i.e., TIM3.7) is the same as
that of the nonmutated 9F6 antibody, i.e., SEQ ID NO: 45. The amino acid sequences of the VH CDR3s of
13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and 17C8 are set forth in SEQ ID NOs: 53-59, respectively.
The amino acid sequence of the VH CDR3s of the mutated 13A3 antibodies (i.e., TIM3.10 to
TIM3.12 is that of the nonmutated 13A3 antibody, i.e., SEQ ID NO: 53. The amino acid sequence of the VH
CDR3s of the mutated 13A3 antibodies TIM3.13 and TIM3.18 is set forth in SEQ ID NO: 126. The amino acid
ce of the VH CDR3s of the mutated 13A3 antibodies TIM3.15 and TIM3.17 is set forth in SEQ ID NO:
128. The amino acid sequences of the VH CDR3s of the mutated 13A3 antibodies TIM3.14 and TIM3.16 are set
forth in SEQ ID NOs: 127 and 129, respectively. The amino acid sequence of the VH CDR3 of the mutated 8B9
dy (i.e., TIM3.8) is that of the nonmutated 8B9 antibody, i.e., SEQ ID NO: 54. The amino acid sequence
of the VH CDR3 of the mutated 9F6 dy (i.e., TIM3.7) is the same as that of the nonmutated 9F6 antibody,
i.e., SEQ ID NO: 57. The amino acid sequences of the VH CDR3s of 13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and
17C8 are set forth in SEQ ID NOs: 53-59, respectively. The amino acid sequences of the VL CDR1s of 13A3,
8B9, 8C4, 17C3, 3G4, and 17C8 are set forth in SEQ ID NO: 64. The amino acid sequences of the VL CDR1 of
9F6 is set forth in SEQ ID NOs: 64 and 65. The amino acid sequences of the VL CDR2s of 13A3, 8B9, 8C4,
17C3, 3G4, and 17C8 are set forth in SEQ ID NO: 66. The amino acid sequences of the VL CDR2 of 9F6 is set
forth in SEQ ID NOs: 66 and 67. The amino acid sequences of the VL CDR3s of 13A3, 17C3, and 3G4 are set
forth in SEQ ID NO: 68. The amino acid sequences of the VL CDR3s of 8B9, 8C4, and 17C8 are set forth in
SEQ ID NO: 69. The amino acid sequences of the VL CDR3 of 9F6 are set forth in SEQ ID NOs: 69, 70, and
71. The amino acid sequences of the VL CDRs of the mutated dies 13A3, 8B9 and 9F6 are those of the
corresponding ated dies. provides a list of the SEQ ID NOs for the CDRs of anti-TIM3
antibodies described herein.
The CDR regions are delineated using the Kabat system (Kabat, E. A., et al. (1991) Sequences of
Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH
Publication No. 91-3242). Kabat system is the most common numbering system for a scheme called the EU
index or EU ing system, which is based on the sequential numbering of the first human IgG1 sequenced
(the EU antibody; Edelman et al. 1969). Based on the Kabat numbering scheme disclosed herein, the antibody
ing can be converted into other s known in the art, e.g., Chotia, IMGT, Martin ced
Chothia), or AHo numbering scheme.
Given that each of these dies bind to human TIM3 and that antigen-binding specificity is
ed primarily by the CDR1, 2 and 3 regions, the VH CDR1, 2 and 3 sequences and VL CDR1, 2 and 3
sequences, e.g., those in , can be "mixed and matched" (i.e., CDRs from different antibodies can be
mixed and match, although each antibody must contain a VH CDR1, 2 and 3 and a VL CDR1, 2 and 3) to create
other anti-TIM3 binding molecules described herein. TIM3 binding of such "mixed and d" antibodies can
be tested using the binding assays described above and in the Examples (e.g., ELISAs). In some embodiments,
when VH CDR sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a particular
VH sequence is replaced with a structurally similar CDR sequence(s). Likewise, when VL CDR sequences are
mixed and matched, the CDR1, CDR2 and/or CDR3 sequence from a particular VL sequence is replaced with a
structurally similar CDR sequence(s). It will be readily apparent to the ordinarily skilled artisan that novel VH
and VL ces can be created by substituting one or more VH and/or VL CDR region ces with
structurally r sequences from the CDR sequences disclosed herein for monoclonal antibodies 13A3, 8B9,
8C4, 17C3, 9F6, 3G4, 17C8 and any one of TIM3.2 to TIM3.18.
Provided herein are isolated anti-human TIM3 antibodies, or antigen g portion f
sing:
(a) a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting
of SEQ ID NOs: 41-45;
(b) a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting
of SEQ ID NOs: 46-52 and 122-125;
(c) a heavy chain variable region CDR3 sing an amino acid sequence selected from the group consisting
of SEQ ID NOs: 53-59 and 126-129;
(d) a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of
SEQ ID NOs: 64-65;
(e) a light chain variable region CDR2 comprising an amino acid sequence ed from the group consisting of
SEQ ID NOs: 66-67; and
(f) a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of
SEQ ID NOs: 68-71;
wherein the antibody specifically binds to human TIM3.
In one embodiment, the anti-human TIM3 antibody comprises heavy and light chain variable
regions, wherein the heavy chain variable region CDR1, CDR2, and CDR3 regions comprise:
(a) SEQ ID NOs: 41, 46, 53;
(b) SEQ ID NOs: 42, 47, 54;
(c) SEQ ID NOs: 43, 48, 55;
(d) SEQ ID NOs: 44, 49, 56;
(e) SEQ ID NOs: 45, 50, 57;
(f) SEQ ID NOs: 45, 51, 58;
(g) SEQ ID NOs: 45, 52, 59;
(h) SEQ ID NOs: 41, 122, 53;
(i) SEQ ID NOs: 41, 123, 53;
(j) SEQ ID NOs: 41, 124, 53;
(k) SEQ ID NOs: 41, 46, 126;
(l) SEQ ID NOs: 41, 46, 127;
(m) SEQ ID NOs: 41, 46, 128;
(n) SEQ ID NOs: 41, 46, 129;
(o) SEQ ID NOs: 41, 122, 128; or
(p) SEQ ID NOs: 41, 122, 126;
wherein the antibody specifically binds to human TIM3.
In some embodiments, the anti-human TIM3 dy comprises heavy and light chain le
regions, wherein the light chain variable region CDR1, CDR2, and CDR3 regions comprise:
(a) SEQ ID NOs: 64, 66, 68;
(b) SEQ ID NOs: 64, 66, 69;
(c) SEQ ID NOs: 65, 67, 70; or
(d) SEQ ID NOs: 64, 66, 71;
wherein the antibody ically binds to human TIM3.
In a particular embodiment, the anti-TIM3 dy comprises heavy and light chain variable
regions, wherein:
(a1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 53, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, respectively;
(a2) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 41, 122, 53,
tively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a3) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 123, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a4) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 124, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a5) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a6) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 127,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a7) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a8) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 129,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a9) the heavy chain le region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a10) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(b1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 47, 54, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(b2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 125, 54,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69,
respectively;
(c) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 43, 48, 55, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(d) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 44, 49, 56, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, tively;
(e) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 69, respectively;
(f) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain le region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 71, tively;
(g1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 65, 67, 70, respectively;
(g2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 71, respectively;
(g3) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(h) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 51, 58, tively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, respectively;
(i) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 52, 59, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
wherein the antibody specifically binds to human TIM3.
A VH domain, or one or more CDRs thereof, described herein can be linked to a constant domain
for forming a heavy chain, e.g., a full length heavy chain. Similarly, a VL domain, or one or more CDRs
thereof, described herein can be linked to a constant domain for forming a light chain, e.g., a full length light
chain. A full length heavy chain (with the exception of the C-terminal lysine (K) or with the exception of the C-
al glycine and lysine (GK), which can be ) and full length light chain combine to form a full length
antibody.
A VH domain bed herein can be fused to the constant domain of a human IgG, e.g., IgG1,
IgG2, IgG3 or IgG4, which are either naturally- occurring or modified, e.g., as further described herein. For
example, a VH domain can comprise the amino acid sequence of any VH domain described herein fused to a
human IgG, e.g., an IgG1, constant region, such as the following ype human IgG1 constant domain amino
acid sequence:
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 291)
or that of an allotypic variant of SEQ ID NO: 291 and have the following amino acid sequences:
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 277; allotype specific amino acid residues are
in bold and underlined)
A VH domain of an anti-TIM3 antibody can comprise the amino acid sequence of any VH domain
described herein fused to an orless constant region, e.g., the ing effectorless human IgG1 constant
domain amino acid ces:
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 294; "IgG1.1f," comprising substitutions
L234A, L235E, G237A, A330S and P331S, which are underlined)
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ
PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 295; "IgG1.3f", comprising
substitutions L234A, L235E and G237A, which are underlined)
For example, an allotypic variant of IgG1 comprises an K97R, D239E, and/or L241M (underlined
and bolded above) and numbering according to that in SEQ ID NOs: 277, 294, and 295. Within the full length
heavy region, e.g., 8C4 (SEQ ID NO: 3) and according to EU numbering, these amino acid substitutions are
numbered K214R, D356E, and L358M. In some embodiments, the constant region of an anti-TIM3 antibody
can further comprises one or more ons or substitutions at amino acids L117, A118, G120, A213, and P214
(underlined above) as numbered in SEQ ID NO: 277, 294, and 295, or L234, A235, G237, A330 and P331, per
EU numbering. In further embodiments, the constant region of an anti-TIM3 antibody comprises one or more
ons or substitutions at amino acids L117A, A118E, G120A, A213S, and P214S of SEQ ID NO: 291, or
L234A, L235E, G237A, A330S and P331S, per EU numbering. The constant region of an anti-TIM3 antibody
may also comprise one or more mutations or substitutions L117A, A118E and G120A of SEQ ID NO: 291, or
L234A, L235E and G237A, per EU numbering
Alternatively, a VH domain of an anti-TIM3 antibody can comprise the amino acid sequence of
any VH domain bed herein fused to a human IgG4 nt , e.g., the following human IgG4 amino
acid sequence or variants thereof:
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS
LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQED
PEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEG
NVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 292, comprising .
A VL domain described herein can be fused to the constant domain of a human Kappa or Lambda
light chain. For example, a VL domain of an anti-TIM3 antibody can comprise the amino acid sequence of any
VL domain described herein fused to the following human IgG1 kappa light chain amino acid ce:
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS
KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 278)
In certain embodiments, the heavy chain constant region comprises a lysine or another amino acid
at the inus, e.g., it comprises the following last amino acids: LSPGK (SEQ ID NO: 279) in the heavy
chain. In n embodiments, the heavy chain constant region is lacking one or more amino acids at the C-
terminus, and has, e.g., the inal sequence LSPG (SEQ ID NO: 280) or LSP (SEQ ID NO: 281).
The amino acid sequences of exemplary heavy and light chains pond to SEQ ID NOs: 1-28 ,
72-111, 301-354, for the heavy chains and SEQ ID NOs: 29-30 and 32-33 for the light chains.
Provided herein are isolated anti-human TIM3 dies, or antigen-binding portion thereof,
comprising:
(a1) heavy and light chain sequences comprising SEQ ID NOs: 301 (or 302) and 29, respectively;
(a2) heavy and light chain sequences comprising SEQ ID NOs: 1 (or 8) and 29, tively;
(a3) heavy and light chain sequences comprising SEQ ID NOs: 15 (or 22) and 29, respectively;
(a4) heavy and light chain sequences comprising SEQ ID NOs: 303 (or 304) and 29, respectively;
(a5) heavy and light chain sequences comprising SEQ ID NOs: 72 (or 82) and 29, respectively;
(a6) heavy and light chain sequences comprising SEQ ID NOs: 92 (or 102) and 29, respectively;
(a7) heavy and light chain ces comprising SEQ ID NOs: 305 (or 306) and 29, respectively;
(a8) heavy and light chain sequences comprising SEQ ID NOs: 73 (or 83) and 29, respectively;
(a9) heavy and light chain sequences comprising SEQ ID NOs: 93 (or 103) and 29, respectively;
(a10) heavy and light chain sequences comprising SEQ ID NOs: 307 (or 308) and 29, respectively;
(a11) heavy and light chain sequences comprising SEQ ID NOs: 74 (or 84) and 29, respectively;
(a12) heavy and light chain sequences comprising SEQ ID NOs: 94 (or 104) and 29, respectively;
(a13) heavy and light chain sequences comprising SEQ ID NOs: 309 (or 310) and 29, respectively;
(a14) heavy and light chain sequences comprising SEQ ID NOs: 75 (or 85) and 29, respectively;
(a15) heavy and light chain sequences comprising SEQ ID NOs: 95 (or 105) and 29, respectively;
(a16) heavy and light chain sequences comprising SEQ ID NOs: 311 (or312) and 29, respectively;
(a17) heavy and light chain sequences comprising SEQ ID NOs: 76 (or 86) and 29, respectively;
(a18) heavy and light chain sequences comprising SEQ ID NOs: 96 (or 106) and 29, respectively;
(a19) heavy and light chain sequences comprising SEQ ID NOs: 313 (or 314) and 29, respectively;
(a20) heavy and light chain sequences comprising SEQ ID NOs: 77 (or 87) and 29, respectively;
(a21) heavy and light chain sequences comprising SEQ ID NOs: 97 (or 107) and 29, tively;
(a22) heavy and light chain sequences comprising SEQ ID NOs: 315 (or 316) and 29, respectively;
(a23) heavy and light chain sequences comprising SEQ ID NOs: 78 (or 88) and 29, respectively;
(a24) heavy and light chain sequences comprising SEQ ID NOs: 98 (or 108) and 29, tively;
(a25) heavy and light chain sequences comprising SEQ ID NOs: 317 (or 318) and 29, respectively;
(a26) heavy and light chain sequences comprising SEQ ID NOs: 79 (or 89) and 29, respectively;
(a27) heavy and light chain sequences comprising SEQ ID NOs: 99 (or 109) and 29, respectively;
(a28) heavy and light chain sequences comprising SEQ ID NOs: 319 (or 320) and 29, respectively;
(a29) heavy and light chain sequences comprising SEQ ID NOs: 349 (or 350) and 29, respectively;
(a30) heavy and light chain sequences comprising SEQ ID NOs: 351 (or 352) and 29, respectively;
(a31) heavy and light chain sequences comprising SEQ ID NOs: 353 (or 354) and 29, respectively;
(b1) heavy and light chain ces comprising SEQ ID NOs: 321 (or 322) and 30, respectively;
(b2) heavy and light chain sequences sing SEQ ID NOs: 2 (or 9) and 30, respectively;
(b3) heavy and light chain sequences comprising SEQ ID NOs: 16 (or 23) and 30, tively;
(b4) heavy and light chain sequences comprising SEQ ID NOs: 323 (or 324) and 30, respectively;
(b5) heavy and light chain sequences comprising SEQ ID NOs: 80 (or 90) and 30, respectively;
(b6) heavy and light chain sequences comprising SEQ ID NOs: 100 (or 110) and 30, respectively;
(b7) heavy and light chain sequences comprising SEQ ID NOs: 325 (or 326) and 30, respectively;
(c1) heavy and light chain sequences comprising SEQ ID NOs: 327 (or 328) and 30, respectively;
(c2) heavy and light chain sequences comprising SEQ ID NOs: 3 (or 10) and 30, respectively;
(c3) heavy and light chain sequences comprising SEQ ID NOs: 17 (or 24) and 30, respectively;
(c4) heavy and light chain sequences comprising SEQ ID NOs: 329 (or 330) and 30, respectively;
(d1) heavy and light chain sequences comprising SEQ ID NOs: 331 (or 332) and 29, respectively;
(d2) heavy and light chain sequences comprising SEQ ID NOs: 4 (or 11) and 29, respectively;
(d3) heavy and light chain sequences comprising SEQ ID NOs: 18 (or 25) and 29, respectively;
(d4) heavy and light chain sequences comprising SEQ ID NOs: 333 (or 334) and 29, tively;
(e1.1) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 32, respectively;
(e1.2) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 33, respectively;
(e1.3) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 31, respectively;
(e2) heavy and light chain sequences comprising SEQ ID NOs: 5 (or 12) and 33, respectively;
(e3) heavy and light chain sequences comprising SEQ ID NOs: 19 (or 26) and 33, respectively;
(e4) heavy and light chain sequences comprising SEQ ID NOs: 337 (or 338) and 33, respectively;
(e5) heavy and light chain ces comprising SEQ ID NOs: 81 (or 91) and 33, respectively;
(e6) heavy and light chain sequences sing SEQ ID NOs: 101 (or 111) and 33, respectively;
(e7) heavy and light chain sequences comprising SEQ ID NOs: 339 (or 340) and 33, respectively;
(f1) heavy and light chain sequences comprising SEQ ID NOs: 341 (or 342) and 29, respectively;
(f2) heavy and light chain sequences comprising SEQ ID NOs: 6 (or 13) and 29, respectively;
(f3) heavy and light chain sequences sing SEQ ID NOs: 20 (or 27) and 29, respectively;
(f4) heavy and light chain sequences comprising SEQ ID NOs: 343 (or 344) and 29, respectively;
(g1) heavy and light chain sequences comprising SEQ ID NOs: 345 (or 346) and 30, respectively;
(g2) heavy and light chain ces comprising SEQ ID NOs: 7 (or 14) and 30, respectively;
(g3) heavy and light chain ces comprising SEQ ID NOs: 21 (or 28) and 30, tively; or
(g4) heavy and light chain sequences comprising SEQ ID NOs: 347 (or 348) and 30, respectively;
wherein the antibody specifically binds to human TIM3.
In certain ments, an anti-TIM3 antibody comprises a ation of a heavy and light
chain sequences set forth herein, e.g., in the preceding paragraph, wherein the antibody comprises two heavy
chains and two light chains, and can further comprise at least one disulfide bond linking the two heavy chains
together. The antibodies can also comprise ide bonds linking each of the light chains to each of the heavy
Heavy and light chains comprising an amino acid sequence that is at least 99%, 98%, 97%, 96%,
95%, 90%, 85%, 80%, 75% or 70% cal to any of the heavy or light chains set forth herein (or their
variable regions), e.g., SEQ ID NOs: 1-33, 72-111, and 4 can be used for forming anti-human TIM3
antibodies having the desired teristics, e.g., those further described herein. Exemplary variants are those
comprising an allotypic variation, e.g., in the constant domain, and/or a mutation in the variable or constant
region, such as the mutations disclosed herein. Heavy and light chains comprising an amino acid sequence that
differs in at most 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3, 1-2 or 1 amino acid (by substitution, addition or
deletion) from any of the heavy or light chains set forth herein (or their variable regions) can be used for
forming uman TIM3 antibodies having the desired characteristics, e.g., those further described .
In various embodiments, the antibodies described above exhibit one or more, two or more, three or
more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or
more, twelve or more, en or more, fourteen or more, fifteen or more, or all of the following functional
properties:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore, e.g., as described in the Examples;
(2) binding to soluble cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore, e.g., as described in the Examples;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the Examples;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
, e.g., as measured by flow cytometry (e.g., as bed in the Examples);
(6) binding to membrane bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by Scatchard analysis, e.g., as described in the Examples;
(7) inducing or enhancing T cell tion (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of xpressing T cells (e.g., Th1 cells or TILs), e.g., as described in the Examples;
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay, e.g., as described in the
Examples;
(9) inhibiting the binding of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" blocking
assay, e.g., as described in the Examples;
(10) not internalizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following s of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297), e.g., as described in the
Examples;
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wildtype
human TIM3, e.g., as described in the Examples;
(13) competing in either ion or both directions for binding to human TIM3 with an dy comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or TIM3.7, TIM3.8, TIM3.10,
TIM3.11, TIM3.12, TIM3.13, TIM3.14, TIM3.15, TIM3.16, TIM3.17, and TIM3.18, e.g., as bed in the
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
IPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the Examples; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to binding to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the Examples; and/or (c)
competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
bed in the Examples.
Such antibodies e, for e, human dies, humanized antibodies, or chimeric
dies.
In one embodiment, anti-TIM3 antibodies described herein bind to a conformational epitope.
In one embodiment, anti-TIM3 antibodies described herein bind to amino acid residues within the
following region of mature human TIM3 extracellular domain (SEQ ID NO: 290):
SEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLT
IENVTLADSGIYCCRIQIPGIMND (SEQ ID NO: 299), corresponding to amino acid residues 1-99 of mature
human TIM3 extracellular domain (SEQ ID NO: 290) or amino acids 22 to 120 of human TIM3 having SEQ ID
NO: 286.
In one embodiment, anti-TIM3 antibodies described herein bind to amino acid residues within the
following region of mature human TIM3 extracellular domain (SEQ ID NO: 290): G (SEQ ID NO:
296), corresponding to amino acid residues 37-43 of mature human TIM3 extracellular domain (SEQ ID NO:
290).
In one embodiment, anti-TIM3 antibodies described herein bind to amino acid residues within the
ing region of mature human TIM3 extracellular domain (SEQ ID NO: 290): WTSRYWLNGDFR (SEQ ID
NO: 297), corresponding to amino acid residues 57-83 of mature human TIM3 extracellular domain (SEQ ID
NO: 290).
In one embodiment, anti-TIM3 antibodies described herein bind to amino acid residues within the
ing region of mature human TIM3 extracellular domain (SEQ ID NO: 290): RIQIPGIMND (SEQ ID
NO:298), corresponding to amino acid residues 90-99 of mature human TIM3 extracellular domain (SEQ ID
NO: 290).
In one embodiment, anti-TIM3 antibodies have the same pattern of binding to wildtype and
mutated human TIM3 as that of one or more of antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 and TIM3.2
to 8. In one embodiment, an anti-TIM3 dy binds to amino acid residues within the following
regions of mature human TIM3 extracellular domain (SEQ ID NO: 290): CPVFECG (SEQ ID NO: 296),
WTSRYWLNGDFRKGDVSLTIENVTLAD (SEQ ID NO: 297), and/or RIQIPGIMND (SEQ ID NO: 298).
In certain embodiments, an anti-TIM3 antibody binds to (1) 49VPVCWGKGACPVFE62 (SEQ ID
NO: 367) and 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) or (2)
40YTPAAPGNLVPVCWGKGACPVFE62 (SEQ ID NO: 369), 66VVLRTDERDVNY77 (SEQ ID NO: 370),
78WTSRYWLNGDFRKGDVSL95 (SEQ ID NO: 371), 110CRIQIPGIMNDEKFNLKL127 (SEQ ID NO: 372), and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described, e.g., in the Examples. In
certain embodiments, an IM3 antibody interacts with regions of amino acid residues 40-62 and 111-127 of
hTIM3, but does not significantly ct with other s, such as the region that is N-terminal to amino acid
residue Y40, the region that is located between amino acid es E62 and R111, and the region that is C-
terminal to amino acid residue L127, as determined by HDX-MS, as described, e.g., in the Examples.
In n embodiments, an anti-TIM3 antibody has reduced binding to human TIM3 in which one
or more of amino acids L48, C58, P59, V60, F61, E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89,
D104, R111, Q113, G116, M118, and D120 (as numbered in SEQ ID NO: 286 ()) is tuted with
another amino acid relative to binding to wildtype human TIM3 and the antibody binds to (1)
49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) or (2)
APGNLVPVCWGKGACPVFE62 (SEQ ID NO: 369), 66VVLRTDERDVNY77 (SEQ ID NO: 370),
78WTSRYWLNGDFRKGDVSL95 (SEQ ID NO: 371), 110CRIQIPGIMNDEKFNLKL127 (SEQ ID NO: 372), and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as bed, e.g., in the Examples.
In certain embodiments, an anti-TIM3 antibody has a similar pattern of binding to wild-type and
mutated human TIM3 as that of 8.IgG1.3 or 13A3, i.e., the antibody:
(i) binds to (1) 49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127
(SEQ ID NO: 368), and 119NDEKFNLKL127 (SEQ ID NO: 373), and, e.g., but does not bind significantly to (a)
peptides having sequences located N-terminal of amino acid residue 49; (b) peptides having sequences located
between amino acid residue 62 and 111 (e.g., 78WTSRYWLNGDFRKGDVSL95 (SEQ ID NO: 371)); and (c)
peptides having sequences that are located C-terminal of amino acid residue 127, as determined by HDX-MS
(e.g., as described in the Examples);
(ii) fails to bind to human TIM3, or has significantly d binding to human TIM3, having one
or more of the following amino acid mutations, as determined, e.g., using a yeast surface display method (e.g.,
as described in the Examples): C58, P59, F61, E62, C63, R111, D120, and optionally D104 and Q113
(numbering per SEQ ID NO: 286 ()); and/or
(iii) has the heavy chain and/or light chain variable s interact with at least 5, 10, 15, 20 or all
of the following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67,
L68, R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as
determined by X-ray crystallography (e.g., as described in the Examples; numbering per SEQ ID NO: 286 ()).
In certain embodiments, an anti-TIM3 antibody comprises a heavy chain and a light chain, wherein
the heavy chain is selected from the group consisting of SEQ ID NOs: 72-111, 305-354, 325-326, and 339-340,
and/or the light chain is selected from the group ting of SEQ ID NOs: 29-33.
As further discussed herein, the heavy chain constant region of anti-TIM3 antibodies bed
herein can be of any isotype, e.g., IgG1, IgG2, IgG3 and IgG4, or combinations thereof and/or modifications
f. An anti-TIM3 antibody can have effector function or can have reduced or no effector function. In
certain ments, anti-TIM3 antibodies comprise a modified heavy chain constant region that provides
ed properties to the antibody.
In certain embodiments, an anti-TIM3 antibody ses a heavy chain and an light chain,
n the heavy chain is selected from the group consisting of SEQ ID NOs: 72-111, and 349-352, and/or the
light chain is selected from the group consisting of SEQ ID NOs: 29-33.
III. dies Having Particular Germline Sequences
In certain embodiments, an anti-TIM3 antibody comprises a heavy chain variable region from a
particular germline heavy chain immunoglobulin gene and/or a light chain variable region from a particular
germline light chain immunoglobulin gene.
As demonstrated herein, human antibodies ic for TIM3 have been prepared that comprise a
heavy chain variable region that is the product of or derived from a human germline VH 4-39 gene, VH 4-59
gene, VH 1-46 gene, VH 3-11, VH 4-17 gene, VH 3-10 gene, VH 6-19 gene, VH 6-13 gene, VH JH5b gene
and/or VH JH6b gene. Accordingly, provided herein are isolated monoclonal antibodies, or antigen-binding
portions f, comprising a heavy chain variable region that is the product of or d from a human VH
germline gene selected from the group consisting of: VH 4-39, VH 4-59, VH 1-46, VH 3-11, VH 4-17, VH 3-
, VH6-19, VH 6-13, VH JH5b, VH JH6b, and any combination thereof.
Human antibodies specific for TIM3 have been prepared that comprise a light chain variable
region that is the product of or derived from a human germline VK A27 gene, VK JK5 gene, VK JK4 gene, VK
L18 gene, and/or VK JK1 gene. Accordingly, provide herein are isolated monoclonal antibodies, or antigenbinding
portions thereof, comprising a light chain variable region that is the product of or derived from a human
VK ne gene ed from the group consisting of: VK A27, VK JK5, VK JK4, VK L18, VK JK1, and
any combination thereof.
Anti-TIM3 antibodies described herein include those comprising a heavy chain variable region that
is the product of or d from one of the above-listed human germline VH genes and also comprising a light
chain variable region that is the product of or derived from one of the above-listed human germline VK genes,
as shown in the Figures.
As used herein, a human antibody comprises heavy and light chain variable regions that are "the
product of or "derived from" a particular germline sequence if the variable regions of the dy are obtained
from a system that uses human germline immunoglobulin genes. Such systems include immunizing a transgenic
mouse carrying human immunoglobulin genes with the antigen of interest or screening a human
immunoglobulin gene library displayed on phage with the antigen of interest. A human antibody that is "the
product of or "derived from" a human germline globulin sequence can be identified as such by
comparing the amino acid sequence of the human antibody to the amino acid sequences of human germline
immunoglobulins and selecting the human ne immunoglobulin sequence that is closest in sequence (i.e.,
greatest % identity) to the sequence of the human dy. A human antibody that is "the product of or "derived
from" a particular human germline immunoglobulin sequence can contain amino acid differences as ed
to the germline sequence, due to, for e, naturally- occurring somatic mutations or intentional introduction
of site-directed mutation. However, a selected human antibody typically is at least 90% identical in amino acids
sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and ns amino
acid residues that identify the human antibody as being human when compared to the germline immunoglobulin
amino acid sequences of other species (e.g., murine germline sequences). In certain cases, a human antibody can
be at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid
sequence encoded by the ne globulin gene. Typically, a human antibody derived from a ular
human germline sequence will display no more than 10 amino acid differences from the amino acid sequence
encoded by the human germline immunoglobulin gene. In certain cases, the human antibody can display no
more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by
the germline immunoglobulin gene.
IV. Homologous Antibodies
Encompassed herein are antibodies having heavy and light chain variable regions comprising
amino acid ces that are homologous to the amino acid sequences of the anti-TIM3 antibodies bed
herein, and wherein the antibodies retain the desired functional properties of the anti-TIM3 antibodies described
herein.
For example, an isolated anti-TIM3 dy, or antigen binding portion thereof, can comprise a
heavy chain variable region and a light chain variable region, wherein:
(a) the heavy chain variable region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%,
96%, 97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs:
34-40,112-121, and 364, or comprises 1, 2, 3, 4, 5, 1-2, 1-3, 1-4, 1-5, 1-10, 1-15, 1-20, 1-25, or 1-50 amino acid
changes (i.e., amino acid substitutions, additions or deletions) relative to an amino acid sequence selected from
the group consisting of SEQ ID NOs: 34-40, 112-121, and 364, wherein optionally the heavy chain variable
region comprises the CDR sequences of one of the anti-TIM3 antibodies bed herein;
(b) the light chain variable region comprises an amino acid ce that is at least 80%, 85%, 90%, 95%, 96%,
97%, 98% or 99% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 60-
63, or comprises 1, 2, 3, 4, 5, 1-2, 1-3, 1-4, 1-5, 1-10, 1-15, 1-20, 1-25, or 1-50 amino acid s (i.e., amino
acid substitutions, additions or ons) relative to an amino acid sequence selected from the group consisting
of SEQ ID NOs: 60-63, wherein ally the light chain variable region comprises the CDR sequences of one
of the IM3 antibodies described herein;
(c) the antibody specifically binds to human TIM3, and
(d) the antibody exhibits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all of the following functional
ties:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by e, e.g., as described in the Examples;
(2) binding to soluble cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore, e.g., as described in the Examples;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the Examples;
(5) g to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as ed by flow cytometry (e.g., as described in the Examples);
(6) binding to membrane bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as ed by Scatchard analysis, e.g., as described in the Examples;
(7) inducing or enhancing T cell activation (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs), e.g., as described in the Examples;
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay, e.g., as described in the
Examples;
(9) inhibiting the g of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" blocking
assay, e.g., as described in the Examples;
(10) not alizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following regions of human TIM3 ellular domain (SEQ ID NO: 290): (a)
CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297), e.g., as bed in the
Examples;
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wildtype
human TIM3, e.g., as described in the Examples;
(13) competing in either direction or both directions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or , TIM3.8, 0,
1, TIM3.12, TIM3.13, TIM3.14, TIM3.15, TIM3.16, TIM3.17, and TIM3.18, e.g., as bed in the
Examples;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., bed in the Examples; ing per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to binding to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the Examples; and/or (c)
competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
described in the Examples.
In various embodiments, the antibody can exhibit one or more, two or more, three or more, four or
more, five or more, six or more, seven or more, eight or more, nine or more, or all of the functional properties
listed as (1) through (16) above. The antibody can be, for example, a human antibody, a humanized antibody or
a chimeric antibody.
An isolated IM3 antibody, or antigen binding portion thereof, can comprise a heavy chain
and a light chain, wherein:
(a) the heavy chain ses an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or
99% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-28, , and
349-352, or comprises 1, 2, 3, 4, 5, 1-2, 1-3, 1-4, 1-5, 1-10, 1-15, 1-20, 1-25, or 1-50 amino acid changes (i.e.,
amino acid substitutions, additions or deletions) relative to an amino acid sequence selected from the group
consisting of SEQ ID NOs: 1-28, 72-111, and 349-352, with the proviso that, in certain ments, if the
sequence is that of an effectorless heavy chain, the mutations rendering the heavy chain effectorless are not
modified (e.g.., no modification is made to R214, A234, E235, A237, S330 and S331) for IgG1.1 constant
regions, and no modification is made to R214, A234 and E235 for IgG1.3 constant regions, wherein optionally
the heavy chain variable region comprises the CDR sequences of one of the anti-TIM3 antibodies described
herein;
(b) the light chain comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or
99% cal to an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-31, or
comprises 1, 2, 3, 4, 5, 1-2, 1-3, 1-4, 1-5, 1-10, 1-15, 1-20, 1-25, or 1-50 amino acid changes (i.e., amino acid
substitutions, additions or deletions) relative to an amino acid sequence selected from the group consisting of
SEQ ID NOs: 29-31, wherein optionally the light chain variable region comprises the CDR sequences of one of
the IM3 antibodies described herein;
(c) the dy specifically binds to human TIM3, and
(d) the antibody exhibits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all of the following functional
properties:
(1) g to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore, e.g., as described in the Examples;
(2) binding to soluble cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
ed by Biacore, e.g., as described in the Examples;
(3) g to ne bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as ed by flow cytometry (e.g., as described in the Examples);
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the es;
) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow try (e.g., as described in the es);
(6) g to membrane bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by Scatchard analysis, e.g., as described in the Examples;
(7) inducing or enhancing T cell activation (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ tion in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
ed proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs), e.g., as described in the Examples;
(8) stimulating T cell proliferation in a mixed lymphocyte on (MLR) assay, e.g., as described in the
Examples;
(9) ting the binding of phosphatidylserine to TIM3, e.g., as ed by PS-hTIM3 "in-tandem" blocking
assay, e.g., as described in the Examples;
(10) not internalizing or downregulating cell e TIM3 when binding to TIM3 on cells;
(11) binding to one of the following regions of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297), e.g., as described in the
Examples;
(12) having reduced g to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wildtype
human TIM3, e.g., as described in the Examples;
(13) competing in either direction or both directions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, TIM3.7, TIM3.8, TIM3.10,
TIM3.11, TIM3.12, TIM3.13, 4, TIM3.15, TIM3.16, TIM3.17, and TIM3.18, e.g., as described in the
Examples;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the Examples; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to g to wildtype human TIM3; (b) g to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the Examples; and/or (c)
completing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
described in the Examples.
Also ed are anti-TIM3 antibodies comprising a VH CDR1, VH CDR2, VH CDR3, VL
CDR1, VL CDR2, and/or VL CDR3 that differs from the corresponding CDR of 13A3, 3G4, 17C3, 17C8, 9F6,
8B9, 8C4 or any of TIM3.2 to TIM3.18 in 1, 2, 3, 4, 5, 1-2, 1-3, 1-4, or 1-5 amino acid s (i.e., amino acid
substitutions, additions or deletions). In certain ments, an anti-TIM3 antibody comprises 1-5 amino acid
changes in each of 1, 2, 3, 4, 5 or 6 of the CDRs relative to the corresponding sequence in 13A3, 3G4, 17C3,
17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to TIM3.18. In certain embodiments, an anti-TIM3 antibody comprises
at total of 1-5 amino acid s across all CDRs relative to the CDRs in 13A3, 3G4, 17C3, 17C8, 9F6, 8B9,
8C4 or any of TIM3.2 to TIM3.18.
In certain embodiments, an anti-TIM3 antibody comprises VH and VL CDRs consisting of those
of 13A3, wherein one or more of the amino acids in one or more CDRs are those of one of the other anti-TIM3
antibodies disclosed .
For example, in certain embodiments, an anti-TIM3 antibody comprises a VH CDR1 comprising
one or more amino acid modifications relative to G (SEQ ID NO: 41), and can comprise, e.g., the
following degenerate sequence: X1X2X3X4YX5X6 (SEQ ID NO: 282), wherein X1 is any amino acid, e.g., S or
none; X2 is any amino acid, e.g., R or none; X3 is any amino acid, e.g., S, R, or D; X4 is any amino acid, e.g., Y
or H; X5 is any amino acid, e.g., W or M; and X6 is any amino acid, e.g., G, N, S, or H.
In certain embodiments, an anti-TIM3 antibody comprises a VH CDR2 comprising one or more
amino acid modifications relative to SIYYSGFTYYNPSLKS (SEQ ID NO: 46), and can comprise, e.g., the
following rate sequence: X1IX2X3X4GX5X6X7X8YX9X10X11X12X13X14 (SEQ ID NO: 283), wherein X1 is
any amino acid, e.g., S, Y, I, or F; X2 is any amino acid, e.g., Y, H, N, or S; X3 is any amino acid, e.g., Y, P, G,
T, or S; X4 is any amino acid, e.g., S, T, R, or G; X5 is any amino acid, e.g., F, S, or D; X6 is any amino acid,
e.g., S, T, or I; X7 is any amino acid, e.g., I or none; X8 is any amino acid, e.g., Y, N, or I; X9 is any amino
acid, e.g., N, Q, S, or A; X10 is any amino acid, e.g., P, S, Q, or D; X11 is any amino acid, e.g., S or K; X12 is
any amino acid, e.g., L, F, or V; X13 is any amino acid, e.g., K or Q; and X14 is any amino acid, e.g., S or G.
In n embodiments, an anti-TIM3 antibody comprises a VH CDR3 comprising one or more
amino acid modifications relative to YAHWFDP (SEQ ID NO: 53), and can comprise, e.g., the
following degenerate sequence: X1X2X3X4X5X6X7X8X9X10YGX11X12X13X14X15X16X17X18 (SEQ ID NO: 284),
wherein X1 is any amino acid, e.g., D, E, or none; X2 is any amino acid, e.g., F, G, or none; X3 is any amino
acid, e.g., Y or none; X4 is any amino acid, e.g., G, S, or none; X5 is any amino acid, e.g., G, T, or S; X6 is any
amino acid, e.g., G or S; X7 is any amino acid, e.g., N, W, or none; X8 is any amino acid, e.g., Y, S, E, or none;
X9 is any amino acid, e.g., Y or none; X10 is any amino acid, e.g., P or Y; X11 is any amino acid, e.g., D or
none; X12 is any amino acid, e.g., Y or none; X13 is any amino acid, e.g., A or none; X14 is any amino acid,
e.g., H or none; X15 is any amino acid, e.g., W or none; X16 is any amino acid, e.g., F or M; X17 is any amino
acid, e.g., D or E; and X18 is any amino acid, e.g., P, I, V, Y, or L.
In certain embodiments, an anti-TIM3 antibody comprises a VH CDR3 sing an amino acid
sequence selected from the group consisting of SEQ ID NOs: 53-59 and 126-129.
In certain embodiments, an anti-TIM3 dy comprises a VL CDR1 comprising an amino acid
sequence as set forth in SEQ ID NO: 64 or SEQ ID NO: 65.
In certain embodiments, an anti-TIM3 antibody comprises a VL CDR2 comprising an amino acid
sequence as set forth in SEQ ID NO: 66 or SEQ ID NO: 67.
In certain embodiments, an IM3 antibody comprises a VL CDR3 sing one or more
amino acid modifications relative to QQYGSSPIT (SEQ ID NO: 68), and can comprise, e.g., the following
degenerate sequence: QQX1X2SX3X4X5T (SEQ ID NO: 285), wherein X1 is any amino acid, e.g., F or Y; X2 is
any amino acid, e.g., N or G; X3 is any amino acid, e.g., Y or S; X4 is any amino acid, e.g., P or none; X5 is any
amino acid, e.g., I, R, or L.
Antibodies having sequences with homology to those of 13A3, 8B9, 8C4, 17C3, 9F6, 3G4, 8C4 or
any of TIM3.2 to TIM3.18, e.g., the VH and VL regions of SEQ ID NOs: 34-40,112-121, or 364, and SEQ ID
NOs: 60-63, respectively, or heavy and light chains of SEQ ID NOs: 1-28, 72-111, or 349-352, and SEQ ID
NOs: 29-33, respectively, or CDRs, can be obtained by mutagenesis (e.g., site-directed or PCR-mediated
mutagenesis) of nucleic acid molecules encoding SEQ ID NOs: 167-173 and/or SEQ ID NOs: 193-196 or SEQ
ID NOs: 134-161 and/or SEQ ID NOs: 162-166, followed by g of the encoded altered antibody for
retained function (i.e., the functions set forth in (1) through (16) above) using the functional assays described
herein.
V. Antibodies with Conservative Modifications
IM3 antibodies can comprise a heavy chain variable region comprising CDR1, CDR2 and
CDR3 sequences and a light chain variable region sing CDR1, CDR2 and CDR3 sequences, wherein one
or more of these CDR sequences comprise specified amino acid sequences based on the anti-TIM3 antibodies
described herein (e.g., 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to TIM3.18), or conservative
modifications thereof, and n the antibodies retain the desired functional properties of the anti-TIM3
antibodies described herein. ingly, an isolated anti-TIM3 antibody, or antigen binding portion thereof,
can comprise a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain
le region comprising CDR1, CDR2, and CDR3 sequences, wherein:
(a) the heavy chain variable region CDR3 sequence ses an amino acid sequence selected from the group
consisting of amino acid sequences of SEQ ID NOs: 53-59 and 126-129, and conservative modifications
thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions, wherein ally the
heavy chain variable region comprises the CDR sequences of one of the anti-TIM3 antibodies described herein;
(b) the light chain variable region CDR3 sequence comprises an amino acid sequence selected from the group
consisting of amino acid sequence of SEQ ID NOs: 68-71, and conservative cations thereof, e.g., 1, 2, 3,
4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions, wherein optionally the light chain variable
region comprises the CDR sequences of one of the anti-TIM3 antibodies described ;
(c) the antibody specifically binds to human TIM3, and
(d) the antibody exhibits 1, 2, 3, 4, 5, 6, 7, 8, 9 or all of the following features:
(1) binding to e human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore, e.g., as bed in the Examples;
(2) binding to soluble cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore, e.g., as described in the Examples;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as ed by flow cytometry (e.g., as described in the Examples);
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the Examples;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(6) binding to ne bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by Scatchard analysis, e.g., as described in the Examples;
(7) inducing or enhancing T cell activation (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs), e.g., as bed in the es;
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay, e.g., as described in the
Examples;
(9) inhibiting the binding of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" ng
assay, e.g., as described in the es;
(10) not internalizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following regions of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297), e.g., as described in the
Examples;
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118 and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wildtype
human TIM3, e.g., as described in the Examples;
(13) competing in either direction or both directions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or TIM3.7, TIM3.8, 0,
TIM3.11, TIM3.12, TIM3.13, TIM3.14, TIM3.15, TIM3.16, TIM3.17, and TIM3.18, e.g., as bed in the
Examples;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain le regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as ined by
X-ray llography (e.g., described in the Examples; ing per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with r amino acid relative to binding to wildtype human TIM3; (b) binding to
WGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the Examples; and/or (c)
competing with or cross-blocking with the binding to human TIM3 of 13A3 or TIM3.18.IgG1.3, e.g., as
described in the Examples.
In one embodiment, the heavy chain variable region CDR2 sequence comprises an amino acid
sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 46-52 and 122-125, and
conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions;
and the light chain variable region CDR2 sequence comprises an amino acid sequence ed from the group
consisting of amino acid sequences of SEQ ID NOs: 66-67, and conservative modifications thereof, e.g., 1, 2, 3,
4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions.
In another embodiment, the heavy chain variable region CDR1 sequence comprises an amino acid
sequence selected from the group consisting of amino acid sequences of SEQ ID NOs: 41-45, and conservative
modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 vative amino acid substitutions; and the light
chain variable region CDR1 sequence comprises an amino acid sequence selected from the group ting of
amino acid sequences of SEQ ID NOs: 64-65, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3,
1-4 or 1-5 conservative amino acid substitutions.
In various embodiments, the antibody can exhibit one or more, two or more, three or more, four or
more, five or more, six or more, seven or more, eight or more, nine or more, or all of the functional properties
listed as (1) h (16) above. Such antibodies can be, for example, human antibodies, humanized antibodies
or chimeric antibodies.
vative amino acid substitutions can also be made in portions of the antibodies other than, or
in addition to, the CDRs. For example, conservative amino acid modifications can be made in a framework
region or in the Fc region. A variable region or a heavy or light chain can comprise 1, 2, 3, 4, 5, 1-2, 1-3, 1-4, 1-
, 1-10, 1-15, 1-20, 1-25, or 1-50 conservative amino acid substitutions relative to the anti-TIM3 antibody
sequences provided herein. In certain embodiments, an anti-TIM3 antibody comprises a combination of
conservative and non-conservative amino acid modification.
VI. dies binding to the same e or competing for binding
Also provided are antibodies that compete for g to human TIM3 with one or more of the
particular anti-TIM3 antibodies described herein (e.g., antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4
and/or TIM3.2-TIM3.18). Such competing antibodies can be fied based on their ability to competitively
inhibit binding to human TIM3 of one or more of monoclonal antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9,
8C4 and/or TIM3.2-TIM3.18 in standard TIM3 binding assays. For example, standard ELISA assays or
competitive ELISA assays can be used in which a recombinant human TIM3 protein is immobilized on the
plate, various concentrations of unlabeled first antibody is added, the plate is , labeled second antibody is
added, and the amount of label is measured. If the sing concentration of the unlabeled (first) antibody
(also ed to as the "blocking antibody") ts the binding of the labeled (second) antibody, the first
antibody is said to inhibit the binding of the second antibody to the target on the plate, or is said to compete with
the binding of the second antibody. Additionally or alternatively, Biacore analysis can be used to assess the
ability of the antibodies to compete. The ability of a test antibody to inhibit the binding of an anti-TIM3
antibody described herein to TIM3 demonstrates that the test antibody can compete with the antibody for
binding to human TIM3.
Accordingly, provided herein are IM3 antibodies that t the binding of an anti-TIM3
antibodies described herein to TIM3 on cells, e.g., activated T cells, by at least 50%, 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% and/or whose binding to
human TIM3 on cells, e.g., activated T cells, is inhibited by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% , e.g., as measured by ELISA or FACS,
such as by using the assay bed in the following paragraph.
An exemplary competition experiment to determine, e.g., whether a first antibody blocks the
binding of (i.e., "competes with") a second antibody, can be conducted as described in the Examples, or as
follows: activated human T cells are prepared as follows: Peripheral Blood Mononuclear Cells (PBMCs) are
isolated from human whole blood using Ficoll gradient and activated with 10μg/mL phytohaemagglutinin
(PHA-L) (USBiol#P3370-30) and 200IU/mL recombinant IL-2 (Peprotech#200-02) for 3 days. The activated T
cells are resuspended in FACS buffer (PBS with 5% Fetal Bovine Serum) and seeded at 105 cells per sample
well in a 96 well plate. The plate is set on ice followed by the addition of unconjugated first antibody at
concentrations ranging from 0 to 50 μg/mL (three-fold titration starting from a highest concentration of 50
μg/mL). An unrelated IgG can be used as an isotype control for the first antibody and added at the same
concentrations -fold ion starting from a highest concentration of 50μg/mL). A sample pre-incubated
with 50μg/mL unlabeled second antibody can be included as a positive l for complete blocking (100%
inhibition) and a sample without antibody in the primary incubation can be used as a negative control (no
competition; 0% inhibition). After 30 minutes of incubation, labeled, e.g., ylated, second antibody is added
at a concentration of 2μg/mL per well without washing. Samples are incubated for another 30 s on ice.
Unbound antibodies are removed by washing the cells with FACS buffer. Cell-bound labeled second antibody is
detected with an agent that detects the label, e.g., PE ated streptavidin (Invitrogen, catalog#S21388) for
detecting biotin. The samples are ed on a FACS Calibur Flow Cytometer (BD, San Jose) and analyzed
with FLOWJO® software (Tree Star, Inc, Ashland, OR). The results can be represented as the % inhibition (i.e.,
subtracting from 100% the amount of label at each concentration divided by the amount of label obtained with
no blocking antibody). Typically, the same experiment is then conducted in the reverse, i.e., the first antibody is
the second antibody and the second antibody is the first dy.
In certain ments, an antibody at least partially (e.g., at least 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, or 90%) or completely (100%) blocks the binding of the other dy to the target, e.g.,
human TIM3 or n thereof, and less of whether inhibition occurs when one or the other antibody is
the first dy. A first and a second antibody "cross-block" binding of each other to the target, when the
antibodies compete with each other both ways, i.e., in competition experiments in which the first antibody is
added first and in competition experiments in which the second antibody is added first.
In certain embodiments, anti-TIM3 antibodies bind to the same epitope as that of the anti-TIM3
antibodies described herein (e.g., 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 and/or TIM3.2-TIM3.18), e.g., as
determined by a given epitope mapping technique. Techniques for determining dies that bind to the "same
e on TIM3" with the anti-TIM3 antibodies bed herein include, for example, epitope g
s, such as, x-ray analyses of crystals of antigen:antibody complexes which provides atomic resolution of
the epitope. Other methods r the binding of the antibody to n fragments or mutated variations of the
antigen where loss of binding due to a modification of an amino acid residue within the antigen sequence is
often considered an indication of an epitope component (see ). In addition, computational combinatorial
methods for epitope mapping can also be used. Methods can also rely on the ability of an antibody of interest to
affinity isolate specific short peptides (either in native three dimensional form or in denatured form) from
atorial phage display e libraries. The peptides are then regarded as leads for the definition of the
epitope corresponding to the antibody used to screen the peptide library. For epitope mapping, computational
algorithms have also been developed which have been shown to map mational discontinuous epitopes.
Antibodies that compete for binding with, or bind to the same epitope as, the anti-TIM3 antibodies
described herein can be identified by using art-known s. For example, mice can be zed with
human TIM3 as described , hybridomas produced, and the resulting monoclonal antibodies screened for
the ability to compete with an antibody described herein for g to human TIM3. Mice can also be
immunized with a smaller fragment of TIM3 containing the epitope to which the antibody binds. The epitope or
region comprising the e can be localized by, e.g., screening for binding to a series of overlapping peptides
spanning TIM3. Alternatively, the method of Jespers et al., Biotechnology 12:899, 1994 can be used to guide
the selection of antibodies having the same epitope and therefore similar properties to an anti-TIM3 antibody
described herein. Using phage display, first the heavy chain of the anti-TIM3 antibody is paired with a repertoire
of ) light chains to select a TIM3-binding antibody, and then the new light chain is paired with a
repertoire of (human) heavy chains to select a (human) TIM3-binding antibody having the same epitope or
epitope region as an anti-TIM3 antibody described herein. Alternatively variants of an antibody described herein
can be obtained by mutagenesis of cDNA encoding the heavy and light chains of the antibody.
Alanine scanning mutagenesis, as described by gham and Wells (1989) Science 244: 1081-
1085, or some other form of point mutagenesis of amino acid residues in TIM3 can also be used to obtain TIM3
antibody binding teristics.
Binding characteristics of a specific antibody can also be determined by ing g of the
antibody to peptides comprising fragments of TIM3, e.g., non-denatured or denatured fragments. A series of
overlapping peptides encompassing the sequence of TIM3 (e.g., human TIM3) can be synthesized and screened
for binding, e.g., in a direct ELISA, a competitive ELISA (where the peptide is assessed for its ability to prevent
binding of an antibody to TIM3 bound to a well of a micro titer plate), or on a chip.
Binding teristics of anti-TIM3 antibodies can also be ed by MS-based protein
inting, such as Hydrogen/deuterium exchange mass spectrometry S) and Fast Photochemical
Oxidation of Proteins (FPOP). HDX-MS can be conducted, e.g., as described in WO2015/18735 and in Wei et
al. (2014) Drug Discovery Today 19:95, the methods of which are specifically orated by reference herein.
FPOP can be ted as described, e.g., in Hambley and Gross (2005) J. American Soc. Mass Spectrometry
16:2057, the methods of which are specifically incorporated by reference herein.
Binding characteristics anti-TIM3 antibodies can also be obtained by structural methods, such as
X-ray crystal ure determination (e.g., WO2005/044853), molecular modeling and nuclear magnetic
resonance (NMR) spectroscopy, including NMR determination of the H-D exchange rates of labile amide
hydrogens in TIM3 when free and when bound in a complex with an antibody of interest (Zinn- Justin et al.
(1992) Biochemistry 31, 11335-11347; Zinn-Justin et al. (1993) Biochemistry 32, 6884-6891).
With regard to X-ray crystallography, crystallization can be accomplished using any of the known
methods in the art (e.g., Giege et al. (1994) Acta Crystallogr. 9-350; McPherson (1990) Eur. J. Biochem.
189: 1-23), including microbatch (e.g., Chayen (1997) Structure 5: 1269-1274), hanging-drop vapor diffusion
(e.g., McPherson (1976) J. Biol. Chem. 00-6303), seeding and dialysis. It is desirable to use a protein
preparation having a concentration of at least about 1 mg/mL or about 10 mg/mL to about 20 mg/mL.
Crystallization can be best achieved in a precipitant solution ning polyethylene glycol 1000-20,000 (PEG;
average molecular weight g from about 1000 to about 20,000 Da), about 5000 to about 7000 Da, or about
6000 Da, with concentrations ranging from about 10% to about 30% (w/v). It can also be desirable to include a
protein stabilizing agent, e.g., glycerol at a concentration ranging from about 0.5% to about 20%. A suitable salt,
such as sodium chloride, lithium chloride or sodium citrate can also be ble in the itant solution, in a
concentration ranging from about 1 mM to about 1000 mM. The precipitant is buffered to a pH of from about
3.0 to about 5.0. Specific buffers useful in the precipitant solution can vary and are well-known in the art
(Scopes, Protein Purification: ples and Practice, Third ed., (1994) Springer- Verlag, New York). es
of useful buffers include, but are not limited to, HEPES, Tris, MES and acetate. Crystals can be grow at a wide
range of temperatures, ing 2° C, 4° C, 8° C and 26° C.
Antibody: antigen crystals can be studied using well-known X-ray diffraction techniques and can
be refined using computer software such as X-PLOR (Yale University, 1992, buted by Molecular
Simulations, Inc.; see e.g., Blundell & Johnson (1985) Meth. Enzymol. 114 & 115, H. W. Wyckoff et al., eds.,
ic Press; U.S. Patent Application Publication No. 2004/0014194), and BUSTER (Bricogne (1993) Acta
Cryst. D49:37-60; Bricogne (1997) Meth. Enzymol. 276A:361-423, Carter & Sweet, eds.; Roversi et al. (2000)
Acta Cryst. D56: 1313-1323), the sures of which are hereby incorporated by reference in their entireties.
Anti-TIM3 antibodies can bind to the same epitope as any of the anti-TIM3 antibodies having
amino acid sequences described herein, as determined by an epitope mapping technique, such as a technique
described herein.
Antibodies binding to human TIM3 and optionally cyno TIM3 with similar binding characteristics
as the anti-TIM3 antibodies described herein and determined by one of the methods used in the Examples, are
encompassed herein.
In certain embodiments, anti-TIM3 antibodies described herein bind to an epitope, e.g., a
conformational epitope, in the extracellular portion of human TIM3, e.g., in the Ig like domain or IgV domain of
the extracellular region, i.e., amino acids 22 to 130 of SEQ ID NO: 286 (). In certain embodiments, an
IM3 antibody binds to an epitope d within amino acids 22 to 120 of human TIM3 extracellular
domain (SEQ ID NO: 286) or 1-99 of mature human TIM3 (SEQ ID NO: 290) (see Examples). In certain
embodiments, an anti-TIM3 antibody binds to, or to an e within, a region consisting of amino acids 58-64
of human TIM3 having SEQ ID NO: 286, which corresponds to amino acid residues 37-43 of mature human
TIM3 (CPVFECG, SEQ ID NO: 296; see ). In certain embodiments, an anti-TIM3 antibody binds to, or
to an e within, a region consisting of amino acids 111-120 of human TIM3 having SEQ ID NO: 286,
which corresponds to amino acid es 90-99 of mature human TIM3 (RIQIPGIMND, SEQ ID NO: 298; see
). In certain embodiments, an anti-TIM3 antibody binds to, or to an epitope within, a region consisting of
amino acids 58-64 of human TIM3 having SEQ ID NO: 286 (CPVFECG, SEQ ID NO296) and a region
consisting of amino acids 111-120 of human TIM3 having SEQ ID NO: 286 (RIQIPGIMND, SEQ ID NO: 298;
see ). In n ments, an anti-TIM3 antibody binds to, or to an epitope within, a region
consisting of amino acids 78-89 of human TIM3 having SEQ ID NO: 286, which corresponds to amino acid
residues 57-83 of mature human TIM3 (WTSRYWLNGDFR, SEQ ID NO: 297; see ).
In one embodiment, an anti-TIM3 antibody binds to substantially the same epitope as that of 13A3.
In certain embodiments, an anti-TIM3 antibody binds to an epitope (or region of human TIM3) comprising one
or more of amino acid residues C58, P59, F61, E62, C63, R111, and D120 of SEQ ID NO: 286 (). In
some embodiments, an anti-TIM3 dy binds to an epitope (or region of human TIM3) comprising one or
more of amino acid es C58, P59, F61, E62, C63, D104, R111, Q113 and D120 of SEQ ID NO: 286 (). In certain embodiments, an anti-TIM3 dy does not bind significantly, or only with significantly
reduced binding ty, to a human TIM3 protein in which one or more of amino acid residues C58, P59, F61,
E62, C63, R111, and D120 of SEQ ID NO: 286 is changed to another amino acid, e.g., in a non-conservative
amino acid substitution. In certain embodiments, an anti-TIM3 dy does not bind significantly, or only
with significantly reduced binding affinity, to a human TIM3 protein in which one or more of amino acid
residues C58, P59, F61, E62, C63, D104, R111, Q113 and D120 of SEQ ID NO: 286 is changed to r
amino acid, e.g., in a non-conservative amino acid substitution.
In some embodiments, an anti-TIM3 dy binds to substantially the same epitope as that of
3G4. In some embodiments, an anti-TIM3 antibody binds to an epitope (or region of human TIM3) comprising
one or more of amino acids residues C58, P59, V60, F61, E62, C63, G116, and M118 of SEQ ID NO: 286 (). In some embodiments, an anti-TIM3 antibody binds to an epitope (or region of human TIM3) comprising
one or more of amino acid residues C58, P59, V60, F61, E62, C63, D104, G116, and M118 of SEQ ID NO: 286
(). In certain embodiments, an anti-TIM3 antibody does not bind significantly, or only with icantly
reduced g affinity, to a human TIM3 protein in which one or more of amino acid residues C58, P59, V60,
F61, E62, C63, G116, and M118 of SEQ ID NO: 286 is d to another amino acid, e.g., in a nonconservative
amino acid substitution. In certain embodiments, an anti-TIM3 antibody does not bind
significantly, or only with significantly reduced binding ty, to a human TIM3 protein in which one or more
of amino acid residues C58, P59, V60, F61, E62, C63, D104, G116, and M118 of SEQ ID NO: 286 is changed
to another amino acid, e.g., in a non-conservative amino acid substitution.
In some embodiments, an anti-TIM3 antibody binds to substantially the same epitope as that of
17C3. In certain embodiments, an anti-TIM3 dy binds to an epitope (or region of human TIM3)
comprising one or more of amino acids residues C58, P59, V60, F61, E62, C63, G64, and G116 of SEQ ID NO:
286 (). In some ments, an anti-TIM3 antibody binds to an e (or region of human TIM3)
comprising one or more of amino acid residues C58, P59, V60, F61, E62, C63, G64, D104, and G116 of SEQ
ID NO: 286 (). In certain embodiments, an anti-TIM3 antibody does not bind icantly, or only with
significantly reduced binding affinity, to a human TIM3 protein in which one or more of amino acid residues
C58, P59, V60, F61, E62, C63, G64, and G116 of SEQ ID NO: 286 is changed to another amino acid, e.g., in a
non-conservative amino acid substitution. In certain embodiments, an anti-TIM3 antibody does not bind
significantly, or only with significantly reduced binding ty, to a human TIM3 protein in which one or more
of amino acid residues C58, P59, V60, F61, E62, C63, G64, D104, and G116 of SEQ ID NO: 286 is changed to
another amino acid, e.g., in a non-conservative amino acid substitution.
In some embodiments, an anti-TIM3 antibody binds to substantially the same epitope as that of
8B9. In certain embodiments, an anti-TIM3 antibody binds to an epitope (or region of human TIM3) comprising
one or more of amino acids residues L48, W78, S80, R81, W83, G86, D87, and R89 of SEQ ID NO: 286 (). In some embodiments, an anti-TIM3 antibody binds to an epitope (or region of human TIM3) comprising
one or more of amino acid residues L48, W78, S80, R81, W83, L84, G86, D87, and R89 of SEQ ID NO: 286
(). In some embodiments, an anti-TIM3 antibody binds to substantially the same epitope as that of 8B9.
In certain embodiments, an anti-TIM3 antibody binds to an epitope (or region of human TIM3) comprising one
or more of amino acids residues L48, W78, S80, R81, W83, G86, D87, R89, and D104 of SEQ ID NO: 286
(). In certain embodiments, an IM3 antibody does not bind significantly, or only with significantly
reduced binding affinity, to a human TIM3 protein in which one or more of amino acid residues L48, W78, S80,
R81, W83, G86, D87, and R89 of SEQ ID NO: 286 is changed to r amino acid, e.g., in a nonconservative
amino acid substitution. In certain embodiments, an anti-TIM3 antibody does not bind
significantly, or only with significantly reduced binding affinity, to a human TIM3 protein in which one or more
of amino acid residues L48, W78, S80, R81, W83, L84, G86, D87, and R89 of SEQ ID NO: 286 is changed to
r amino acid, e.g., in a non-conservative amino acid substitution. In n embodiments, an anti-TIM3
antibody does not bind significantly, or only with significantly reduced binding affinity, to a human TIM3
n in which one or more of amino acid residues L48, W78, S80, R81, W83, G86, D87, R89, and D104 of
SEQ ID NO: 286 () is d to another amino acid, e.g., in a nservative amino acid
substitution.
In certain embodiments, anti-TIM3 antibodies compete for binding to human TIM3 with (or inhibit
binding of) anti-TIM3 antibodies comprising CDRs or variable regions bed herein, e.g., those of
antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 and any of TIM3.2 to TIM3.18. In certain embodiments,
anti-TIM3 antibodies t binding of antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to
TIM3.18 to human TIM3 by at least 50%, 60%, 70%, 80%, 90% or by 100%. In certain ments, 13A3,
3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to TIM3.18 inhibit binding of anti-TIM3 antibodies to
human TIM3 by at least 50%, 60%, 70%, 80%, 90% or by 100%. In certain embodiments, anti-TIM3 antibodies
inhibit binding of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to 8 to human TIM3 by at
least 50%, 60%, 70%, 80%, 90% or by 100% and 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to
TIM3.18 inhibit binding of the anti-TIM3 antibodies to human TIM3 by at least 50%, 60%, 70%, 80%, 90% or
by 100% (e.g., e in both directions).
VII. Engineered and Modified dies
Also provided are engineered and modified antibodies that can be prepared using an antibody
having one or more of the VH and/or VL sequences disclosed herein as starting material to engineer a modified
antibody, which modified antibody can have d properties from the ng antibody. An antibody can be
engineered by modifying one or more residues within one or both variable regions (i.e., VH and/or VL), for
example within one or more CDR regions and/or within one or more framework regions. Additionally or
alternatively, an antibody can be engineered by modifying residues within the constant region(s), for example to
alter the effector on(s) of the dy.
One type of variable region engineering that can be performed is CDR grafting. Antibodies interact
with target ns predominantly through amino acid residues that are located in the six heavy and light chain
complementarity determining regions (CDRs). For this reason, the amino acid sequences within CDRs are more
diverse between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible
for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties
of specific naturally occurring antibodies by constructing sion vectors that include CDR sequences from
the specific naturally occurring antibody grafted onto framework ces from a different antibody with
different properties (see, e.g., ann, L. et al. (1998) Nature 332:323-327; Jones, P. et al. (1986) Nature
321 :522-525; Queen, C. et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86: 10029-10033; U.S. Patent No. 5,225,539
to Winter, and U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen et al.).
Accordingly, another embodiment described herein pertains to an ed monoclonal antibody, or
antigen binding portion thereof, sing a heavy chain variable region comprising CDR1, CDR2, and CDR3
sequences comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-45, SEQ
ID NOs: 46-52, 122-125, and SEQ ID NOs: 53-59, 126-129, respectively, and a light chain variable region
comprising CDR1, CDR2, and CDR3 sequences comprising an amino acid sequence ed from the group
consisting of SEQ ID NOs: 64-65, SEQ ID NOs: 66-67, and SEQ ID NOs: 68-71, respectively. Thus, such
antibodies contain the VH and VL CDR sequences of monoclonal antibodies 13A3, 3G4, 17C3, 17C8, 9F6,
8B9, 8C4 or any one of TIM3.2 to TIM3.18, yet can contain different framework ces from these
antibodies.
Such framework sequences can be obtained from public DNA databases or published references
that include germline antibody gene sequences. For example, germline DNA sequences for human heavy and
light chain variable region genes can be found in the "VBase" human germline sequence database able on
the Internet at www.mrc-cpe.cam.ac.uk/vbase), as well as in Kabat, E. A., et al. (1991) Sequences of Proteins of
Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.
91-3242; Tomlinson, I. M., et al. (1992) "The Repertoire of Human Germline VH Sequences Reveals about Fifty
Groups of VH Segments with Different Hypervariable Loops" /. Mol. Biol. 227:776-798; and Cox, J. P. L. et al.
(1994) "A ory of Human Germ-line VH Segments s a Strong Bias in their Usage" Eur. J. Immunol.
24:827-836; the contents of each of which are expressly incorporated herein by nce.
In some embodiments, the framework sequences for use in the anti-TIM3 antibodies described
herein are those that are structurally similar to the framework ces used by the anti-TIM3 antibodies
described herein. The VH CDR1, 2 and 3 sequences, and the VL CDR1, 2 and 3 sequences, can be grafted onto
framework s that have the cal sequence as that found in the germline immunoglobulin gene from
which the framework sequence derive, or the CDR sequences can be grafted onto framework regions that
n one or more mutations as compared to the germline sequences. For example, it has been found that in
certain instances it is beneficial to mutate residues within the framework regions to maintain or enhance the
antigen g ability of the antibody (see e.g., U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and
6,180,370 to Queen et al).
Engineered anti-TIM3 antibodies described herein include those in which modifications have been
made to framework residues within VH and/or VL, e.g., to improve the properties of the dy, e.g., a
mutation at amino acid 107 in 9F6. Typically such ork modifications are made to decrease the
immunogenicity of the antibody. For example, one approach is to "backmutate" one or more framework residues
to the ponding germline sequence. More specifically, an antibody that has undergone somatic mutation
can contain framework es that differ from the germline sequence from which the antibody is derived. Such
residues can be identified by comparing the antibody framework sequences to the germline ces from
which the antibody is derived. To return the framework region sequences to their germline configuration, the
somatic mutations can be "backmutated" to the germline sequence by, for example, site-directed mutagenesis or
PCR-mediated mutagenesis. Such "backmutated" antibodies are also intended to be encompassed. Another type
of ork modification involves mutating one or more residues within the framework region, or even within
one or more CDR regions, to remove T cell epitopes to thereby reduce the potential immunogenicity of the
antibody. This ch is also referred to as "deimmunization" and is described in further detail in U.S. Patent
Publication No. 20030153043 by Carr et al.
r type of variable region modification is to mutate amino acid residues within the VH
and/or VL CDR1, CDR2 and/or CDR3 regions to thereby improve one or more binding ties (e.g., affinity)
of the antibody of st. Site-directed mutagenesis or PCR-mediated mutagenesis can be performed to
introduce the mutation(s) and the effect on antibody g, or other onal property of interest, can be
ted in in vitro or in vivo assays as described herein and provided in the Examples. In some embodiments,
conservative modifications (as discussed above) are introduced. The mutations can be amino acid substitutions,
additions or deletions. Moreover, typically no more than one, two, three, four or five residues within a CDR
region are altered.
Accordingly, also provided are isolated anti-TIM3 monoclonal antibodies, or antigen g
portions thereof, comprising a heavy chain variable region comprising:
(a) a VH CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
41-45, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or
ons as compared to SEQ ID NOs: 41-45;
(b) a VH CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
46-52 and 5, or an amino acid sequence having one, two, three, four or five amino acid substitutions,
deletions or additions as compared to SEQ ID NOs: 46-52 and 122-125;
(c) a VH CDR3 region sing an amino acid sequence selected from the group consisting of SEQ ID NOs:
53-59 and 126-129, or an amino acid sequence having one, two, three, four or five amino acid substitutions,
deletions or additions as compared to SEQ ID NOs: 53-59 and 126-129;
(d) a VL CDR1 region sing an amino acid ce ed from the group consisting of SEQ ID NOs:
64-65, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or
additions as compared to SEQ ID NOs: 64-65;
(e) a VL CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
66-67, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or
additions as compared to SEQ ID NOs: 66-67; and
(f) a VL CDR3 region comprising an amino acid ce selected from the group consisting of SEQ ID NOs:
68-71, or an amino acid sequence having one, two, three, four or five amino acid substitutions, deletions or
additions as compared to SEQ ID NOs: 68-71.
Methionine residues in CDRs of antibodies can be oxidized, resulting in potential chemical
degradation and consequent ion in potency of the antibody. Accordingly, also provided are anti-TIM3
antibodies which have one or more methionine residues in the heavy and/or light chain CDRs replaced with
amino acid residues which do not o oxidative degradation. In one embodiment, the methionine residues
in the CDRs of antibodies 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4 or any of TIM3.2 to TIM3.18 are replaced
with amino acid residues which do not undergo oxidative degradation.
Similarly, deamidation sites can be removed from anti-TIM3 antibodies, particularly in the CDRs.
IM3 le regions described herein can be linked (e.g., covalently linked or fused) to an
Fc, e.g., an IgG1, IgG2, IgG3 or IgG4 Fc, which can be of any allotype or isoallotype, e.g., for IgG1: Glm,
Glml(a), Glm2(x), Glm3(f), Glml7(z); for IgG2: G2m, G2m23(n); for IgG3: G3m, gl), G3m28(g5),
G3ml l(b0), G3m5(bl), G3ml3(b3), G3ml4(b4), G3ml0(b5), G3ml5(s), G3ml6(t), G3m6(c3), G3m24(c5),
G3m26(u), G3m27(v); and for K: Km, Km1, Km2, Km3 (see, e.g., Jefferies et al. (2009) mAbs 1:1).
In certain embodiments, IM3 variable regions described herein are linked to an effectorless
or mostly effectorless Fc, e.g., IgG1.
Generally, variable regions described herein can be linked to an Fc comprising one or more
modification, typically to alter one or more functional properties of the antibody, such as serum half-life,
complement fixation, Fc receptor binding, and/or antigen-dependent cellular cytotoxicity. Furthermore, an
antibody described herein can be chemically modified (e.g.,, one or more al moieties can be attached to
the antibody) or be modified to alter its glycosylation, to alter one or more functional properties of the antibody.
Each of these embodiments is described in further detail below. The numbering of residues in the Fc region is
that of the EU index of Kabat.
The Fc region encompasses domains derived from the constant region of an immunoglobulin,
ing a fragment, analog, variant, mutant or derivative of the constant region. Suitable immunoglobulins
include IgG1, IgG2, IgG3, IgG4, and other classes such as IgA, IgD, IgE and IgM, The constant region of an
immunoglobulin is defined as a naturally- occurring or synthetically-produced polypeptide homologous to the
immunoglobulin C-terminal region, and can include a CH1 domain, a hinge, a CH2 domain, a CH3 domain, or a
CH4 domain, tely or in combination.
Ig molecules interact with multiple classes of cellular receptors. For example IgG les
ct with three classes of Fcγ receptors (FcγR) specific for the IgG class of antibody, namely FcγRI, ,
and FcγRIII. The ant sequences for the binding of IgG to the FcγR receptors have been reported to be
located in the CH2 and CH3 domains. The serum half-life of an antibody is nced by the ability of that
antibody to bind to an Fc receptor (FcR).
In certain embodiments, the Fc region is a variant Fc , e.g., an Fc sequence that has been
modified (e.g., by amino acid tution, deletion and/or insertion) relative to a parent Fc sequence (e.g., an
unmodified Fc polypeptide that is subsequently modified to generate a variant), to provide desirable structural
features and/or biological activity,
Generally, variants of the constant region or portions thereof, e.g., CH1, CL, hinge, CH2 or CH3
domains can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more mutations, and/or at most 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1
on, or 1-10 or 1-5 mutations, or comprise an amino acid sequence that is at least about 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% identical to that of the corresponding wild-type region or domain (CH1,
CL, hinge, CH2, or CH3 domain, tively), provided that the heavy chain nt region comprising the
specific variant retains the necessary ical activity.
For e, one can make modifications in the Fc region in order to generate an Fc variant that
(a) has increased or decreased antibody-dependent cell-mediated cytotoxicity (ADCC), (b) increased or
decreased complement mediated cytotoxicity (CDC), (c) has increased or decreased affinity for C1q and/or (d)
has sed or decreased affinity for a Fc receptor ve to the parent Fc. Such Fc region variants will
generally comprise at least one amino acid modification in the Fc region. Combining amino acid modifications
is thought to be particularly desirable. For example, the variant Fc region can include two, three, four, five, etc
substitutions n, e.g., of the ic Fc region positions identified herein.
A variant Fc region can also comprise a sequence alteration wherein amino acids involved in
disulfide bond formation are removed or replaced with other amino acids. Such removal can avoid reaction with
other cysteine-containing proteins present in the host cell used to produce the anti-TIM3 antibodies described
herein. Even when cysteine residues are d, single chain Fc domains can still form a dimeric Fc domain
that is held er non-covalently. In other embodiments, the Fc region can be modified to make it more
compatible with a selected host cell. For example, one can remove the PA sequence near the N-terminus of a
l native Fc region, which can be recognized by a digestive enzyme in E. coli such as proline
iminopeptidase. In other ments, one or more glycosylation sites within the Fc domain can be removed.
Residues that are typically glycosylated (e.g., asparagine) can confer tic response. Such residues can be
d or substituted with unglycosylated residues (e.g., alanine). In other embodiments, sites involved in
interaction with complement, such as the C1q g site, can be removed from the Fc region. For example,
one can delete or substitute the EKK sequence of human IgG1. In certain embodiments, sites that affect g
to Fc receptors can be removed, preferably sites other than salvage receptor binding sites. In other embodiments,
an Fc region can be modified to remove an ADCC site. ADCC sites are known in the art; see, for example,
Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. Specific examples of t Fc
s are disclosed for example, in WO 97/34631 and WO 96/32478.
In one embodiment, the hinge region of Fc is modified such that the number of cysteine residues in
the hinge region is altered, e.g., increased or decreased. This approach is described further in U.S. Patent No.
425 by Bodmer et al. The number of cysteine residues in the hinge region of Fc is altered to, for example,
facilitate ly of the light and heavy chains or to increase or decrease the stability of the antibody. In one
embodiment, the Fc hinge region of an antibody is mutated to decrease the biological half-life of the antibody.
More specifically, one or more amino acid ons are introduced into the CH2-CH3 domain interface region
of the Fc-hinge fragment such that the antibody has impaired Staphylococcyl protein A (SpA) binding relative
to native ge domain SpA binding. This approach is described in further detail in U.S. Patent No.
6,165,745 by Ward et al.
In yet other embodiments, the Fc region is altered by replacing at least one amino acid residue with
a different amino acid residue to alter the or function(s) of the antibody. For example, one or more amino
acids selected from amino acid residues 234, 235, 236, 237, 297, 318, 320, 322, 330, and/or 331 can be replaced
with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains
the antigen-binding ability of the parent antibody. The effector ligand to which affinity is altered can be, for
example, an Fc receptor or the C1 component of complement. This approach is described in further detail in
U.S. Patent Nos. 5,624,821 and 5,648,260, both by Winter et al.
In another example, one or more amino acids selected from amino acid residues 329, 331 and 322
can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or
reduced or abolished ment dependent cytotoxicity (CDC). This approach is described in further detail in
U.S. Patent Nos. 6,194,551 by Idusogie et al.
In another example, one or more amino acid residues within amino acid positions 231 and 239 are
d to thereby alter the y of the antibody to fix complement. This approach is described further in PCT
Publication WO 94/29351 by Bodmer et al.
In yet another example, the Fc region can be modified to decrease antibody dependent cellular
cytotoxicity (ADCC) and/or to se the affinity for an Fcγ receptor by modifying one or more amino acids
at the following ons: 234, 235, 236, 238, 239, 240, 241 , 243, 244, 245, 247, 248, 249, 252, 254, 255, 256,
258, 262, 263, 264, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295,
296, 298, 299, 301, 303, 305, 307, 309, 312, 313, 315, 320, 322, 324, 325, 326, 327, 329, 330, 331, 332, 333,
334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 433, 434, 435, 436, 437,
438 or 439. Exemplary substitutions include 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T, 332D, and
332E. Exemplary variants e 239D/332E, 236A/332E, 236A/239D/332E, 268F/324T, 267E/268F,
267E/324T, and 267E/268F7324T. Other modifications for ing FcγR and complement interactions
include but are not d to substitutions 298 A, 333A, 334A, 326A, 2471, 339D, 339Q, 280H, 290S, 298D,
298V, 243L, 292P, 300L, 396L, 3051, and 396L. These and other modifications are reviewed in Strohl, 2009,
Current Opinion in Biotechnology 20:685-691.
Fc modifications that se binding to an Fcγ receptor include amino acid modifications at any
one or more of amino acid positions 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272,
279, 280, 283, 285, 298, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 312, 315, 324, 327, 329,
330, 335, 337, 338, 340, 360, 373, 376, 379, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439
of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in abat
42072).
Other Fc modifications that can be made to Fcs are those for reducing or ablating binding to FcγR
and/or complement proteins, thereby reducing or ablating Fc-mediated effector functions such as ADCC,
ADCP, and CDC. Exemplary cations e but are not limited substitutions, insertions, and deletions at
positions 234, 235, 236, 237, 267, 269, 325, 328, 330, and/or 331 (e.g., 330 and 331), n ing is
according to the EU index. Exemplary substitutions include but are not limited to 234A, 235E, 236R, 237A,
267R, 269R, 325L, 328R, 330S, and 331S (e.g., 330S, and 331S), wherein numbering is according to the EU
index. An Fc variant can comprise 236R/328R. Other modifications for reducing FcγR and complement
interactions include substitutions 297A, 234A, 235A, 237A, 318A, 228P, 236E, 268Q, 309L, 330S, 331 S,
220S, 226S, 229S, 238S, 233P, and 234V, as well as removal of the glycosylation at position 297 by mutational
or enzymatic means or by production in organisms such as bacteria that do not glycosylate proteins. These and
other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20:685-691.
Optionally, the Fc region can comprise a non-naturally occurring amino acid residue at additional
and/or alternative positions known to one skilled in the art (see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375;
6,737,056; 6,194,551; 7,317,091; 720; PCX Patent Publications WO 00/42072; WO 01/58957; WO
02/06919; WO 04/016750; WO 04/029207; WO 04/035752; WO 04/074455; WO 04/099249; WO 04/063351;
WO 05/070963; WO 05/040217, WO 05/092925 and WO 06/0201 14).
Fc variants that enhance affinity for an inhibitory or FcγRIIb can also be used. Such variants
can e an Fc fusion protein with immunomodulatory activities d to FcγRIIb cells, including for
example B cells and monocytes. In one embodiment, the Fc variants provide selectively enhanced affinity to
FcγRIIb relative to one or more activating receptors. Modifications for altering g to FcγRIIb include one
or more modifications at a position selected from the group consisting of 234, 235, 236, 237, 239, 266, 267, 268,
325, 326, 327, 328, 330, 331, and 332, according to the EU index. Exemplary substitutions for enhancing
FcγRllb affinity include but are not limited to 234A, 234D, 234E, 234F, 234W, 235D, 235E, 235F, 235R, 235Y,
236D, 236N, 237A, 237D, 237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W,
328Y, 330S, 331S, and 332E. Exemplary substitutions include 235Y, 236D, 239D, 266M, 267E, 268D, 268E,
328F, 328W, and 328Y. Other Fc variants for ing binding to FcγRIIb include 67E, 236D/267E,
68D, 239D/267E, 267E/268D, 267E/268E, and 28F.
The affinities and binding properties of an Fc region for its ligand can be ined by a variety
of in vitro assay methods (biochemical or immunological based assays) known in the art including but not
limited to, equilibrium methods (e.g., enzyme-linked immunoabsorbent assay (ELISA), or radioimmunoassay
(RIA)), or kinetics (e.g., BIACORE analysis), and other methods such as ct binding , itive
inhibition , fluorescence resonance energy transfer (FRET), gel electrophoresis and chromatography (e.g.,
gel filtration). These and other methods can utilize a label on one or more of the components being examined
and/or employ a variety of detection methods including but not limited to chromogenic, fluorescent,
luminescent, or isotopic labels. A detailed description of binding affinities and cs can be found in Paul, W.
E., ed., Fundamental immunology, 4th Ed., Lippincott-Raven, elphia (1999), which focuses on antibodyimmunogen
interactions.
In certain embodiments, the dy is modified to increase its biological half-life. Various
ches are possible. For example, this can be done by increasing the binding affinity of the Fc region for
FcRn, For example, one or more of more of following residues can be mutated: 252, 254, 256, 433, 435, 436, as
bed in U.S. Pat. No. 6,277,375. Specific exemplary substitutions include one or more of the following:
T252L, T254S, and/or T256F. Alternatively, to increase the biological half life, the antibody can be altered
within the CH1 or CL region to contain a salvage receptor binding epitope taken from two loops of a CH2
domain of an Fc region of an IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022 by Presta et al.
Other exemplary variants that increase binding to FcRn and/or improve pharmacokinetic properties include
tutions at positions 259, 308, 428, and 434, including for e 2591, 308F, 428L, 428M, 434S, 4341 1.
434F, 434Y, and 434X1. Other variants that increase Fc binding to FcRn include: 250E, 250Q, 428 L, 428F,
250Q/428L (Hinton et al. 2004, J. Biol. Chem. 279(8): 6213-6216, Hinton et al. 2006 Journal of Immunology
176:346-356), 256A, 272A, 286A, 305A, 307A, 307Q, 31 1A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields
et al., Journal of Biological try, 2001, 276(9):6591-6604), 252F, 252T, 252Y, 252W, 254T, 256S, 256R,
256Q, 256E, 256D, 256T, 309P, 31 1 S, 433R, 433S, 4331, 433P, 433Q, 434H, 434F, 434Y, 252Y/254T/256E,
433K/434F/436H, 308T/309P/311S (Dall Acqua et al. Journal of Immunology, 2002, 169:5171-5180,
cqua et al., 2006, Journal of Biological Chemistry 281:23514-23524). Other modifications for modulating
FcRn binding are described in Yeung et al., 2010, J Immunol, 182:7663-7671.
In n embodiments, hybrid IgG isotypes with particular biological characteristics can be used.
For example, an IgG1/IgG3 hybrid variant can be constructed by substituting IgG1 positions in the CH2 and/or
CH3 region with the amino acids from IgG3 at positions where the two isotypes differ. Thus a hybrid variant
IgG antibody can be constructed that comprises one or more substitutions, e.g., 274Q, 276K, 300F, 339T, 356E,
358M, 384S, 392N, 397M, 4221, 435R, and 436F. In other embodiments described herein, an IgG1/IgG2 hybrid
variant can be constructed by substituting IgG2 positions in the CH2 and/or CH3 region with amino acids from
IgG1 at ons where the two isotypes differ. Thus a hybrid t IgG antibody can be constructed that
comprises one or more substitutions, e.g., one or more of the following amino acid substitutions: 233E, 234L,
235L, -236G (referring to an insertion of a glycine at position 236), and 327A.
Moreover, the binding sites on human IgG1 for FcγRI, , FcγRIII and FcRn have been
mapped and variants with improved binding have been described (see Shields, R.L. et al. (2001) J. Biol. Chem.
276:6591-6604). Specific mutations at ons 256, 290, 298, 333, 334 and 339 were shown to improve
binding to FcγRIII. Additionally, the following combination mutants were shown to improve FcγRIII binding:
T256A/S298A, S298A/E333A, S298A/K224A and S298A/E333A/K334A, which has been shown to exhibit
enhanced FcγRIIIa binding and ADCC ty (Shields et al., 2001). Other IgG1 variants with strongly
enhanced binding to FcγRIIIa have been identified, including variants with I332E and
S239D/I332E/A330L mutations which showed the greatest increase in affinity for FcγRIIIa, a se in
FcγRIIb binding, and strong cytotoxic activity in cynomolgus monkeys (Lazar et al., 2006). Introduction of the
triple mutations into antibodies such as alemtuzumab specific), trastuzumab (HER2/neu-specific),
rituximab (CD20-specific), and cetuximab (EGFR- specific) translated into greatly enhanced ADCC activity in
vitro, and the I332E variant showed an enhanced capacity to deplete B cells in monkeys (Lazar et al.,
2006). In addition, IgG1 mutants containing L235V, F243L, R292P, Y300L and P396L ons which
exhibited enhanced binding to FcγRIIIa and concomitantly enhanced ADCC activity in transgenic mice
expressing human FcγRIIIa in models of B cell malignancies and breast cancer have been identified
(Stavenhagen et al., 2007; Nordstrom et al., 2011). Other Fc mutants that can be used include:
S298A/E333A/L334A, S239D/I332E, S239D/I332E/A330L, L235V/F243L/R292P/Y300L/ P396L, and
M428L/N434S.
In certain embodiments, an Fc is chosen that has reduced binding to FcγRs. An exemplary Fc, e.g.,
IgG1 Fc, with reduced FcγR binding ses the following three amino acid substitutions: L234A, L235E and
G237A.
In n embodiments, an Fc is chosen that has reduced complement fixation. An ary Fc,
e.g., IgG1 Fc, with reduced complement fixation has the following two amino acid substitutions: A330S and
P331S.
In n embodiments, an Fc is chosen that has essentially no effector function, i.e., it has
reduced g to FcγRs and reduced complement fixation. An exemplary Fc, e.g., IgG1 Fc, that is effectorless
comprises the following five mutations: L234A, L235E, G237A, A330S and P331S.
When using an IgG4 constant domain, it can include the substitution S228P, which mimics the
hinge sequence in IgG1 and thereby stabilizes IgG4 molecules.
In still another embodiment, the glycosylation of an antibody is modified. For example, an
aglycoslated antibody can be made (i.e., the antibody lacks ylation). Glycosylation can be altered to, for
example, se the affinity of the dy for antigen. Such carbohydrate modifications can be accomplished
by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or
more amino acid substitutions can be made that result in elimination of one or more le region framework
glycosylation sites to thereby ate glycosylation at that site. Such aglycosylation can increase the affinity
of the antibody for antigen. Such an approach is bed in further detail in U.S. Patent Nos. 5,714,350 and
6,350,861 by Co et al.
Glycosylation of the constant region on N297 can be prevented by mutating the N297 e to
another residue, e.g., N297A, and/or by mutating an adjacent amino acid, e.g., 298 to thereby reduce
glycosylation on N297.
onally or atively, an antibody can be made that has an altered type of glycosylation,
such as a hypofucosylated antibody having reduced amounts of l residues or an antibody having increased
bisecting GlcNac structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC
ability of antibodies. Such carbohydrate modifications can be accomplished by, for example, expressing the
antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation ery have
been described in the art and can be used as host cells in which to express recombinant anti-TIM3 antibodies
described herein to thereby produce an antibody with altered ylation. For example, EP 1,176,195 by
Hanai et al. describes a cell line with a onally disrupted FUT8 gene, which encodes a fucosyl transferase,
such that dies expressed in such a cell line exhibit hypofucosylation. PCT Publication WO 03/035835 by
Presta describes a variant CHO cell line, Led 3 cells, with reduced ability to attach fucose to Asn(297)-linked
carbohydrates, also resulting in hypofucosylation of antibodies expressed in that host cell (see also Shields, R.L.
et al. (2002) J. Biol. Chem. 277:26733-26740). PCT Publication WO 42 by Umana et al. describes cell
lines engineered to express glycoprotein-modifying glycosyl transferases {e.g., beta(l,4)-N-
acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell lines exhibit
increased bisecting GlcNac structures which s in increased ADCC activity of the antibodies (see also
Umana et al. (1999) Nat. Biotech. 17: 176-180).
Another modification of the anti-TIM3 antibodies described herein is pegylation. An antibody can
be pegylated to, for example, increase the biological (e.g., serum) half-life of the antibody. To pegylate an
antibody, the dy, or fragment f, typically is reacted with polyethylene glycol (PEG), such as a
reactive ester or de derivative of PEG, under conditions in which one or more PEG groups become
attached to the antibody or antibody fragment. In some embodiments, the pegylation is carried out via an
acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive oluble
polymer). As used herein, the term "polyethylene " is intended to encompass any of the forms of
PEG that have been used to derivatize other ns, such as mono (CI-CIO) alkoxy- or aryloxy-polyethylene
glycol or polyethylene glycol-maleimide. In certain embodiments, the antibody to be pegylated is an
aglycosylated antibody. Methods for pegylating proteins are known in the art and can be applied to the anti-
TIM3 antibodies described herein. See for example, EP 0 154 316 by Nishimura et al. and EP 0 401 384 by
Ishikawa et al.
In some embodiments, an anti-TIM3 dy comprises a heavy chain constant region and a light
chain constant region, wherein the heavy chain constant region is selected from the group ting of SEQ ID
NOs: 263-266.
VIII. Antibody Physical Properties
Anti-TIM3 antibodies, e.g., those described herein, have some or all of the physical characteristics
of the specific IM3 antibodies described herein, such as the characteristics described in the Examples.
Anti-TIM3 antibodies described herein can contain one or more glycosylation sites in either the
light or heavy chain variable region. Such glycosylation sites can result in increased immunogenicity of the
antibody or an alteration of the pK of the antibody due to altered antigen binding (Marshall et al., (1972) Annu
Rev Biochem 41:673-702; Gala and Morrison (2004) J. Immunol 172:5489-94; Wallick et al., (1988) J Exp Med
168: 1099-109; Spiro (2002) Glycobiology 12:43R-56R; Parekh et al., (1985) Nature 316:452-7; Mimura et al.,
(2000) Mol l 37:697-706). Glycosylation has been known to occur at motifs containing an N-X-S/T
sequence. In some instances, an anti-TIM3 antibody does not n variable region glycosylation. This can be
achieved either by selecting antibodies that do not contain the glycosylation motif in the variable region or by
ng residues within the glycosylation region.
In certain embodiments, the anti-TIM3 antibodies described herein do not contain asparagine
isomerism sites. The deamidation of asparagine can occur on N-G or D-G ces and result in the creation of
an artic acid residue that introduces a kink into the polypeptide chain and decreases its stability
(isoaspartic acid effect).
Each antibody will have a unique ctric point (pi), which generally falls in the pH range
between 6 and 9.5. The pi for an IgG1 dy typically falls within the pH range of 7-9.5 and the pi for an
IgG4 antibody typically falls within the pH range of 6-8. There is speculation that antibodies with a pi e
the normal range can have some unfolding and instability under in vivo conditions. Thus, an anti-TIM3 antibody
can n a pi value that falls in the normal range. This can be achieved either by selecting dies with a pi
in the normal range or by mutating d surface residues.
Each antibody will have a characteristic melting temperature, with a higher melting temperature
indicating greater overall stability in vivo (Krishnamurthy R and g M C (2002) Curr Pharm Biotechnol
3:361-71). Generally, the TMi (the temperature of initial unfolding) can be greater than 60 °C, greater than 65
°C, or greater than 70 °C. The melting point of an antibody can be measured using differential scanning
calorimetry (Chen et al., (2003) Pharm Res 20: 1952-60; Ghirlando et al.,(1999) Immunol Lett 68:47-52) or
ar dichroism (Murray et al., (2002) J. Chromatogr Sci -9).
In one embodiment, antibodies are selected that do not degrade rapidly. Degradation of an
antibody can be measured using capillary electrophoresis (CE) and MALDI-MS (Alexander A J and Hughes D
E (1995) Anal Chem 67:3626-32).
In r ment, antibodies are selected that have minimal aggregation s, which can
lead to the triggering of an unwanted immune response and/or altered or unfavorable pharmacokinetic
properties. Generally, antibodies are acceptable with aggregation of 25% or less, 20% or less, 15% or less, 10%
or less, or 5% or less. Aggregation can be measured by several ques, including size-exclusion column
(SEC), high performance liquid chromatography (HPLC), and light scattering.
In certain embodiments, an anti-TIM3 antibody has a combination of structures and properties
described in ns (I), (II), (III), (IV), (V), (VI), (VII), (VIII), and (IX) above. In one embodiment, an anti-
TIM3 antibody cross-competes with Antibodies 13A3, 17C3, 8B9, 8C4, 3G4, 17C8, and 9F6, as described in
Sections I and/or VI, derived from the germline sequence as described in Section III, has conserved mutations as
described in Section V, and/or has homology to the anti-TIM3 antibodies in Section I and II as described in
Section IV in combination with one or more functional properties described anywhere herein.
IX. Methods of Engineering Antibodies
As discussed above, the anti-TIM3 antibodies having VH and VL sequences disclosed herein can
be used to create new anti-TIM3 antibodies by modifying the VH and/or VL sequences, or the constant
region(s) attached thereto. Thus, in another aspect described , the structural es of an anti-TIM3
antibody bed herein are used to create structurally d anti-TIM3 antibodies that retain at least one
functional property of the anti-TIM3 antibodies described herein, such as binding to human TIM3 and
cynomolgus TIM3. For example, one or more CDR regions of 17C3, 8B9, 8C4, 3G4, 17C8, 9F6, 13A3, or any
of TIM3.2 to TIM3.18 can be combined recombinantly with known framework regions and/or other CDRs to
create additional, recombinantly-engineered, anti-TIM3 antibodies bed herein, as sed above. Other
types of modifications include those described in the previous section. The starting material for the engineering
method is one or more of the VH and/or VL sequences provided , or one or more CDR s thereof. To
create the engineered antibody, it is not necessary to ly prepare (i.e., express as a protein) an antibody
having one or more of the VH and/or VL sequences provided herein, or one or more CDR regions thereof.
Rather, the information contained in the sequence(s) is used as the starting material to create a "second
generation" sequence(s) derived from the al sequence(s) and then the "second generation" sequence(s) is
prepared and expressed as a protein.
Accordingly, provided herein are s for preparing an anti-TIM3 antibody comprising:
(a) providing: (i) a heavy chain variable region antibody ce comprising a CDR1 sequence selected from
the group consisting of SEQ ID NOs: 41 to 45, a CDR2 ce selected from the group ting of SEQ ID
NOs: 46 to 52 and 122-125, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 53 to
59 and 126-129; and (ii) a light chain variable region dy sequence comprising a CDR1 sequence selected
from the group consisting of SEQ ID NOs: 64 and 65, a CDR2 sequence selected from the group consisting of
SEQ ID NOs: 66 and 67, and/or a CDR3 sequence selected from the group consisting of SEQ ID NOs: 68 to 71;
(b) altering at least one amino acid residue within the heavy chain variable region antibody sequence and/or the
light chain variable region antibody ce to create at least one altered antibody sequence; and
(c) expressing the altered antibody ce as a protein.
Standard molecular biology ques can be used to prepare and express the altered antibody
sequence. In some embodiments, the antibody encoded by the altered dy sequence(s) is one that retains
one, some or all of the functional properties of the anti-TIM3 antibodies described herein, which include:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore, e.g., as described in the Examples;
(2) binding to soluble cynomolgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore, e.g., as described in the Examples;
(3) binding to ne bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
measured by Scatchard analysis, e.g., as described in the Examples;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow cytometry (e.g., as described in the Examples);
(6) binding to membrane bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by Scatchard analysis, e.g., as described in the Examples;
(7) inducing or enhancing T cell activation (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs), e.g., as described in the Examples;
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay, e.g., as described in the
Examples;
(9) inhibiting the binding of phosphatidylserine to TIM3, e.g., as measured by PS-hTIM3 "in-tandem" blocking
assay, e.g., as described in the Examples;
(10) not internalizing or gulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following s of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
G (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and RIQIPGIMND (SEQ
ID NOs: 296 and 298, respectively); and (d) LNGDFR (SEQ ID NO: 297), e.g., as described in the
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118, and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to pe
human TIM3, e.g., as described in the Examples;
(13) competing in either direction or both directions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or TIM3.7, TIM3.8, TIM3.10,
TIM3.11, TIM3.12, TIM3.13, TIM3.14, TIM3.15, 6, TIM3.17, and TIM3.18, e.g., as described in the
Examples;
(14) binding to human TIM3 regions 49VPVCWGKGACPVFE62 (SEQ ID NO: 367) and
111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS, e.g., as described in the
Examples;
(15) having the heavy chain and/or light chain variable s interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the Examples; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid ve to binding to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as described in the es; and/or (c)
ing with or cross-blocking with the binding of 13A3 or TIM3.18.IgG1.3, e.g., as described in the
Examples.
The altered antibody can exhibit one or more, two or more, three or more, four or more, five or
more, six or more, seven or more, eight or more, nine or more, or all of the functional properties set forth as (1)
through (16) above. The functional properties of the altered dies can be assessed using rd assays
available in the art and/or described herein, such as those set forth in the Examples (e.g., ELISAs, FACS).
In certain embodiments of the methods of engineering the anti-TIM3 antibodies described ,
mutations can be uced randomly or selectively along all or part of an anti-TIM3 antibody coding sequence
and the resulting modified anti-TIM3 antibodies can be screened for binding activity and/or other functional
properties as described herein. Mutational methods have been described in the art. For example, PCT
Publication WO 02/092780 by Short describes methods for creating and screening antibody mutations using
saturation mutagenesis, synthetic ligation assembly, or a combination thereof. Alternatively, PCT Publication
WO 03/074679 by Lazar et al. describes methods of using computational screening methods to optimize
physiochemical properties of antibodies.
X. Nucleic Acid Molecules
r aspect described herein pertains to c acid molecules that encode the anti-TIM3
antibodies described herein. The nucleic acids can be present in whole cells, in a cell lysate, or in a partially
ed or substantially pure form. A nucleic acid is "isolated" or "rendered substantially pure" when ed
away from other cellular components or other contaminants, e.g., other cellular nucleic acids (e.g., other
chromosomal DNA, e.g., the chromosomal DNA that is linked to the isolated DNA in nature) or proteins, by
standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, restriction
enzymes, agarose gel electrophoresis and others well known in the art. See, F. Ausubel, et al., ed. (1987)
Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York. A nucleic acid
described herein can be, for example, DNA or RNA and can or cannot contain ic sequences. In a certain
embodiments, the nucleic acid is a cDNA molecule.
Nucleic acids described herein can be obtained using standard molecular biology techniques. For
antibodies expressed by hybridomas (e.g., hybridomas prepared from transgenic mice carrying human
immunoglobulin genes as described further , cDNAs ng the light and heavy chains of the antibody
made by the hybridoma can be obtained by standard PCR amplification or cDNA cloning ques. For
antibodies ed from an globulin gene library (e.g., using phage y techniques), nucleic acid
encoding the dy can be recovered from the library.
Some nucleic acids les described herein are those ng the VH and VL sequences of
the 13A3, 8B9, 8C4, 17C3, 9F6, 3G4, 17C8 or any of TIM3.2 to TIM3.18 dies. Exemplary DNA
sequences ng the VH sequences of 13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and 17C8 are set forth in SEQ ID
NOs: 167 to 173, 245 to 254, and 359. Exemplary DNA sequences encoding the VL sequences of 13A3, 17C3,
and 3G4 are set forth in SEQ ID NO: 193. Exemplary DNA sequences encoding the VL sequences of 8B9, 8C4,
and 17C8 are set forth in SEQ ID NO: 194. Exemplary DNA sequences encoding the VL sequences of 9F6 are
set forth in SEQ ID NOs: 194 to 196. ary DNA sequences encoding the heavy chain sequences of 13A3,
8B9, 8C4, 17C3, 9F6, 3G4, and 17C8 are set forth in SEQ ID NOs: 134 to 161, 205 to 244, and 355-358.
Exemplary DNA sequences encoding the light chain sequences of 13A3, 8B9, 8C4, 17C3, 9F6, 3G4, and 17C8
are set forth in SEQ ID NOs: 162-166.
ary nucleic acids encoding the mature VH and VL domains of 13A3.IgG1.1 and
13A3.IgG1.3 (same variable region) antibodies are set forth as SEQ ID NOs: 167 and 193, respectively.
Exemplary nucleic acids encoding the mature heavy chains of 13A3.IgG1.1 and 13A3.IgG1.3 antibodies are set
forth as SEQ ID NOs: 134 and 148, respectively, and an exemplary nucleic acid encoding the mature light chain
of 13A3.IgG1.1 and 13A3.IgG1.3 antibodies is set forth as SEQ ID NO: 162.
Exemplary nucleic acids encoding the mature VH and VL domains of 8B9.IgG1.1 and 8B9.IgG1.3
(same variable region) antibodies are set forth as SEQ ID NOs: 168 and 194, respectively. Exemplary nucleic
acids encoding the mature heavy chains of 8B9.IgG1.1 and 8B9.IgG1.3 dies are set forth as SEQ ID NOs:
135 and 149, respectively, and an exemplary c acid encoding the mature light chain of 8B9.IgG1.1 and
8B9.IgG1.3 antibodies is set forth as SEQ ID NO: 163.
Exemplary nucleic acids encoding the mature VH and VL domains of 8C4.IgG1.1 and 8C4.IgG1.3
(same variable region) antibodies are set forth as SEQ ID NOs: 169 and 194, respectively. ary nucleic
acids encoding the mature heavy chains of 8C4.IgG1.1 and 8C4.IgG1.3 dies are set forth as SEQ ID NOs:
136 and 150, respectively, and an exemplary nucleic acid encoding the mature light chain of 8C4.IgG1.1 and
8C4.IgG1.3 antibodies is set forth as SEQ ID NO: 163.
Exemplary nucleic acids encoding the mature VH and VL domains of 17C3.IgG1.1 and
17C3.IgG1.3 (same le region) antibodies are set forth as SEQ ID NOs: 170 and 193, respectively.
Exemplary nucleic acids encoding the mature heavy chains of 17C3.IgG1.1 and 17C3.IgG1.3 antibodies are set
forth as SEQ ID NOs: 137 and 151, tively, and an exemplary nucleic acid encoding the mature light chain
of 17C3.IgG1.1 and 17C3.IgG1.3 antibodies is set forth as SEQ ID NO: 162.
Exemplary c acids encoding the mature VH and VL domains of 9F6.IgG1.1 and 9F6.IgG1.3
(same variable region) antibodies are set forth as SEQ ID NOs: 171 and 197, respectively. ary nucleic
acids encoding the mature heavy chains of 9F6.IgG1.1 and 9F6.IgG1.3 antibodies are set forth as SEQ ID NOs:
138 and 152, tively, and an exemplary c acid encoding the mature light chain of 9F6.IgG1.1 and
9F6.IgG1.3 antibodies is set forth as SEQ ID NO: 166.
Exemplary nucleic acids encoding the mature VH and VL domains of 3G4.IgG1.1 and 3G4.IgG1.3
(same variable region) antibodies are set forth as SEQ ID NOs: 172 and 193, respectively. ary nucleic
acids encoding the mature heavy chains of 3G4.IgG1.1 and 3G4.IgG1.3 antibodies are set forth as SEQ ID NOs:
139 and 153, tively, and an exemplary nucleic acid encoding the mature light chain of 3G4.IgG1.1 and
3G4.IgG1.3 antibodies is set forth as SEQ ID NO: 162.
Exemplary nucleic acids encoding the mature VH and VL domains of 17C8.IgG1.1 and
17C8.IgG1.3 (same variable region) antibodies are set forth as SEQ ID NOs: 173 and 194, respectively.
ary nucleic acids encoding the mature heavy chains of 17C8.IgG1.1 and gG1.3 antibodies are set
forth as SEQ ID NOs: 140 and 154, respectively, and an ary nucleic acid encoding the mature light chain
of 17C8.IgG1.1 and 17C8.IgG1.3 antibodies is set forth as SEQ ID NO: 163.
The above exemplary nucleic acids can further include a signal peptide set forth in SEQ ID NOs:
267 to 271 and 361. The nucleotide sequences encoding these signal peptides are set forth as SEQ ID NOs: 272
to 276, 362, and 363.
The nucleic acid molecules described herein may be modified to delete specific sequences, e.g.,
restriction enzyme recognition sequences, or to optimize .
A method for making 13A3 IgG1.1, 8B9 IgG1.1, 8C4 IgG1.1, 17C3 IgG1.1, 9F6 IgG1.1, 3G4
IgG1.1, 17C8 IgG1.1 and/or TIM3.2 to TIM3.18 IgG1.1 can comprise expressing the heavy chain and the light
chains in a cell line comprising the nucleotide sequences encoding the heavy and light chains with a signal
peptide, e.g., for 13A3 IgG1.1, SEQ ID NOs: 269 and 268, respectively. A method for making 13A3 IgG1.3,
8B9 IgG1.3, 8C4 IgG1.3, 17C3 IgG1.3, 9F6 IgG1.3, 3G4 IgG1.3, and/or 17C8 IgG1.3 can comprise expressing
the heavy chain and the light chains in a cell line comprising the nucleotide sequences encoding the heavy and
light chains with a signal peptide, e.g., for 13A3 IgG1.3, SEQ ID NOs: 274 and 273, respectively. Host cells
comprising these nucleotide sequences are encompassed herein.
Once DNA fragments encoding VH and VL ts are obtained, these DNA fragments can be
further manipulated by standard recombinant DNA techniques, for example to convert the variable region genes
to full-length antibody chain genes, to Fab fragment genes or to a scFv gene. In these lations, a VL- or
VH-encoding DNA fragment is operatively linked to another DNA fragment encoding another n, such as
an antibody constant region or a flexible . The term tively linked", as used in this context, is
intended to mean that the two DNA fragments are joined such that the amino acid sequences encoded by the two
DNA fragments remain in-frame.
The isolated DNA encoding the VH region can be converted to a full-length heavy chain gene by
operatively linking the VH-encoding DNA to another DNA molecule ng heavy chain constant regions
(hinge, CH1, CH2, and/or CH3). The sequences of human heavy chain nt region genes are known in the
art (see e.g., Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.
Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments encompassing
these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgG1,
IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD nt region, for e, an IgG1 region. For a Fab fragment
heavy chain gene, the VH-encoding DNA can be operatively linked to another DNA molecule encoding only the
heavy chain CH1 constant .
The isolated DNA encoding the VL region can be converted to a full-length light chain gene (as
well as a Fab light chain gene) by operatively linking the VL-encoding DNA to another DNA molecule
ng the light chain constant region, CL. The sequences of human light chain nt region genes are
known in the art (see e.g., Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth
Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242) and DNA fragments
encompassing these regions can be obtained by standard PCR amplification. The light chain constant region can
be a kappa or lambda constant region.
To create a scFv gene, the VH- and VL-encoding DNA fragments are ively linked to another
fragment encoding a le linker, e.g., encoding the amino acid sequence (Gly4-Ser)3, such that the VH and
VL sequences can be expressed as a contiguous single-chain protein, with the VL and VH regions joined by the
flexible linker (see e.g., Bird et al., (1988) Science 242:423-426; Huston et al., (1988) Proc. Natl. Acad. Sci.
USA 85:5879-5883; McCafferty et al., (1990) Nature 348:552-554).
Also provided herein are nucleic acid les ng VH and VL sequences that are
homologous to those of the 17C3, 8B9, 8C4, 3G4, 17C8, 9F6, 13A3 and any of TIM3.2 to TIM3.18 antibodies.
Exemplary nucleic acid molecules encode VH and VL sequences that are at least 70% identical, for example, at
least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical, to nucleic acid
molecules encoding the VH and VL sequences of the 17C3, 8B9, 8C4, 3G4, 17C8, 9F6, 13A3 or any of TIM3.2
to 8 antibodies. Also provided herein are nucleic acid molecules with conservative substitutions (i.e.,
substitutions that do not alter the resulting amino acid ce upon translation of nucleic acid molecule), e.g.,
for codon optimization.
Also provided are nucleic acids encoding the VH and/or VL regions of anti-TIM3 antibodies, such
as the anti-TIM3 antibodies described herein, which nucleic acids comprise a nucleotide sequence that is at least
about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to any of the nucleotide sequences
encoding the VH and/or VL regions of IM3 antibodies described herein.
Also provided are nucleic acids encoding the heavy chain and/or the light chain of anti-TIM3
antibodies, such as the anti-TIM3 antibodies described herein, which nucleic acids comprise a nucleotide
ce that is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% cal to any of the
nucleotide sequences encoding the heavy and/or light chains of anti-TIM3 dies described herein.
XI. Antibody Production
Monoclonal anti-TIM3 antibodies described herein can be produced using a variety of known
techniques, such as the standard c cell hybridization technique described by Kohler and Milstein, Nature
256: 495 (1975). Although c cell hybridization procedures are preferred, in principle, other ques for
producing monoclonal antibodies also can be employed, e.g., viral or oncogenic transformation of B
lymphocytes, phage display technique using libraries of human antibody genes.
The preferred animal system for preparing hybridomas is the murine system. Hybridoma
production in the mouse is a very well-established procedure. Immunization protocols and ques for
isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells)
and fusion procedures are also known.
Chimeric or humanized anti-TIM3 antibodies described herein can be prepared based on the
sequence of a murine monoclonal antibody prepared as described above. DNA encoding the heavy and light
chain immunoglobulins can be obtained from the murine hybridoma of interest and ered to contain nonmurine
(e.g., human) immunoglobulin sequences using standard molecular biology techniques. For example, to
create a chimeric antibody, the murine le regions can be linked to human constant regions using methods
known in the art (see e.g., U.S. Patent No. 4,816,567 to Cabilly et al.). To create a humanized antibody, the
murine CDR regions can be ed into a human framework using methods known in the art (see e.g., U.S.
Patent No. 5,225,539 to Winter, and U.S. Patent Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen
et al).
In one embodiment, the anti-TIM3 dies bed herein are human monoclonal antibodies.
Such human monoclonal dies directed against TIM3 can be generated using transgenic or
transchromosomic mice ng parts of the human immune system rather than the mouse system. These
transgenic and transchromosomic mice include mice referred to herein as HuMAb mice and KM mice,
respectively, and are collectively referred to herein as "human Ig mice."
The HUMAB-MOUSE® (Medarex, Inc.) contains human immunoglobulin gene miniloci that
encode unrearranged human heavy (μ and γ) and κ light chain immunoglobulin sequences, together with
targeted mutations that inactivate the endogenous μ and κ chain loci (see e.g., Lonberg, et al., (1994) Nature
368(6474): 856-859). Accordingly, the mice exhibit d expression of mouse IgM or κ, and in se to
immunization, the uced human heavy and light chain transgenes undergo class switching and somatic
on to generate high affinity human IgGK monoclonal (Lonberg, N. et al. , supra; reviewed in
Lonberg, N. (1994) Handbook of Experimental Pharmacology 113:49-101; Lonberg, N. and , D. (1995)
Intern. Rev. l. 13: 65-93, and Harding, F. and Lonberg, N. (1995) Ann. N.Y. Acad. Sci. 764:536-546).
The preparation and use of HuMab mice, and the genomic modifications carried by such mice, is further
described in Taylor, L. et al. (1992) Nucleic Acids ch 20:6287-6295; Chen, J. et al., (1993) ational
Immunology 5: 647-656; on et al. (1993) Proc. Natl. Acad. Sci. USA 90:3720-3724; Choi et al. (1993)
Nature Genetics 4:117-123; Chen, J. et al. (1993) EMBO J. 12: 821-830; Tuaillon et al. (1994) Immunol.
152:2912-2920; Taylor, L. et al. (1994) International Immunology 6: 579-591; and Fishwild, D. et al. (1996)
Nature Biotechnology 14: 845-851. See further, U.S. Patent Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425;
,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; and 5,770,429; all to Lonberg and Kay; U.S. Patent No.
807 to Surani et al.,; PCT Publication Nos. WO 92/03918, WO 93/12227, WO 85, WO 97/13852,
WO 98/24884 and WO 99/45962, all to Lonberg and Kay; and PCT Publication No. WO 01/14424 to Korman
et al.
In certain embodiments, the anti-TIM3 antibodies described herein are raised using a mouse that
carries human globulin sequences on transgenes and transchomosomes, such as a mouse that carries a
human heavy chain transgene and a human light chain transchromosome. Such mice, referred to herein as "KM
mice", are described in detail in PCT Publication WO 02/43478 to Ishida et al.
Still further, ative transgenic animal systems expressing human immunoglobulin genes are
available in the art and can be used to raise anti-TIM3 dies described herein. For example, an alternative
transgenic system referred to as the Xenomouse (Abgenix, Inc.) can be used; such mice are described in, for
example, U.S. Patent Nos. 5,939,598; 6,075,181; 6,114,598; 6, 150,584 and 6,162,963 to Kucherlapati et al.
Moreover, alternative transchromosomic animal systems expressing human immunoglobulin genes
are available in the art and can be used to raise anti-TIM3 antibodies described herein. For example, mice
carrying both a human heavy chain transchromosome and a human light chain tranchromosome, referred to as
"TC mice" can be used; such mice are described in Tomizuka et al. (2000) Proc. Natl. Acad. Sci. USA 97:722-
727. Furthermore, cows carrying human heavy and light chain transchromosomes have been described in the art
(Kuroiwa et al. (2002) Nature Biotechnology -894) and can be used to raise anti-TIM3 antibodies
described herein.
Additional mouse systems described in the art for raising human antibodies, e.g., human anti-TIM3
antibodies, include (i) the VELOCLMMUNE® mouse (Regeneron Pharmaceuticals, Inc.), in which the
endogenous mouse heavy and light chain le regions have been replaced, via gous recombination,
with human heavy and light chain variable regions, operatively linked to the endogenous mouse constant
regions, such that chimeric antibodies (human V/mouse C) are raised in the mice, and then subsequently
converted to fully human antibodies using standard recombinant DNA techniques; and (ii) the MEMO® mouse
(Merus Biopharmaceuticals, Inc.), in which the mouse contains unrearranged human heavy chain variable
regions but a single nged human common light chain variable region. Such mice, and use thereof to raise
antibodies, are described in, for e,
2011/097603,
2012/0073004.
Human monoclonal anti-TIM3 antibodies described herein can also be prepared using phage
display methods for screening libraries of human immunoglobulin genes. Such phage display methods for
isolating human antibodies are established in the art. See for example: U.S. Patent Nos. 5,223,409; 484;
and 5,571,698 to Ladner et al.; U.S. Patent Nos. 5,427,908 and 5,580,717 to Dower et al.; U.S. Patent Nos.
,969,108 and 6,172,197 to erty et al.; and U.S. Patent Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313;
6,582,915 and 6,593,081 to Griffiths et al.
Human monoclonal IM3 antibodies bed herein can also be ed using SCID mice
into which human immune cells have been reconstituted such that a human dy response can be generated
upon immunization. Such mice are described in, for example, U.S. Patent Nos. 5,476,996 and 5,698,767 to
Wilson et al.
XI.A. Immunizations
To generate fully human antibodies to TIM3, transgenic or transchromosomal mice containing
human immunoglobulin genes (e.g., HCol2, HCo7 or KM mice) can be immunized with a purified or enriched
preparation of the TIM3 antigen and/or cells expressing TIM3 or fragment thereof, as described for other
antigens, for example, by Lonberg et al., (1994) Nature 368(6474): 856-859; Fishwild et al., (1996) Nature
Biotechnology 14: 845-851 and WO 98/24884. Alternatively, mice can be zed with DNA encoding
human TIM3 or fragment thereof. In some embodiments, the mice can be 6-16 weeks of age upon the first
on. For e, a purified or enriched preparation (5-50 μg) of the recombinant TIM3 antigen can be
used to immunize the HuMAb mice intraperitoneally. In the event that immunizations using a ed or
enriched ation of the TIM3 antigen do not result in antibodies, mice can also be immunized with cells
expressing TIM3, e.g., a cell line, to promote immune responses. Exemplary cell lines include TIM3-
overexpressing stable CHO and Raji cell lines.
Cumulative experience with various antigens has shown that the HuMAb transgenic mice respond
best when initially immunized eritoneally (IP) or subcutaneously (SC) with antigen in Ribi's adjuvant,
followed by every other week IP/SC immunizations (up to a total of 10) with antigen in Ribi's adjuvant. The
immune response can be red over the course of the immunization protocol with plasma samples being
obtained by retroorbital bleeds. The plasma can be screened by ELISA and FACS (as described below), and
mice with sufficient titers of anti-TIM3 human globulin can be used for fusions. Mice can be boosted
intravenously with antigen 3 days before sacrifice and removal of the spleen and lymph nodes. It is expected
that 2-3 fusions for each immunization can need to be performed. Between 6 and 24 mice are typically
immunized for each antigen. Usually, HCo7, HCol2, and KM strains are used. In on, both HCo7 and
HCol2 transgene can be bred together into a single mouse having two different human heavy chain transgenes
(HCo7/HCol2).
XI.B. Generation of Hybridomas Producing Monoclonal Antibodies to TIM3
To generate hybridomas producing human monoclonal anti-TIM3 antibodies described herein,
cytes and/or lymph node cells from immunized mice can be isolated and fused to an appropriate
immortalized cell line, such as a mouse myeloma cell line. The resulting hybridomas can be ed for the
production of antigen- specific antibodies. For example, single cell suspensions of c lymphocytes from
immunized mice can be fused to Sp2/0 nonsecreting mouse a cells (ATCC, CRL 1581) with PEG. Cells
can be plated in flat bottom microtiter plate, followed by incubation in selective medium. After several weeks,
cells can be cultured in medium. Individual wells can then be screened by ELISA for human monoclonal IgM
and IgG antibodies. Once extensive hybridoma growth occurs, medium can be observed usually after 10-14
days. The antibody secreting hybridomas can be ed, screened again, and if still positive for human IgG, the
onal antibodies can be subcloned at least twice by limiting dilution. The stable nes can then be
cultured in vitro to generate small amounts of antibody in tissue culture medium for characterization.
To purify human monoclonal antibodies, selected hybridomas can be grown in two-liter spinnerflasks
for onal antibody purification. Supernatants can be filtered and concentrated before affinity
chromatography with protein A-sepharose (Pharmacia, Piscataway, N.J.). Eluted IgG can be d by gel
electrophoresis and high performance liquid chromatography to ensure purity. The buffer solution can be
exchanged into PBS, and the concentration can be determined by OD280 using 1.43 extinction coefficient. The
monoclonal dies can be aliquoted and stored.
XI.C. Generation of Transfectomas Producing Monoclonal Antibodies to TIM3
Antibodies can be produced in a host cell transfectoma using, for example, a combination of
recombinant DNA techniques and gene transfection methods as is well known in the art (Morrison, S. (1985)
Science 229: 1202).
For example, to express antibodies, or antibody fragments thereof, DNAs encoding partial or fulllength
light and heavy , can be obtained by standard lar biology techniques (e.g., PCR
amplification or cDNA cloning using a hybridoma that expresses the antibody of st) and the DNAs can be
ed into expression vectors such that the genes are operatively linked to riptional and translational
control ces. In this context, the term "operatively linked" is intended to mean that an antibody gene is
ligated into a vector such that riptional and ational control sequences within the vector serve their
intended function of regulating the ription and translation of the antibody gene. The expression vector and
expression control sequences are chosen to be compatible with the expression host cell used. The antibody light
chain gene and the antibody heavy chain gene can be inserted into separate vector or both genes are inserted into
the same expression vector. The antibody genes are inserted into the expression vector(s) by standard methods
(e.g., ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation
if no restriction sites are present). The light and heavy chain variable regions of the anti-TIM3 antibodies
described herein can be used to create full-length antibody genes of any antibody isotype by inserting them into
expression vectors already encoding heavy chain constant and light chain constant regions of the desired isotype
such that the VH segment is ively linked to the CH t(s) within the vector and the VL segment is
operatively linked to the CL segment within the vector.
Additionally or alternatively, the recombinant expression vector can encode a signal peptide that
facilitates secretion of the antibody chain from a host cell. The antibody chain gene can be cloned into the vector
such that the signal e is linked in-frame to the amino terminus of the antibody chain gene. The signal
peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a
non-immunoglobulin protein).
In exemplary embodiments, the following signal peptides from human antibody heavy and light
chains can be used: MDWTWRVFCLLAVAPGAHS (SEQ ID NO: 267); METPAQLLFLLLLWLPDTTG (SEQ ID
NO: 268); MKHLWFFLLLVAAPRWVLS (SEQ ID NO: 269); MEFGLSWVFLVAIIKGVQC (SEQ ID NO: 270);
AQLLGLLLWLPGARC (SEQ ID NO: 271) or MRAWIFFLLCLAGRALA (SEQ ID NO: 361). In a
particular embodiment, a signal sequence used for expression of any one of the anti-TIM3 antibodies described
herein is SEQ ID NO: 361.Heavy and light chains of IM3 antibodies can be expressed with the respective
signal sequence that was linked to each chain in the hybridoma from which they were cloned. Below are the
signal sequences of s anti-TIM3 antibodies as present in the hybridoma from which they were cloned,
which signal sequences can be used to express the same antibody or r antibody:
(i) Amino acid sequence of 13A3 VH signal sequence: MKHLWFFLLLVAAPRWVLS (SEQ ID NO: 269)
(ii) Nucleic acid sequence of 13A3 VH signal ce:
ATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCC (SEQ ID NO:
(iii) Amino acid sequence of 13A3 VL signal sequence: METPAQLLFLLLLWLPDTTG (SEQ ID NO: 268)
(iv) Nucleic acid sequence of 13A3 VL signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273)
(v) Amino acid sequence of 8B9 VH signal ce: MKHLWFFLLLVAAPRWVLS (SEQ ID NO: 269)
(vi) Nucleic acid sequence of 8B9 VH signal sequence:
ATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCC (SEQ ID NO:
(vii) Amino acid sequence of 8B9 VL signal sequence: METPAQLLFLLLLWLPDTTG (SEQ ID NO: 268)
(viii) Nucleic acid sequence of 8B9 VL signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273)
(ix) Amino acid sequence of 8C4 VH signal ce: MKHLWFFLLLVAAPRWVLS (SEQ ID NO: 269)
(x) Nucleic acid sequence of 8C4 VH signal sequence:
ATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCC (SEQ ID NO:
(xi) Amino acid sequence of 8C4 VL signal sequence: LLFLLLLWLPDTTG (SEQ ID NO: 268)
(xii) Nucleic acid sequence of 8C4 VL signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273)
(xiii) Amino acid sequence of 17C3 VH signal sequence: MDWTWRVFCLLAVAPGAHS (SEQ ID NO: 267)
(xiv) Nucleic acid sequence of 17C3 VH signal sequence:
ACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 272)
(xv) Amino acid sequence of 17C3 VL signal sequence: METPAQLLFLLLLWLPDTTG (SEQ ID NO: 268)
(xvi) Nucleic acid sequence of 17C3 VL signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273)
(xvii) Amino acid sequence of 9F6 VH signal sequence: MEFGLSWVFLVAIIKGVQC (SEQ ID NO: 270)
(xviii) Nucleic acid sequence of 9F6 VH signal ce:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA(SEQ ID
NO: 275)
(xix) Amino acid sequence of 9F6 VL1 signal sequence: AQLLGLLLLWLPGARC (SEQ ID NO:
(xx) Nucleic acid sequence of 9F6 VL1 signal sequence:
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCAGATGT
(SEQ ID NO: 276)
(xxi) Amino acid sequence of 9F6 VL2 and VL3 signal sequence: METPAQLLFLLLLWLPDTTG (SEQ ID
NO: 268)
(xxii) c acid sequence of 9F6 VL2 and VL3 signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273)
(xxiii) Amino acid sequence of 3G4 VH signal sequence: WVFLVAIIKGVQC (SEQ ID NO: 270)
(xxiv) Nucleic acid sequence of 3G4 VH signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA(SEQ ID
NO: 275)
(xxv) Amino acid sequence of 3G4 VL signal sequence: METPAQLLFLLLLWLPDTTG (SEQ ID NO: 268)
(xxvi) Nucleic acid sequence of 3G4 VL signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273)
(xxvii) Amino acid sequence of 17C8 VH signal sequence: MEFGLSWVFLVAIIKGVQC (SEQ ID NO: 270)
(xxviii) Nucleic acid sequence of 17C8 VH signal ce:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA(SEQ ID
NO: 275)
(xxix) Amino acid sequence of 17C8 VL signal sequence: METPAQLLFLLLLWLPDTTG (SEQ ID NO: 268)
(xxx) Nucleic acid sequence of 17C8 VL signal sequence:
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGA (SEQ ID
NO: 273).
In r embodiment, the heavy and light chains of the anti-TIM3 antibodies (e.g., TIM3.2 to
TIM3.18) can be engineered with signal sequences that differ from those present in the hybridomas from which
they were cloned. Examples of such sequences include, but not limited to, the following:
(i) Nucleic acid sequence of signal ce for the heavy chain:
ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGAGAGCGCTCGCA (SEQ ID NO: 362)
(ii) Nucleic acid sequence of signal sequence for the light chain:
ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGCGCGCCTTGGCC (SEQ ID NO: 363)
(iii) Amino acid sequence of signal sequence for the heavy and light chains: MRAWIFFLLCLAGRALA (SEQ
ID NO: 361).
In addition to the antibody chain genes, recombinant expression vectors can carry regulatory
sequences that control the expression of the antibody chain genes in a host cell. The term "regulatory sequence"
is intended to include promoters, ers and other expression control ts (e.g., enylation s)
that control the transcription or translation of the antibody chain genes. Such regulatory sequences are described,
for example, in Goeddel (Gene Expression Technology. Methods in Enzymology 185, Academic Press, San
Diego, CA (1990)). It will be appreciated by those skilled in the art that the design of the expression vector,
including the selection of regulatory sequences, can depend on such factors as the choice of the host cell to be
ormed, the level of expression of protein desired, etc. Preferred regulatory sequences for mammalian host
cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as
promoters and/or enhancers derived from galovirus (CMV), Simian Virus 40 (SV40), irus, (e.g.,
the adenovirus major late promoter ) and polyoma. atively, nonviral regulatory sequences can be
used, such as the ubiquitin promoter or β-globin promoter. Still further, regulatory elements composed of
sequences from different s, such as the SRa promoter system, which contains sequences from the SV40
early promoter and the long terminal repeat of human T cell leukemia virus type 1 (Takebe, Y. et al. (1988)
Mol. Cell. Biol. 8:466-472).
In addition to the antibody chain genes and regulatory sequences, recombinant expression vectors
can carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g.,
origins of ation) and selectable marker genes. The selectable marker gene facilitates selection of host cells
into which the vector has been introduced (see, e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017, all by
Axel et al). For e, typically the selectable marker gene confers resistance to drugs, such as G418,
hygromycin or methotrexate, on a host cell into which the vector has been introduced. Preferred selectable
marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr- host cells with methotrexate
selection/amplification) and the neo gene (for G418 selection).
For expression of the light and heavy , the expression vector(s) encoding the heavy and light
chains is transfected into a host cell by standard techniques. The various forms of the term "transfection" are
ed to encompass a wide variety of techniques commonly used for the uction of ous DNA into
a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran
transfection and the like.
Although it is theoretically possible to express the anti-TIM3 antibodies described herein in either
prokaryotic or eukaryotic host cells, expression of antibodies in eukaryotic cells, and most preferably
mammalian host cells, is the most preferred because such eukaryotic cells, and in particular mammalian cells,
are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active
antibody. Prokaryotic expression of antibody genes has been reported to be ineffective for tion of high
yields of active antibody (Boss, M. A. and Wood, C. R. (1985) Immunology Today 6: 12-13).
Certain mammalian host cells for expressing the inant IM3 antibodies bed
herein include Chinese Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and Chasin,
(1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in R.
J. Kaufman and P. A. Sharp (1982) Mol. Biol. 759:601-621), NSO myeloma cells, COS cells and SP2 cells. In
particular, for use with NSO myeloma cells, r sion system is the GS gene expression system
disclosed in WO 87/04462, WO 36 and EP 338,841. When recombinant expression s ng
antibody genes are introduced into mammalian host cells, the antibodies are ed by culturing the host cells
for a period of time sufficient to allow for expression of the antibody in the host cells or, more preferably,
secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered
from the culture medium using standard protein purification methods.
XII. Assays
Anti-TIM3 antibodies described herein can be tested for binding to human TIM3 by, for example,
standard ELISA. Briefly, microtiter plates are coated with purified TIM3, and then blocked with bovine serum
albumin. Dilutions of antibody (e.g., dilutions of plasma from TIM3-immunized mice) are added to each well
and incubated. The plates are washed and incubated with secondary reagent (e.g., for human antibodies, a goatanti-human
IgG Fc-specific polyclonal reagent) conjugated to horseradish peroxidase (HRP). After g, the
plates can be developed and ed by a spectrophotometer. Sera from immunized mice can then be further
screened by flow cytometry for binding to a cell line expressing human TIM3, but not to a l cell line that
does not express TIM3. Briefly, the g of anti-TIM3 antibodies can be assessed by incubating TIM3
sing CHO cells with the anti-TIM3 antibody. The cells can be washed and binding can be detected with
an anti-human IgG Ab. Flow tric es can be performed using a n flow cytometry (Becton
Dickinson, San Jose, CA). Mice which develop the highest titers can be used for fusions.
An ELISA assay as described above can be used to screen for antibodies and, thus, hybridomas
that produce antibodies that show positive reactivity with the TIM3 immunogen. Hybridomas that produce
antibodies that bind with high affinity to TIM3 can then be subcloned and further characterized. One clone from
each hybridoma, which retains the reactivity of the parent cells (by ELISA), can then be chosen for making a
cell bank, and for antibody purification.
To purify anti-TIM3 antibodies, selected hybridomas can be grown for onal antibody
purification. Supernatants can be filtered and concentrated before affinity chromatography. Eluted IgG can be
checked by gel electrophoresis and high performance liquid chromatography to ensure purity. The buffer
solution can be exchanged, and the concentration can be determined. The monoclonal antibodies can be
aliquoted and stored.
To determine if the selected anti-TIM3 monoclonal antibodies bind to unique epitopes, each
antibody can be biotinylated using commercially available reagents (Pierce, Rockford, IL). Biotinylated MAb
binding can be detected with a streptavidin labeled probe. Competition studies using unlabeled monoclonal
antibodies and biotinylated monoclonal dies can be performed using TIM3 coated-ELISA plates as
described above.
To determine the isotype of purified antibodies, isotype ELISAs can be performed using reagents
specific for antibodies of a particular isotype. For example, to determine the isotype of a human monoclonal
dy, wells of microtiter plates can be coated with 1 μg/ml of anti-human globulin overnight at 4
°C. After blocking with 1% BSA, the plates are reacted with 1 μg /ml or less of test monoclonal antibodies or
purified isotype controls, at ambient temperature for one to two hours. The wells can then be reacted with either
human IgG1 or human IgM-specific alkaline atase-conjugated probes. Plates are developed and analyzed
as described above.
To test the binding of monoclonal antibodies to live cells expressing TIM3, flow cytometry can be
used, as described in the Examples. Briefly, cell lines expressing membrane-bound TIM3 (grown under standard
growth conditions) are mixed with s concentrations of onal antibodies in PBS containing 0.1%
BSA at 4 °C for 1 hour. After washing, the cells are reacted with Fluorescein-labeled anti-IgG antibody under
the same conditions as the primary dy staining. The samples can be analyzed by FACScan ment
using light and side scatter properties to gate on single cells and binding of the d antibodies is determined.
An alternative assay using fluorescence microscopy can be used (in on to or instead of) the flow cytometry
assay. Cells can be stained exactly as described above and examined by fluorescence microscopy. This method
allows visualization of individual cells, but can have diminished sensitivity depending on the density of the
antigen.
Anti-TIM3 antibodies can be further tested for reactivity with the TIM3 antigen by Western
blotting. Briefly, cell extracts from cells expressing TIM3 can be prepared and subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis. After electrophoresis, the separated antigens will be transferred to
nitrocellulose membranes, blocked with 20% mouse serum, and probed with the monoclonal antibodies to be
tested. IgG binding can be detected using anti-IgG ne phosphatase and ped with BCIP/NBT
substrate tablets (Sigma Chem. Co., St. Louis, MO).
Methods for analyzing binding affinity, cross-reactivity, and binding kinetics of various anti-TIM3
antibodies include standard assays known in the art, for example, BIACORE™ surface plasmon resonance
(SPR) analysis using a BIACORE™ 2000 SPR instrument re AB, Uppsala, Sweden).
A variety of assays can be used to characterize the biological activity of anti-TIM3 antibodies
(which can be used, e.g., for ing ent IM3 antibodies), such as those described herein:
(1) T cell activation assays, such as assays using ed T cells obtained from PBMCs of human
donors. Assays can be conducted with total T cells or subpopulations thereof, e.g., Th1 cells, T cytotoxic cells,
Treg cells, CD4+ T cells, CD8+ T cells, provided that they express TIM3. Activation may be measured by
ining the level of secretion of certain cytokines, e.g., interferon-γ or IL-2 or the level of proliferation of
the T cells. Without wanting to be limited to a particular mechanism of action, binding of TIM3 antibodies to
TIM3 on T cells may prevent binding of TIM3 to a TIM3 ligand (TIM3 putative s include Galectin-9,
HMGB1, Semaphorin-4A, CEACAM-1, ILT-4 and phosphatidylserine) and thereby prevent TIM3 ed
ing in the T cell y preventing negatively regulation of T cells by TIM3. Exemplary assays,
including Th1 assays, TIL assays and mixed lymphocyte reactions (MLRs) are provided in the Examples;
(2) assays measuring stimulation of macrophages, e.g., M1 or M2 macrophage; and
(3) assays measuring secretion of myeloid-associated cytokines, e.g., TNFα, IL-1β, GM-CSF, IL-
6, IL-2, IL-10, CCL2, CCL3, CCL4 or CCL5 from TIM3 positive myeloid cells. In certain ment, anti-
TIM3 antibodies ate the secretion of TNFα, IL-1β, GM-CSF, IL-6, and IL-2 and/or inhibit the secretion of
IL-10, CCL2, CCL3, CCL4 or CCL5 from TIM3 ve myeloid cells.
Generally, any method for testing the biological activity of an agent that inhibits immune
responses can be used to characterize the biological activity of anti-TIM3 antibodies, e.g., those described in the
literature (including patents and patent applications) relating to TIM3.
XIII. Immunoconjugates, Antibody Derivatives and Diagnostics
Anti-TIM3 antibodies described herein can be used for diagnostic purposes, including sample
testing and in vivo imaging, and for this purpose the antibody (or binding fragment thereof) can be conjugated to
an appropriate detectable agent, to form an immunoconjugate. For diagnostic purposes, appropriate agents are
detectable labels that include radioisotopes, for whole body imaging, and radioisotopes, s, fluorescent
labels and other suitable dy tags for sample testing.
The detectable labels that can be linked to any TIM3 antibody described herein can be any of the
various types used tly in the field of in vitro diagnostics, including particulate labels including metal sols
such as colloidal gold, isotopes such as I125 or Tc99 presented for instance with a peptidic chelating agent of the
N2S2, N3S or N4 type, chromophores including fluorescent markers, luminescent markers, phosphorescent
s and the like, as well as enzyme labels that convert a given substrate to a detectable marker, and
polynucleotide tags that are ed following amplification such as by polymerase chain reaction. Suitable
enzyme labels include horseradish peroxidase, ne phosphatase and the like. For instance, the label can be
the enzyme alkaline phosphatase, detected by measuring the presence or formation of chemiluminescence
following conversion of 1,2 dioxetane substrates such as adamantyl methoxy phosphoryloxy phenyl dioxetane
(AMPPD), disodium 3-(4-(methoxyspiro{l,2-dioxetane-3,2'-(5'-chloro)tricyclo{3.3.1.1 3,7}decan}yl) phenyl
phosphate (CSPD), as well as CDP and CDP-STAR® or other luminescent substrates well-known to those in the
art, for example the chelates of suitable lanthanides such as Terbium(III) and Europium(III). The ion
means is determined by the chosen label. Appearance of the label or its reaction products can be ed using
the naked eye, in the case where the label is particulate and accumulates at appropriate levels, or using
instruments such as a spectrophotometer, a luminometer, a meter, and the like, all in accordance with
standard practice.
In some embodiments, conjugation methods result in es which are substantially (or nearly)
non-immunogenic, e.g., e- (i.e., amide-), sulfide-, (sterically ed), disulfide-, hydrazone-, and ether
linkages. These linkages are nearly non-immunogenic and show able stability within serum (see e.g.,
Senter, P. D., Curr. Opin. Chem. Biol. 13 (2009) 235-244;
Depending on the biochemical nature of the moiety and the antibody, ent conjugation
strategies can be employed. In case the moiety is naturally occurring or recombinant of between 50 to 500
amino acids, there are standard procedures in text books describing the chemistry for synthesis of protein
conjugates, which can be easily followed by the d artisan (see e.g., Hackenberger, C. P. R., and Schwarzer,
D., Angew. Chem. Int. Ed. Engl. 47 (2008) 10030-10074). In one embodiment the reaction of a maleinimido
moiety with a cysteine residue within the antibody or the moiety is used. This is an especially suited coupling
chemistry in case e.g., a Fab or ragment of an dy is used. atively in one embodiment coupling
to the C-terminal end of the antibody or moiety is performed. inal modification of a protein, e.g., of a
agment, can be performed as described (Sunbul, M. and Yin, J., Org. Biomol. Chem. 7 (2009) 3361-
3371).
In general, site specific reaction and covalent coupling is based on transforming a natural amino
acid into an amino acid with a reactivity which is onal to the reactivity of the other functional groups
present. For example, a specific cysteine within a rare sequence context can be enzymatically converted in an
aldehyde (see Frese, M. A., and Dierks, T., ChemBioChem. 10 (2009) 425-427). It is also possible to obtain a
desired amino acid modification by ing the specific enzymatic reactivity of certain s with a natural
amino acid in a given sequence context (see, e.g., Taki, M. et al., Prot. Eng. Des. Sel. 17 (2004) 119-126;
Gautier, A. et al. Chem. Biol. 15 (2008) 128-136; and Protease-catalyzed formation of C— N bonds is used by
Bordusa, F., Highlights in anic Chemistry (2004) 389-403). Site specific reaction and covalent coupling
can also be achieved by the selective reaction of terminal amino acids with appropriate modifying reagents.
The reactivity of an N-terminal cysteine with benzonitrils (see Ren, H. et al., Angew. Chem. Int.
Ed. Engl. 48 (2009) 9658-9662) can be used to achieve a pecific covalent coupling.
Native chemical ligation can also rely on C-terminal cysteine residues (Taylor, E. Vogel;
Imperiali, B, Nucleic Acids and Molecular y , 22 (Protein ering), 65-96).
US6437095 B1 describes a conjugation method which is based on the faster reaction of a cysteine
within a stretch of negatively charged amino acids with a cysteine located in a stretch of positively charged
amino acids.
The moiety can also be a synthetic peptide or peptide mimic. In case a polypeptide is chemically
synthesized, amino acids with orthogonal chemical reactivity can be incorporated during such synthesis (see
e.g., de Graaf, A. J. et al., Bioconjug. Chem. 20 (2009) 1281-1295). Since a great variety of orthogonal
functional groups is at stake and can be introduced into a synthetic peptide, ation of such peptide to a
linker is standard chemistry.
In order to obtain a mono-labeled polypeptide, the conjugate with 1:1 stoichiometry can be
separated by chromatography from other conjugation side-products. This procedure can be facilitated by using a
dye labeled g pair member and a charged linker. By using this kind of d and highly negatively
charged binding pair member, mono conjugated polypeptides are easily separated from non-labeled
polypeptides and polypeptides which carry more than one linker, since the difference in charge and molecular
weight can be used for separation. The fluorescent dye can be useful for purifying the x from un-bound
components, like a d monovalent binder.
In one ment the moiety attached to an anti-TIM3 antibody is selected from the group
consisting of a binding moiety, a labeling moiety, and a biologically active moiety.
Anti-TIM3 antibodies described herein can also be conjugated to a therapeutic agent to form an
immunoconjugate such as an dy-drug conjugate (ADC). le therapeutic agents include
antimetabolites, alkylating agents, DNA minor groove binders, DNA intercalators, DNA crosslinkers, histone
ylase inhibitors, nuclear export inhibitors, proteasome inhibitors, topoisomerase I or II tors, heat
shock protein inhibitors, tyrosine kinase inhibitors, antibiotics, and anti-mitotic agents. In the ADC, the antibody
and therapeutic agent preferably are conjugated via a linker ble such as a yl, disulfide, or hydrazone
linker. In other embodiments, the linker is a peptidyl linker such as Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys,
Pro-Val-Gly-Val-Val (SEQ ID NO: 300), Ala-Asn-Val, Val-Leu-Lys, a-Asn, Cit-Cit, Val-Lys, Lys, Cit,
Ser, or Glu. The ADCs can be prepared as described in U.S. Pat. Nos. 7,087,600; 452; and 7,129,261;
PCT Publications WO 02/096910; WO 07/038658; WO 07/051081; WO 07/059404; WO 08/083312; and WO
08/103693; U.S. Patent Publications 20060024317; 20060004081; and 20060247295.
Anti-TIM3 antibodies, e.g., those described herein, can also be used for detecting TIM3, such as
human TIM3, e.g., human TIM3 in tissues or tissue samples. The antibodies can be used, e.g., in an ELISA
assay or in flow cytometry. In certain embodiments, an IM3 antibody is contacted with cells, e.g., cells in
a tissue, for a time appropriate for specific binding to occur, and then a reagent, e.g., an antibody that detects the
anti-TIM3 antibody, is added. Exemplary assays are provided in the Examples. The anti-TIM3 antibody can be a
fully human dy, or it can be a chimeric antibody, such as an dy having human variable regions and
murine constant regions or a portion thereof. Exemplary methods for detecting TIM3, e.g., human TIM3, in a
sample (cell or tissue sample) comprise (i) ting a sample with an anti-TIM3 antibody, for a time sufficient
for allowing ic g of the anti-TIM3 antibody to TIM3 in the sample, and (2) contacting the sample
with a detection reagent, e.g., an antibody, that specifically binds to the anti-TIM3 antibody, such as to the Fc
region of the anti-TIM3 antibody, to thereby detect TIM3 bound by the anti-TIM3 antibody. Wash steps can be
included after the incubation with the antibody and/or ion reagent. Anti-TIM3 antibodies for use in these
methods do not have to be linked to a label or detection agents, as a separate detection agent can be used.
Other uses for IM3 antibodies, e.g., as monotherapy or combination therapy, are provided
elsewhere herein, e.g., in the n ning to combination treatments.
XIV. Bispecific Molecules
Anti-TIM3 antibodies described herein can be used for forming bispecific molecules. An anti-
TIM3 antibody, or antigen-binding portions thereof, can be derivatized or linked to another functional molecule,
e.g., another peptide or protein (e.g., another antibody or ligand for a receptor) to generate a bispecific le
that binds to at least two different binding sites or target molecules. For example, an anti-TIM3 antibody can be
linked to an antibody or scFv that binds specifically to any protein that can be used as potential targets for
combination treatments, such as the proteins described herein (e.g., antibodies to PD-1, PD-L1, GITR, or LAG-
3). The antibody described herein can in fact be derived or linked to more than one other functional molecule to
generate multispecific molecules that bind to more than two different binding sites and/or target les; such
multispecific molecules are also intended to be encompassed by the term "bispecific molecule" as used herein.
To create a bispecific molecule bed herein, an antibody described herein can be functionally linked (e.g.,
by al coupling, genetic fusion, noncovalent association or otherwise) to one or more other g
molecules, such as another antibody, antibody fragment, peptide or binding c, such that a bispecific
molecule results.
Accordingly, provided herein are bispecific molecules comprising at least one first binding
icity for TIM3 and a second binding specificity for a second target epitope. In an embodiment described
herein in which the bispecific molecule is multispecific, the molecule can further include a third binding
icity.
In one embodiment, the bispecific molecules described herein comprise as a binding specificity at
least one dy, or an antibody fragment thereof, ing, e.g., , an Fab, Fab', F(ab')2, Fv, or a single chain
Fv (scFv). The antibody can also be a light chain or heavy chain dimer, or any minimal fragment thereof such as
a Fv or a single chain construct as described in Ladner et al. U.S. Patent No. 4,946,778.
While human monoclonal antibodies are preferred, other antibodies which can be ed in the
bispecific molecules described herein are murine, chimeric and humanized monoclonal antibodies.
The ific molecules described herein can be prepared by ating the constituent binding
specificities using methods known in the art. For example, each binding specificity of the bispecific molecule
can be generated separately and then conjugated to one another. When the binding icities are proteins or
peptides, a variety of coupling or cross-linking agents can be used for covalent conjugation. Examples of crosslinking
agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5'-dithiobis(2-
enzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl(2-pyridyldithio)propionate
(SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohaxanecarboxylate (sulfo-SMCC) (see e.g.,
Karpovsky et al. (1984) J. Exp. Med. 160: 1686; Liu, MA et al. (1985) Proc. Natl. Acad. Sci. USA 82:8648).
Other methods include those described in Paulus (1985) Behring Ins. Mitt. No. 78, 2; Brennan et al.
(1985) Science 229:81-83), and Glennie et al. (1987) J. Immunol. 139: 2367-2375). Some conjugating agents
are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).
When the binding specificities are antibodies, they can be conjugated via sulfhydryl bonding of the
C-terminus hinge regions of the two heavy chains. In a particular embodiment, the hinge region is modified to
contain an odd number of sulfhydryl es, preferably one, prior to conjugation.
Alternatively, both binding specificities can be d in the same vector and expressed and
led in the same host cell. This method is particularly useful where the bispecific molecule is a mAb x
mAb, mAb x Fab, mAb x (scFv)2, Fab x 2 or ligand x Fab fusion protein. A bispecific antibody can
comprise an antibody comprising an scFv at the inus of each heavy chain. A bispecific molecule
described herein can be a single chain molecule comprising one single chain antibody and a binding
determinant, or a single chain bispecific molecule comprising two g determinants. Bispecific molecules
can comprise at least two single chain les. s for preparing ific molecules are described for
example in U.S. Patent Number 5,260,203; U.S. Patent Number 5,455,030; U.S. Patent Number 4,881,175; U.S.
Patent Number 5,132,405; U.S. Patent Number 5,091,513; U.S. Patent Number 5,476,786; U.S. Patent Number
,013,653; U.S. Patent Number 5,258,498; and U.S. Patent Number 5,482,858.
Binding of the bispecific molecules to their specific targets can be confirmed using art-recognized
methods, such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay
(RIA), FACS analysis, bioassay (e.g., , growth tion), or n Blot assay. Each of these
assays generally detects the presence of protein-antibody complexes of particular interest by employing a
labeled reagent (e.g., , an antibody) specific for the complex of interest.
XV. Compositions
Further provided are compositions, e.g., a pharmaceutical compositions, containing one or a
combination of anti-TIM3 antibodies or combination with antibodies to other targets, or n-binding
portion(s) thereof, bed herein, formulated together with a pharmaceutically acceptable carrier. Such
compositions can include one or a combination of (e.g., two or more different) antibodies, or immunoconjugates
or bispecific molecules described herein. For example, a pharmaceutical composition described herein can
comprise a combination of antibodies (or immunoconjugates or bispecifics) that bind to different epitopes on the
target antigen or that have complementary activities.
In certain embodiments, a composition comprises an anti-TIM3 antibody at a concentration of at
least 1 mg/ml, 5 mg/ml, 10 mg/ml, 50 mg/ml, 100 mg/ml, 150 mg/ml, 200 mg/ml, 1-300 mg/ml, or 100-300
mg/ml.
Pharmaceutical itions described herein also can be administered in combination y,
i.e., combined with other agents. For example, the ation therapy can include an anti-TIM3 antibody
described herein combined with at least one other anti-cancer and/or immunomodulating, e.g., T-cell stimulating
(e.g., activating) agent. Examples of therapeutic agents that can be used in combination therapy are described in
greater detail below in the section on uses of the anti-TIM3 antibodies described herein.
In some embodiments, therapeutic compositions disclosed herein can include other compounds,
drugs, and/or agents used for the treatment of cancer. Such compounds, drugs, and/or agents can e, for
e, chemotherapy drugs, small molecule drugs or antibodies that stimulate the immune response to a given
cancer. In some instances, therapeutic compositions can include, for example, one or more of an anti-CTLA-4
antibody, an anti-PD-1 dy, an anti-PD-L1 antibody, an anti-OX40 (also known as CD134, TNFRSF4,
ACT35 and/or TXGP1L) antibody, an anti-CD137 antibody, an anti-LAG-3 antibody, an anti-GITR antibody, or
any combination thereof.
As used herein, aceutically acceptable carrier" includes any and all solvents, dispersion
media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that
are physiologically compatible. In some embodiments, the carrier is suitable for intravenous, intramuscular,
subcutaneous, parenteral, spinal or mal stration (e.g., by injection or infusion). Depending on the
route of administration, the active nd, i.e., antibody, immunoconjugate, or ific molecule, can be
coated in a material to protect the compound from the action of acids and other natural conditions that can
inactivate the compound.
The ceutical compounds described herein can include one or more pharmaceutically
acceptable salts. A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological ty
of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S.M., et al.
(1977) J. Pharm. Sci. 66: 1-19). Examples of such salts include acid addition salts and base addition salts. Acid
addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric,
sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as
aliphatic mono- and dicarboxylic acids, - tuted alkanoic acids, hydroxy alkanoic acids, ic
acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline
earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic
amines, such as Ν,Ν'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, nolamine,
ethylenediamine, procaine and the like.
A pharmaceutical composition described herein can also include a pharmaceutically acceptable
xidant. Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such
as ic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2)
oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene
(BHT), in, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, ic acid, phosphoric acid, and the like.
es of suitable s and nonaqueous carriers that can be employed in the pharmaceutical
compositions described herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene
glycol, and the like), and suitable mixtures thereof, ble oils, such as olive oil, and injectable organic
esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such
as lecithin, by the maintenance of the required le size in the case of dispersions, and by the use of
surfactants.
These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying
agents and dispersing agents. Prevention of presence of microorganisms can be d both by sterilization
procedures, supra, and by the inclusion of various cterial and antifungal , for example, paraben,
chlorobutanol, phenol sorbic acid, and the like. It can also be desirable to include isotonic agents, such as sugars,
sodium chloride, and the like into the compositions. In on, ged absorption of the injectable
pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum
monostearate and gelatin.
Pharmaceutically acceptable carriers include sterile s solutions or dispersions and sterile
powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media
and agents for pharmaceutically active substances is known in the art. Except insofar as any tional media
or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions described
herein is contemplated. A pharmaceutical composition can se a preservative or can be devoid of a
preservative. Supplementary active compounds can be incorporated into the compositions.
Therapeutic compositions typically must be sterile and stable under the conditions of manufacture
and storage. The composition can be formulated as a solution, microemulsion, liposome, or other d
structure le to high drug concentration. The carrier can be a solvent or dispersion medium containing, for
example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the
like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating
such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of
surfactants. In many cases, the compositions can include isotonic agents, for example, sugars, polyalcohols such
as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the able
compositions can be brought about by including in the composition an agent that delays absorption, for
example, monostearate salts and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound in the required
amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required,
followed by sterilization microfiltration. lly, dispersions are prepared by incorporating the active
compound into a sterile vehicle that ns a basic dispersion medium and the required other ingredients from
those enumerated herein. In the case of e powders for the preparation of sterile injectable solutions, some
methods of preparation are vacuum drying and freeze-drying ilization) that yield a powder of the active
ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
The amount of active ingredient which can be combined with a carrier material to produce a single
dosage form will vary depending upon the subject being treated, and the particular mode of administration. The
amount of active ingredient which can be combined with a carrier material to e a single dosage form will
generally be that amount of the ition which es a therapeutic effect. Generally, out of one hundred
percent, this amount will range from about 0.01 t to about ninety-nine percent of active ingredient, from
about 0.1 percent to about 70 percent, or from about 1 percent to about 30 percent of active ingredient in
combination with a pharmaceutically acceptable carrier.
Dosage regimens are adjusted to provide the m desired response (e.g., a therapeutic
response). For example, a single bolus can be administered, several divided doses can be administered over time
or the dose can be proportionally d or sed as ted by the exigencies of the therapeutic situation.
It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration
and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary
dosages for the subjects to be treated; each unit contains a predetermined quantity of active nd
ated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The
specification for the dosage unit forms described herein are dictated by and directly dependent on (a) the unique
characteristics of the active nd and the particular therapeutic effect to be achieved, and (b) the
limitations inherent in the art of compounding such an active nd for the treatment of sensitivity in
individuals.
For administration of an anti-TIM3 antibody, e.g., bed herein, the dosage ranges from about
0.0001 to 100 mg/kg, and more y 0.01 to 5 or 10 mg/kg, of the host body weight. For example dosages
can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg
body weight or within the range of 1- 10 mg/kg. An exemplary treatment regime entails administration once per
week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3
months or once every three to 6 months. Exemplary dosage regimens for an anti-TIM3 antibody described
herein include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, with the antibody
being given using one of the following dosing schedules: (i) every four weeks for six dosages, then every three
months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three
weeks.
An IM3 antibody can be administered at a flat dose (flat dose n). In other
embodiments, an anti-TIM3 antibody can be administered at a fixed dose with another antibody. In certain
embodiments, an anti-TIM3 antibody is administered at a dose based on body .
In some methods, two or more monoclonal antibodies with different binding specificities are
administered simultaneously, in which case the dosage of each antibody administered falls within the ranges
indicated. Antibody is usually administered on multiple occasions. Intervals between single s can be, for
example, weekly, monthly, every three months or yearly. Intervals can also be irregular as indicated by
measuring blood levels of antibody to the target antigen in the patient. In some methods, dosage is adjusted to
achieve a plasma antibody concentration of about 1-1000 μg/ml and in some methods about 25-300 μg/ml.
An IM3 antibody can be administered with another dy at the dosage regimen of the
other antibody. For example, an anti-TIM3 antibody can be administered with an anti-PD-1 antibody, such as
nivolumab (OPDIVO®), every two weeks as an i.v. infusion over 60 minutes until disease progression or
unacceptable toxicity occurs. An anti-TIM3 antibody can be administered with pembrolizumab (KEYTRUDA®)
every 3 weeks as an i.v. infusion over 30 minutes until e progression or unacceptable toxicity occurs. An
anti-TIM3 antibody can be administered with atezolizumab (TECENTRIQTM) every 3 weeks as an i.v. infusion
over 60 or 30 minutes until disease progression or unacceptable toxicity occurs.
An antibody can be administered as a ned e formulation, in which case less frequent
administration is required. Dosage and frequency vary depending on the half-life of the dy in the t.
In general, human antibodies show the t half-life, followed by humanized antibodies, chimeric antibodies,
and an antibodies. The dosage and frequency of administration can vary ing on whether the
treatment is prophylactic or eutic. In prophylactic applications, a relatively low dosage is administered at
relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest
of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes
required until progression of the disease is reduced or terminated, and until the patient shows partial or complete
amelioration of symptoms of e. fter, the patient can be administered a lactic regime.
Actual dosage levels of the active ingredients in the pharmaceutical compositions described herein
can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired
therapeutic response for a particular patient, composition, and mode of administration, t being toxic to the
patient. The selected dosage level will depend upon a variety of pharmacokinetic factors ing the activity
of the particular compositions described herein employed, or the ester, salt or amide thereof, the route of
administration, the time of administration, the rate of excretion of the particular compound being employed, the
duration of the ent, other drugs, compounds and/or materials used in combination with the particular
itions employed, the age, sex, weight, condition, general health and prior medical history of the patient
being treated, and like factors well known in the medical arts.
A peutically effective dosage" of an anti-TIM3 antibody described herein can result in a
decrease in severity of e symptoms, an increase in frequency and duration of disease symptom-free
periods, or a prevention of impairment or disability due to the disease affliction. In the context of cancer, a
therapeutically effective dose can result in sed survival, e.g., overall survival, and/or prevention of further
deterioration of physical symptoms associated with cancer. Symptoms of cancer are well-known in the art and
include, for example, unusual mole features, a change in the appearance of a mole, including asymmetry,
border, color and/or diameter, a newly pigmented skin area, an abnormal mole, darkened area under nail, breast
lumps, nipple changes, breast cysts, breast pain, death, weight loss, weakness, excessive fatigue, difficulty
eating, loss of appetite, chronic cough, worsening breathlessness, ng up blood, blood in the urine, blood
in stool, nausea, vomiting, liver ases, lung metastases, bone metastases, abdominal fullness, bloating,
fluid in peritoneal cavity, vaginal bleeding, constipation, abdominal distension, perforation of colon, acute
peritonitis (infection, fever, pain), pain, vomiting blood, heavy sweating, fever, high blood pressure, anemia,
diarrhea, jaundice, dizziness, chills, muscle spasms, colon metastases, lung metastases, bladder metastases, liver
ases, bone metastases, kidney ases, and pancreatic metastases, difficulty swallowing, and the like.
A eutically effective dose can prevent or delay onset of cancer, such as can be desired when
early or preliminary signs of the disease are t. Laboratory tests utilized in the diagnosis of cancer include
chemistries (including the measurement of TIM3 levels), hematology, serology and radiology. Accordingly, any
clinical or biochemical assay that monitors any of the ing can be used to determine whether a particular
treatment is a therapeutically ive dose for treating cancer. One of ordinary skill in the art would be able to
ine such s based on such factors as the subject's size, the severity of the subject's symptoms, and
the particular ition or route of administration selected.
A composition described herein can be administered via one or more routes of administration
using one or more of a variety of methods known in the art. As will be appreciated by the skilled artisan, the
route and/or mode of administration will vary depending upon the d results. Routes of administration for
the anti-TIM3 antibodies described herein can e intravenous, intramuscular, intradermal, intraperitoneal,
subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion. The
phrase teral administration" as used herein means modes of administration other than enteral and topical
administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial,
intrathecal, intracapsular, intraorbital, ardiac, intradermal, intraperitoneal, transtracheal, subcutaneous,
subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and
infusion.
Alternatively, an antibody described herein could potentially be administered via a non-parenteral
route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally,
vaginally, rectally, sublingually or topically.
The active nds can be prepared with carriers that will protect the compound against rapid
release, such as a controlled release formulation, including implants, transdermal patches, and
microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene
vinyl e, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods
for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g.,
Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York,
1978.
eutic itions can be administered with medical devices known in the art. For
e, in a particular embodiment, a eutic composition described herein can be administered with a
needleless hypodermic injection , such as the devices disclosed in U.S. Patent Nos. 5,399,163; 5,383,851;
335; 5,064,413; 4,941,880; 4,790,824; or 4,596,556. Examples of well-known implants and modules for
use with anti-TIM3 antibodies described herein include: U.S. Patent No. 4,487,603, which discloses an
implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4,486,194,
which ses a therapeutic device for administering medicaments through the skin; U.S. Patent No.
4,447,233, which ses a medication infusion pump for delivering medication at a precise infusion rate; U.S.
Patent No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug
delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having chamber
compartments; and U.S. Patent No. 196, which discloses an osmotic drug delivery system. These patents
are incorporated herein by nce. Many other such implants, delivery s, and modules are known to
those skilled in the art.
In certain embodiments, the anti-TIM3 antibodies described herein can be formulated to ensure
proper distribution in vivo. For example, the brain barrier (BBB) excludes many highly hydrophilic
compounds. To ensure that the therapeutic compounds described herein cross the BBB (if desired, e.g., for brain
cancers), they can be formulated, for e, in liposomes. For methods of manufacturing liposomes, see, e.g.,
U.S. Patents 4,522,811; 5,374,548; and 5,399,331. The liposomes can comprise one or more moieties which are
selectively transported into specific cells or organs, thus e targeted drug delivery (see, e.g., V.V. Ranade
(1989) J. Clin. Pharmacol. 29:685). Exemplary targeting moieties include folate or biotin (see, e.g., U.S. Patent
,416,016 to Low et al.); mannosides (Umezawa et al., (1988) m. Biophys. Res. Commun. 153: 1038);
antibodies (P.G. n et al. (1995) FEBS Lett. 357: 140; M. Owais et al. (1995) Antimicrob. Agents
Chemother. 39: 180); surfactant protein A receptor (Briscoe et al. (1995) Am. J. Physiol. 1233: 134); pl20
(Schreier et al. (1994) J. Biol. Chem. 90); see also K. Keinanen; M.L. nen (1994) FEBS Lett. 346:
123; J.J. Killion; I.J. Fidler (1994) Immunomethods 4:273.
XVI. Uses and Methods
The dies, antibody compositions and methods described herein have numerous in vitro and
in vivo utilities involving, for example, enhancement of immune response, such as by inhibiting (or
antagonizing) TIM3 (e.g., signaling), or detection of TIM3. In one embodiment, the anti-TIM3 antibodies
bed herein are human antibodies. For example, anti-TIM3 antibodies described herein can be administered
to cells in culture, in vitro or ex vivo, or to human subjects, e.g., in vivo, to enhance immunity in a variety of
diseases. Accordingly, provided herein are methods of modifying an immune response in a subject comprising
administering to the subject an anti-TIM3 antibody, or antigen-binding portion thereof, described herein such
that the immune response in the subject is modified. In some embodiments, the response is enhanced, stimulated
or up-regulated.
Subjects suitable for the present methods include human ts in whom enhancement of an
immune response would be desirable. The methods are particularly suitable for treating human patients having a
disorder that can be treated by ting an immune response (e.g., a T-cell mediated immune response, e.g.,
an antigen specific T cell response). In a particular embodiment, the methods are ularly suitable for
treatment of cancer in vivo. To achieve antigen- ic enhancement of immunity, anti-TIM3 antibodies
described herein can be administered together with an antigen of interest or the antigen can y be present in
the subject to be treated (e.g., a tumor-bearing or virus-bearing subject). When antibodies to TIM3 are
administered together with another agent, the two can be administered separately or simultaneously.
Also encompassed are methods for ing the presence of human TIM3 antigen in a sample, or
measuring the amount of human TIM3 antigen, comprising ting the sample, and a control sample, with a
monoclonal dy, e.g., a human monoclonal antibody, or an antigen binding portion thereof, which
specifically binds to human TIM3, under conditions that allow for formation of a complex between the antibody
or portion f and human TIM3. The formation of a x is then ed, wherein a ence x
formation n the sample ed to the control sample is indicative the presence of human TIM3 antigen
in the sample. Moreover, the anti-TIM3 antibodies described herein can be used to purify human TIM3 via
immunoaffinity purification.
Given the ability of anti-TIM3 antibodies described herein to stimulate or co-stimulate T cell
ses, e.g., antigen- specific T cell responses, such as by inhibiting negative effects of TIM3, provided
herein are in vitro and in vivo methods of using the anti-TIM3 antibodies described herein to stimulate, enhance
or upregulate antigen-specific T cell responses, e.g., anti-tumor T cell responses. In certain embodiments, CD3
ation is also provided (e.g., by coincubation with a cell expressing membrane CD3), which stimulation
can be provided at the same time, before, or after stimulation with an anti-TIM3 antibody. For example,
provided herein are methods of stimulating an antigen- specific T cell response comprising contacting said T
cell with an anti-TIM3 antibody described herein, and optionally with an D3 antibody, such that an
antigen- specific T cell response is stimulated.
Any suitable indicator of an antigen-specific T cell se can be used to measure the antigenspecific
T cell response. Non-limiting examples of such suitable tors include increased T cell proliferation
in the ce of the antibody and/or increase cytokine production in the presence of the antibody. In some
embodiments, interleukin-2 and/or interferon-γ production by the antigen- specific T cell is stimulated.
T cells that can be enhanced or co-stimulated with anti-TIM3 antibodies include CD4+ T cells and
CD8+ T cells. The T cells can be Teff cells, e.g., CD4+ Teff cells, CD8+ Teff cells, Thelper (Th) cells (e.g., Th1
cells) or T cytotoxic (Tc) cells.
Further encompassed are methods of stimulating an immune response (e.g., an antigen-specific T
cell response) in a subject comprising administering an anti-TIM3 antibody described herein to the subject such
that an immune response (e.g., an antigen-specific T cell response) in the subject is ated. In some
embodiments, the subject is a tumor-bearing subject and an immune response against the tumor is stimulated. A
tumor can be a solid tumor or a liquid tumor, e.g., a logical malignancy. In certain embodiments, a tumor
is an immunogenic tumor. In certain ments, a tumor is non-immunogenic. In certain embodiments, a
tumor is PD-L1 positive. In certain embodiments a tumor is PD-L1 negative. A subject can also be a virusbearing
subject and an immune response against the virus is stimulated.
Further provided are methods for ting growth of tumor cells in a subject sing
administering to the subject an anti-TIM3 antibody described herein such that growth of the tumor is inhibited in
the subject. Also provided are methods of treating a viral infection in a subject comprising administering to the
subject an anti-TIM3 antibody bed herein such that the viral infection is treated in the subject.
In certain ments, an anti-TIM3 antibody is given to a subject as an tive therapy.
ents of subjects having cancer with an anti-TIM3 dy can lead to prolonged survival, e.g., long-term
durable response relative to the current standard of care; long term survival of at least 3 months, 6 months, 9
, 1, 2, 3, 4, 5, 10 or more years, or recurrence-free survival of at least 3 months, 6 months, 9 months, 1, 2,
3, 4, 5, or 10 or more years. In n embodiments, treatment of a subject having cancer with an anti-TIM3
antibody prevents recurrence of cancer or delays recurrence of cancer by, e.g., 3 months, 6 months, 9 months, 1,
2, 3, 4, 5, or 10 or more years. An anti-TIM3 treatment can be used as a first-, second-, or third-line treatment.
Treatment of a subject having cancer with an anti-TIM3 antibody described herein, e.g.,
TIM3.18.IgG1, can result in, e.g., stable disease, partial response, sed overall survival, increased disease
free survival, or enhanced progression free survival.
In certain embodiments, an anti-TIM3 antibody bed herein is not icantly toxic. For
example, a TIM3 dy is not significantly toxic to an organ of a human, e.g., one or more of the liver,
kidney, brain, lungs, and heart, as determined, e.g., in clinical trials. In certain embodiments, a TIM3 dy
does not significantly trigger an undesirable immune response, e.g., autoimmunity or inflammation.
In certain embodiments, treatment of a subject with an anti-TIM3 antagonist (e.g., an anti-TIM3
antibody described herein) does not result in overstimulation of the immune system to the extent that the
subject's immune system then attacks the subject itself (e.g., autoimmune response) or results in, e.g.,
anaphylaxis. Thus, in some embodiments, anti-TIM3 dies do not cause anaphylaxis.
In certain embodiments, treatment of a t with an anti-TIM3 antibody described herein, e.g.,
an antibody comprising the CDRs or variable regions of 13A3 or a variant thereof (e.g., as described ) or
other anti-TIM3 antibodies described , does not cause significant inflammatory reactions, e.g., immunemediated
pneumonitis, immune-mediated colitis, immune mediated hepatitis, immune-mediated nephritis or
renal dysfunction, immune-mediated hypophysitis, immune-mediated hypothyroidism and hyperthyroidism, or
other immune-mediated e reactions. In n embodiments, an anti-TIM3 antibody comprising the
CDRs or variable regions of 13A3 or a variant thereof (e.g., as described herein) causes fewer inflammatory
reactions, e.g., immune-mediated pneumonitis, immune-mediated colitis, immune mediated hepatitis, immunemediated
nephritis or renal dysfunction, immune-mediated hypophysitis, immune-mediated yroidism and
hyperthyroidism, anaphylaxis or other immune-mediated adverse reactions, than other anti-TIM3 antibodies. In
certain embodiments, treatment of a subject with an anti-TIM3 antibody described herein, e.g., an antibody
comprising the CDRs or variable regions of 13A3 or a variant thereof (e.g., as described herein) or other anti-
TIM3 antibodies described herein, does not cause significant cardiac disorders, e.g., ventricular arrhythmia; eye
disorders, e.g., iridocyclitis; infusion-related reactions; increased amylase, increased lipase; nervous system
ers, e.g., dizziness, eral and sensory neuropathy; skin and subcutaneous tissue disorders, e.g., rash,
pruritus, exfoliative dermatitis, erythema multiforme, vitiligo or psoriasis; respiratory, ic and mediastinal
disorders, e.g., cough; fatigue; nausea; decreased appetite; constipation; arthralgia; or diarrhea.
In n embodiments, an anti-TIM3 antibody provides synergistic anti-tumor effects in
ation with another cancer therapy, such as a compound that stimulates the immune system (e.g., an
-oncology agent), e.g., a nd described herein or a compound modulating a target described
Using human antibodies, as opposed to chimeric or humanized dies, may result in a lower
levels of anti-drug antibodies (ADA). Accordingly, the human anti-TIM3 antibodies described , e.g.,
TIM3.18.IgG1.3, may have lower ADA relative to anti-TIM3 antibodies that are not human antibodies (e.g.,
relative to humanized or chimeric anti-TIM3 antibodies).
These and other methods described herein are sed in further detail below.
XVI.A. Cancer
tion of TIM3 by anti-TIM3 antibodies can enhance the immune response to cancerous cells
in a patient having cancer. Provided herein are methods for treating a subject having cancer, comprising
administering to the subject an anti-TIM3 antibody described herein, such that the subject is treated, e.g., such
that growth of ous tumors is inhibited or reduced and/or that the tumors regress and/or that prolonged
al is achieved. An anti-TIM3 antibody can be used alone to inhibit the growth of cancerous tumors.
Alternatively, an anti-TIM3 antibody can be used in conjunction with another agent, e.g., another immunogenic
agent, a standard cancer treatment, or another antibody, as described below.
Accordingly, provided herein are methods of treating cancer, e.g., by ting growth of tumor
cells, in a subject, comprising administering to the subject a therapeutically effective amount of an anti-TIM3
antibody described , e.g., TIM3.2, TIM3.4, TIM3.5, TIM3.6, 9F6, 8B9, TIM3.9, TIM3.10, 1,
TIM3.12, TIM3.13, TIM3.14, TIM3.15, 6, TIM3.17, TIM3.18, TIM3.7, and TIM3.8 having a wildtype
IgG constant region or a constant region having d effector function, e.g., IgG1.1 or , or antigenbinding
portion thereof. The antibody can be a human anti-TIM3 antibody (such as any of the human antihuman
TIM3 antibodies described herein). Cancers whose growth can be inhibited using the antibodies of the
disclosure e cancers typically responsive to immunotherapy and those that are not typically responsive to
immunotherapy. Cancers that can be treated also include TIM3 positive cancers. Cancers can be cancers with
solid tumors or blood malignancies (liquid tumors). miting examples of cancers for treatment include
squamous cell carcinoma, small-cell lung cancer, non-small cell lung cancer, squamous non-small cell lung
cancer (NSCLC), nonsquamous NSCLC, glioma, gastrointestinal cancer, renal cancer (e.g., clear cell
carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer (e.g., renal cell
carcinoma (RCC)), prostate cancer (e.g., hormone refractory prostate adenocarcinoma), thyroid cancer,
neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma orme), al cancer, stomach cancer,
bladder cancer, hepatoma, breast cancer, colon carcinoma, and head and neck cancer (or carcinoma), gastric
cancer, germ cell tumor, pediatric a, sinonasal natural killer, melanoma (e.g., metastatic malignant
melanoma, such as cutaneous or cular malignant melanoma), bone , skin cancer, uterine cancer,
cancer of the anal , testicular cancer, carcinoma of the fallopian tubes, oma of the endometrium,
carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the
small intestine, cancer of the endocrine system, cancer of the parathyroid gland, cancer of the adrenal gland,
sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, cancer of the ureter,
carcinoma of the renal pelvis, neoplasm of the l nervous system (CNS), primary CNS lymphoma, tumor
angiogenesis, spinal axis tumor, brain cancer, brain stem glioma, pituitary adenoma, 's sarcoma,
epidermoid cancer, squamous cell , T-cell lymphoma, environmentally-induced cancers including those
induced by asbestos, virus-related cancers or cancers of viral origin (e.g., human papilloma virus (HPV-related
or -originating tumors)), and hematologic malignancies derived from either of the two major blood cell lineages,
i.e., the myeloid cell line (which produces granulocytes, erythrocytes, thrombocytes, macrophages and mast
cells) or lymphoid cell line (which produces B, T, NK and plasma cells), such as all types of leukemias,
lymphomas, and myelomas, e.g., acute, chronic, lymphocytic and/or myelogenous leukemias, such as acute
leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic
myelogenous leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (Ml), myeloblastic
leukemia (M2; with cell maturation), locytic leukemia (M3 or M3 variant , myelomonocytic
ia (M4 or M4 variant with eosinophilia [M4E]), monocytic leukemia (M5), erythroleukemia (M6),
megakaryoblastic leukemia (M7), isolated granulocytic sarcoma, and chloroma; lymphomas, such as Hodgkin's
lymphoma (HL), dgkin's lymphoma (NHL), B cell hematologic ancy, e.g., B-cell lymphomas, T-
cell lymphomas, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, -associated id
tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) large-cell lymphoma, adult T-cell lymphoma/leukemia,
mantle cell lymphoma, angio immunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell
lymphoma, primary mediastinal B-cell lymphoma, precursor hoblastic lymphoma, T-lymphoblastic; and
lymphoma/leukaemia y/T-ALL), peripheral T- cell lymphoma, lymphoblastic lymphoma, posttransplantation
proliferative disorder, true histiocytic lymphoma, y central nervous system
lymphoma, primary effusion lymphoma, B cell ma, lymphoblastic lymphoma (LBL), hematopoietic
tumors of lymphoid e, acute lymphoblastic ia, e large B-cell lymphoma, Burkitt's lymphoma,
follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B -
lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also called mycosis fungoides or Sezary
me), and lymphoplasmacytoid lymphoma (LPL) with strom's macroglobulinemia; myelomas,
such as IgG myeloma, light chain myeloma, nonsecretory myeloma, smoldering myeloma (also called indolent
myeloma), solitary plasmocytoma, and multiple myelomas, chronic lymphocytic leukemia (CLL), hairy cell
lymphoma; hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, including fibrosarcoma
and rhabdomyoscarcoma; seminoma, teratocarcinoma, tumors of the central and peripheral nervous, including
astrocytoma, schwannomas; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyoscaroma, and
osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, ma,
thyroid follicular cancer and teratocarcinoma, hematopoietic tumors of lymphoid lineage, for example T-cell
and B-cell tumors, including but not limited to T-cell disorders such as T-prolymphocytic leukemia (T-PLL),
including of the small cell and cerebriform cell type; large granular lymphocyte leukemia (LGL) of the T-cell
type; a/d T-NHL hepatosplenic lymphoma; peripheral/post-thymic T cell lymphoma (pleomorphic and
immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; cancer of the head or neck, renal cancer, rectal
cancer, cancer of the thyroid gland; acute myeloid lymphoma, as well as any combinations of said cancers. The
methods described herein can also be used for treatment of metastatic cancers, unresectable, refractory s
(e.g., cancers refractory to previous immunotherapy, e.g., with a blocking CTLA-4 or PD-1 antibody), and/or
recurrent cancers.
In certain embodiments, an anti-TIM3 antibody is administered to patients having a cancer that
exhibited an inadequate response to, or progressed on, a prior ent, e.g., a prior treatment with an immunooncology
or immunotherapy drug, or patients having a cancer that is tory or resistant, either intrinsically
refractory or resistant (e.g., tory to a PD-1 pathway antagonist), or a wherein the resistance or refractory
state is acquired. For example, subjects who are not responsive or not sufficiently responsive to a first therapy or
who see disease progression following treatment, e.g., anti-PD-1 ent, can be treated by administration of
an anti-TIM3 antibody alone or in combination with r therapy (e.g., with an anti-PD-1 therapy).
In certain embodiments, an anti-TIM3 antibody is administered to patients who have not
previously ed (i.e., been treated with) an immuno-oncology agent, e.g., a PD-1 pathway antagonist.
In certain embodiments, a method of treating cancer in a subject comprises first determining
whether the subject is TIM3 ve, e.g., has tumor cells or TILs that express TIM3, and if the t has
TIM3 positive cancer or TIL cells, then stering to the subject an anti-TIM3 antibody, e.g., described
herein. A method of ng a subject having cancer with an anti-TIM3 antibody may comprise administering
to a t who has cancer cells or TIL cells that express TIM3, a therapeutically effective amount of a TIM3
antibody. Also provided herein are methods for predicting whether a subject will respond to treatment with an
anti-TIM3 antibody, wherein the methods comprise determining the level of TIM3 in cancer or TIL cells of the
patient, and if cancer or TIL cells of the subject are TIM3 positive, then the subject is likely to respond to a
treatment with a TIM3 antibody.
In certain embodiments, a method of treating cancer in a subject ses first determining
whether the subject is PD-L1 or PD-1 positive, e.g., has tumor cells or TILs that s PD-L1 or PD-1, and if
the subject has PD-L1 or PD-1 positive cancer or TIL cells, then administering to the subject an IM3
antibody (and optionally a PD-1 or PD-L1 antagonist), e.g., described herein. A method of treating a subject
having cancer with an anti-TIM3 antibody (and optionally a PD-1 or PD-L1 nist) may comprise
administering to a subject who has cancer cells or TIL cells that express PD-L1 or PD-1, a therapeutically
ive amount of a TIM3 dy (and optionally a PD-1 or PD-L1 antagonist). Also provided herein are
methods for predicting whether a subject will respond to treatment with an anti-TIM3 antibody (and optionally a
PD-1 or PD-L1 antagonist), wherein the methods comprise determining the level of PD-L1 or PD-1 in cancer or
TIL cells of the patient, and if cancer or TIL cells of the subject are PD-L1 or PD-1 positive, then the subject is
likely to respond to a treatment with a TIM3 dy(and ally a PD-1 or PD-L1 antagonist).
An anti-TIM3 antibody can be administered with a standard of care treatment. An anti-TIM3
antibody can be stered as a maintenance therapy, e.g., a therapy that is intended to prevent the occurrence
or recurrence of tumors.
An anti-TIM3 antibody can be administered with another treatment, e.g., radiation, surgery, or
chemotherapy. For example e, anti-TIM3 antibody adjunctive therapy can be administered when there is a risk
that micrometastases can be present and/or in order to reduce the risk of a relapse.
An anti-TIM3 antibody can be administered as a monotherapy, or as the only immuno stimulating
therapy. Antibodies to TIM3, e.g., the anti-TIM3 , can also be combined with an immunogenic agent, such as
cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate
molecules), cells, and cells ected with genes encoding immune ating nes (He et al.,(2004) J.
Immunol. 173:4919-28). Non-limiting es of tumor vaccines that can be used include peptides of
ma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MART1 and/or tyrosinase, or tumor
cells transfected to s the cytokine GM-CSF ssed further below).
In humans, some tumors have been shown to be immunogenic such as melanomas. By lowering
the threshold of T cell activation via TIM3 inhibition, the tumor responses in the host can be activated, allowing
treatment of non-immunogenic tumors or those having limited immunogenicity.
An anti-TIM3 antibody, e.g., an IM3 antibody described herein, can be combined with a
vaccination protocol. Many experimental strategies for vaccination against tumors have been devised (see
Rosenberg, S., 2000, pment of Cancer Vaccines, ASCO ional Book : 60-62; Logothetis, C,
2000, ASCO Educational Book Spring: 300-302; Khayat, D. 2000, ASCO ional Book Spring: 414-428;
Foon, K. 2000, ASCO Educational Book Spring: 730-738; see also Restifo, N. and Sznol, M., Cancer es,
Ch. 61, pp. 043 in DeVita et al. (eds.), 1997, Cancer: Principles and Practice of Oncology, Fifth Edition).
In one of these strategies, a vaccine is prepared using autologous or allogeneic tumor cells. These cellular
vaccines have been shown to be most effective when the tumor cells are transduced to express GM-CSF. GMCSF
has been shown to be a potent activator of antigen presentation for tumor vaccination (Dranoff et al. (1993)
Proc. Natl. Acad. Sci U.S.A. 90: 3539-43).
The study of gene expression and large scale gene expression patterns in s tumors has led to
the definition of so called tumor specific ns (Rosenberg, S A (1999) ty 10: 281-7). In many cases,
these tumor specific antigens are entiation antigens expressed in the tumors and in the cell from which the
tumor arose, for example melanocyte antigens gp100, MAGE antigens, and Trp-2. More importantly, many of
these antigens can be shown to be the targets of tumor specific T cells found in the host. TIM3 inhibition can be
used in conjunction with a collection of recombinant ns and/or peptides expressed in a tumor in order to
generate an immune response to these proteins. These proteins are normally viewed by the immune system as
self antigens and are therefore tolerant to them. The tumor antigen can include the protein rase, which is
required for the synthesis of telomeres of chromosomes and which is expressed in more than 85% of human
cancers and in only a limited number of somatic tissues (Kim et al. (1994) Science 266: 2011-2013). Tumor
antigen can also be "neo-antigens" expressed in cancer cells because of somatic mutations that alter protein
sequence or create fusion proteins between two unrelated sequences (i.e., bcr-abl in the Philadelphia
chromosome), or idiotype from B cell tumors.
Other tumor vaccines can e the proteins from viruses implicated in human cancers such a
Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus
(KHSV). Another form of tumor specific antigen which can be used in conjunction with TIM3 inhibition is
purified heat shock proteins (HSP) isolated from the tumor tissue itself. These heat shock proteins contain
fragments of proteins from the tumor cells and these HSPs are highly efficient at delivery to antigen presenting
cells for eliciting tumor immunity (Suot & Srivastava (1995) Science 269: 1585-1588; Tamura et al. (1997)
Science 278: 117-120).
tic cells (DC) are potent antigen presenting cells that can be used to prime antigen-specific
responses. DCs can be produced ex vivo and loaded with various protein and e antigens as well as tumor
cell extracts e et al. (1998) Nature Medicine 4: 328-332). DCs can also be transduced by genetic means to
express these tumor antigens as well. DCs have also been fused ly to tumor cells for the purposes of
immunization (Kugler et al. (2000) Nature Medicine 6:332-336). As a method of vaccination, DC immunization
can be effectively combined with TIM3 inhibition to activate more potent anti-tumor responses.
TIM3 inhibition can also be combined with standard cancer treatments (e.g., surgery, radiation,
and chemotherapy). TIM3 inhibition can be effectively combined with chemotherapeutic regimes. In these
instances, it can be possible to reduce the dose of chemotherapeutic t administered (Mokyr et al. (1998)
Cancer Research 58: 5301-5304). An example of such a combination is an anti-TIM3 antibody in combination
with azine for the treatment of melanoma. Another example of such a combination is an anti-TIM3
antibody in combination with interleukin-2 (IL-2) for the treatment of melanoma. The scientific rationale behind
the combined use of TIM3 inhibition and chemotherapy is that cell death, that is a consequence of the cytotoxic
action of most chemotherapeutic compounds, should result in sed levels of tumor n in the antigen
tation pathway. Other combination ies that can result in synergy with TIM3 inhibition through cell
death are radiation, surgery, and hormone ation. Each of these protocols creates a source of tumor antigen
in the host. Angiogenesis tors can also be combined with TIM3 inhibition. Inhibition of angiogenesis leads
to tumor cell death which can feed tumor antigen into host n presentation pathways.
The anti-TIM3 antibodies described herein can also be used in combination with bispecific
antibodies that target Fcα or Fcγ receptor-expressing effectors cells to tumor cells (see, e.g., U.S. Pat. Nos.
,922,845 and 5,837,243). Bispecific antibodies can be used to target two te antigens. For example anti-Fc
receptor/anti tumor antigen (e.g., Her-2/neu) bispecific antibodies have been used to target macrophages to sites
of tumor. This targeting can more effectively activate tumor specific responses. The T cell arm of these
responses would be augmented by the inhibition of TIM3. Alternatively, antigen can be delivered directly to
DCs by the use of ific antibodies which bind to tumor antigen and a dendritic cell specific cell surface
Tumors evade host immune surveillance by a large variety of mechanisms. Many of these
mechanisms can be overcome by the inactivation of proteins which are expressed by the tumors and which are
immunosuppressive. These include among others TGF-β (Kehrl et al. (1986) J. Exp. Med. 163: 1037-1050), IL-
(Howard & O'Garra (1992) logy Today 13: 198-200), and Fas ligand (Hahne et al. (1996) Science
274: 1363-1365). Antibodies to each of these entities can be used in ation with anti-TIM3 antibodies to
counteract the effects of the immunosuppressive agent and favor tumor immune responses by the host.
Other antibodies which te host immune responsiveness can be used in combination with anti-
TIM3 antibodies. These include molecules on the surface of dendritic cells which activate DC function and
antigen presentation. Anti-CD40 antibodies are able to substitute effectively for T cell helper activity (Ridge et
al. (1998) Nature 393: 474-478) and can be used in conjunction with anti-TIM3 antibodies. Activating
antibodies to T cell costimulatory molecules such as CTLA-4 (e.g., U.S. Pat. No. 5,811,097), OX-40 (Weinberg
et al. (2000) Immunol 164: 169), 4-lBB (Melero et al. (1997) Nature Medicine 3: 682-685 (1997), and
ICOS (Hutloff et al. (1999) Nature 397: 262-266) can also e for increased levels of T cell activation.
Inhibitors of PD1 or PD-L1 can also be used in conjunction with an IM3 antibody. Other combination are
provided elsewhere herein.
Bone marrow transplantation is currently being used to treat a variety of tumors of hematopoietic
origin. While graft versus host disease is a consequence of this treatment, therapeutic benefit can be obtained
from graft vs. tumor responses. TIM3 inhibition can be used to increase the effectiveness of the donor engrafted
tumor specific T cells.
There are also l experimental treatment protocols that involve ex vivo activation and
expansion of antigen specific T cells and adoptive transfer of these cells into recipients in order to stimulate
antigen- specific T cells t tumor (Greenberg & Riddell (1999) Science 285: 546-51). These methods can
also be used to activate T cell responses to ious agents such as CMV. Ex vivo activation in the presence of
anti-TIM3 antibodies can increase the frequency and activity of the adoptively erred T cells.
XVI.B. Infectious Diseases
Methods described herein can also be used to treat patients that have been d to particular
toxins or pathogens. Accordingly, another aspect described herein provides a method of treating an ious
disease in a t comprising administering to the subject an anti-TIM3 antibody, or antigen-binding portion
thereof, such that the t is treated for the infectious disease. Additionally or atively, the antibody can
be a ic or humanized antibody.
Similar to its application to tumors as discussed above, antibody-mediated TIM3 inhibition can be
used alone, or as an adjuvant, in combination with vaccines, to stimulate the immune response to pathogens,
toxins, and self-antigens. Examples of pathogens for which this therapeutic approach can be particularly useful,
e pathogens for which there is currently no effective vaccine, or pathogens for which conventional
vaccines are less than completely ive. These include, but are not limited to HIV, Hepatitis (A, B, & C),
Influenza, Herpes, a, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas nosa. TIM3
inhibition can be useful against established infections by agents such as HIV that present altered antigens over
the course of the ions. These novel epitopes are ized as foreign at the time of anti-human TIM3
antibody administration, thus provoking a strong T cell response.
Some examples of pathogenic viruses causing infections treatable by methods described herein
include HIV, hepatitis (A, B, or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, n Barr
virus), adenovirus, nza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory
syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus,
dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis
virus.
Some examples of enic bacteria causing infections ble by methods described herein
include chlamydia, tsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci,
meningococci and gonococci, klebsiella, proteus, serratia, monas, legionella, diphtheria, salmonella,
i, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lymes disease ia.
Some examples of pathogenic fungi causing infections ble by methods bed herein
include Candida (albicans, , ta, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus,
niger, etc.), Genus Mucorales (mucor, absidia, rhizopus), hrix schenkii, Blastomyces dermatitidis,
Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.
Some examples of enic tes causing infections treatable by methods described herein
e Entamoeba ytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia,
Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei,
osoma cruzi, Leishmania donovani, Toxoplasma gondii, and Nippostrongylus brasiliensis.
In all of the above methods, TIM3 inhibition can be combined with other forms of therapy,
e.g., those described herein, such as cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), or bispecific
dy therapy, which provides for enhanced presentation of tumor ns (see, e.g., er (1993) Proc.
Natl. Acad. Sci. USA 90:6444-6448; Poljak (1994) Structure 2: 1121-1123).
XVI.C. Autoimmune Reactions
Anti-TIM3 antibodies could provoke and amplify autoimmune responses. Indeed, induction of
umor responses using tumor cell and peptide vaccines s that many antitumor responses involve antiself
reactivities (van Elsas et al. (2001) J. Exp. Med. 194:481-489; Overwijk, et al. (1999) Proc. Natl. Acad. Sci.
U.S.A. 96: 2982-2987; z, (2000) supra; Rosenberg & White (1996) J. Immunother Emphasis Tumor
Immunol 19 (1): 81-4). Therefore, it is possible to consider using anti-TIM3 antibodies in conjunction with
various self proteins in order to devise ation protocols to efficiently generate immune ses against
these self proteins for disease treatment. For example, Alzheimer's disease involves inappropriate accumulation
of Αβ peptide in amyloid deposits in the brain; antibody responses against amyloid are able to clear these
amyloid deposits (Schenk et al., (1999) Nature 400: 173-177).
Other self proteins can also be used as targets such as IgE for the treatment of allergy and asthma,
and TNF-α for rheumatoid arthritis. Finally, antibody responses to various hormones can be induced by the use
of anti-TIM3 antibodies. Neutralizing antibody responses to reproductive hormones can be used for
contraception. Neutralizing antibody response to hormones and other soluble factors that are required for the
growth of particular tumors can also be considered as possible vaccination targets.
Analogous methods as described above for the use of anti-TIM3 antibodies can be used for
induction of therapeutic autoimmune responses to treat patients having an inappropriate accumulation of other
self-antigens, such as amyloid deposits, including Αβ in Alzheimer's disease, cytokines such as TNF-α, and IgE.
XVI.D. Vaccines
Anti-TIM3 antibodies described herein can be used to stimulate antigen- specific immune
responses by co-administration of an anti-TIM3 antibody with an antigen of interest (e.g., a vaccine).
Accordingly, provided herein are methods of enhancing an immune response to an antigen in a subject,
comprising stering to the subject: (i) the antigen; and (ii) an anti-TIM3 antibody, or antigen-binding
portion thereof, such that an immune response to the antigen in the subject is enhanced. The antibody can be a
human anti-human TIM3 antibody (such as any of the human anti-TIM3 antibodies described herein).
Additionally or alternatively, the antibody can be a chimeric or humanized dy. The antigen can be, for
example, a tumor antigen, a viral n, a bacterial antigen or an antigen from a pathogen. Non-limiting
examples of such antigens include those discussed in the ns above, such as the tumor antigens (or tumor
vaccines) discussed above, or antigens from the viruses, bacteria or other pathogens bed above.
In certain embodiments, a peptide or fusion protein comprising the epitope to which an anti-TIM3
dy binds is used as a vaccine instead of, or in addition to, an anti-TIM3 antibody.
Suitable routes of administering the antibody compositions (e.g., human monoclonal antibodies,
multispecific and bispecific molecules and immunoconjugates) bed herein in vivo and in vitro are well
known in the art and can be ed by those of ordinary skill. For example, the antibody compositions can be
administered by injection (e.g., intravenous or subcutaneous). le dosages of the molecules used will
depend on the age and weight of the t and the concentration and/or formulation of the antibody
composition.
As previously described, anti-TIM3 dies described herein can be co-administered with one
or other more therapeutic agents, e.g., a cytotoxic agent, a radiotoxic agent or an immunosuppressive agent. The
antibody can be linked to the agent (as an immuno-complex) or can be administered separate from the agent. In
the latter case (separate administration), the antibody can be administered before, after or concurrently with the
agent or can be coadministered with other known therapies, e.g., an anti-cancer therapy, e.g., radiation. Such
therapeutic agents include, among others, anti-neoplastic agents such as doxorubicin (adriamycin), cisplatin
bleomycin sulfate, carmustine, chlorambucil, dacarbazine and cyclophosphamide hydroxyurea which, by
themselves, are only ive at levels which are toxic or subtoxic to a patient. Cisplatin is intravenously
administered as a 100 mg/ml dose once every four weeks and adriamycin is intravenously stered as a 60-
75 mg/ml dose once every 21 days. Co-administration of anti-TIM3 antibodies, or n binding fragments
thereof, described herein with chemotherapeutic agents provides two anti-cancer agents which operate via
different mechanisms which yield a cytotoxic effect to human tumor cells. Such coadministration can solve
problems due to development of resistance to drugs or a change in the nicity of the tumor cells which
would render them unreactive with the antibody.
Also within the scope described herein are kits comprising the antibody compositions described
herein (e.g., human antibodies, bispecific or multispecific molecules, or immunoconjugates) and instructions for
use. The kit can r contain at least one additional reagent, or one or more additional human anti-TIM3
antibodies described herein (e.g., a human antibody having a complementary activity which binds to an epitope
in TIM3 antigen distinct from the first human antibody). Kits typically include a label indicating the intended
use of the ts of the kit. The term label includes any writing, or recorded material supplied on or with the
kit, or which ise accompanies the kit.
XVI.E. Combination Therapies
In addition to the combinations therapies provided above, anti-TIM3 antibodies, e.g., those
bed , can also be used in combination therapy, e.g., for treating cancer, as described below.
Provided herein are methods of combination therapy in which an anti-TIM3 antibody is
coadministered with one or more additional agents, e.g., small molecule drugs, antibodies or antigen binding
portions thereof, that are effective in stimulating immune responses to thereby further enhance, stimulate or
upregulate immune responses in a subject.
Generally, an anti-TIM3 antibody, e.g., bed herein, can be combined with (i) an agonist of a
stimulatory (e.g., co-stimulatory) molecule (e.g., receptor or ) and/or (ii) an antagonist of an inhibitory
signal or le (e.g., receptor or ligand) on immune cells, such as T cells, both of which result in amplifying
immune responses, such as n-specific T cell responses. In certain aspects, an immuno-oncology agent is
(i) an agonist of a stimulatory (including a co-stimulatory) molecule (e.g., or or ligand) or (ii) an
antagonist of an inhibitory (including a co-inhibitory) molecule (e.g., receptor or ligand) on cells, e.g., those
inhibiting T cell activation or those involved in innate immunity, e.g., NK cells, and n the immunooncology
agent enhances innate immunity. Such immuno-oncology agents are often referred to as immune
checkpoint regulators, e.g., immune checkpoint inhibitor or immune checkpoint stimulator.
In certain embodiments, an anti-TIM3 antibody is administered with an agent that targets a
stimulatory or tory molecule that is a member of the immunoglobulin super family (IgSF). For example,
anti-TIM3 antibodies, e.g., described herein, can be administered to a t with an agent that targets a
member of the IgSF family to increase an immune response. For example, an anti-TIM3 antibody can be
administered with an agent that targets (or binds specifically to) a member of the B7 family of membrane -
bound ligands that includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC ), B7-H2 (ICOS-L), B7-H3, B7-H4,
B7-H5 (VISTA), and B7-H6 or a co-stimulatory or co-inhibitory receptor or ligand g specifically to a B7
family member.
An anti-TIM3 antibody can also be administered with an agent that targets a member of the TNF
and TNFR family of molecules (ligands or receptors), such as CD40 and CD40L, OX-40, OX-40L, CD70,
CD27L, CD30, CD30L, 4-lBBL, CD137, TRAIL/Apo2-L, TRAILR1/DR4, 2/DR5, TRAILR3,
TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn 14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL,
BCMA, LTpR, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDA1, EDA2, TNFR1, Lymphotoxin
a/TNFp, TNFR2, TNFa, LTpR, Lymphotoxin a 1β2, FAS, FASL, RELT, DR6, TROY, and NGFR (see, e.g.,
Tansey (2009) Drug Discovery Today 00: 1).
T cell responses can be stimulated by a combination of anti-TIM3 antibodies having the variable
regions of, e.g., TIM3.2, , TIM3.5, TIM3.6, 9F6, 8B9, TIM3.9, TIM3.10, 1, 2, TIM3.13,
TIM3.14, TIM3.15, TIM3.16, TIM3.17, TIM3.18, TIM3.7, and , and one or more of the following
agents:
(1) An antagonist (inhibitor or ng agent) of a protein that inhibits T cell activation (e.g.,
immune checkpoint tors), such as CTLA-4, PD-1, PD-L1, PD-L2, GITR, and LAG-3, Galectin 9,
CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, B7-H3, B7-H4, 2B4, CD48, GARP,
PD1H, LAIR1, TIM-1, and TIM-4; and/or
(2) An agonist of a n that ates T cell activation, such as B7-1, B7-2, CD28, 4-1BB
(CD137), 4-1BBL, GITR, ICOS, ICOS-L, OX40, OX40L, CD70, CD27, CD40, DR3 and CD28H.
Exemplary agents that modulate one of the above proteins and can be combined with anti-TIM3
antibodies, e.g., those described herein, for treating cancer, include: YERVOY® (ipilimumab) or Tremelimumab
(to CTLA-4), galiximab (to B7.1), BMS-936558 (to PD-1), MK-3475 (to PD-1), atezolizumab (TECENTRIQ®),
AMP224 (to B7DC), BMS-936559 (to , MPDL3280A (to B7-H1), MEDI-570 (to ICOS), AMG557 (to
B7H2), MGA271 (to B7H3), IMP321 (to LAG-3), BMS-663513 (to CD137), PF-05082566 (to CD137), CDX-
1127 (to CD27), anti-OX40 (Providence Health Services), huMAbOX40L (to OX40L), Atacicept (to TACI),
CP-870893 (to CD40), mumab (to CD40), Dacetuzumab (to CD40), Muromonab-CD3 (to CD3); anti-
GITR antibodies MK4166, TRX518, Medi1873, INBRX-110, LK2-145, GWN-323, GITRL-Fc, or any
combination thereof.
Other molecules that can be combined with anti-TIM3 antibodies for the treatment of cancer
include antagonists of inhibitory receptors on NK cells or ts of activating receptors on NK cells. For
example, anti-TIM3 antibodies can be combined with antagonists of KIR (e.g., lirilumab).
T cell activation is also regulated by soluble cytokines, and anti-TIM3 antibodies can be
administered to a subject, e.g., having cancer, with antagonists of cytokines that inhibit T cell activation or
agonists of cytokines that stimulate T cell activation.
In certain embodiments, anti-TIM3 dies can be used in combination with (i) antagonists (or
inhibitors or ng agents) of proteins of the IgSF family or B7 family or the TNF family that inhibit T cell
activation or antagonists of cytokines that inhibit T cell tion (e.g., IL-6, IL-10, TGF-β, VEGF;
"immunosuppressive cytokines") and/or (ii) agonists of stimulatory receptors of the IgSF family, B7 family or
the TNF family or of cytokines that stimulate T cell activation, for stimulating an immune se, e.g., for
treating proliferative diseases, such as .
Yet other agents for combination therapies include agents that inhibit or deplete hages or
tes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including
RG7155 (WO11/70024, WO11/107553, 31407, W013/87699, W013/119716, WO13/132044) or FPA-
008 (WO11/140249; W013169264; WO14/036357).
Anti-TIM3 antibodies can also be administered with agents that inhibit TGF-β signaling.
Additional agents that can be ed with an anti-TIM3 antibody include agents that e
tumor antigen presentation, e.g., dendritic cell vaccines, GM-CSF secreting cellular vaccines, CpG
ucleotides, and mod, or therapies that enhance the immunogenicity of tumor cells (e.g.,
cyclines).
Yet other therapies that can be combined with an anti-TIM3 antibody include therapies that deplete
or block Treg cells, e.g., an agent that specifically binds to CD25.
Another therapy that can be combined with an anti-TIM3 antibody is a y that inhibits a
metabolic enzyme such as indoleamine dioxigenase (IDO), dioxigenase, arginase, or nitric oxide synthetase.
Another class of agents that can be used with an anti-TIM3 antibody includes agents that t
the ion of adenosine, e.g., CD73 inhibitors, or inhibit the adenosine A2A receptor.
Other therapies that can be combined with an anti-TIM3 antibody for treating cancer include
therapies that reverse/prevent T cell anergy or exhaustion and therapies that trigger an innate immune activation
and/or inflammation at a tumor site.
Other therapies that can be combined with an anti-TIM3 antibody for ng cancer include
therapies that block IL-8, e.g., with HuMax-IL8.
An anti-TIM3 antibody can be combined with more than one immuno-oncology agent, and can be,
e.g., combined with a combinatorial approach that targets multiple elements of the immune pathway, such as
one or more of the following: a therapy that enhances tumor antigen presentation (e.g., dendritic cell vaccine,
GM-CSF secreting cellular es, CpG ucleotides, imiquimod); a therapy that inhibits negative
immune regulation e.g., by inhibiting CTLA-4 and/or PD1/PD-L1/PD-L2 pathway and/or depleting or blocking
Tregs or other immune suppressing cells; a therapy that stimulates positive immune regulation, e.g., with
ts that stimulate the CD-137, OX-40, and/or CD40 or GITR pathway and/or stimulate T cell effector
function; a therapy that ses systemically the frequency of anti-tumor T cells; a therapy that depletes or
ts Tregs, such as Tregs in the tumor, e.g., using an antagonist of CD25 (e.g., umab) or by ex vivo
anti-CD25 bead depletion; a therapy that impacts the function of suppressor myeloid cells in the tumor; a
therapy that es genicity of tumor cells (e.g., anthracyclines); adoptive T cell or NK cell transfer
including genetically modified cells, e.g., cells modified by chimeric antigen receptors (CAR-T therapy); a
therapy that inhibits a metabolic enzyme such as amine dioxigenase (IDO), dioxigenase, arginase, or nitric
oxide synthetase; a therapy that reverses/prevents T cell anergy or exhaustion; a therapy that triggers an innate
immune activation and/or inflammation at a tumor site; administration of immune atory cytokines; or
blocking of immuno repressive nes.
Anti-TIM3 antibodies described herein can be used together with one or more of agonistic agents
that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors,
nists, and one or more agents that se systemically the frequency of anti-tumor T cells, agents that
overcome distinct immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory
receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25
monoclonal antibody (e.g., umab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic s
such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation
and/or inflammation at tumor sites.
In n embodiments, an anti-TIM3 antibody is administered to a subject together with a BRAF
inhibitor if the subject is BRAF V600 mutation positive.
Suitable PD-1 antagonists for use in the combination therapy described herein, include, without
tion, ligands, antibodies (e.g., monoclonal antibodies and bispecific antibodies), and multivalent agents. In
one embodiment, the PD-1 antagonist is a fusion protein, e.g., an Fc fusion protein, such as AMP-244. In one
embodiment, the PD-1 antagonist is an anti-PD-1 or anti-PD-L1 antibody.
An exemplary anti-PD-1 antibody is mab 36558) or an antibody that comprises the
CDRs or variable regions of one of antibodies 17D8, 2D3, 4H1, 5C4, 7D3, 5F4 and 4A11 described in WO
2006/121168. In certain embodiments, an anti-PD-l antibody is 5 (Lambrolizumab) described in
WO2012/ ; AMP-514 described in
other PD-1 tors include those described in
2011/066389,
Publication No. 2009/0317368. Any of the anti-PD-1 antibodies disclosed in WO2013/173223 can also be used.
An anti-PD-1 antibody that competes for binding with, and/or binds to the same epitope on PD-1 as, as one of
these antibodies can also be used in combination treatments.
In some embodiments, the D-L1 antibody useful for the combination therapy is BMS-
936559 (referred to as 12A4 in
the CDRs or le s of 3G10, 12A4, 10A5, 5F8, 10H10, 1B12, 7H1, 11E6, 12B7 and 13G4, which are
described in PCT Publication WO 07/005874 and US Patent No. 7,943,743. In certain embodiment an anti-PDL1
antibody is MEDI4736 (also known as durvalumab and Anti-B7-H1), MPDL3280A (also known as
atezolizumab and RG7446), MSB0010718C (also known as avelumab; WO2013/79174), or rHigM12B7. Any
of the anti-PD-L1 antibodies sed in WO2013/173223, WO2011/066389, WO2012/ 145493, U.S. Patent
Nos. 7,635,757 and 8,217,149 and U.S. Publication No. 2009/145493 can also be used. Anti-PD-L1 antibodies
that compete with and/or bind to the same epitope as that of any of these antibodies can also be used in
combination treatments.
In certain embodiments, the anti-TIM3 antibody of the disclosure can be used with a CTLA-4
nist, e.g., an anti-CTLA-4 antibody. In one embodiment, an anti-CTLA-4 antibody is an antibody ed
from the group of: YERVOY® (ipilimumab or antibody 10D1, described in PCT Publication WO 01/14424),
tremelimumab (formerly ticilimumab, CP-675,206), monoclonal or an anti-CTLA-4 antibody described in any
of the following publications: WO 98/42752; WO 00/37504; U.S. Pat. No. 6,207,156; z et al. (1998) Pro.
Natl. Acad. Sci. USA : 10067-10071; Camacho et al. (2004) J. Clin. Oncology 22(145): ct No.
2505 (antibody CP-675206); and Mokyr et al. (1998) Cancer Res. 58:5301-5304. Any of the TLA-4
antibodies disclosed in WO2013/173223 can also be used.
In other embodiments, an anti-TIM3 antibody of the disclosure is used in combination with a
LAG3 antagonist. Examples of anti-LAG3 antibodies include antibodies comprising the CDRs or variable
regions of antibodies 25F7, 26H10, 25E3, 8B7, 11F2 or 17E5, which are described in U.S. Patent Publication
No. US2011/0150892, WO10/19570 and WO2014/008218. In one embodiment, an anti-LAG-3 antibody is
BMS-986016. Other art recognized anti-LAG-3 dies that can be used include IMP731 and IMP-321,
described in US 2011/007023, WO08/132601, and WO09/44273. Anti-LAG-3 antibodies that compete with
and/or bind to the same epitope as that of any of these antibodies can also be used in combination ents.
In some embodiments, an anti-TIM3 dy of the disclosure can be administered in
combination with a CD137 (4-1BB) t, such as an agonistic CD137 antibody. Suitable CD137 antibodies
e, for example, urelumab or PF-05082566 (W012/32433).
In other embodiments, an anti-TIM3 antibody can be administered in combination with an OX40
agonist, such as an agonistic OX40 antibody. Suitable OX40 dies include, for example, MEDI-6383,
MEDI-6469 or MOXR0916 8; 29879).
In one embodiment, an anti-TIM3 antibody is administered in combination with a CD40 agonist,
such as an agonistic CD40 antibody. In certain embodiments, the immuno-oncology agent is a CD40 antagonist,
such as an nistic CD40 antibody. Suitable CD40 antibodies include, for example, lucatumumab
(HCD122), dacetuzumab (SGN-40), CP-870,893 or Chi Lob 7/4.
In one embodiment, an anti-TIM3 antibody is administered in combination with a CD27 agonist,
such as an agonistic CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab (CDX-1127).
In certain embodiments, the anti-TIM3 antibody is administered together with an anti-GITR
dy, e.g., an antibody having the CDR sequences of 6C8, e.g., a humanized antibody having the CDRs of
6C8, as bed, e.g., in WO2006/105021; an antibody comprising the CDRs of an anti-GITR antibody
bed in WO2011/028683; an antibody comprising the CDRs of an anti-GITR antibody described in
JP2008278814, an dy comprising the CDRs of an anti- GITR antibody described in WO2015/031667,
WO2015/187835, WO2015/184099, WO2016/054638, WO2016/057841 or WO2016/057846 or other anti-
GITR antibody described or referred to herein.
In other embodiments, an IM3 antibody is administered in combination with MGA271 (to
B7H3) (WO11/109400).
In some embodiments, an anti-TIM3 antibody is stered in combination with a KIR
antagonist, such as lirilumab.
In other embodiments, an anti-TIM3 antibody is administered in combination with an IDO
antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006/122150, WO07/75598,
6653, WO08/36642), indoximod, NLG-919 (WO09/73620, WO09/1156652, WO11/56652,
WO12/142237) or F001287.
In yet other embodiments, an IM3 antibody is administered in combination with a Toll-like
receptor agonist, e.g., a TLR2/4 agonist (e.g., Bacillus te-Guerin); a TLR7 t (e.g., Hiltonol or
Imiquimod); a TLR7/8 agonist (e.g., Resiquimod); or a TLR9 agonist (e.g., CpG7909).
In one embodiment, an anti-TIM3 is administered in combination with a TGF-β inhibitor, e.g.,
GC1008, LY2157299, TEW7197, or IMC-TR1.
The anti-TIM3 antibodies and combination therapies described herein can also be used in
conjunction with other well-known therapies that are selected for their particular usefulness against the
indication being d (e.g., cancer). Combinations of the anti-TIM3 antibodies described herein can be used
sequentially with known pharmaceutically able agent(s).
For example, the anti-TIM3 antibodies and combination therapies described herein can be used in
combination (e.g., simultaneously or separately) with an additional treatment, such as irradiation and/or
chemotherapy, e.g., using camptothecin (CPT-11), 5-fluorouracil (5-FU), cisplatin, doxorubicin, irinotecan,
paclitaxel, gemcitabine, cisplatin, paclitaxel, carboplatin-paclitaxel (Taxol), doxorubicin, or camptothecin +
apo21/TRAIL (a 6X combo)), one or more proteasome inhibitors (e.g., bortezomib or MG132), one or more
Bcl-2 inhibitors (e.g., BH3I-2' (bcl-xl inhibitor), indoleamine dioxygenase-1 tor (e.g., INCB24360,
mod, NLG-919, or F001287), AT-101 (R-(-)-gossypol derivative), ABT-263 (small molecule), GX
070 (obatoclax), or MCL-1 (myeloid leukemia cell differentiation protein- 1) antagonists), iAP itor of
apoptosis protein) antagonists (e.g., smac7, smac4, small molecule smac mimetic, synthetic smac es (see
Fulda et al., Nat Med 2002;8:808-15), ISIS23722 (LY2181308), or AEG-35156 (GEM-640)), HDAC (histone
deacetylase) inhibitors, anti-CD20 antibodies (e.g., rituximab), angiogenesis inhibitors (e.g., bevacizumab), giogenic
agents targeting VEGF and VEGFR (e.g., Avastin), synthetic triterpenoids (see Hyer et al, Cancer
Research 5:4799-808), c-FLIP (cellular FLICE-inhibitory protein) modulators (e.g., natural and synthetic
ligands of PPARy (peroxisome proliferator-activated receptor γ), 5809354 or 5569100), kinase inhibitors (e.g.,
Sorafenib), zumab, Cetuximab, Temsirolimus, mTOR inhibitors such as rapamycin and temsirolimus,
omib, JAK2 inhibitors, HSP90 inhibitors, PI3K-AKT inhibitors, ldomide, GSK3P tors, IAP
inhibitors and/or genotoxic drugs.
The anti-TIM3 antibodies and combination therapies described herein can further be used in
combination with one or more roliferative cytotoxic agents. Classes of compounds that can be used as
roliferative cytotoxic agents e, but are not limited to, the following:
Alkylating agents (including, without limitation, en mustards, ethylenimine derivatives, alkyl
sulfonates, nitrosoureas and triazenes): Uracil mustard, Chlormethine, Cyclophosphamide (CYTOXAN®)
fosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine,
Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, and Temozolomide.
Antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine
analogs and adenosine deaminase inhibitors): Methotrexate, 5-Fluorouracil, Floxuridine, Cytarabine, 6-
Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, and Gemcitabine.
le anti-proliferative agents for combining with anti-TIM3 antibodies, without limitation,
taxanes, paclitaxel (paclitaxel is commercially ble as TAXOL™), docetaxel, discodermolide (DDM),
dictyostatin (DCT), Peloruside A, lones, epothilone A, epothilone B, epothilone C, epothilone D,
epothilone E, epothilone F, furanoepothilone D, desoxyepothilone Bl, [17]-dehydrodesoxyepothilone B,
dehydrodesoxyepothilones B, C12,13-cyclopropyl-epothilone A, C6-C8 bridged epothilone A, trans-9,10-
oepothilone D, cis-9,10-dehydroepothilone D, 16-desmethylepothilone B, epothilone BIO,
discoderomolide, patupilone (EPO-906), 2, KOS-1584, ZK-EPO, ABJ-789, XAA296A
(Discodermolide), 27 (soblidotin), ILX-651 (tasidotin hydrochloride), Halichondrin B, in mesylate
(E-7389), Hemiasterlin (HTI-286), E-7974, Cyrptophycins, LY-355703, Maytansinoid immunoconjugates (DM-
1), MKC-1, ABT-751, 67, T-900607, SB-715992 (ispinesib), SB-743921, MK-0731, STA-5312,
eleutherobin, 17beta-acetoxyethoxyoxo-B-homo-estra-l,3,5(10)-trienol, cyclostreptin, isolaulimalide,
laulimalide, 4-epidehydroxy-14,16-didemethyl-(+)-discodermolides, and cryptothilone 1, in addition to other
microtubuline stabilizing agents known in the art.
In cases where it is desirable to render aberrantly proliferative cells quiescent in conjunction with
or prior to treatment with anti-TIM3 antibodies described herein, hormones and steroids (including synthetic
analogs), such as 17a-Ethinylestradiol, Diethylstilbestrol,Testosterone, Prednisone, Fluoxymesterone,
Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyl-testosterone,
Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine,
Medroxyprogesteroneacetate, Leuprolide, Flutamide, fene, ZOLADEX®, can also be administered to the
patient. When employing the s or compositions described herein, other agents used in the modulation of
tumor growth or asis in a al setting, such as metics, can also be stered as desired.
In certain embodiments, the combination of the anti-TIM3 antibody and a second agent discussed
herein can be administered concurrently as a single composition in a ceutically acceptable carrier, or
concurrently as separate itions with the IM3 antibody and the second agent in a pharmaceutically
acceptable carrier. In another embodiment, the combination of the anti-TIM3 antibody and the second agent can
be administered sequentially. The stration of the two agents can start at times that are, e.g., 30 minutes,
60 minutes, 90 minutes, 120 minutes, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 3 days, 5 days, 7
days, or one or more weeks apart, or administration of the second agent can start, e.g., 30 minutes, 60 minutes,
90 minutes, 120 minutes, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 3 days, 5 days, 7 days, or one
or more weeks after the first agent has been administered.
In some embodiments, an anti-neoplastic antibody that can be combined with an anti-TIM3
antibody and/or a second agent includes N® (rituximab), HERCEPTIN® (trastuzumab), BEXXAR®
(tositumomab), ZEVALIN® umomab), CAMPATH® (alemtuzumab), LYMPHOCIDE® (eprtuzumab),
AVASTIN® (bevacizumab), and TARCEVA® (erlotinib), or any combination thereof. In other embodiments,
the second antibody useful for the combination therapy with an anti-TIM3 antibody can be an antibody drug
conjugate.
In other ment, an anti-TIM3 antibody alone or in combination with another agent is used
concurrently or sequentially with bone marrow transplantation to treat a variety of tumors of hematopoietic
Provided herein are methods for altering an e event associated with treatment of a
hyperproliferative disease (e.g., cancer) with an immuno stimulatory agent, comprising administering an anti-
TIM3 antibody with or without a second agent, to a subject. For example, the methods described herein provide
for a method of reducing the incidence of immuno stimulatory therapeutic antibody-induced colitis or diarrhea
by administering a non-absorbable steroid to the patient. As used herein, a "non-absorbable steroid" is a
glucocorticoid that exhibits extensive first pass metabolism such that, following metabolism in the liver, the
bioavailability of the steroid is low, i.e., less than about 20%. In one embodiment described herein, the nonabsorbable
steroid is nide. nide is a y- acting glucocorticosteroid, which is extensively
metabolized, primarily by the liver, ing oral administration. ENTOCORT EC® (Astra-Zeneca) is a pH-
and time-dependent oral formulation of budesonide ped to optimize drug ry to the ileum and
throughout the colon. ENTOCORT EC® is approved in the U.S. for the treatment of mild to moderate Crohn's
disease involving the ileum and/or ascending colon. In still further embodiments, an anti-TIM3 antibody in
conjunction with a sorbable steroid can be further combined with a salicylate. Salicylates e 5-ASA
agents such as, for example: sulfasalazine (AZULFIDINE®, Pharmacia & Up John); olsalazine (DJPENTUM®,
Pharmacia & Up John); azide AL®, Salix Pharmaceuticals, Inc.); and mesalamine (ASACOL®,
Procter & Gamble Pharmaceuticals; PENTASA®, Shire US; ®, Axcan Scandipharm, Inc.;
ROWASA®, Solvay).
Table 1.
SEQ Description Sequences
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
TIM3.5 (13A3) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
1 IgG1.1f Heavy SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNSSLKS
RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
8B9 IgG1.1f SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
2 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
Heavy Chain CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.6 (8C4) QVQLQESGPGLVKPSETLSLTCTVSGGSISRYYWSWIRQPPGKGLEWIGYIHYTGSTNYNPSLKS
3 RVTISVDTSKNQFSLKLSSVTAADTAVYYCATDTGYYGMDVWGQGTTVTVSSASTKGPSVFPLAP
IgG1.1f Heavy SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
SEQ Description Sequences
Chain CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPRGDSIIYAQKFQ
TIM3.2 (17C3) GRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDFYGSGNYYYGMDVWGQGTTVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
4 IgG1.1f Heavy SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
GRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTAVTVSSASTKGPS
9F6 IgG1.1f SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISTSGSIIYYADSVK
TIM3.4 (3G4) GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSWSYYYGMDVWGQGTTVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
6 IgG1.1f Heavy PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMI
Chain TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISSSGSIIYYADSVK
TIM3.9 (17C8) GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGYSSGWEYYGMDVWGQGTTVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
7 IgG1.1f Heavy SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.5 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.1f Heavy VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
8 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain (without RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
8B9 IgG1.1f QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNSSLKS
RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
Heavy Chain SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
9 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
(without C- CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
terminal K) KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.6 (8C4) QVQLQESGPGLVKPSETLSLTCTVSGGSISRYYWSWIRQPPGKGLEWIGYIHYTGSTNYNPSLKS
RVTISVDTSKNQFSLKLSSVTAADTAVYYCATDTGYYGMDVWGQGTTVTVSSASTKGPSVFPLAP
f Heavy SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
Chain (without CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
inal K) KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.2 (17C3) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPRGDSIIYAQKFQ
GRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDFYGSGNYYYGMDVWGQGTTVTVSSASTKGPS
IgG1.1f Heavy VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
11 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain (without CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
9F6 IgG1.1f GRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTAVTVSSASTKGPS
12 Heavy Chain VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
(without C- RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
SEQ Description Sequences
terminal K) GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.4 (3G4) QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISTSGSIIYYADSVK
GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSWSYYYGMDVWGQGTTVTVSSASTKGP
IgG1.1f Heavy PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
13 PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMI
Chain (without TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
C-terminal K) YKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.9 (17C8) QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISSSGSIIYYADSVK
GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGYSSGWEYYGMDVWGQGTTVTVSSASTKGPS
IgG1.1f Heavy VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
14 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain (without RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.5 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
IgG1.3f Heavy SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Chain
KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNSSLKS
DTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
8B9 IgG1.3f SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
16 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
Heavy Chain CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLQESGPGLVKPSETLSLTCTVSGGSISRYYWSWIRQPPGKGLEWIGYIHYTGSTNYNPSLKS
TIM3.6 (8C4) DTSKNQFSLKLSSVTAADTAVYYCATDTGYYGMDVWGQGTTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
17 IgG1.3f Heavy QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
Chain
KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPRGDSIIYAQKFQ
TIM3.2 (17C3) GRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDFYGSGNYYYGMDVWGQGTTVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
18 IgG1.3f Heavy SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Chain
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
GRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTAVTVSSASTKGPS
9F6 f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
19 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISTSGSIIYYADSVK
TIM3.4 (3G4) GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSWSYYYGMDVWGQGTTVTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
IgG1.3f Heavy PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMI
Chain SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISSSGSIIYYADSVK
TIM3.9 (17C8) GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGYSSGWEYYGMDVWGQGTTVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
21 IgG1.3f Heavy SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
SEQ Description Sequences
TIM3.5 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
f Heavy VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
22 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain (no C- RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNSSLKS
8B9 IgG1.3f RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
23 Heavy Chain (no QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
C-terminal K) CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.6 (8C4) QVQLQESGPGLVKPSETLSLTCTVSGGSISRYYWSWIRQPPGKGLEWIGYIHYTGSTNYNPSLKS
RVTISVDTSKNQFSLKLSSVTAADTAVYYCATDTGYYGMDVWGQGTTVTVSSASTKGPSVFPLAP
IgG1.3f Heavy GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
24 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
Chain (no C- CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
terminal K) IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.2 (17C3) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPRGDSIIYAQKFQ
GRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDFYGSGNYYYGMDVWGQGTTVTVSSASTKGPS
IgG1.3f Heavy VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain (no C- RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
9F6 IgG1.3f RDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTAVTVSSASTKGPS
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
26 Heavy Chain (no SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K)
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.4 (3G4) QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISTSGSIIYYADSVK
GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSWSYYYGMDVWGQGTTVTVSSASTKGP
IgG1.3f Heavy SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV
27 PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMI
Chain (no C- SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
terminal K) YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.9 (17C8) QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISSSGSIIYYADSVK
GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGYSSGWEYYGMDVWGQGTTVTVSSASTKGPS
IgG1.3f Heavy VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
28 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Chain (no C- RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
al K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
SGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
TIM3.10 (13A3) SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
72 IgG1.1f (N60Q) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYSPSL
TIM3.11 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
73 IgG1.1f (N60S) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
74 TIM3.12 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYAPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
SEQ Description Sequences
IgG1.1f (N60A) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.13 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
75 IgG1.1f (D101E) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
SGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.14 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDVWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
76 f (P102V) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.15 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
77 f (P102Y) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
6 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDLWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
78 IgG1.1f (P102L) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.17 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
IgG1.1f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
79 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
(N60Q/P102Y) RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.18 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
IgG1.1f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
349 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
(N60Q/D101E) CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNPSLKS
TIM3.8 (8B9) RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
80 IgG1.1f (S61P) QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
Heavy Chain
KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
TIM3.7 (9F6) GRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTTVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
81 IgG1.1f (A108T) QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.10 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
82 KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.1f (N60Q) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
SEQ Description Sequences
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
C-terminal K) GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.11 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYSPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.1f (N60S) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
83 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
2 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYAPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.1f (N60A) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
84 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
inal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.13 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
IgG1.1f (D101E) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
85 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
inal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.14 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDVWGQGTLVTVSSASTKGPS
IgG1.1f (P102V) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
86 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.15 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
IgG1.1f (P102Y) SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
87 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.16 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDLWGQGTLVTVSSASTKGPS
IgG1.1f (P102L) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
88 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
7 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
IgG1.1f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
89 (N60Q/P102Y)
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain (no KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
C-terminal K)
TIM3.18 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
IgG1.1f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
350 (N60Q/D101E)
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain (no KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
C-terminal K)
QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNPSLKS
90 TIM3.8 (8B9) RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
SEQ Description Sequences
IgG1.1f (S61P) QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
Heavy Chain (no KALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
C-terminal K)
TIM3.7 (9F6) QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
GRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTTVTVSSASTKGPS
IgG1.1f (A108T) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
91 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
TIM3.10 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
92 IgG1.3f (N60Q) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYSPSL
TIM3.11 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
93 IgG1.3f (N60S) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
SGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYAPSL
TIM3.12 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
94 IgG1.3f (N60A) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.13 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
95 IgG1.3f (D101E) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.14 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDVWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
96 IgG1.3f (P102V) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.15 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
97 IgG1.3f (P102Y) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.16 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDLWGQGTLVTVSSASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
98 IgG1.3f ) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.17 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
99 SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
IgG1.3f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
SEQ Description Sequences
(N60Q/P102Y) RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
Heavy Chain GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.18 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
351 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
(N60Q/D101E) RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNPSLKS
TIM3.8 (8B9) RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
100 IgG1.3f (S61P) QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
Heavy Chain
KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
SGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
TIM3.7 (9F6) GRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTTVTVSSASTKGPS
SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
101 IgG1.3f ) SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain
KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*
TIM3.10 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.3f (N60Q) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
102 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.11 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYSPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.3f (N60S) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
103 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.12 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYAPSL
SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPS
IgG1.3f (N60A) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
104 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.13 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
f (D101E) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
105 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.14 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDVWGQGTLVTVSSASTKGPS
IgG1.3f (P102V) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
106 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
TIM3.15 (13A3) KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
107 IgG1.3f (P102Y) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
SEQ Description Sequences
C-terminal K) GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.16 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSL
SVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDLWGQGTLVTVSSASTKGPS
IgG1.3f (P102L) VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
108 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.17 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVTVSSASTKGPS
f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
109 (N60Q/P102Y)
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain (no KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
C-terminal K)
8 (13A3) QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSL
KSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPS
IgG1.3f VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
352 (N60Q/D101E) RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
Heavy Chain (no KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
C-terminal K)
TIM3.8 (8B9) QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYNPSLKS
RVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSASTKGPSVFPLAP
IgG1.3f (S61P) SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
110 QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVT
Heavy Chain (no CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN
C-terminal K) KALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.7 (9F6) QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYYADSVK
RDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTTVTVSSASTKGPS
IgG1.3f ) SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
111 SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMIS
Heavy Chain (no RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
C-terminal K) KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN
GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG*
TIM3.5 (13A3), EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
SGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGT
TIM3.2 (17C3), ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC*
29 TIM3.4 (3G4)
IgG1 Light
Chain
8B9, TIM3.6 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSG
SGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGT
(8C4), TIM3.9 ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC*
(17C8) IgG1
Light Chain
9F6 VK1 IgG1 AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGS
32 GSGTDFTLTISSLQPEDFATYYCQQFNSYPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA
Light Chain SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
VTHQGLSSPVTKSFNRGEC*
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
TIM3.5 (13A3) CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
134 IgG1.1f Heavy GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
Chain GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
SEQ ption Sequences
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATTCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
TGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
GACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
8B9 f CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
135 TTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
Heavy Chain CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACACTGGGAGCACCAACTACAACCCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
AGCGGACACGGCCGTGTATTACTGTGCGACAGATACGGGCTACTACGGTATGGACGTCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TIM3.6 (8C4) TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
136 IgG1.1f Heavy CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
Chain
GTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG
CAAGGCATCTGGATACACTTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAG
TIM3.2 (17C3) GGCTTGAGTGGATGGGAATAATCAACCCTAGGGGTGATAGCATAATCTACGCACAGAAGTTCCAG
137 IgG1.1f Heavy GGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAG
ATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTCTATGGTTCGGGAAACTACTACTACG
Chain GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
SEQ Description Sequences
TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
9F6 IgG1.1f TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
138 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTACTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAAGGGTATAGCAGCAGCTGGTCCTACTACT
ACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCA
TCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT
GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCG
TIM3.4 (3G4) TGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
139 IgG1.1f Heavy GGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCAC
CTGAAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
Chain
ACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTT
CAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAA
AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACC
AGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGC
AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT
CCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTAGTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
TIM3.9 (17C8) TTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
140 IgG1.1f Heavy AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGGTATAGCAGTGGCTGGGAGTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
Chain GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
SEQ Description Sequences
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.5 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f Heavy AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
141 GAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain (without AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATTCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
TGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
8B9 IgG1.1f ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
CCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
Heavy Chain CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
142 CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
(without C- CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
terminal K) TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACACTGGGAGCACCAACTACAACCCCTCCCTCAAGAGT
TIM3.6 (8C4) CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
IgG1.1f Heavy AGCGGACACGGCCGTGTATTACTGTGCGACAGATACGGGCTACTACGGTATGGACGTCTGGGGCC
143 AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
Chain (without TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
C-terminal K) TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
SEQ Description Sequences
GTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG
ATCTGGATACACTTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAG
GGCTTGAGTGGATGGGAATAATCAACCCTAGGGGTGATAGCATAATCTACGCACAGAAGTTCCAG
GGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAG
GGACACGGCCGTGTATTACTGTGCGAGAGATTTCTATGGTTCGGGAAACTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
CCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.2 (17C3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f Heavy TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
144 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain (without AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
TTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
9F6 IgG1.1f CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
Heavy Chain TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
145 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
(without C- AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTACTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
TIM3.4 (3G4) AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAAGGGTATAGCAGCAGCTGGTCCTACTACT
IgG1.1f Heavy ACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCA
146 TCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT
Chain (without GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
C-terminal K) CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
GGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCAC
CTGAAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTT
CAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
SEQ Description Sequences
ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAA
AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACC
GCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGC
AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT
CCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTAGTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGGTATAGCAGTGGCTGGGAGTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.9 (17C8) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f Heavy AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
147 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain (without AAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.5 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
148 IgG1.3f Heavy GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
AGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC
ACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGGG
ACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATTCCTCCCTCAAGAGTC
GAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCT
GCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCCA
AGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCT
8B9 IgG1.3f CCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
149 CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCT
Heavy Chain ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCC
AGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCC
AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGTC
AGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACAT
GCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTG
GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAG
CACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA
AAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAG
SEQ Description Sequences
GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT
CAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACT
ACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAA
CCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CTCTGGTGGCTCCATCAGTCGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACACTGGGAGCACCAACTACAACCCCTCCCTCAAGAGT
ACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
AGCGGACACGGCCGTGTATTACTGTGCGACAGATACGGGCTACTACGGTATGGACGTCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TIM3.6 (8C4) TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
150 f Heavy CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
Chain
GTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
GCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG
CAAGGCATCTGGATACACTTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAG
GGCTTGAGTGGATGGGAATAATCAACCCTAGGGGTGATAGCATAATCTACGCACAGAAGTTCCAG
GGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAG
ATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTCTATGGTTCGGGAAACTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
CCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.2 (17C3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
151 IgG1.3f Heavy GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
9F6 IgG1.3f CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
152 ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
Heavy Chain TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
SEQ Description Sequences
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTACTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAAGGGTATAGCAGCAGCTGGTCCTACTACT
ACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCA
TCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT
GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCG
TIM3.4 (3G4) TGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
153 IgG1.3f Heavy GGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCAC
Chain CTGAAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTT
CAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
CGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAA
AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACC
AGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGC
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT
CCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTAGTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
TTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGGTATAGCAGTGGCTGGGAGTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
CCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.9 (17C8) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
154 IgG1.3f Heavy GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.5 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
IgG1.3f Heavy ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
155 TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
Chain (no C- GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
SEQ Description Sequences
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
AGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC
ACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGGG
ACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATTCCTCCCTCAAGAGTC
GAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGCT
GCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCCA
AGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCT
CCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCT
8B9 IgG1.3f ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCC
AGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCC
156 Heavy Chain (no AAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGTC
C-terminal K) CCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACAT
GCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTG
GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAG
CACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA
AAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAG
GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGT
CAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACT
ACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAA
CCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTTACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACACTGGGAGCACCAACTACAACCCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
AGCGGACACGGCCGTGTATTACTGTGCGACAGATACGGGCTACTACGGTATGGACGTCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
AAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
TIM3.6 (8C4) ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
f Heavy CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
157 CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
Chain (no C- CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
terminal K) GTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
CACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG
CAAGGCATCTGGATACACTTTCACCAGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAG
GGCTTGAGTGGATGGGAATAATCAACCCTAGGGGTGATAGCATAATCTACGCACAGAAGTTCCAG
GGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAG
ATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTCTATGGTTCGGGAAACTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.2 (17C3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f Heavy TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
158 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain (no C- AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
159 9F6 IgG1.3f CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
SEQ Description Sequences
Heavy Chain (no TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
C-terminal K) GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTACTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAAGGGTATAGCAGCAGCTGGTCCTACTACT
ACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCA
TCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT
TIM3.4 (3G4) GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCG
TGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG
IgG1.3f Heavy CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
160 GGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCAC
Chain (no C- CCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC
terminal K) TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTT
CAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACA
ACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAA
AGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACC
GCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGC
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTT
CCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
TGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTAGTAGTGGTAGTATCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAG
AGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGGTATAGCAGTGGCTGGGAGTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.9 (17C8) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f Heavy TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
161 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Chain (no C- AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
0 (13A3) CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
205 CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
IgG1.1f (N60Q) GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
SEQ Description Sequences
Heavy Chain AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACTCACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
1 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
206 IgG1.1f (N60S) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACGCACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.12 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
207 IgG1.1f (N60A) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
TIM3.13 (13A3) CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
208 IgG1.1f (D101E) GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
Heavy Chain GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
SEQ Description Sequences
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACGTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.14 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
209 IgG1.1f (P102V) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.15 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
210 IgG1.1f (P102Y) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
TIM3.16 (13A3) CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
211 IgG1.1f (P102L) AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
Heavy Chain GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
SEQ Description Sequences
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
CCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.17 (13A3) CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
212 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
P102Y) AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
CGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.18 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
355 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
(N60Q/D101E) AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGG
TIM3.8 (8B9) GACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATCCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
213 IgG1.1f (S61P) TGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCC
Heavy Chain AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
SEQ ption Sequences
CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
TTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
ACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
CCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.7 (9F6) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
214 IgG1.1f (A108T) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.10 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f (N60Q) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
215 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
TIM3.11 (13A3) GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACTCACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
IgG1.1f (N60S) GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
216 GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
Heavy Chain (no GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
C-terminal K) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
SEQ Description Sequences
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACGCACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.12 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f (N60A) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
217 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.13 (13A3) CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f (D101E) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
218 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
TIM3.14 (13A3) CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
IgG1.1f (P102V) GGTTCGACGTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
219 GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
Heavy Chain (no CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
inal K) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
SEQ ption Sequences
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.15 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f ) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
220 GAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.16 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.1f (P102L) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
221 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
7 (13A3) AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
IgG1.1f GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
222 (N60Q/P102Y) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
Heavy Chain (no
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
inal K) GAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
SEQ Description Sequences
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
TIM3.18 (13A3) GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
IgG1.1f ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
356 (N60Q/D101E) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain (no
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
inal K) CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGG
GACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATCCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
TGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
TIM3.8 (8B9) ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
IgG1.1f (S61P) CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
223 CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
Heavy Chain (no CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
C-terminal K) TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
GGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
TIM3.7 (9F6) GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
IgG1.1f ) CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
224 ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
Heavy Chain (no TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
C-terminal K) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAAGCAGCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
SEQ ption Sequences
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.10 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
225 IgG1.3f (N60Q) GAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACTCACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
1 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
226 IgG1.3f (N60S) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACGCACCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.12 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
227 IgG1.3f (N60A) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
SEQ ption Sequences
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
CCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.13 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
228 IgG1.3f (D101E) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACGTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.14 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
229 IgG1.3f (P102V) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.15 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
230 f (P102Y) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
SEQ Description Sequences
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.16 (13A3) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
231 IgG1.3f (P102L) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.17 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
232 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
(N60Q/P102Y) AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.18 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
357 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
(N60Q/D101E) AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
233 TIM3.8 (8B9) CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGG
SEQ Description Sequences
IgG1.3f (S61P) GACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATCCCTCCCTCAAGAGT
CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
Heavy Chain TGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCC
AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
TCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
CTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
GGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TIM3.7 (9F6) ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
234 IgG1.3f (A108T) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA
CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
ACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.10 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f (N60Q) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
235 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
TIM3.11 (13A3) CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
236 CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
IgG1.3f (N60S) GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACTCACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
SEQ Description Sequences
Heavy Chain (no GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
C-terminal K) GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACGCACCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.12 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
f (N60A) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
237 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.13 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f (D101E) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
238 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
TIM3.14 (13A3) CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
IgG1.3f ) GGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
239 AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
Heavy Chain (no GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
C-terminal K) GGTTCGACGTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
SEQ Description Sequences
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
CGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
CGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.15 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f (P102Y) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
240 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACAACCCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGACCTATGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
6 (13A3) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f (P102L) AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
241 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
TIM3.17 (13A3) CAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
IgG1.3f GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
242 (N60Q/P102Y) GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
Heavy Chain (no GGTTCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
C-terminal K) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
SEQ ption ces
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
TIM3.18 (13A3) GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
IgG1.3f ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
358 (N60Q/D101E) GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Heavy Chain (no
CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
C-terminal K) CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGCAGTAGAAGTTACTACTGGGGCTGGATTCGCCAGCCCCCAG
GGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGTGGGTTCACCTACTACCAACCGTCCCTC
AAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGT
GACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTACGCCCACT
GGTTCGAACCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
TIM3.18 (13A3) GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
IgG1.3f CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
D101E) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
374 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
(T168C) Heavy AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
Chain (no C- CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
terminal K) GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTG
CACTGTCTCTGGTGGCTCCATCAGTCGTCACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGG
TIM3.8 (8B9) GACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGCACCAACTACAATCCCTCCCTCAAGAGT
IgG1.3f (S61P) CGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAGCTGAGCTCTGTGACCGC
243 TGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATCTGGGGCC
Heavy Chain (no AAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCC
AAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA
C-terminal K) ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC
TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCC
SEQ Description ces
CAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGAAGGGGCCCCGT
CAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA
TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGT
GGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACA
CACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGG
TCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC
ACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGT
GGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACA
ACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGG
GGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTACCATATACTACGCAGACTCTGTGAAG
GGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGCAAATGAACAGCCTGAG
AGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACTACTACG
GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCG
GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGT
TIM3.7 (9F6) CAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGC
ACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
IgG1.3f (A108T) TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGT
244 GGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTG
Heavy Chain (no AAGCCGAAGGGGCCCCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC
C-terminal K) CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACA
GCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC
AAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGG
GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGG
TCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
CTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA
TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTC
TIM3.5 (13A3), CTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGG
CTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGC
TIM3.2 , AGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTA
162 TIM3.4 (3G4) TTACTGTCAGCAGTATGGTAGCTCACCGATCACCTTCGGCCAAGGGACACGACTGGAGATTAAAC
TGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT
IgG1 Light GTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGA
TAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT
Chain ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC
GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTC
CTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGG
8B9, TIM3.6 CTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGC
(8C4), TIM3.9 AGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTA
163 TTACTGTCAGCAGTATGGTAGCTCACCTCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC
(17C8) IgG1 GTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT
GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGA
Light Chain TAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT
ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC
GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAC
TTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTC
TCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGT
9F6 VK1 IgG1 GGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTA
165 CTGTCAACAGTTTAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGTA
Light Chain CGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCC
TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAA
CGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACA
GCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAA
GTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
9F6 VK2 IgG1 GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTC
166 CTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGG
Light Chain CTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGC
SEQ Description Sequences
TCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTA
TTACTGTCAGCAGTATGGTAGCTCACTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGTA
CGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCC
TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAA
CGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACA
GCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAA
GTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTC
CTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGG
CTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGC
9F6 VK3 IgG1 AGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTA
164 TTACTGTCAGCAGTATGGTAGCTCACCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC
Light Chain GTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT
GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGA
TAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT
ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC
GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG
The practice of the present disclosure will employ, unless ise indicated, conventional
techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA,
and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See,
for example, Sambrook et al., ed. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor
Laboratory Press); Sambrook et al., ed. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor
Laboratory, NY); D. N. Glover ed., (1985) DNA g, s I and II; Gait, ed. (1984) Oligonucleotide
Synthesis; Mullis et al. U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization;
Hames and s, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan
R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To
lar Cloning; the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Miller and Calos eds.
(1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu et al., eds.,
Methods In Enzymology, Vols. 154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods In Cell
And Molecular Biology (Academic Press, London); Weir and Blackwell, eds., (1986) Handbook Of
Experimental Immunology, Volumes I-IV; Manipulating the Mouse Embryo, Cold Spring Harbor tory
Press, Cold Spring Harbor, N.Y., (1986); ); Crooks, Antisense drug Technology: Principles, strategies and
applications, 2nd Ed. CRC Press (2007) and in Ausubel et al. (1989) Current Protocols in Molecular Biology
(John Wiley and Sons, Baltimore, Md.).
All of the references cited above, as well as all references cited herein, are orated herein by
reference in their entireties.
The following examples are offered by way of illustration and not by way of limitation.
EXAMPLES
Example 1: Identification of human anti-TIM3 dies
Human IgG enic (KM) mice were immunized with the plasma membrane on of
HEK-293 human cells transfected with human TIM-3. Lymph node cells from all immunized mice were fused
to the SP2/0 fusion partner. oma supernatants were first screened for the presence of human IgG
antibodies using a high throughput assay. Antigen icity was then determined by FACS binding on human
TIM-3 transfected cells. Briefly, 47 s were performed, 3935 IgG positive clones were identified, of which
448 were identified as being positive for hTIM3 by ELISA, and of these 126 were found to be positive by
hTIM3 FACS. Of these, 117 clones (or antibodies) were further analyzed by a variety of methods including: (1)
epitope binning performed by Biacore; (2) TIM3 binding to a transfected cell line IM3) to
determine EC50; (3) Th1 assays (as further described below); and (4) TIL assays (as further described below).
Of the 117, seven hybridomas expressing fully human anti-human TIM3 antibodies were selected as having
desirable characteristics: 13A3, 8B9, 8C4, 17C3, 9F6, 3G4 and 17C8. The amino acid of, and nucleotide
ces ng, the variable domains of the antibodies ed by these hybridomas are provided in FIGs
1-7, and the SEQ ID NOs of the CDRs, variable s and heavy and light chains as well as their isotype are
provided in (see rows with hybridoma names). A hydriboma and dy secreted by it have the same
name (e.g., 13A3).
Antibodies comprising the CDRs and/or variable domains of antibodies 13A3, 8B9, 8C4, 17C3,
9F6, 3G4 and 17C8 were also expressed recombinantly in host cells. Recombinant antibodies are referred to
herein with the names "TIM3.2" to "TIM3.18." When referring to any of these recombinant antibodies by their
names 2" to "TIM3.18", no specific constant region is referred to, i.e., antibodies TIM3.2 to TIM3.18
may have any d constant region, e.g., those shown in .
CDRs and variable domains were expressed in the context of an effectorless IgG1 constant region
(allotype "f"), which comprises the substitutions L234A, L235E, G237A, A330S and P331S ("IgG1.1f") and
IgG1.3f, an orless IgG1 constant region (allotype "f"), which comprises substitutions L234A, L235E,
G237A, i.e., it differs from IgG1.1f only in not having the A330S and P331S substitutions. The CDRs and
variable regions may also be used in the context of IgG4, e.g., IgG4P (i.e., IgG4 with a "S228P" substitution).
Certain CDRs and framework regions of these antibodies have also been mutated. Specifically, VHCDR2 of
13A3 and 8B9, VHCDR3 of 13A3 and VHFR4 have been mutated. A list of IgG1.1f and IgG1.3f antibodies that
have been produced and other antibodies that can be made is ed in , Table 1 and in the sequence
listing. Antibodies expressed recombinantly include those described in the Examples below, as well as
antibodies 3G4, 8C4, 9F6, 8B9, 17C8, 5D6 that have been expressed as IgG1.1f antibodies.
A sequence alignment of the heavy and light chain variable regions of antibodies 13A3, 8B9, 8C4,
17C3, 9F6, 3G4 and 17C8 is provided in FIGs 8A and 9A, respectively. The VH and VL region sequence
designation are provided in FIGs 8B and 9B, respectively. A sequence alignment of the pe and mutated
13A3 VH chains is ed in . A sequence alignment of the wildtype and mutated 9F6 VH chain is
provided in . A sequence alignment of the wildtype and d 8B9 VH chains is provided in .
Example 2: Characterization of the human anti-TIM3 dies
The selected anti-TIM3 antibodies were assayed for binding to TIM3-expressing cells. A
shows the binding of various anti-TIM3 antibodies to cells transfected with human TIM3 (A), and to
anti-CD3/anti-CD28-activated human T cells (B), as determined by flow cytometry. The antibodies were
also tested for binding to cyno TIM3 by using cells transfected with cyno TIM3 (A) and anti-CD3/anti-
CD28-activated cyno T cells (B). A shows that 13A3 has the best g EC50 for cyno-TIM3
transfected cell line, and it is the only anti-TIM3 antibody that is reactive with activated cyno T cells.
Example 3: Binding affinity of TIM3 antibodies to human and cyno TIM3 determined by e Plasmon
Resonance
cs and affinity of IM3 13A3 Fab fragments towards human and cyno TIM3 were
determined on a Biacore T200 instrument at 37 °C in PBS pH 7.4 supplemented with 0.05% (v/v) Tween-20, as
further described below. The human TIM3 n used consisted of the extracellular domain (ECD) of human
TIM3 linked to a mouse Fc, thereby forming a dimeric hTIM3 ECD-Fc protein ("hTIM3-mFc"). This fusion
protein was expressed from stably transfected CHO cells, and purified out of the medium using protein A
affinity, followed by size exclusion chromatography. The recombinant cynomolgus TIM3 protein used consisted
of the ellular domain of cynomolgus TIM3 followed by linker and affinity tags, thereby forming a
monomeric cynoTIM3 ECD protein ("cyno TIM3-MycHisAvi"). This fusion protein was expressed from
transiently transfected Expi293 cells (Life Tech) and the protein was isolated from the medium and purified out
using affinity tag (6x His), followed by size exclusion tography.
The amino acid sequence of hTIM3-mFc was as follows:
SEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLT
ADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGHGPAETQTLGSLPDI
NLTQISTLANELRDSRLANDLRDSGATIRIGASVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCV
VVAISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTIS
KTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNV
QKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 375)
The amino acid sequence of cynoTIM3-MycHisAvi was as follows:
AEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLT
IENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKSPGGGSGGGSEQKLISEEDLGHHHHHHGLNDIFEAQKI
EWHE (SEQ ID NO: 376)
Fabs of 13A3 and TIM3.18.IgG1.3 linked to a histidine tail were used. The amino acid sequence of
13A3 Heavy Chain (HC) Fab 6xHis was as follows:
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYNPSLKSRVTISVDT
SKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CGGHHHHHH (SEQ ID NO: 365)
The amino acid sequence of 13A3 Heavy Chain (HC) N60Q D101E Fab 6xHis was as s:
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSLKSRVTISVDT
SKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CGGHHHHHH (SEQ ID NO: 366)
Recombinant 13A3 and 8.IgG1.3 Fabs were made using ent transfection of Expi293
(Life Tech). The expressed Fab comprised the heavy chain variable region followed by the CH1 of hIgG1, and
light chain variable region followed by the CL domain of hKappa. The expressed Fab was secreted into the
medium and purified using affinity tag (6x His).
An anti-mouse antibody capture chip was prepared on a Biacore CM4 series S chip (GE
Healthcare Life Sciences g #BR34) using the Biacore capture kit for mouse antibodies (catalog
#BR38). Human TIM3-mouse Fc fusion protein was captured on flow cells 2 and 3 in two different
surface densities. Cyno TIM3-mouse Fc fusion protein was captured on flow cell 4. Flow cell 1 (blank e
surface) served as a nce. Recombinantly expressed, His-tagged antibody Fab fragments were flowed as
analytes over all surfaces in a 3-fold, 6-membered dilution series with 1.0 µM top concentration and 4.1 nM
bottom concentration. Resulting sensorgrams were double-referenced (using flow cell 1 and a buffer blank) and
fitted to a 1:1 ir binding model with mass transport. Data from flow cells 2 and 3 were fitted globally.
The rate of complex formation (Ka) and dissociation (KD) as well as overall dissociation constant
(KD) are provided in Table 2.
Table 2: Kinetics and affinity of binding of anti-TIM3 antibodies 13A3 and TIM3.18.IgG1.3 to human and cyno
TIM3 proteins
Ligand Analytes ka (1/Ms) kd (1/s) KD (nM)
Human TIM3 hTIM3Fc/13A3 Fab 3.2 x106 6.9 x10-3 2.2
Cyno TIM3 cynoTIM3Fc/13A3 Fab 2.4 x106 5.3 x10-2 22
Human TIM3 hTIM3Fc/TIM3.18 Fab 3.2 x106 5 x10-3 1.6
Cyno TIM3 cynoTIM3Fc/TIM3.18 Fab 3.4 x106 5.9 x10-2 17
The experiments with 13A3 were not conducted on the same day as those with TIM3.18.
Example 4: Binding affinity of TIM3 antibodies to human and cyno TIM3 determined by Scatchard analysis
TIM3.18.IgG1.3 antibody was radioiodinated with 125I-Na (1mCi; PerkinElmer Catalog
H001 MC) using IODO-GEN® solid phase iodination reagent (1,3,4,6-tetrachloro-3a-6adiphenylglycouril
; Pierce g 28601). Excess iodide was removed using a desalting column (Pierce Catalog
43243). Fractions of labeled antibody were collected and ed for radioactivity on a Wizard 1470 gamma
counter (PerkinElmer). The IM3.18.IgG1.3 antibody concentration in each fraction was calculated with the
Qubit fluorometer from Invitrogen. Radiopurity was established by thin layer chromatography of peak protein
and radioactive fractions (Pinestar Technology Catalog 151-005).
Radio iodinated TIM3.18.IgG1.3 antibody binding to CHO cells expressing human or cyno TIM3
was demonstrated by incubating the CHO cells expressing human or cyno TIM3 with a titration of 125ITIM3.18.IgG1.3
antibody. Nonspecific binding was determined by binding in the presence of a titration of a 100
fold molar excess of led antibody and was subtracted from total CPM to calculate specific binding. A
linear standard curve of 125I-TIM3.18.IgG1.3 antibody concentration versus CPM was used to extrapolate
ic activity, maximal nM bound 125I- TIM3.18.IgG1.3 dy and y calculate receptor number per
cell.
The results are shown in FIGs 27A and 27B. The 125I-TIM3.18.IgG1.3 antibody standard curve
(A) shows that 1 nM of 125I labeled dy equals 3 cpm. The number of receptors per cell is
calculated by the following equation: (Bmax) x (Avogadro's number) x (Assay Volume) / # of cells per well.
The results show that the 8.IgG1.3 antibody has an affinity of .48 nM for pressed human
TIM3 on CHO cells (having 414,720 receptors per cell) and an affinity of 0.36-0.48 nM for overexpressed cyno
TIM3 (having 235,944 receptors per cell).
A similar analysis conducted with IM3.18.IgG1.3 antibody on activated human Th1 cells
from 2 donors (50,000 cells/well) provided an affinity of 0.125 – 0.164 nM, despite an almost four fold
difference in number of receptors per cell between donors (). Radio iodinated TIM3.18.IgG1.3 binding
to human TIM3 was demonstrated by incubating activated primary human Th1 cells (prepared as described in
other Examples herein) with a titration of 125I-TIM3.18.IgG1.3. Nonspecific binding was determined by binding
in the presence of a titration of a 100 fold molar excess of unlabeled antibody and was subtracted from total
CPM to calculate specific binding. A linear standard curve of 125I-TIM3.18.IgG1.3 concentration versus CPM
was used to extrapolate maximal nM bound 125I-TIM3.18.IgG1.3 and thereby calculate receptor s per
cell.
e 5: Lack of cross-reactivity of TIM3.18.IgG1.3 to human TIM1, human TIM4 and mouse TIM3
Upon a blast search of the TIM-3 IgV domain against the entire gene bank, the highest
homologous molecules were TIM1 and TIM4 (45% identity). Selectivity profiling of TIM3.18.IgG1.3 using
human TIM1 or TIM4-transfected cell lines by flow cytometry showed no cross-reactivity to TIM1 or TIM4. It
was also shown by flow cytometry on mouse TIM3 transfected cells, that TIM3.18.IgG1.3 is not cross-reactive
with mouse TIM-3 ected cells.
Example 6: IFN-γ tion by tumor infiltrating lymphocytes (TILs) is enhanced by anti-TIM3 antibodies
To characterize the anti-TIM3 antibodies r and identify those that are more likely to have
significant T cell stimulating activity in vivo, a specific T cell assay was ped. The assay measures the
amount of IFN-γ secreted from tumor infiltrating cytes (TILs), isolated from fresh tumor tissue, and
incubated in the presence of irradiated CHO cells, expressing CD3 ("CHO-OKT3 cells"), in the presence or
absence of a TIM3 dy (or control). Without wanting to be limited by a specific mechanism of ,
ion of IFN-γ in the presence of a given anti-TIM3 antibody indicates that the antibody inhibits the negative
signaling normally provided by TIM3 on the TILs, and stimulates activation (i.e., IFN-γ production) of the TILs.
Fresh tumor tissue (including tumor infiltrating lymphocytes (TILs)) from a renal cell carcinoma
patient was prepared into a single cell suspension by enzymatic digestion (Miltenyi, Catalog #130929).
The cell viability was more than 80%, as determined by FACS. 1.5 105 cells were co-cultured for 5 days with
2.5 104 irradiated (67,000 RAD for 1 hr 20 min; Rad Source Irradiator, RS-2000 ical System) CHOOKT3
cells in ILcontaining medium (IL-2 (Peprotech, Catalog # 200-02) at 20 IU/ml) in the presence of
either an isotype control antibody or anti-TIM3 antibody at different concentrations. At day 5 of the culture, the
cell supernatant was collected and the IFN-γ level was assessed by ELISA (BD Opteia hIFNγ ELISA kit, BD,
Catalog # 555152). The results, which are shown in , indicate that the anti-TIM3 antibodies 13A3, 3G4,
17C3, 17C8 and 9F6 stimulate IFN-γ tion by renal cell carcinoma TILs.
Fresh tumor tissue from a lung cancer t was digested with a Miltenyi enzymatic digestion kit
(Miltenyi, Catalog #130929). The single cell suspension was tured with irradiated (67,000 RAD for
1 hr 20 min; Rad Source ator, RS-2000 Biological System) CHO-OKT3 cells in ILcontaining medium
(IL-2 (Peprotech, Catalog # 200-02) at 20 IU/ml in the presence of an isotype control antibody or anti-TIM3
antibody at ent concentrations. At day 5 of the culture, the cell supernatant was collected for IFN-γ ELISA
(BD Opteia hIFNγ ELISA kit, BD, Catalog # 555152). The results, which are shown in A, indicate that
the anti-TIM3 antibodies tested (i.e., 13A3 and 3G4) stimulate IFN-γ production by lung cancer TILs.
In addition, at day 3.5 of a co-culture of the cell suspension from the lung cancer tumor tissue with
irradiated (67,000 RAD for 1 hr 20 min; Rad Source ator, RS-2000 Biological System) CHO-OKT3 cells
treated with an isotype control antibody or anti-TIM3 antibody in the ce of IL-2, cells were incubated
with BD GolgiStop overnight. Subsequently, the cells were first stained with cell surface markers, CD45, CD4,
CD8, TIM3 and PD1, and then fixed and permeabilized with BD Cytofix/ Cytoperm kit ed by
intracellular IFN-γ staining. The results, which are shown in B, show that the percentage of intracellular
IFN-γ expressing cells is increased in CD8+ cells (lower panel) upon anti-TIM3 antibody treatment.
shows the pooled data from multiple tumor TIL experiments (performed as described
above in this Example) in response to anti-TIM-3 dies clones 13A3 or 3G4 (i.e., every dot on the figure
represents TILs from one patient tumor sample treated with either 13A3 or 3G4). Several renal cell carcinoma
(RCC) and lung cancer TILs responded to anti-TIM-3 antibody in promoting IFN-γ production, while a single
TIL ation from a thyroid tumor failed to do so.
Example 7: FACS based cross-blocking of anti-TIM3 dies
Total human T cells were isolated from PBMC using a Miltenyi T cell purification kit and
activated with plate-bound anti-CD3 (1µg/ml; Anti-CD3 clone OKT3, eBioscience, Catalog # 1685) and
soluble anti-CD28 (1µg/ml; Anti-CD28 clone CD28.2, BD Biosciences, Catalog # 555725) for 4 days. TIM3
was expressed in >80% of T cells, as determined by FACS. The T cells were incubated with various anti-TIM3
antibodies for 30 minutes, ed by incubation with selected biotin-labeled anti-TIM3 antibodies for 30
minutes and detected by PE-conjugated streptavidin. The results, which are shown in , te that
dies 13A3, 3G4, 17C3, 17C8, and 9F6 are in the same binning group (Group I), i.e., cross-compete each
other, while antibodies 8B9 and 8C4 are in a separate binning group (Group II), i.e., do not cross-compete with
the antibodies in Group I, but cross-compete with each other. The antibodies in g group I were shown to
have biological activity (see Examples), while those in binning group II had weaker activity. Two anti-TIM3
antibodies which did not cross-compete with either Group I or Group II, did not appear to have any biological
activity. The antibodies of g group I were also those that interfered with TIM3 binding to PS (as further
described herein).
Example 8: Epitope Mapping by Yeast e Display Method
The nucleotide sequence encoding the extracellular domain of human TIM3 (NM_032782), i.e.,
AEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGD
FRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPAKVTPAPTRQRDFTAAFPRMLTTRGH
GPAETQTLGSLPDINLTQISTLANELRDSRLANDLRDSGATIRIG, (SEQ ID NO: 290) was cloned into the
yeast display plasmid PDV0023 by ligation into the XhoI and NotI ction enzyme sites. Low rate random
mutagenesis was performed on the sequence to generate single point mutations across the TIM3 coding region
using the rph II Random Mutagenesis kit from Agilent Technologies. A y of 9.8 x 106 clones was
generated in VWK18gal S. cerevisiae cells. 2 X 108 library cells were passaged and induced for antibody
labeling and cell sorting. About 2 X 107 induced cells were incubated with 100nM a primary target uman
TIM3 antibody and 100nM anti cMyc (9E10) antibody for 1 hr at 25 °C. Cells were washed then detected with
fluorescently labeled goat anti human IgG-PE and goat anti-mouse IgG-A633 secondary antibodies for 45min at
4 °C to detect the bound primary antibodies on the cell surface. Labeled cells were sorted on a BD FACSARIA
II instrument into yeast e media. Cells that were positively labeled with anti-Myc antibody and negatively
labeled with anti-human TIM3 were collected. The APC+ / PE- population of cells were expanded, passaged
and induced for a second round of identical labeling and sorting to enrich the desired populations. Yeast plasmid
DNA was purified out of about 2 107 cells from the unselected library and both rounds of selected, sorted cells.
For each cell population the TIM3 target sequence was rescued and purified out of the yeast plasmid DNA by
PCR using vector specific primers that flank the human TIM3 sequence. The target sequence PCR products
were subjected to NGS library preparation using the Nextera XT DNA Library kit for Illumina Sequencing from
Illumina. The prepared ies were sent to EA/Q2 Solutions for high throughput sequencing on the MiSeq
platform from Illumina with 300 cycles / flow cell. Between 0.5 and 1.0 million sequence reads for each library
were compared to the wild type TIM3 sequence, and mutations at each position along the sequence were
ted. The difference in onal frequency at each residue position between the ed rounds and the
unselected library were calculated and used to determine critical residues for antibody binding. Positions with
high mutation ncy were examined for surface exposure using a human TIM3 structural model based on
known crystal structures of mouse TIM3 (PDB: 2OYP, and PDB: 3BIB). High mutation frequency, surface
d residues are ered part of epitopes, while high mutation frequency, buried residues are considered
as false positives. False positive residues are usually those that disrupt either local or core g of the protein,
and indirectly alter binding of the Ab to its surface epitope.
shows the residues that were determined to be part of the epitope on human TIM3 for each
of the antibodies used. In addition, D104 shows positive mutational score, in all mappings, and may be a
structural salt bridge to R81. For the 8B9 epitope, L84 shows high on frequency, though appears buried in
the structure supporting the epitope residues. Q113 shows a low, but positive score for 13A3. It likely plays an
epitope region structural supporting role, but has some surface exposure.
Example 9: Blocking of TIM3-PtdSer ction by TIM3 dies
The "tandem blocking assay" shown in A was used to determine whether the anti-TIM3
antibodies inhibit the interaction between human TIM3 and atidylserine ("PtSer" or "PS"). Since PS is
not water soluble, PS-liposome was made for the assay. Briefly, lipids were mixed with methanol/chloroform
and then chloroform was evaporated under nitrogen stream and vacuum overnight. Subsequently, the lipids were
sonicated with micro tip to fully disperse lipid to create liposome. They were further passed h an extruder
>10 times to ensure homogenous size.
PS liposome are generated with PS (L-α-phosphatidylserine (Brain, Porcine) Avanti Polar Lipids
Cat# 840032C) suspended in chloroform. PS stock is first d in form to the necessary amount, and
the chloroform is evaporated under a nitrogen stream until no liquid is visible. To remove trace s of
chloroform, dried PS is placed under vacuum overnight. Dried PS is then suspended in PBS via vortex and brief
sonication until the solution turns cloudy. To create size defined PS liposomes, an extruder with a 100nm filter
is used. ded PS is loaded into the extruder and passed through the filter at least 10 times. At this point
the PS liposome is diluted in PBS to the needed concentration.
In the "tandem blocking assay", TIM3 (ECD)-Fc was captured on Octet biosensor, and anti-TIM3
antibody and osomes were allowed to bind to the TIM3 protein. When anti-TIM3 binds to a region that is
blocking PS binding, PS-liposome shows no binding.
The results, which are shown in B, indicate that antibodies 3G4, 13A3, 17C3, and 17C8
inhibit binding of PtSer to human TIM3, whereas 2 other anti-TIM3 antibodies, i.e., AbA and AbB, do not
inhibit binding of PtSer to human TIM3. As r described in the Examples, the antibodies that inhibit PtSer
binding are also those who have the est onal activity (as determined in the Th1 and TIL assays).
Example 10: HDX-MS Epitope Mapping of TIM3 antibodies
Hydrogen/deuterium exchange mass spectrometry (HDX-MS) was ed to probe binding
epitopes of hTIM-3 with antibodies 13A3 and 3G4.
HDX-MS probes protein conformation and conformational dynamics in solution by monitoring the
rate and extent of deuterium exchange of backbone amide hydrogen atoms [1, 2]. The level of HDX depends on
the solvent accessibility of backbone amide hydrogen atoms and the protein hydrogen bonds. The mass increase
of the n upon HDX can be precisely measured by MS. When this que is paired with enzymatic
digestion, structure features at the peptide level can be resolved, enabling differentiation of surface exposed
es from those folded , or from those sequestered at the interface of a protein-protein complex.
Typically, the deuterium labeling and subsequent quenching experiments are performed, followed by enzymatic
digestion, peptide tion, and MS analysis.
Prior to epitope mapping experiments, non-deuteriated experiments were carried out to generate a
list of common es for recombinant human TIM-3 ((hTIM3-ECD (22-200) His-tagged (see ); 10
µM, Sino Biological Inc.) and n complexes of hTIM-3 with Fab of antibodies 13A3 and 3G4 (1:1 molar
ratio). The samples were injected into Waters Enzymate BEH pepsin enzyme column (2.1 X 30 mm), and
digested for 3 min at 200 °C. The cooling chamber of the UPLC system, which housed all the chromatographic
elements, was held at 0.0 ± 0.1 °C for the entire time of the measurements. The injected peptides were trapped
and desalted for 3 min at 100 μL/min and then separated in 6 min by a 5– 40% acetonitrile–water gradient at 65
μL/min. The separation column was a 1.0 mm × 50.0 mm ACQUITY UPLC BEH C18 column (Waters).
Identification of the peptic peptides was accomplished h a combination of exact mass is and MSE
using ProteinLynx Global SERVER 2.5 (Waters) on Waters HDX-MS system.
In the HDX-MS experiment, 5 µL of each sample (hTIM-3 or hTIM-3 with Fab of dy 13A3
or 3G4) was diluted into 55 µL of D2O buffer (10 mM phosphate buffer, D2O, pH7.0) to start the labeling
reactions. The reactions were carried out for ent periods of time: 1 min, 10 min and 240 min. By the end of
each labeling reaction period, the reaction was ed by adding quenching buffer (100 mM phosphate buffer
with 4M GdnCl and 0.4M TCEP, pH 2.5, 1:1, v/v). 50 µL of quenched sample was was digested online using
the same conditions as in non-deuteriated experiments. All comparison experiments were performed under
identical experimental conditions. All experiments were performed in duplicate. The resulting relative
deuterium levels were plotted versus the exchange time with use of the re program DynamX 3.0™
(Waters).
As shown in , sequence coverage of 97.3% of hTIM-3 was ed in HDX-MS
experiments. As shown in , HDX-MS data analysis of hTIM-3 upon binding with Fab of antibodies
13A3 and 3G4 identified the following discontinuous epitopes:
mAb 13A3: 49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID
NO: 368), and fragment KFNLKL127 thereof; and
mAb 3G4: 40YTPAAPGNLVPVCWGKGACPVFE62 (SEQ ID NO: 369), 66VVLRTDERDVNY77
(SEQ ID NO: 370), 78WTSRYWLNGDFRKGDVSL95 (SEQ ID NO: 371), and 110CRIQIPGIMNDEKFNLKL127
(SEQ ID NO: 372).
shows the HDX-MS peptides to which antibodies 13A3 and 3G4 bind, as determined
using the HDX-MS protocol described in this Example.
Thus, dy 13A3 interacts with regions of amino acid es 49-62 and 111-127 of hTIM3,
but does not icantly interact with other regions, such as the region that is N-terminal to amino acid residue
Y40 or V49, the region that is located between amino acid residues E62 and R111, and the region that is C-
al to amino acid residue L127. 13A3 binds to the phosphatidylserine binding loop of the TIM-3 IgV
domain.
Example 11: get IHC staining by TIM3.18 in human tissue cross-reactivity
histochemistry (IHC) was performed with 13A3 on frozen sections of human and
cynomolgus monkey spleen. In both species, 13A3 (0.5 µg/mL) stained the endothelium of venous sinusoids. As
expected, antibody 3G4, which does not cross-react with cynomolgus TIM-3, stained the human spleen but not
the cynomolgus spleen.
In preliminary tissue cross-reactivity analysis, FITC-conjugated TIM3.18.IgG1.3 was applied to
frozen sections or smears from 20 types of normal human tissues, which include cerebrum, cerebellum, heart,
liver, lung, , PBMC smears, spleen, tonsil, thymus, skin, colon, small intestine, stomach, pancreas,
peripheral nerve, pituitary, d, prostate, and placenta (1 donor each). Specific staining was ed in a
subset of mononuclear cells (MNC) in PBMC, spleen, and tonsil, as well as in epithelial reticular cells or
macrophages in the thymus. The most profound staining was in macrophage/DC-like cells, which were observed
in every tissue examined, including tissue-specific macrophages (e.g., Kupffer cells in the liver, dermal
macrophages/DC in the skin, and Hofbauer cells in the placenta). At the organ level, the strongest staining was
found in the spleen. Besides small subsets of MNC, strong staining was very frequently seen in splenic
endothelial cells in the red pulp. In addition, ve staining was observed in a small subset of cortical tubular
epithelial cells in the kidney cortex.
Example 12: Anti-tumor activity of combined anti-TIM3 and PD-1 antibodies in mice
Rat anti-mouse TIM-3 (RMT3 23) and PD-1 (RMP1-14) commercial antibodies (Bio-X-Cell) were
evaluated in a CT26 colorectal tumor model. The experimental design was similar to a previously bed in
vivo study Ngiow et al. (2011) Cancer Res. 71:3540. Since TIM-3 is expressed relatively late (Day 15) in this
tumor model, a small volume of tumor cells (2 x 105) was implanted in the flank of each mouse so that tumor
growth would be minimal, allowing time for TIM-3 expression. When tumors became le at Day 8, mice
were randomized into 4 treatment groups of 10 mice each, with a mean tumor volume of 40 mm3. 3
(anti-TIM-3 antibody) and RMP1-14 (anti-PD-1 antibody) were administered by intraperitoneal injection, either
as single or combined agents (250 µg/per injection of each antibody); the isotype control was administered at
500 µg/per injection. Each study animal received 250 µg of one antibody or 500 µg of 2 combined antibodies
for each injection and for a total of 3 doses. Tumor size was assessed biweekly. Mice in each group receiving
single or combined test articles exhibited antitumor activity, with 2/10 mice in the anti-PD-1 monotherapy group
and 6/10 mice in the combined D-1 and anti-TIM-3 group remained tumor-free at study ation (A). A previous CT26 study of the same design produced similar results, with 3/10 mice in the D-1
erapy group and 7/10 mice in the combined anti-PD-1 and anti-TIM-3 group tumor-free. There was little
or no antitumor activity with anti-TIM-3 administered as a single agent.
Of note, the EC50 value of RMT3-23 binding to activated mouse T cells is 1.7 nM, which is 17-
fold weaker than the EC50 of TIM3.18 for binding to human TIM-3. Another rat ouse TIM-3 antibody,
(Ab M), which cross-blocks RMT3-23, has an EC50 of 0.1 nM in binding to activated mouse T cells, which is
equivalent to the EC50 of TIM3.18. Like RMT3-23, Ab M maps to the PS-binding loops of mouse TIM-3. Use
of this dy with a mIgG1-D265A (Fc-inert isotype) heavy chain nt region in the CT26 tumor model
demonstrated that it enhanced the antitumor response to anti-PD-1 (B).
Example 13: Th1 Cell Proliferation Assay with TIM3 Antibody (full length or Fab) Blockade
To further characterize the anti-TIM3 antibodies, a specific T cell proliferation assay using in vitro
polarized Th1 cells was developed. Polarized Th1 cells were obtained by repeatedly restimulating naïve CD4+
T cells. These cells were then incubated with ated (growth arrested) CHO-OKT3 cells in the presence of
anti-TIM3 antibodies (or control) and Th1 cell proliferation was measured.
Naïve CD4 T cells were zed to Th1 memory-like T cells as s. Naïve CD4 T cells were
purified from PBMCs using a naïve CD4 T cell isolation kit from Miltenyi. The cells were cultured for 3-4 days
in IMDM/10% FBS at 3.6x105 cells/ml in the presence of: CD3/CD28 coated (80%/20% respectively) beads at
1 bead to 1 cell ratio; 10 ng/ml human IL-2; 1 ng/ml human IL-12 and 10000 ng/ml anti-human IL-4 antibody.
After the incubation, the cells were ted in a tube, the beads were removed with a magnet and the cells
were returned to culture in a new flask. Recombinant human IL-2 was added to a final concentration of 4 ng/ml,
and the cells were incubated for an additional 3 days. The cells were then collected and washed with 1X
IMDM/10% FBS. The cells were counted, resuspended in IMDM/10% FBS at 4.1x105 cells/ml, and cultured
for 3-4 days in the presence of: CD3/CD28 coated (80%/20% tively) beads at 1 bead to 1 cell ratio; 10
ng/ml human IL-2; 1 ng/ml human IL-12 and 10000 ng/ml anti-human IL-4 antibody. After the incubation, the
cells were collected in a tube, the beads were removed with a magnet and the cells were returned to culture in a
new flask. Recombinant human IL-2 was added to a final concentration of 4 ng/ml, and the cells were incubated
for an additional 2-3 days. The polarized Th1 cells were then harvested and washed 3 times. On the day of
assay set-up, the polarized Th1 cells were re-suspended in complete medium.
The ing reagents were used:
Dynabeads M-450 Epoxy Dynal Biotech ASA 140.11
100mM Sodium Phosphate Buffer, pH 8.5 Teknova 0214-250
Functional Grade anti-hCD3 Clone UCHT-1 eBioscience 1685
Functional Grade anti-hCD28 Clone CD28.2 eBioscience 1685
Recombinant Human IL-2 PeproTech, Inc. 200-02
Recombinant Human IL-12 PeproTech, Inc. 200-12
anti-human IL-4 eBioscience 1685
Iscove's DMEM ech, Inc. 10CM
Fetal Bovine Serum (heat-inactivated) e SH30071.03
The CHO-OKT3 cell line was grown in shaker flasks and irradiated 0 RAD for 1 hr 20 min;
Rad Source Irradiator, RS-2000 Biological ) on the day of assay set-up. The irradiated CHO-OKT3 cells
provided T cell stimulation and exposed phophatidylserine (PS) as med by n V staining.
TIM3.18.IgG1.3 or isotype control was titrated from 20 µg/mL by 4-fold serial ons, with each
ion set up in triplicate. TIM3.18.IgG1.3 Fab was titrated from 53µg/mL also by 4-fold serial on. The
TIM3.18.IgG1.3 Fab fragment was the same as that used in the crystallography experiment (see Examples).
The cultures were set up in flat-bottom TC-treated 96-well plates (Costar) with 1×105 polarized
Th1 cells and 2.5×104 irradiated CHO-OKT3 cells (CHO:T cell ratio of 1:4) in 200 µL complete medium per
well in the presence of 0.1 µg/ml anti-CD28 (clone CD28.2, BD Biosciences, Catalog # ), and incubated
for 3 days at 37°C and 5% CO2. The plates were then pulsed with 1 µCi tritiated thymidine (Perkin Elmer,
Catalog # NET027001MC) per well for 16 hours and then the cells were ted onto filter plates (Perkin
Elmer) for analysis of ted thymidine incorporation in order to assess proliferation.
The results, which are shown in FIGs 29A and 29B, indicate that the anti-TIM3 antibody
TIM3.18.IgG1.3 increased Th1 cell proliferation in a dose-dependent manner in the CHO-OKT3/Th1 co-culture
cell assay. The overall activity of TIM3.18.IgG1.3 is equivalent to that of its parental antibody, 13A3 (IgG4
isotype) (A). TIM3.18.IgG1.3 Fab fragment also exhibited a dose-dependent induction of proliferation
(B) in the T3/Th1 cell assay.
Thus, TIM3.18.IgG1.3 (both full length and Fab) potentiated Th1 cell activity in a dose-dependent
manner in co-culture with irradiated CHO-OKT3 cells. The presence of activity with the Fab fragment indicated
that TIM3.18.IgG1.3 works as an antagonistic antibody and that TIM-3 is an inhibitory receptor for T cell
function. No Fc cross-linking was required for TIM3.18.IgG1.3 biological activity.
Example 14: Th1 Cell Proliferation Assay With TIM 3 and PD 1 ckade
This assay was a co-culture between irradiated (growth arrested; 67,000 RAD for 1 hr 20 min; Rad
Source Irradiator, RS-2000 Biological System) CHO-OKT3 cells transfected with human PD-L1 KT3-
PD-L1), and Th1 cells at a CHO:T cell ratio of 1:4 in the presence of anti-CD28. The CHO-OKT3-PD-L1 cell
line was grown in shaker flasks and irradiated on the day of assay set-up. The polarized Th1 cells were prepared
as described in the other Examples described herein. On the day of assay set-up, the polarized Th1 cells were
re-suspended in complete medium.
D-1 antibody mab was titrated from 10 µg/mL by 10-fold serial dilutions, with each
condition set up in triplicate. TIM-3 antibody TIM3.18.IgG1.3 or isotype control was spiked in at 20 µg/mL.
The cultures were set up in flat-bottom TC-treated 96-well plates (Costar) with 1×105 Th1 cells
and 2.5×104 CHO-OKT3-PD-L1 cells in 200 µL complete medium per well [in the presence of 0.1 µg/ml anti-
CD28 (clone CD28.2, BD Biosciences, Catalog # 555725), and incubated for 3 days at 37°C and 5% CO2. The
plates were then pulsed with 1 µCi tritiated thymidine (Perkin Elmer, Catalog # NET027001MC) per well for 16
hours and then the cells were harvested onto filter plates (Perkin Elmer) for analysis of tritiated thymidine
incorporation in order to assess eration.
The s, which are shown in , indicate that anti-PD-1 antibody nivolumab increased
proliferation of Th1 T cells ated with T3-PD-L1 cells in a ependent manner, and that the
proliferation was greatly ed in combination with TIM3.18.IgG1.3. Co-blockade of TIM-3 and PD-1
pathways showed additive effect in this assay.
Example 15: Tumor-Infiltrating Lymphocyte IFN-γ Release Assay With TIM3.18.IgG1.3 Blockade
For this assay, fresh tumor s were obtained from a surgically d human renal cell
carcinoma sample or breast cancer sample. The tumor-infiltrating lymphocytes (TIL) were isolated using an
enzymatic iation kit (Miltenyi, Catalog 130929). TILs were supplemented with 20 IU/mL IL-2
(Recombinant human IL-2, Peprotech, Catalog 200-02) and co-cultured with irradiated (growth arrested; 67,000
RAD for 1 hr 20 min; Rad Source Irradiator, RS-2000 Biological System) CHO-OKT3 cells at a CHO:T ratio of
1:6. The CHO-OKT3 cell line was grown in shaker flasks and irradiated on the day of assay set-up.
TIM-3 antibody TIM3.18.IgG1.3 or isotype control was titrated from 20 µg/mL by 4-fold serial
dilutions, with each condition set up in triplicate. The cultures were set up in flat-bottom TC-treated 96-well
plates (Costar) with 1.5×105 T cells and 2.5×104 irradiated CHO-OKT3 cells in 200 µL per well in IMDM + 5%
FBS and 5% human AB serum (Gemini, Catalog # 100-512), and incubated for 5 days at 37°C and 5% CO2.
The supernatant was harvested from each sample for IFN-γ measurement by ELISA (BD Opteia hIFN-γ ELISA
kit, BD, g 555152).
The results, which are shown in , for the renal cell carcinoma TILs, and in , for the
breast cancer TILs indicate that 8.IgG1.3 increased IFN-γ production in a dose-dependent manner in the
CHO-OKT3/TIL co-culture assay, with up to 4-fold increase over negative controls at higher concentrations of
TIM3.18.IgG1.3 in the renal cell carcinoma TIL assay.
Example 16: TIM3.18.IgG1.3 promotes IFN-γ Secretion in M0:T Allogeneic MLR Assay
Isolated CD14+ monocytes from healthy donors were differentiated to the M0 stage in culture
medium containing M-CSF. After Day 6 in culture, a significant population of macrophages were expressing
CD163+ and CD206+ on the cell surface by FACS staining, tent with the signature of suppressive
macrophages. By flow try with an anti-TIM-3 antibody, TIM-3 was shown to be expressed in the M0
macrophages (). These M0 macrophages were then irradiated (5,000 RAD for 7 min; Rad Source
Irradiator, RS-2000 Biological System) and co-cultured with an allogenic donor’s total T cells, and at Day 6
post-co-culturing, the mixed cells were pulsed with 3H-thymidine overnight for ing T cell proliferation.
The results, which are shown in , indicate that TIM3.18.IgG1.3 increased T cell
eration as ed to isotype control.
Example 17: Crystal structure of TIM3.18.IgG1.3 Fab interacting with hTIM3
hTIM3 IgV region was co-crystallized with a Fab fragment of TIM3.18 as follows. The sequences
used were the following:
hTim3_IgV:
HHHHHHSAALEVLFQGPGSEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYW
NGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIKPA (SEQ ID NO: 377; TIM3
sequence is underlined)
Tim3.18_Fab:
QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTYYQPSLKSRVTISVDT
SKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CGGHHHHHH (SEQ ID NO: 366)
Tim3.18_kappa:
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLT
ISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
VDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ
ID NO: 29)
Expression and purification. A histidine tagged hTim3 IgV domain was expressed in E.Coli (BL21
DE3) with a pET47b vector. Purification and refolding was done following published protocol for mTim3
(DeKruyff et al. J. Immunology 2010). Tim3.18 Fab was transiently expressed in HEK293 cells, and purified
via the inal His Tag on the heavy chain.
Crystallization of x and structure determination. The crystal structure of hTim3 IgV domain
with Tim3.18 Fab was resolved to 1.5Å. The Fab:antigen complex was first screened for cyrstallization
conditions with various screens from Hampton Research, and crystals clusters were observed in conditions with
PEG 3350 with pH ranging from 6.5 to 5.5. The l growth condition was further optimized to allow the
growth of single ls. Single crystals were harvested with glycerol as the cryoprotectent, and flash frozen in
liquid nitrogen. Data collection was ted at IMCA-CAT at APS using s-6M detector. Diffraction
images were processed with Global Phasing software, and phased using a Fab model of Tim3.18. Multiple
rounds of refinement were done using CCP4 suite, Coot, Phenix, and Global Phasing suite of software.
The resolved hTim3 IgV domain matches well to that of the published hTim3 structure (PDB:
5F71; worldwideweb.rcsb.org/pdb/explore/explore.do?pdbId=5F71), as well as to mTim3 structure (PDB:
3KAA; worldwideweb.rcsb.org/pdb/explore/explore.do?structureId=3kaa; Rosemarie et al. (2010) J
Immunol 184:1918) that was resolved in complex with PS. The PS binding pocket in hTim3 was inferred from
these ural alignments. Additionally, the location of the PS binding pocket is conserved among the TIM
members in human and mouse (Freemen et al. (2010) Immunol Rev. 235: 172).
The t residues for TIM3.18 on the hTim3 protein were identified by calculating the
ence in ible e area between the TIM3.18 Fab crystal structure and hTIM3 structure
alone ("surface burial method"). hTIM3 residues that show buried surface area upon complex formation with
TIM3.18 Fab were defined as being part of the contact residues. The solvent-accessible surface of a protein was
defined as the locus of the center of a probe sphere (representing a solvent molecule of 1.4-Å radius) as it rolls
over the Van der Waals surface of the protein. The solvent-accessible surface area was ated by generating
surface points on an extended sphere about each atom (at a distance from the atom center equal to the sum of the
atom and probe radii), and eliminating those that lied within equivalent spheres associated with neighboring
atoms as implemented in the program AREAIMOL
(http://www.ccp4.ac.uk/newsletters/newsletter38/03_surfarea.html).
The results, which are shown in FIGs 35 and 36, provide that the following amino acids are contact
residues, as fied by the above described surface burial method: P29, V30, C31, P38, V39, F40, E41, C42,
G43, N44, V45, V46, L47, R48, T49, D50, E51, D53, R90, Q92, G95, I96, M97, D99 (numbering according to
SEQ ID NO: 290, which is the mature hTIM3 extracellular domain) or P50, V51, C52, P59, V60, F61, E62,
C63, G64, N65, V66, V67, L68, R69, T70, D71, E72, D74, R111, Q113, G116, I117, M118, D120 (numbering
per SEQ ID NO: 286 (), which is hTIM3 with a signal peptide). These results indicate that the t
residues of TIM3.18.IgG1.3 on human TIM3 overlap with the PS binding pocket on human TIM3. Specifically,
the heavy chain CDR2 of 8 occupies the PS g pocket. onal contacts with the PS binding
loops are made by heavy chain CDR1 and CDR3. The structural data generated here confirms the results
obtained in the PS blocking assay (see Examples).
The crystallography s also show that the following amino acid residues of hTIM3 have an
atom that is located within 5 Å of an atom of an amino acid residue (the "5 Å distance method") of the TIM3.18
Fab: P29, V30, C31, P38, V39, F40, E41, C42, G43, N44, V45, V46, L47, R48, D50, E51, D53, R90, I91, Q92,
G95, I96, M97, D99 (numbering according to SEQ ID NO: 290, which is the mature hTIM3 extracellular
domain) or P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68, R69, D71, E72, D74, R111,
I112, Q113, G116, I117, M118, D120 (numbering per SEQ ID NO: 286 (), which is hTIM3 with a
signal peptide). The specific interacting residues of the Fab and hTIM3 protein are set forth in Table 3.
Table 3. Listing of human TIM3 residues interacting with Fab residues
Tim3 Tim3.18 Antibody
residue heavy/light chain residue # residue type
29(PRO) H/ 56 (SER)
H/ 57 (GLY)
H/ 58 (PHE)
(VAL) H/ 56 (SER)
H/ 58 (PHE)
31(CYS) H/ 58 (PHE)
H/ 55 (TYR)
38(PRO) H/ 106 (TYR)
) H/ 60 (TYR)
H/ 106 (TYR)
L/ 92 (TYR)
L/ 93 (GLY)
L/ 94 (SER)
L/ 95 (SER)
40(PHE) H/ 49 (TRP)
H/ 54 (TYR)
H/ 60 (TYR)
H/ 106 (TYR)
H/ 108 (HIS)
L/ 95 (SER)
L/ 97 (ILE)
41(GLU) H/ 54 (TYR)
H/ 55 (TYR)
H/ 56 (SER)
H/ 58 (PHE)
H/ 60 (TYR)
H/ 103 (TYR)
42(CYS) H/ 103 (TYR)
H/ 104 (GLY)
43(GLY) H/ 103 (TYR)
H/ 104 (GLY)
H/ 105 (ASP)
H/ 106 (TYR)
44(ASN) H/ 103 (TYR)
H/ 104 (GLY)
H/ 105 (ASP)
) H/ 32 (ARG)
H/ 33 (SER)
H/ 55 (TYR)
H/ 103 (TYR)
H/ 104 (GLY)
46(VAL) H/ 32 (ARG)
47(LEU) H/ 32 (ARG)
H/ 55 (TYR)
48(ARG) H/ 30 (SER)
H/ 31 (SER)
H/ 32 (ARG)
H/ 55 (TYR)
50(ASP) H/ 55 (TYR)
H/ 56 (SER)
51(GLU) H/ 30 (SER)
53(ASP) H/ 32 (ARG)
) H/ 58 (PHE)
H/ 60 (TYR)
91(ILE) H/ 58 (PHE)
92(GLN) H/ 57 (GLY)
H/ 58 (PHE)
H/ 59 (THR)
H/ 60 (TYR)
95(GLY) H/ 66 (LYS)
) H/ 66 (LYS)
97(MET) H/ 66 (LYS)
99(ASP) H/ 58 (PHE)
H/ 60 (TYR)
A comparison of the amino acid residues identified by both methods shows that the residues are
ially the same, except for residue T49 that is identified only by the surface burial method, and residue I91
that is identified only by the "5 Å distance method."
Example 18: Additional characteristics of TIM3.18.IgG1.3
Biophysical characteristics of TIM3.18.IgG1.3 expressed in CHO cells are provided in Table 4.
Table 4: Biophysical Characteristics of TIM3.18.IgG1.3
Property Method Results
Identity LC-MS/MS peptide map osylated MW =145,619 Da (as predicted)
Deglycosylated, reduced and alkylated HC = 50,068 Da
Aglycosylated, reduced and alkylated LC = 23,683 Da
> 99 % sequence and disulfide structure confirmed by
Peptide mapping and mass spec
Purity/Homogeneity CE-SDS 95.1% r, impurities include 2.9% HHL, 0.9% HL,
0.5% HH, 0.6% LC; Non-glycosylated heavy chain 2.1%
SEC 98.5% monomer
SE-MALS 99.94% (150 kDa), 0.06% (322 kDa)
HIC-HPLC 92% main peak, 1% pre-main peak, 7% post main peak
CE (Glycans) GOF (79.3%), G1F (12.2%), G2F (0.7%), Man5 (6.8%),
G0 (0.9%).
cIEF Main peak pI = 8.6 , pI range 8.17-8.66
Chemical Modifications LC-MS/MS peptide map Very low
Thermal Stability DSC (diluted into storage o
and Reversibility buffer) Tm1 = , Tm2 = 80.3°C, Tm3=82.6 C
Reversibility at 74oC = 96 %, at 80oC =26 %
A single N glycosylation site was confirmed at N297 on the heavy chain, with a glycan profile that
is consistent with the glycan profile of CHO-expressed IgG1 monoclonal antibodies. TIM3.18.IgG1.3 does not
bind to CD16, CD32, or CD64, suggesting that it is inert to any Fc-FcR mediated effector function.
TIM3.18.IgG1.3 has good thermal stability (Tm1 = , Tm2 = 80.3oC, Tm3 = ) and thermal
reversibility (95.6 % at 74oC, 25.5 % at 80oC), which suggest that the molecule retains its structural integrity
under thermal stress and has robust refolding properties when stress is released.
Stability teristics of 8.IgG1.3 are provided in Table 5.
Table 5: ity of TIM3.18.IgG1.3
ty Method(s) Results
Freeze/Thaw UV, SEC No freeze/thaw stability risk revealed
(1 h @ -80°C, 1 h @ RT × 6)
Solubility/Concentration Profile UV, SEC At least 60 mg/mL
Accelerated Stability SEC, DLS, HIC, cIEF, 12w @ 40°C = 2%/month increase in LMW
50 mg/mL 12w @ 4°C, 25°C, and 40°C LC-MS/MS peptide 12w @ 40°C < 1% increase in HMW
in the platform formulation mapping
12w @ 40°C = 18%/month increase in acidic
variants
No physical stability issues were observed during freeze-thaw stress (6 cycles) at 50 mg/mL.
Forced degradation studies at 50 mg/mL were set up at 4, 25, and 40oC. No chemical cations in the CDR
region were ed over 12 weeks under any condition tested.
The potential immunogenicity risk of TIM3.18.IgG1.3 was evaluated by in silico methods. The in
silico iDAB analysis of TIM3.18.IgG1.3 showed few potential HLA binding ces in the CDRs of this
mAb, indicating a low risk of inducing a human immune response.
e 19: PK/PD of TIM3.18.IgG1.3 in Monkeys
In a single-dose PK/PD and tolerability study, all s were immunized intramuscularly with
2.5 mg of keyhole limpet anin (KLH) and nonproliferative recombinant adenovirus-5 (Ad5) vectors
expressing simian immunodeficiency virus (SIV) Nef and Gag proteins (3×109 of each vector). Following
immunization, s were intravenously stered TIM3.18.IgG1.3 at doses of 0 (vehicle), 0.5, 10, or 25
mg/kg (N = 3/group; mixed sex). Serum samples were collected for up to 42 days for the assessment of
pharmacokinetics (PK) and anti-drug antibody (ADA), and blood samples were collected for up to 42 days for
assessment of receptor occupancy. Additional serum samples were reserved for other atory endpoints
including soluble TIM-3 levels.
AUC0-168h was dose proportional from 0.5 to 25 mg/kg. TIM3.18.IgG1.3 demonstrated a T1/2 of
about 2 weeks and total serum clearance of 0.18 mL/h/kg. Volume of distribution at the steady state ranged from
68 to 84 mL/kg, suggesting that TIM3.18.IgG1.3 inantly resides in the extracellular space (Table 6).
Table 6: Pharmacokinetic Parameters of TIM3.18.IgG1.3 after IV Administration in
Cynomolgus Monkeys
Monkey Dose INF) T1/2 CLT Vss
Study
number (mg/kg) (μM × h) (h) kg) (mL/kg)
3 0.5 NC NC NC NC
DT16095 3 10 358 ± 90* 337 ± 91 0.19 ± 0.047 84 ± 3.8
3 25 1076 ± 324 321 ± 104 0.17 ± 0.053 68 ± 7.4
* Extrapolated AUC exceeded 20% cutoff and ranged from 21% to 55%.
Based on PK in cynomolgus monkeys and allometric g, the projected human total serum
clearance is 0.10 mL/h/kg and Vss of 88 mL/kg. As a result, the projected human half-life is about 26 days.
Example 20: Preliminary Cytokine Release Assay
To determine if ent with TIM3.18.IgG1.3 poses a risk of cytokine release syndrome, whole
blood from 16 human donors was incubated with 20 μg/mL of TIM3.18.IgG1.3 or positive controls in solution.
A panel of 75 serum cytokines and chemokines was examined for each donor. There was no ce of
enhanced T-cell-derived cytokine or chemokine release, suggesting a low risk of cytokine release syndrome. In
whole blood assays from some donors, there was elevation of IL-1β, IL-6, IL-10, TNF-α, and G-CSF, consistent
with evidence presented above that TIM-3 blockade increases production of monocyte or macrophage-derived
cytokines.
Example 21: TIM3.18.IgG1.3 does not cause receptor downregulation or internalization
To determine whether 13A3 downregulates or internalizes human TIM3 on the cell membrane
when binding to it, the fluorescence quenching study shown in was conducted. The results after a 3
hour treatment, which are shown in , indicate that neither 13A3 antibody nor variants D101E or N60Q
caused dose-dependent accumulation of intra-cellular TIM3 antibody in activated donor CD8+ T cells,
suggesting that the antibody is not internalized.
For determining potential downregulation, activated donor CD8+ T cells were incubated for 2
hours in the presence of various amounts of 13A3, 13A3.D101.Ig1.1f, 101E/N60Q.IgG1.1f or a control
antibody or no antibody, and the amount of TIM3 on the cell surface was determined. The results indicated that
incubation with the anti-TIM3 antibodies did not downregulate cell e TIM3.
The following numbered paragraphs define particular s of the present disclosure:
1. An isolated dy (e.g., a human dy), or antigen binding portion thereof, which binds to
human T-cell immunoglobulin and mucin-domain containing-3 (TIM3) and exhibits the following properties:
(a) binds to soluble human TIM3;
(b) binds to membrane bound human TIM3;
(c) induces or enhances T cell activation; and optionally:
(d) binds to soluble cynomolgus TIM3; and
(e) binds to membrane cynomolgus TIM3.
2. The antibody, or antigen g portion thereof, of paragraph 1, wherein the antibody stimulates an
anti-tumor immune response.
3. The antibody, or antigen g portion thereof, of paragraph 1 or 2, n the antibody stimulates
an antigen-specific T cell se.
4. The antibody, or antigen g portion thereof, of any one of the preceding aphs, wherein the
antibody increases IFN-γ production in TIM3-expressing T cells.
. The antibody, or n binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody increases T cell proliferation.
6. The antibody, or antigen g portion thereof, of any one of the preceding paragraphs, wherein the
antibody does not bind to Fc receptors, or wherein the antibody lacks effector function.
7. The antibody, or antigen binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody binds to soluble human TIM3 with a KD of 10 nM or less as measured by Biacore.
8. The antibody, or antigen binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody binds to soluble cynomolgus TIM3 with a KD of 100 nM or less as measured by e.
9. The antibody, or antigen binding fragment thereof, of any one of the preceding paragraphs, wherein the
antibody is an antagonist antibody that inhibits negative cell (e.g., T cell) signaling by TIM3.
. The antibody, or antigen binding n thereof, of any one of the preceding aphs, n the
antibody binds to membrane bound human TIM3 with an EC50 of 0.1 or 1 μg/mL or less as measured by flow
11. The antibody, or antigen binding portion thereof, of any one of the preceding paragraphs, n the
antibody binds to membrane bound human TIM3 with KD of 1 nM or less as measured by Scatchard analysis.
12. The dy, or antigen binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody binds to membrane bound cynomolgus TIM3 with an EC50 of 1 μg/mL or less as measured by flow
cytometry, or wherein the antibody binds to membrane bound cyno TIM3 with KD of 1 nM or less as measured
by ard analysis.
13. The antibody, or n binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody or antigen binding portion thereof comprises heavy chain CDR1, CDR2, and CDR3 and light chain
CDR1, CDR2, and CDR3, wherein the heavy chain CDR3 comprises an amino acid sequence selected from the
group consisting of: SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ
ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129.
14. The antibody, or antigen binding n thereof, of paragraph 13, wherein the heavy chain CDR1
comprises X1, X2, X3, X4, Y, X5, and X6, and wherein X1 is S or none, X2 is R or none, X3 is S, R, or D, X4
is Y or H, X5 is W or M, and X6 is G, N, S, or H.
. The antibody, or antigen binding portion thereof, of paragraph 13 or 14, wherein the heavy chain
CDR1 comprises X1, Y, Y, M, and X2, and wherein X1 is S or D and X2 is H or S.
16. The antibody, or n binding portion thereof, of paragraph 13 or 14, wherein the heavy chain
CDR1 comprises R, X1, Y, W, and X2, and wherein X1 is H or Y and X2 is N or S.
17. The antibody, or antigen binding portion thereof, of any one of paragraphs 13 to 16, wherein the heavy
chain CDR2 ses X1, I, X2, X3, X4, G, X5, X6, X7, X8, Y, X9, X10, X11, X12, X13, and X14, and
wherein X1 is S, Y, I, or F, X2 is Y, H, N, or S, X3 is Y, P, G, T, or S, X4 is S, T, R, or G, X5 is F, S, or D, X6
is S, T, or I, X7 is I or none, X8 is Y, N, or I, X9 is N, Q, S, or A, X10 is P, S, Q, or D, X11 is S or K, X12 is L,
F, or V, X13 is K or Q, and X14 is S or G.
18. The antibody, or antigen binding portion thereof, of any one of paragraphs 13 to 17, wherein the heavy
chain CDR2 comprises Y, I, H, Y, X1, G, S, T, N, Y, N, X2, S, L, K, and S, and wherein X1 is S or T and X2 is
S or P.
19. The antibody, or antigen binding portion f, of any one of paragraphs 13 to 17, wherein the heavy
chain CDR2 comprises F, I, S, X1, X2, G, S, X3, I, Y, Y, A, D, S, V, K, and G, and wherein X1 is G, T or S, X2
is G or S, and X3 is T or I.
. The dy, or n binding portion thereof, of any one of aphs 13 to 17, wherein the heavy
chain CDR2 comprises I, I, N, P, R, G, D, S, I, I, Y, A, Q, K, F, Q, and G.
21. The antibody, or antigen binding n thereof, of any one of aphs 13 to 20, wherein the light
chain CDR1 comprises SEQ ID NO: 64 or SEQ ID NO: 65.
22. The antibody, or antigen binding portion thereof, of any one of paragraphs 13 to 21, wherein the light
chain CDR2 comprises SEQ ID NO: 66 or SEQ ID NO: 67.
23. The antibody, or antigen binding portion thereof, of any one of aphs 13 to 22, wherein the light
chain CDR3 comprises SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71.
24. The antibody, or antigen binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody or antigen binding portion thereof comprises heavy chain CDR1, CDR2, and CDR3 and light chain
CDR1, CDR2, and CDR3, wherein
(a) the heavy chain CDR1 is selected from the group consisting of SEQ ID NO: 41, SEQ ID NO: 42; SEQ ID
NO: 43; SEQ ID NO: 44; and SEQ ID NO: 45;
(b) the heavy chain CDR2 is selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47; SEQ ID
NO: 48; SEQ ID NO: 49; SEQ ID NO: 50; SEQ ID NO: 51; SEQ ID NO: 52; SEQ ID NO: 122; SEQ ID NO:
123; SEQ ID NO: 124 and SEQ ID NO: 125;
(c) the heavy chain CDR3 is selected from the group ting of SEQ ID NO: 53, SEQ ID NO: 54; SEQ ID
NO: 55; SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 126; SEQ ID NO:
127; SEQ ID NO:128 and SEQ ID NO: 129;
(d) the light chain CDR1 comprises SEQ ID NO: 64 or SEQ ID NO: 65;
(e) the light chain CDR2 comprises SEQ ID NO: 66 or SEQ ID NO: 67; and
(f) the light chain CDR3 comprises SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71.
. An isolated antibody, or antigen binding portion thereof, which binds to human TIM3, comprising:
(a1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 53, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, respectively;
(a2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a3) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 41, 123, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a4) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 124, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(a5) the heavy chain le region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 41, 46, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
tively;
(a6) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 127,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 68,
respectively;
(a7) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a8) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 129,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a9) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a10) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(b1) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 42, 47, 54, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(b2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 125, 54,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 69,
respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 43, 48, and 55, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 64, 66, and 69, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 44, 49, and 56, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 71, respectively;
(g1) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 67, and 70, respectively;
(g2) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 71, respectively;
(g3) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 51, and 58, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 45, 52, and 59, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
26. The antibody, or antigen binding portion thereof, of paragraph 25, wherein the antibody comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 41, 46, and 53, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively.
27. The antibody, or antigen g portion thereof, of paragraph 25, wherein the dy comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 42, 47, and 54, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
28. The antibody, or antigen binding n thereof, of aph 25, wherein the dy comprises
heavy chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 43, 48, and 55, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
29. The antibody, or antigen binding portion thereof, of paragraph 25, wherein the dy comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 44, 49, and 56, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively.
. The antibody, or antigen binding n thereof, of aph 25, wherein the antibody comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
31. The antibody, or antigen binding portion thereof, of paragraph 25, wherein the antibody comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 71, respectively.
32. The antibody, or antigen g portion thereof, of paragraph 25, wherein the antibody comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 67, and 70, tively.
33. The antibody, or antigen binding portion thereof, of aph 25, wherein the antibody ses
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 51, and 58, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, tively.
34. The antibody, or antigen binding portion f, of paragraph 25, n the antibody comprises
heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 52, and 59, respectively, and/or
light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
. An isolated dy, or antigen binding portion thereof, which binds to human TIM3 and comprises
heavy and light chain variable regions, wherein the heavy chain variable region comprises an amino acid
sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about
96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid
sequence selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, 38, 39, 40, 112, 113, 114, 115, 116,
117, 118, 119, 120, 121, and 364.
36. An isolated antibody, or antigen binding portion thereof, which binds to human TIM3 and comprises
heavy and light chain variable regions, wherein the light chain le region comprises an amino acid
sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about
96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid
sequence selected from the group consisting of SEQ ID NOs: 60, 61, 62, and 63.
37. An ed antibody, or antigen binding portion thereof, which binds to human TIM3 and ompetes
for binding to human TIM3 with a reference antibody comprising a VH and a VL, wherein the VH
and the VL are selected from the group ting of:
(a) a VH comprising the amino acid sequence set forth in SEQ ID NO: 34 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(b) a VH comprising the amino acid sequence set forth in SEQ ID NO: 35 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(c) a VH comprising the amino acid sequence set forth in SEQ ID NO: 36 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(d) a VH comprising the amino acid sequence set forth in SEQ ID NO: 37 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(e) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(f) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL sing the amino acid
sequence set forth in SEQ ID NO: 62;
(g) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 63;
(h) a VH comprising the amino acid sequence set forth in SEQ ID NO: 39 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(i) a VH comprising the amino acid sequence set forth in SEQ ID NO: 40 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61.
(j) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 121 and a VL comprising the amino acid
sequence set forth in 63, tively;
(k) a VH sing the amino acid sequence set forth in SEQ ID NOs: 120 and a VL comprising the amino
acid sequence set forth in 61, respectively;
(l) a VH sing the amino acid sequence set forth in SEQ ID NOs: 112 and a VL comprising the amino acid
ce set forth in 60, respectively;
(m) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 113 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(n) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 114 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(o) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 115 and a VL comprising the amino
acid ce set forth in 60, respectively;
(p) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 116 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(q) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 117 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(r) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 118 and a VL comprising the amino
acid sequence set forth in 60, tively;
(s) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 119 and a VL comprising the amino
acid ce set forth in 60, respectively; and
(t) a VH sing the amino acid sequence set forth in SEQ ID NOs: 364 and a VL comprising the amino acid
sequence set forth in 60, respectively.
38. The antibody, or antigen binding portion thereof, of paragraph 37, which binds to TIM3 at the same
epitope as the reference antibody, as determined, e.g., by one or methods ed herein.
39. The antibody, or antigen binding portion f, of paragraph 37 or 38, which comprises a VH and a
VL, selected from the group consisting of:
(a) a VH comprising the amino acid sequence set forth in SEQ ID NO: 34 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(b) a VH comprising the amino acid sequence set forth in SEQ ID NO: 35 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(c) a VH comprising the amino acid sequence set forth in SEQ ID NO: 36 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(d) a VH comprising the amino acid sequence set forth in SEQ ID NO: 37 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(e) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(f) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 62;
(g) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL sing the amino acid
sequence set forth in SEQ ID NO: 63;
(h) a VH comprising the amino acid sequence set forth in SEQ ID NO: 39 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(i) a VH comprising the amino acid sequence set forth in SEQ ID NO: 40 and a VL sing the amino acid
sequence set forth in SEQ ID NO: 61;
(j) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 121 and a VL comprising the amino acid
ce set forth in 63, respectively;
(k) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 120 and a VL comprising the amino
acid sequence set forth in 61, respectively;
(l) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 112 and a VL comprising the amino acid
sequence set forth in 60, respectively;
(m) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 113 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(n) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 114 and a VL comprising the amino
acid ce set forth in 60, respectively;
(o) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 115 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(p) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 116 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(q) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 117 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(r) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 118 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(s) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 119 and a VL comprising the amino
acid sequence set forth in 60, respectively; and
(t) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 364 and a VL comprising the amino acid
sequence set forth in 60, respectively.
40. The dy, or antigen binding portion f, of paragraph 37or 38, which comprises a VH
comprising an amino acid sequence selected from the group ting of SEQ ID NO: 34, SEQ ID NO: 112,
SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118,
SEQ ID NO: 119, and SEQ ID NO: 364 and a VL comprising the amino acid sequence set forth in SEQ ID NO:
41. The dy, or antigen binding portion thereof, of paragraph 37 or 38, which ses a VH
comprising the amino acid sequence set forth in SEQ ID NO: 35 or SEQ ID NO: 120 and a VL comprising the
amino acid sequence set forth in SEQ ID NO: 61.
42. The antibody, or antigen binding portion thereof, of paragraph 37 or 38, which comprises a VH
comprising the amino acid sequence set forth in SEQ ID NO: 36 and a VL comprising the amino acid ce
set forth in SEQ ID NO: 61.
43. The antibody, or antigen binding portion thereof, of paragraph 37 or 38, which ses a VH
comprising the amino acid sequence set forth in SEQ ID NO: 37 and a VL comprising the amino acid sequence
set forth in SEQ ID NO: 60.
44. The antibody, or antigen binding portion thereof, of paragraph 37 or 38, which comprises a VH
comprising the amino acid sequence set forth in SEQ ID NO: 38 or SEQ ID NO: 121 and a VL comprising the
amino acid ce set forth in SEQ ID NO: 61, SEQ ID NO: 63, or SEQ ID NO: 62.
45. The antibody, or antigen binding portion thereof, of paragraph 37 or 38, which comprises a VH
comprising the amino acid sequence set forth in SEQ ID NO: 39 and a VL comprising the amino acid ce
set forth in SEQ ID NO: 60.
46. The antibody, or antigen g portion thereof, of paragraph 37 or 38, which comprises a VH
comprising the amino acid sequence set forth in SEQ ID NO: 40 and a VL comprising the amino acid sequence
set forth in SEQ ID NO: 61.
47. The antibody, or antigen binding portion thereof, of any one of the preceding paragraphs, wherein the
antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4 or a variant thereof.
48. The antibody, or antigen binding portion f, of aph 47, wherein the antibody is an IgG1
antibody.
49. The antibody, or antigen binding portion thereof, of paragraph 47, wherein the antibody comprises an
effectorless IgG1 Fc.
50. The antibody, or antigen binding portion thereof, of paragraph 49, wherein the antibody, or antigen
binding portion thereof, comprises an effectorless IgG1 Fc that ses the following mutations: L234A,
L235E, G237A, and ally A330S and P331S.
51. The antibody, or antigen binding portion thereof, of any of the preceding paragraphs, comprising a
heavy chain constant region comprising an amino acid sequence selected from the group ting of SEQ ID
NOs: 263-266.
52. The antibody, or antigen binding portion thereof, of any one of paragraphs 1-51, wherein the antibody,
or antigen binding n thereof, is a human or humanized antibody.
53. The antibody of any one of aphs 1-52, n the antibody comprises:
(a1) heavy and light chain ces comprising SEQ ID NOs: 301 (or 302) and 29, respectively;
(a2) heavy and light chain sequences comprising SEQ ID NOs: 1 (or 8) and 29, respectively;
(a3) heavy and light chain sequences comprising SEQ ID NOs: 15 (or 22) and 29, respectively;
(a4) heavy and light chain sequences comprising SEQ ID NOs: 303 (or 304) and 29, respectively;
(a5) heavy and light chain sequences comprising SEQ ID NOs: 72 (or 82) and 29, respectively;
(a6) heavy and light chain sequences comprising SEQ ID NOs: 92 (or 102) and 29, respectively;
(a7) heavy and light chain sequences comprising SEQ ID NOs: 305 (or 306) and 29, respectively;
(a8) heavy and light chain sequences comprising SEQ ID NOs: 73 (or 83) and 29, tively;
(a9) heavy and light chain ces comprising SEQ ID NOs: 93 (or 103) and 29, respectively;
(a10) heavy and light chain sequences comprising SEQ ID NOs: 307 (or 308) and 29, respectively;
(a11) heavy and light chain sequences sing SEQ ID NOs: 74 (or 84) and 29, respectively;
(a12) heavy and light chain sequences comprising SEQ ID NOs: 94 (or 104) and 29, respectively;
(a13) heavy and light chain sequences comprising SEQ ID NOs: 309 (or 310) and 29, tively;
(a14) heavy and light chain sequences comprising SEQ ID NOs: 75 (or 85) and 29, respectively;
(a15) heavy and light chain sequences comprising SEQ ID NOs: 95 (or 105) and 29, tively;
(a16) heavy and light chain sequences comprising SEQ ID NOs: 311 (or 312) and 29, respectively;
(a17) heavy and light chain ces comprising SEQ ID NOs: 76 (or 86) and 29, respectively;
(a18) heavy and light chain sequences comprising SEQ ID NOs: 96 (or 106) and 29, respectively;
(a19) heavy and light chain sequences comprising SEQ ID NOs: 313 (or 314) and 29, respectively;
(a20) heavy and light chain sequences comprising SEQ ID NOs: 77 (or 87) and 29, respectively;
(a21) heavy and light chain sequences comprising SEQ ID NOs: 97 (or 107) and 29, respectively;
(a22) heavy and light chain sequences comprising SEQ ID NOs: 315 (or 316) and 29, respectively;
(a23) heavy and light chain ces comprising SEQ ID NOs: 78 (or 88) and 29, respectively;
(a24) heavy and light chain sequences comprising SEQ ID NOs: 98 (or 108) and 29, respectively;
(a25) heavy and light chain sequences comprising SEQ ID NOs: 317 (or 318) and 29, respectively;
(a26) heavy and light chain sequences comprising SEQ ID NOs: 79 (or 89) and 29, respectively;
(a27) heavy and light chain sequences comprising SEQ ID NOs: 99 (or 109) and 29, respectively;
(a28) heavy and light chain sequences comprising SEQ ID NOs: 319 (or 320) and 29, respectively;
(a29) heavy and light chain sequences comprising SEQ ID NOs: 349 (or 350) and 29, respectively;
(a30) heavy and light chain sequences comprising SEQ ID NOs: 351 (or 352) and 29, respectively;
(a31) heavy and light chain sequences comprising SEQ ID NOs: 353 (or 354) and 29, respectively;
(b1) heavy and light chain sequences comprising SEQ ID NOs: 321 (or 322) and 30, respectively;
(b2) heavy and light chain sequences comprising SEQ ID NOs: 2 (or 9) and 30, respectively;
(b3) heavy and light chain sequences comprising SEQ ID NOs: 16 (or 23) and 30, respectively;
(b4) heavy and light chain sequences comprising SEQ ID NOs: 323 (or 324) and 30, tively;
(b5) heavy and light chain ces comprising SEQ ID NOs: 80 (or 90) and 30, respectively;
(b6) heavy and light chain sequences comprising SEQ ID NOs: 100 (or 110) and 30, respectively;
(b7) heavy and light chain ces comprising SEQ ID NOs: 325 (or 326) and 30, respectively;
(c1) heavy and light chain sequences comprising SEQ ID NOs: 327 (or 328) and 30, respectively;
(c2) heavy and light chain ces comprising SEQ ID NOs: 3 (or 10) and 30, respectively;
(c3) heavy and light chain sequences comprising SEQ ID NOs: 17 (or 24) and 30, respectively;
(c4) heavy and light chain ces comprising SEQ ID NOs: 329 (or 330) and 30, respectively;
(d1) heavy and light chain sequences sing SEQ ID NOs: 331 (or 332) and 29, respectively;
(d2) heavy and light chain sequences comprising SEQ ID NOs: 4 (or 11) and 29, respectively;
(d3) heavy and light chain sequences comprising SEQ ID NOs: 18 (or 25) and 29, respectively;
(d4) heavy and light chain sequences comprising SEQ ID NOs: 333 (or 334) and 29, respectively;
(e1.1) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 32, tively;
(e1.2) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 33, respectively;
(e1.3) heavy and light chain sequences comprising SEQ ID NOs: 335 (or 336) and 31, respectively;
(e2) heavy and light chain sequences comprising SEQ ID NOs: 5 (or 12) and 33, respectively;
(e3) heavy and light chain sequences comprising SEQ ID NOs: 19 (or 26) and 33, respectively;
(e4) heavy and light chain sequences comprising SEQ ID NOs: 337 (or 338) and 33, respectively;
(e5) heavy and light chain sequences comprising SEQ ID NOs: 81 (or 91) and 33, tively;
(e6) heavy and light chain sequences comprising SEQ ID NOs: 101 (or 111) and 33, respectively;
(e7) heavy and light chain sequences comprising SEQ ID NOs: 339 (or 340) and 33, respectively;
(f1) heavy and light chain sequences comprising SEQ ID NOs: 341 (or 342) and 29, respectively;
(f2) heavy and light chain sequences comprising SEQ ID NOs: 6 (or 13) and 29, respectively;
(f3) heavy and light chain sequences comprising SEQ ID NOs: 20 (or 27) and 29, respectively;
(f4) heavy and light chain sequences sing SEQ ID NOs: 343 (or 344) and 29, respectively;
(g1) heavy and light chain sequences comprising SEQ ID NOs: 345 (or 346) and 29, respectively;
(g2) heavy and light chain sequences comprising SEQ ID NOs: 7 (or 43) and 30, respectively;
(g3) heavy and light chain sequences comprising SEQ ID NOs: 21 (or 28) and 30, respectively; or
(g4) heavy and light chain sequences comprising SEQ ID NOs: 347 (or 348) and 30, respectively;
wherein the antibody specifically binds to human TIM3.
54. The antibody or antigen binding portion thereof, of any of paragraphs 1-53, wherein the antibody or
antigen binding portion f has one or more of the following properties:
(1) binding to soluble human TIM3, e.g., with a KD of 10 nM or less (e.g., 0.01 nM to 10 nM), e.g., as measured
by Biacore;
(2) binding to soluble lgus TIM3, e.g., with a KD of 100 nM or less (e.g., 0.01 nM to 100 nM), e.g., as
measured by Biacore;
(3) binding to membrane bound human TIM3, e.g., with an EC50 of 1 ug/mL or less (e.g., 0.01 ug/mL to 1
ug/mL), e.g., as measured by flow cytometry;
(4) binding to membrane bound human TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM), e.g., as
ed by Scatchard analysis;
(5) binding to membrane bound cynomolgus TIM3, e.g., with an EC50 of 20 ug/mL or less (e.g., 0.01 ug/mL to
ug/mL), e.g., as measured by flow cytometry;
(6) binding to membrane bound cynomolgus TIM3, e.g., with a KD of 1nM or less (e.g., 0.01 nM to 10 nM),
e.g., as measured by ard is;
(7) inducing or enhancing T cell activation (e.g., by blocking or reducing the inhibitory effect of TIM3), as
evidenced by (i) increased IFN-γ production in TIM3-expressing T cells (e.g., Th1 cells or TILs) and/or (ii)
enhanced proliferation of TIM3-expressing T cells (e.g., Th1 cells or TILs);
(8) stimulating T cell proliferation in a mixed lymphocyte reaction (MLR) assay;
(9) inhibiting the binding of atidylserine to TIM3, e.g., as measured by M3 "in-tandem" blocking
assay;
(10) not alizing or downregulating cell surface TIM3 when binding to TIM3 on cells;
(11) binding to one of the following regions of human TIM3 extracellular domain (SEQ ID NO: 290): (a)
CPVFECG (SEQ ID NO: 296); (b) RIQIPGIMND (SEQ ID NO: 298); (c) CPVFECG and IMND (SEQ
ID NOs: 296 and 298, respectively); and (d) WTSRYWLNGDFR (SEQ ID NO: 297);
(12) having reduced binding to human TIM3 in which one or more of amino acids L48, C58, P59, V60, F61,
E62, C63, G64, W78, S80, R81, W83, L84, G86, D87, R89, D104, R111, Q113, G116, M118 and D120 (as
numbered in SEQ ID NO: 286 ()) is substituted with another amino acid relative to binding to wildtype
human TIM3;
(13) competing in either direction or both ions for binding to human TIM3 with an antibody comprising
VH and VL domains of any one of 13A3, 3G4, 17C3, 17C8, 9F6, 8B9, 8C4, or TIM3.7, TIM3.8, TIM3.10,
TIM3.11, TIM3.12, TIM3.13, TIM3.14, TIM3.15, TIM3.16, TIM3.17, and TIM3.18;
(14) binding to human TIM3 regions WGKGACPVFE62 (SEQ ID NO: 367) and
111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) as determined by HDX-MS
(15) having the heavy chain and/or light chain variable regions interact with at least 5, 10, 15, 20 or all of the
following amino acids of human TIM3: P50, V51, C52, P59, V60, F61, E62, C63, G64, N65, V66, V67, L68,
R69, D71, E72, D74, R111, Q113, G116, I117, M118, D120, and optionally T70 and/or I112, as determined by
X-ray crystallography (e.g., described in the Examples; numbering per SEQ ID NO: 286 ()); and/or
(16) (a) having reduced binding to human TIM3 in which 1, 2, 3, 4, 5, 6, 7, 8 or 9 of amino acids C58, P59, F61,
E62, C63, R111, D120, and optionally D104 and Q113 (numbering per SEQ ID NO: 286 ()) are
substituted with another amino acid relative to binding to wildtype human TIM3; (b) binding to
49VPVCWGKGACPVFE62 (SEQ ID NO: 367), 111RIQIPGIMNDEKFNLKL127 (SEQ ID NO: 368) and
119NDEKFNLKL127 (SEQ ID NO: 373), as determined by HDX-MS, as bed in the Examples; and/or (c)
competing with or cross-blocking with the g to human TIM3 of 13A3 or TIM3.18.IgG1.3.
55. A ific molecule comprising the antibody of any one of the preceding paragraphs linked to a
molecule having a second binding specificity.
56. A c acid encoding the heavy and/or light chain le region of the antibody, or n binding
portion thereof, of any one of paragraphs 1-54.
57. An expression vector comprising the nucleic acid molecule of paragraph 56.
58. A cell transformed with an expression vector of paragraph 57.
59. An immunoconjugate comprising the antibody according to any one of aphs 1-54, linked to an
agent.
60. A composition comprising the antibody, or n binding portion thereof, bispecific molecule or
immunoconjugate, of any one of paragraphs 1-55 and 59, and a carrier.
61. A kit comprising the dy, or antigen binding portion thereof, or bispecific le, or
immunoconjugate of any one of paragraphs 1-55 and 59 and instructions for use.
62. A method of preparing an anti-TIM3 antibody, or antigen binding portion thereof, comprising
expressing the antibody, or antigen binding portion thereof, in the cell of paragraph 58 and ing the
antibody, or antigen binding portion f, from the cell.
63. A method of stimulating an antigen- specific T cell response comprising contacting the T cell with the
antibody, or antigen binding portion thereof, bispecific molecule or immunoconjugate, of any one of paragraphs
1-55 and 59 such that an antigen- specific T cell response is stimulated.
64. A method of activating or co-stimulating an effector T cell, comprising contacting an effector T cell
with an anti-TIM3 antibody, or antigen binding portion thereof, bispecific molecule or immunoconjugate, of any
one of paragraphs 1-55 and 59 and CD3, wherein the effector T cell is activated or co- stimulated.
65. A method of increasing IFN-γ production in a T cell comprising contacting the T cell with an effective
amount of the antibody, or antigen binding portion thereof, ific molecule or immunoconjugate, of any one
of paragraphs 1-55 and 59.
66. A method of increasing T cell proliferation comprising contacting the cell with an effective amount of
the antibody, or antigen g n thereof, bispecific molecule or immunoconjugate, of any one of
paragraphs 1-55 and 59.
67. A method of increasing IFN-γ production in T cells in a subject comprising administering an effective
amount of the antibody, or antigen binding portion thereof, bispecific molecule or immunoconjugate, of any one
of paragraphs 1-55 and 59, to increase IFN-γ production from the T cells.
68. A method of stimulating TIL activity in a subject, comprising administering to a subject a
therapeutically effective amount of an anti-TIM3 dy of any one of paragraphs 1-54.
69. A method of stimulating an immune response in a subject comprising administering the antibody, or
antigen binding portion thereof, bispecific molecule or immunoconjugate, of any one of aphs 1-55 and 59
to the t such that an immune response in the subject is ated.
70. The method of paragraph 69, wherein the subject has a tumor and an immune response against the
tumor is stimulated.
71. A method for inhibiting the growth of tumors or reducing the size of tumors in a subject comprising
stering to the subject the dy, or antigen binding portion thereof, bispecific molecule or
immunoconjugate, of any one of paragraphs 1-55 and 59, such that growth of the tumor is inhibited in the
subject.
72. A method of treating cancer comprising administering to a subject in need thereof a therapeutically
effective amount of the antibody, or n binding portion thereof, bispecific molecule or immunoconjugate,
of any one of paragraphs 1-55 and 59, to treat the cancer.
73. The method of paragraph 72, wherein the cancer is ed from the group consisting of: bladder
cancer, breast , uterine/cervical cancer, ovarian cancer, prostate cancer, ular cancer, esophageal
cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck
cancer, lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, d cancer, skin ,
neoplasm of the central nervous , lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.
74. The method of paragraph 72 or 73, wherein the cancer is a metastatic cancer, refractory , or
recurrent cancer.
75. The method of any one of paragraphs 67-74, further comprising administering one or more additional
therapeutics.
76. The method of paragraph 75, wherein the onal therapy is an anti-PD-l antibody, an AG-3
antibody, an anti-CTLA-4 antibody, an anti-GITR dy, or an anti-PD-L1 antibody.
77. A method of detecting the presence of T-cell immunoglobulin and mucin-domain containing-3 (TIM3)
in a sample comprising contacting the sample with the antibody, or antigen binding portion thereof, of any one
of paragraphs 1-54, under conditions that allow for formation of a x between the antibody, or antigen
binding portion thereof, and TIM3, and detecting the formation of a complex.
What is claimed:
1. An isolated antibody (e.g., a human antibody), or antigen binding portion thereof, which binds to
human T-cell immunoglobulin and mucin-domain containing-3 (TIM3) and exhibits the following properties:
(a) binds to soluble human TIM3;
(b) binds to membrane bound human TIM3;
(c) induces or enhances T cell activation; and optionally:
(d) binds to soluble cynomolgus TIM3; and
(e) binds to membrane cynomolgus TIM3.
2. The antibody, or antigen binding n thereof, of claim 1, wherein the antibody stimulates an antitumor
immune response.
3. The antibody, or antigen binding portion f, of claim 1 or 2, wherein the antibody stimulates an
antigen-specific T cell response.
4. The antibody, or antigen binding portion f, of any one of the preceding , n the
antibody increases IFN-γ production in TIM3-expressing T cells.
. The antibody, or antigen binding portion thereof, of any one of the preceding claims, wherein the
antibody increases T cell proliferation.
6. An isolated dy, or n binding portion thereof, which binds to human TIM3, comprising:
(a1) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 53, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68, respectively;
(a2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a3) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 41, 123, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a4) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 124, 53,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a5) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 126,
respectively, and the light chain le region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 68,
tively;
(a6) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 127,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a7) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 68,
respectively;
(a8) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 46, 129,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a9) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 128,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(a10) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 41, 122, 126,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 68,
respectively;
(b1) the heavy chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 42, 47, 54, respectively,
and the light chain le region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(b2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 42, 125, 54,
respectively, and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69,
respectively;
(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 43, 48, and 55, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively;
(d) heavy chain CDR1, CDR2, and CDR3 ces comprising SEQ ID NOs: 44, 49, and 56, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively;
(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 71, respectively;
(g1) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 50, and 57, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 65, 67, and 70, respectively;
(g2) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 ses SEQ ID NOs: 64, 66, 71, respectively;
(g3) the heavy chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 45, 50, 57, respectively,
and the light chain variable region CDR1, CDR2, and CDR3 comprises SEQ ID NOs: 64, 66, 69, respectively;
(h) heavy chain CDR1, CDR2, and CDR3 sequences sing SEQ ID NOs: 45, 51, and 58, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 68, respectively;
(i) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 45, 52, and 59, respectively,
and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 64, 66, and 69, respectively.
7. An isolated antibody, or antigen binding portion thereof, which binds to human TIM3 and comprises
heavy and light chain le regions, wherein the heavy chain variable region comprises an amino acid
ce which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about
96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid
ce selected from the group consisting of SEQ ID NOs: 34, 35, 36, 37, 38, 39, 40, 112, 113, 114, 115, 116,
117, 118, 119, 120, 121, and 364.
8. An isolated antibody, or antigen binding portion thereof, which binds to human TIM3 and comprises
heavy and light chain variable regions, n the light chain variable region comprises an amino acid
sequence which is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about
96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid
sequence ed from the group consisting of SEQ ID NOs: 60, 61, 62, and 63.
9. An isolated antibody, or antigen binding portion thereof, which binds to human TIM3 and crosscompetes
for binding to human TIM3 with a reference antibody comprising a VH and a VL, wherein the VH
and the VL are selected from the group consisting of:
(a) a VH comprising the amino acid sequence set forth in SEQ ID NO: 34 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 60;
(b) a VH comprising the amino acid sequence set forth in SEQ ID NO: 35 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(c) a VH sing the amino acid sequence set forth in SEQ ID NO: 36 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(d) a VH comprising the amino acid sequence set forth in SEQ ID NO: 37 and a VL comprising the amino acid
ce set forth in SEQ ID NO: 60;
(e) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61;
(f) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 62;
(g) a VH comprising the amino acid sequence set forth in SEQ ID NO: 38 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 63;
(h) a VH comprising the amino acid sequence set forth in SEQ ID NO: 39 and a VL comprising the amino acid
ce set forth in SEQ ID NO: 60;
(i) a VH sing the amino acid sequence set forth in SEQ ID NO: 40 and a VL comprising the amino acid
sequence set forth in SEQ ID NO: 61.
(j) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 121 and a VL comprising the amino acid
sequence set forth in 63, tively;
(k) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 120 and a VL comprising the amino
acid sequence set forth in 61, tively;
(l) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 112 and a VL comprising the amino acid
sequence set forth in 60, respectively;
(m) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 113 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(n) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 114 and a VL comprising the amino
acid ce set forth in 60, respectively;
(o) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 115 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(p) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 116 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(q) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 117 and a VL comprising the amino
acid sequence set forth in 60, tively;
(r) a VH comprising the amino acid ce set forth in SEQ ID NOs: 118 and a VL comprising the amino
acid sequence set forth in 60, respectively;
(s) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 119 and a VL sing the amino
acid ce set forth in 60, respectively; and
(t) a VH comprising the amino acid sequence set forth in SEQ ID NOs: 364 and a VL comprising the amino acid
sequence set forth in 60, respectively.
. A bispecific molecule comprising the antibody of any one of the preceding claims linked to a molecule
having a second g specificity.
11. A c acid encoding the heavy and/or light chain variable region of the antibody, or antigen binding
portion thereof, of any one of claims 1-9.
12. An expression vector comprising the nucleic acid molecule of claim 11.
13. A cell transformed with an expression vector of claim 12.
14. An immunoconjugate comprising the antibody according to any one of claims 1-9, linked to an agent.
. A composition comprising the antibody, or antigen binding portion thereof, bispecific le or
immunoconjugate, of any one of claims 1-10 and 14, and a carrier.
16. A kit comprising the antibody, or antigen binding portion thereof, or bispecific molecule, or
immunoconjugate of any one of claims 1-10 and 14 and instructions for use.
17. A method of preparing an IM3 antibody, or antigen binding portion thereof, comprising
expressing the antibody, or antigen binding portion thereof, in the cell of claim 13 and isolating the dy, or
antigen binding portion thereof, from the cell.
18. A method of stimulating an antigen- specific T cell response comprising contacting the T cell with the
antibody, or antigen binding portion thereof, bispecific molecule or conjugate, of any one of claims 1-
and 14 such that an antigen- specific T cell response is stimulated.
19. A method of activating or co-stimulating an effector T cell, comprising ting an effector T cell
with an anti-TIM3 antibody, or antigen binding n thereof, bispecific molecule or immunoconjugate, of any
one of claims 1-10 and 14 and CD3, wherein the effector T cell is activated or co- stimulated.
. A method of increasing IFN-γ production in a T cell comprising contacting the T cell with an effective
amount of the antibody, or antigen binding portion thereof, bispecific molecule or conjugate, of any one
of claims 1-10 and 14.
21. A method of increasing T cell proliferation comprising contacting the cell with an effective amount of
the antibody, or antigen binding portion thereof, bispecific molecule or immunoconjugate, of any one of claims
1-10 and 14.
22. A method of increasing IFN-γ tion in T cells in a subject sing administering an effective
amount of the antibody, or antigen binding n thereof, bispecific molecule or immunoconjugate, of any one
of claims 1-10 and 14, to increase IFN-γ production from the T cells.
23. A method of stimulating TIL ty in a subject, comprising administering to a subject a
therapeutically effective amount of an anti-TIM3 antibody of any one of claims 1-9.
24. A method of stimulating an immune response in a subject comprising administering the dy, or
antigen binding portion thereof, bispecific molecule or conjugate, of any one of claims 1-10 and 14 to
the subject such that an immune response in the subject is stimulated.
. A method for inhibiting the growth of tumors or reducing the size of tumors in a subject comprising
administering to the subject the antibody, or n g portion thereof, bispecific molecule or
immunoconjugate, of any one of claims 1-10 and 14, such that growth of the tumor is inhibited in the subject.
26. A method of treating cancer comprising administering to a subject in need thereof a therapeutically
effective amount of the antibody, or antigen binding n thereof, bispecific molecule or conjugate,
of any one of claims 1-10 and 14, to treat the cancer.
27. The method of claim 26, wherein the cancer is selected from the group consisting of: bladder cancer,
breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer,
gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck cancer,
lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm
of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.
28. The method of claim 26 or 27, wherein the cancer is a atic , refractory cancer, or recurrent
cancer.
29. A method of detecting the presence of T-cell immunoglobulin and domain containing-3 (TIM3)
in a sample sing contacting the sample with the antibody, or antigen binding portion thereof, of any one
of claims 1-9, under conditions that allow for formation of a complex between the dy, or antigen binding
portion f, and TIM3, and detecting the formation of a complex.
IM-3 13A3 VH1
V segment: 4-39
D segment: 4-17
J segment: JH5b
Q L Q L Q E 3 G P G L V K P S E T
1 CAG CTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GAG ACC
_CDR1
L s L C T S G G S I s s R s Y
52 CTG ch CTC ACC TGC ACT GTC TCT GGT GGC TCC ATC AGC AGT AGA AGT TAC
Y w G I R P P G K G L E W I G
103 TAC TGG GGC TGG ATC CGC CAG CCC CCA GGG AAG GGG CTG GAG TGG ATT GGG
_CDR2
s I Y S G T Y Y N P S L K S R
154 AGT ATC TAT TAT AGT GGG TTC ACC TAC TAC AAC CCG TCC CTC AAG AGT CGA
v T I V D S K N Q F S L K L S
205 GTC ACC ATA TCC GTT GAC ACG TCC AAG AAC CAG TTC TCC CTG AAG CTG AGC
_CDR3
s v T A D A V Y Y C A T G G P
256 TCT GTG ACC GCC GCA GAC ACG GCT GTG TAT TAT TGT GCG ACA GGG GGG ccc
Y G D A H F D P W G Q G T L V
307 TAC GGT GAC TAC GCC CAC TGG TTC GAC CCC TGG GGC CAG GGA ACC CTG GTC
T v s
358 ACC GTC TCC TCA
Anti-TIM-3 13A3 VKl
V segment: A27
J segment: JKS
E I V L T Q S P G T L S L S P G E
1 GAA ATT GTG TTG ACG CAG TCT CCA GGC Acc CTG TCT TTG TCT CCA GGG GAA
_CDR1
RATLSCRASQSVSSSYL
52 AGA GCC Acc CTC ch TGC AGG ccc AGT CAG AGT GTT AGc AGc AGC TAc TTA
A W Y Q Q K P G Q A P R L L I Y G
103 GCC TGG TAc CAG CAG AAA CCT GGC CAG GCT ccc AGG CTC CTC ATc TAT GGT
_CDR2
GIPDRFSGSGS
154 GCA ch AGC AGG GCC ACT GGC ATc CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D E‘ T L T I S R L E P E D F A
205 GGG ACA GAC TTC ACT CTC Acc ATc AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
VYYCQQYGSSPITFGQG
256 GTG TAT TAc TGT CAG CAG TAT GGT AGc TCA ccc ATc Acc TTC GGC CAA GGG
T R L E I K
307 ACA CGA CTG GAG ATT AAA
13A3 NT VH1
ATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTCCTGTCCCAGCTGCAGCTGCAGGAG
TCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGCAGT
AGAAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTATAGT
GGGTTCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCCGTTGACACGTCCAAGAACCAGTTCTCC
CTGAAGCTGAGCTCTGTGACCGCCGCAGACACGGCTGTGTATTATTGTGCGACAGGGGGGCCCTACGGTGACTAC
GCCCACTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
13A3 AA VH1
MKHLWFFLLLVAAPRWVLSQLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYS
GFTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVTVSS
13A3 NT VKl
ATGGAXACECCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGATCACCTTCGGCCAAGGGACACGACTG
13A3 AA VKl
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK
IM-3 8B9 VH1
V segment: 4-59
D segment: 4-17
J segment: JH6b
Q V Q L Q E 5 G P G L V K P S E T
CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GAG ACC
_CDR1
S L C T v s G s I s R H Y W
52 CTG TCC CTC ACC TGC ACT GTC TCT GGT GGC ch ATc AGT CGT CAc TAC TGG
_CDR2_
W I Q P P G K L E W I G Y I
103 TGG ATC CGG CAG CCC CCA GGG AAG GGA CTG GAG TGG ATT GGG TAT ATC
Y S G S T N Y N S L K S R V T
154 TAC AGT GGA AGC ACC AAC TAC AAT TCC TCC CTC AAG AGT CGA GTC ACC
V T S K N Q S L K L S S V
205 TCA GTA GAC ACG TCC AAG AAc CAG TTC TCC CTG AAG CTG AGC TCT GTG
_CDR3
A A T A v Y Y A R D T G Y Y
256 GCT GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA GAT ACT GGG TAC TAC
M D W G Q G T V T V S S
307 ATG GAC ATC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA
Anti-TIM-3 8B9 VKl (hKappa)
V segment: A27
J segment: JK4
E I V L T Q S P G T L S L S P G B
1 GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT TTG TCT CCA GGG GAA
_CDR1
RATLSCRASQSVSSSYL
52 AGA GCC ACC CTC TCC TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA
A W Y Q Q K P G Q A P R L L I Y G
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
_CDR2
ASSRATGIPDRE‘SGSGS
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC ACT GGG TCT
G T D F T L T I S R L E‘. P E D F A
205 GGG ACA GAC TTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
VYYCQQYGSSPLTFGGG
256 GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA CCT CTC ACT TTC GGC GGA GGG
T K V E I K
307 ACC AAG GTG GAG ATC AAA
8B9 NT VH1
ATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGCTGCAGGAG
TCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTCGT
CACTACTGGAACTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCCATTACAGTGGAAGC
ACCAACTACAATTCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAG
TCTGTGACCGCTGCGGACACGGCCGTGTATTACTGTGCGAGAGATACTGGGTACTACGGTATGGACATC
TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
8B9 AA VH1
MKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGS
TNYNSSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSS
8B9 NT VKl
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCTCACTTTCGG
CGGAGGGACCAAGGTGGAGATCAAA
8B9 AA VKl
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK
Anti-TIM-3 8C4 VH1
V segment: 4-59
D segment: 4-17
J t: JH6b
Q V Q L Q E S G P G L V K P S E T
CAG GTG CAG CTG CAG GAG TCG GGC CCA GGA CTG GTG AAG CCT TCG GAG ACC
_CDR1
S L C T S G G s I s R Y Y w
52 CTG TCC CTC ACC TGC ACT TCT GGT GGC ch ATC AGT CGT TAC TAC TGG
__CDR2___
W I Q P G K G L E w I G Y I
103 AGC TGG ATC CGG CAG CCC GGG AAG GGA CTG GAG TGG ATT GGG TAT ATC
Y T S T Y N P S L K S R V T
154 CAT TAC ACT GGG AGC ACC TAC AAC CCC TCC CTC AAG AGT CGA GTC ACC
S V T S N Q F S L K L S S V
205 ATA TCA GTA GAC ACG TCC AAC CAG TTC TCC CTG AAG CTG AGC TCT GTG
_CDR3
A A T A Y Y c A T D T G Y
256 ACC GCA GCG GAC ACG GCC GTG TAT TAC TGT GCG ACA GAT ACG GGC TAC
G M V W Q G T T V T V S 5
307 TAC GGT ATG GAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA
Anti-TIM-3 8C4 VKl
V t: A27
J segment: JK4
E I V L T Q S P G T L S L S P G E
1 GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT TTG TCT CCA GGG GAA
_CDR1
RATLSCRASQSVSSSYL
52 AGA GCC ACC CTC ch TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA
A W Y Q Q K P G Q A P R L L I Y G
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
A S S R A T G I P D R F S G S G S
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D E‘ T L T I S R L E P E D F A
205 GGG ACA GAC TTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
VYYCQQYGSSPLTFGGG
256 GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA CCG CTC ACT TTC GGC GGA GGG
T K V E I K
307 ACC AAG GTG GAG ATC AAA
8C4_NT_VH1
ATGAAACATCTGTGGTTCTTCCTTCTCCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAGCTGCAGGAG
TCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAGTCGT
TACTACTGGAGCTGGATCCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCCATTACACTGGGAGC
ACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTGAAG
CTGAGCTCTGTGACCGCAGCGGACACGGCCGTGTATTACTGTGCGACAGATACGGGCTACTACGGTATGGACGTC
TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
acaijynl
MKHLWFFLLLVAAPRWVLSQVQLQESGPGLVKPSETLSLTCTVSGGSISRYYWSWIRQPPGKGLEWIGYIHYTGS
TNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATDTGYYGMDVWGQGTTVTVSS
8C4_NT_VK1
ACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGCTCACTTTCGGCGGAGGGACCAAGGTG
GAGATCAAA
8C4_AA_VK1
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK
W0 13818 PCT/U$2017/041946
/78
Anti-TIM-3 17C3 VH1
V segment: 1-46
D segment: 3-10
J segment: JH6b
Q V Q L V Q 5 G A E v K K P G A s
1 CAG GTG CAG TTG GTG CAG TCT GGG GCT GAG GTG AAG CCT GGG GCC TCA
_CDR1
V K V C K A S G Y T T s Y Y M
52 GTG AAG GTC TCC TGC AAG GCA TCT GGA TAC ACT TTC Acc AGc TAc TAT ATG
_CDR2__
H W V P G Q G L w M G I I
103 CAC TGG GTG CGA CAG GCC CCT GGA CAA GGG CTT GAG TGG ATG GGA ATA ATc
N P R I I Y A Q E Q G R v
154 AAC CCT AGG GGT GAT AGC ATA ATC TAC GCA CAG TTC CAG GGC AGA GTC
T M T T S T S T V M E L s s
205 ACC ATG ACC AGG GAC ACG TCC ACG AGC ACA GTC ATG GAG CTG AGc AGC
_CDR3
L R S T A V Y Y C R D F Y G
256 CTG AGA TCT ACG GCC GTG TAT TAC TGT AGA GAT TTC TAT GGT
S G N G M D V W G Q G T T v
307 TCG GGA AAC TAC TAC GGT ATG GAC GTC TGG GGC CAA GGG Acc ACG GTC
T V S
358 ACC GTC TCC
11/78
Anti-TIM-3 17C3 VKl
V segment: A27
J segment: JKS
E I V L T Q S P G T L S L S P G E
1 GAA ATT GTG TTG ACG CAG TCT CCA GGC Acc CTG TCT TTG TCT CCA GGG GAA
_CDR1
RASQSVSSSYL
52 AGA GCC Acc CTC ch TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAc TTA
A W Y Q Q K P G Q A P R L L I Y G
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
A S S R A T G I P D R F S G S G S
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D E‘ T L T I S R L E P E D F A
205 GGG ACA GAC TTC ACT CTC Acc ATc AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
VYYCQQYGSSPITFGQG
256 GTG TAT TAc TGT CAG CAG TAT GGT AGC TCA CCG ATC Acc TTC GGC CAA GGG
T R L E I K
307 ACA CGA CTG GAG ATT AAA
12/78
17C3_NT_VH1
ATGGACTGGACCTGGAGGGTCTTCTGCTTGCTGGCTGTAGCTCCAGGTGCTCACTCCCAGGTGCAGTTGGTGCAG
TCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCATCTGGATACACTTTCACCAGC
TACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGGGGTGAT
ATCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATG
GAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATTTCTATGGTTCGGGAAACTAC
TACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
17C3_AA_VH1
MDWTWRVFCLLAVAPGAHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPRGD
SIIYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDFYGSGNYYYGMDVWGQGTTVTVSS
17C3_NT_VK1
ACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGATCACCTTCGGCCAAGGGACACGACTG
GAGATTAAA
17C3_AA_VK1
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK
1 3/78
Anti-TIM-3 9F6 VH1
V t: 3-11
D segment: 6-19
J segment: JH6b
Q V Q L V E S G G G L V K P G G S
l CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC AAG CCT GGA GGG TCC
_CDR1
L R L C A A S G F T F s D Y Y M
52 CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT GAC TAC TAC ATG
_CDR2_
S W I Q A P G K G L E W v s F I
103 AGC TGG ATC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTT TCA TTC ATT
S G G S T I Y Y A D S V K G R F
154 AGT GGT GGT GGT AGT ACC ATA TAC TAC GCA GAC TCT GTG AAG GGC CGA TTC
T I S D N A K N S L F L Q M N S
205 ACC ATC TCC AGG GAC AAC GCC AAG AAC TCG CTG TTT CTG CAA ATG AAC AGC
_CDR3
L R V D T A V Y Y C A R D G Y s
256 CTG AGA GTC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGA GAT GGC TAT AGC
S G W Y Y G M D V W G Q G T A V
307 AGT GGC TGG TAC TAC TAC GGT ATG GAC GTC TGG GGC CAA GGG ACC GCG GTC
T V S
358 ACC GTC TCC
14/78
FIG. SB
Anti-TIM-3 9F6 VK]
V segment: L18
J segment: JK]
A I Q L T Q S P S S L S A S V G D
GCC ATC CAG TTG ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA GAC
_CDR1
R V I T c R A s Q G I s s A L A
52 AGA GTC ACC ATC ACT TGC CGG GCA AGT CAG GGC ATT AGC AGT GCT TTA GCC
__CDR2__
W Y Q K P G K A P K L L I Y D A
103 TGG TAT CAG CAG AAA CCA GGG AAA GCT CCT AAG CTC CTG ATC TAT GAT GCC
S S E‘. S G V P S R F S G S G S G
154 TCC AGT TTG GAA AGT GGG GTC CCA TCA AGG TTC AGC GGC AGT GGA TCT GGG
T D T L T I S S L Q P E D F A T
205 ACA GAT TTC ACT CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT GCA ACT
_CDR3
Y Y Q Q F N s Y P R T F G Q G T
256 TAT TAC TGT CAA CAG TTT AAT AGT TAC CCT CGG ACG TTC GGC CAA GGG ACC
K V I K
307 AAG GTG GAA ATC AAA
1 5/78
Anti-TIM-3 9F6 VK2
V segment: A27
J t: JK4
E I V L T Q S P G T L S L S P G E
1 GAA ATT GTG TTG ACG CAG TCT CCA GGC Acc CTG TCT TTG TCT CCA GGG GAA
_CDR1
RATLSCRASQSVSSSYL
52 AGA GCC Acc CTC ch TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAc TTA
A W Y Q Q K P G Q A P R L L I Y G
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
A S S R A T G I P D R F S G S G S
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D F T L T I S R L E P E D F A
205 GGG ACA GAC TTC ACT CTC Acc ATc AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
VYYCQQYGSSLTFGGGT
256 GTG TAT TAc TGT CAG CAG TAT GGT AGC TCA CTC ACT TTC GGC GGA GGG Acc
K V E I K
307 AAG GTG GAG ATC AAA
16/78
IlVI-3 9F6 VK3
V segment: A27
J segment: JK4
E I V L T Q S P G T L S L S P G E
1 GAA ATT GTG TTG ACG CAG TCT CCA GGC Acc CTG TCT TTG TCT CCA GGG GAA
_CDR1
RATLSCRASQSVSSSYL
52 AGA GCC Acc CTC ch TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAc TTA
A W Y Q Q K P G Q A P R L L I Y G
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
A S S R A T G I P D R F S G S G S
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D E‘ T L T I S R L E P E D F A
205 GGG ACA GAC TTC ACT CTC Acc ATc AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
VYYCQQYGSSPLTFGGG
256 GTG TAT TAc TGT CAG CAG TAT GGT AGC TCA CCG CTC ACT TTC GGC GGA GGG
T K V E I K
307 ACC AAG GTG GAG ATC AAA
17/78
TGGAGTTTGGGCTGAGCTGGGTTTTCCTTGTTGCTATTATAAAAGGTGTCCAGTGTCAGGTGCAGCTGGTGGAGT
CTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACT
ACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTGGTGGTGGTAGTA
CCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCGCTGTTTCTGC
AAATGAACAGCCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGCTATAGCAGTGGCTGGTACT
ACTACGGTATGGACGTCTGGGGCCAAGGGACCGCGGTCACCGTCTCCTCA
MEFGLSWVFLVAIIKGVQCQVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGS
TIYYADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTAVTVSS
9F6_NT_VK1
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCAGATGTGCCATCCAG
TTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGGC
ATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGT
TTGGAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTG
CAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCTCGGACGTTCGGCCAAGGGACCAAG
GTGGAAATCAAA
9F6_AA_VK1
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASS
LESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPRTFGQGTKVEIK
9F6_NT_VK2
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACTCACTTTCGGCGGAGGGACCAAGGTGGAG
ATCAAA
9F6_AA_VK2
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLTFGGGTKVEIK
9F6_NT_VK3
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGCTCACTTTCGG
CGGAGGGACCAAGGTGGAGATCAAA
9F6_AA;VK3
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK
1 8/78
IM-3 3G4 VH1
V segment: 3-11
D segment: 6-13
J segment: JH6b
Q V Q L V E S G G G L V K P G G S
CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC AAG CCT GGA GGG TCC
_CDR1
S C A A S G F T F s D Y Y M
52 CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT GAC TAC TAC ATG
_CDR2_
R Q A P G K G L E w v s F I
103 TGG ATC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTT TCA TTC ATT
G S I I Y Y A D S V K G R F
154 ACT AGT GGT AGT ATC ATA TAC TAC GCA GAC TCT GTG AAG GGC CGA TTC
R D N A K N S L Y L Q M N S
205 ATC TCC AGG GAC AAC GCC AAG AAC TCA CTG TAT CTG CAA ATG AAC AGC
_CDR3
E D T A V Y Y C A R E G Y s
256 AGA GCC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGA GAA GGG TAT AGC
S Y Y Y G M D V W G Q G T T
307 AGC TGG TCC TAC TAC TAC GGT ATG GAC GTC TGG GGC CAA GGG ACC ACG
S S
358 ACC GTC TCC TCA
19/78
Anti-TIM-3 3G4 VKl
V segment: A27
J segment: JKS
E I V L T Q S P G T L S L S P G E
GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT TTG TCT CCA GGG GAA
_CDRl
R A T SCRASQSVSSSY
52 AGA GCC ACC CTC ch TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA
A W Y Q K P G Q A P R L L I Y
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
A S S A T G I P D R F S G S G
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D T L T I S R L E‘. P E‘. D F
205 GGG ACA GAC TTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
V Y Y Q Q Y G s s P I T F G Q
256 GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA CCG ATC ACC TTC GGC CAA GGG
T R L I K
307 ACA CGA CTG GAG ATT AAA
/78
3G4_NT_VH1
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTTGTTGCTATTATAAAAGGTGTCCAGTGTCAGGTGCAGCTGGTGGAG
TCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGAC
TACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTACTAGTGGTAGT
ATCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTG
CAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAAGGGTATAGCAGCAGCTGGTCC
TACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
3GQJVLVH1
MEFGLSWVFLVAIIKGVQCQVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISTSGS
IIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGYSSSWSYYYGMDVWGQGTTVTVSS
3G4_NT_VK1
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
TACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGATCACCTTCGGCCAAGGGACACGACTG
GAGATTAAA
3G4_AA_VK1
METPAQLLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK
21/78
Anti-TIM-3 17C8 VH1
V t: 3-11
D segment: 6-19
J segment: JH6b
Q V Q L V E S G G G L V K P G G S
CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC TTG GTC AAG CCT GGA GGG TCC
_CDR1
L S C A A S G F T F S D Y Y
52 CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT GAC TAC TAC ATG
I R Q A P G K G L E W V S F
103 TGG ATC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTT TCA TTC ATT
S G S I I Y Y A D S V K G R F
154 AGT AGT GGT AGT ATC ATA TAC TAC GCA GAC TCT GTG AAG GGC CGA TTC
S R D N A K N S L Y L Q M N
205 ATC TCC AGG GAC AAC GCC AAG AAC TCA CTG TAT CTG CAA ATG AAC AGC
_CDR3
A E D T A V Y Y C A R D G Y
256 AGA GCC GAG GAC ACG GCT GTG TAT TAC TGT GCG AGA GAT GGG TAT AGC
W E Y Y G M D V W G Q G T T V
307 GGC TGG GAG TAC TAC GGT ATG GAC GTC TGG GGC CAA GGG ACC ACG GTC
S S
358 GTC TCC TCA
22/78
IM-3 17C8 VKl
V segment: A27
J segment: JK4
E I V L T Q S P G T L S L S P G E
GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT TTG TCT CCA GGG GAA
_CDRl
R A T SCRASQSVSSSY
52 AGA GCC ACC CTC ch TGC AGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA
A W Y Q K P G Q A P R L L I Y
103 GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT GGT
A S S A T G I P D R F S G S G
154 GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT
G T D T L T I S R L E‘. P E‘. D F
205 GGG ACA GAC TTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT GCA
_CDR3
V Y Y Q Q Y G s s P L T F G G
256 GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA CCG CTC ACT TTC GGc GGA GGG
T K V I K
307 ACC AAG GTG GAG ATC AAA
23/78
17C8_NT_VH1
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTTGTTGCTATTATAAAAGGTGTCCAGTGTCAGGTGCAGCTGGTGGAG
GGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTGAC
TACTACATGAGCTGGATCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCATTCATTAGTAGTAGTGGTAGT
ATCATATACTACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTATCTG
CAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATGGGTATAGCAGTGGCTGGGAG
TACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
17C8_AA_VH1
MEFGLSWVFLVAIIKGVQCQVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISSSGS
IIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGYSSGWEYYGMDVWGQGTTVTVSS
17C8_NT_VK1
ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCAGATACCACCGGAGAAATTGTGTTGACG
CAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC
AGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGG
GCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAG
CCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCGCTCACTTTCGGCGGAGGGACCAAGGTG
GAGATCAAA
17C8_AA_VK1
LLFLLLLWLPDTTGEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK
24/78
Sequence Alignment for Heavy Chain Variable Regions
FRI FRZ CDRZ
13A3 QLQLQESGPGLVKPSETLSLTCTVSGGSI - IRQPPGKGLEWIG IYYSGFT- 59
BB9 QVQLQESGPGLVKPSETLSLTCTVSGGSI‘ IRQPPGKGLEWIG IHYSGST— 57
sc4 QVQLQESGPGLVKPSETLSLTCTVSGGSI‘ IRQPPGKGLEWIG IHYTGST- 57
17c3 QVQLVQSGAEVKKPGASVKVSCKASGYT VRQAPGQGLEWMGIINPRGDSI 58
9F6 QVQLVESGGGLVKPGGSLRLSCAASGFTF‘ IRQAPGKGLEWVS 58
3G4 QVQLVESGGGLVKPGGSLRLSCAASGFTF‘ KGLEWVSIISTSGSII 58
17cs QVQLVESGGGLVKPGGSLRLSCAASGFTF‘ IRQAPGKGLEWVS 58
*:** :** **' ::* '** no ** **.****
: ::
FR3 CDR3
13A3 VTISVDTSKNQFSLKLSSVTAADTAVYYCA --—GG—--PYGDYAHWFDP 112
BB9 VTISVDTSKNQFSLKLSSVTAADTAVYYCA 106
8C4 NYNPSLKSPVTISVDTSKNQFSLKLSSVTAADTAVYYCA m---TG---YYG-----MD 106
17C3 ~ VTMTRDTSTSTVYMELSSLRSEDTAVYYCA' 112
9F6 FTISRDNAKNSLFLQMNSLRVEDTAVYYCA"DGYSSGWY—YYG-----MD 112
364 FTISRDNAKNSLYLQMNSLRAEDTAVYYCA‘IGYSSSWSYYYG-----MD 113
17C8 FTISRDNAKNSLYLQMNSLRAEDTAVYYCA"nGYSSGWE—YYG—————MD 112
******** '
.... .*:: *.:.. . :::.*:
13A3 WGQGTLVTVSS 123
889 WGQGTTVTVSS 117
8C4 WGQGTTVTVSS 117
17C3 WGQGTTVTVSS 123
9F6 WGQGTAVTVSS 123
364 WGQGTTVTVSS 124
17GB WGQGTTVTVSS 123
***** *****
VH Region Sequence Designation
SEQ ID NO-
R3 VH ts
13A3. 34 41 112 113 116
(N600) (N605) (N60A) ) (P102V)
117 118 119
(P102Y) (P102L) (N600, (N600,
P102Y) D101E)
33:", -
m _
_-s7l£-I_38 _
(A108T)
WO 13818 PCT/U52017/04l946
/78
Sequence Alignment for Light Chain Variable Regions
FRI FRZ
13A3 EIVLTQSPGTLSLSPGERATLSOP‘SQSVSSSY YQQKPGQAPRLLI 60
17c3 EIVLTQSPGTLSLSPGERATLSOI'‘SQSVSSSYT YQQKPGQAPRLLI 60
3G4 EIVLTQSPGTLSLSPGERATLSOP‘SQSVSSSYT YQQKPGQAPRLLI 60
BB9 EIVLTQSPGTLSLSPGERATLSOP SQSVSSSY YQQKPGQAPRLLI 60
8C4 EIVLTQSPGTLSLSPGERATLS'P‘SQSVSSSY' YQQKPGQAPRLLI 60
9F6_VK3 EIVLTQSPGTLSLSPGERATLSOP‘SQSVSSSY' YQQKPGQAPRLLI 60
17cs EIVLTQSPGTLSLSPGERATLSOP SQSVSSSY YQQKPGQAPRLLI 60
9F6_VK2 EIVLTQSPGTLSLSPGERATLSOP‘SQSVSSSYT QAPRLLI 60
9F6_VK1 AIQLTQSPSSLSASVGDRVTITOP SQGISSA- YQQKPGKAPKLLI DASSLES VP 59
9! * -*~k * *-~k *--~k**~k* -**- *********-**-~k*** *** .~k-*
.- - - .- .. n . n - . .
FR3 FR4
13A3 DRFSGSGSGTDFTLTISRLEPEDFAVYYOOQYGSSPIIFGQGTRLEIK 108
1703 DRFSGSGSGTDFTLTISRLEPEDFAVYYOOQYGSSPIIFGQGTRLEIK 108
364 DRFSGSGSGTDFTLTISRLEPEDFAVYYOOQYGSSPIIFGQGTRLEIK 108
8B9 GSGTDFTLTISRLEPEDFAVYY00OYGSSPLIFGGGTKVEIK 108
8C4 DRFSGSGSGTDFTLTISRLEPEDFAVYYOOQYGSSPLIFGGGTKVEIK 108
9F6_VK3 DRFSGSGSGTDFTLTISRLEPEDFAVYYOOQYGSSPLIFGGGTKVEIK 108
17cs DRFSGSGSGTDFTLTISRLEPEDFAVYYOOQYGSSPLIFGGGTKVEIK 108
9F6_VK2 DRFSGSGSGTDFTLTISRLEPEDFAVYYCOQYGSS-LIFGGGTKVEIK 107
9F6_VK1 SRFSGSGSGTDFTLTISSLQPEDFATYYOOQFNSYPRIFGQGTKVEIK 107
.****~k*+********* *:§****.~k*+*i *i-i'
_ **::***
Light Chain ce Designation
<r- (1 CDRZ
8n.5 0101 h’be
9F6(VK1) NJ U1
9F6(VK2) 010101 U) \l\l HC
9F6(VK3) #3
3G1.5
17C8. 01 rd lilliliilliliillillillillillll\l
26/78
Sequence alignment of the heavy chain of 13A3.IgGl.3f and ts
TIM3.5 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.11 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.12 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.13 SGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.10 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.18 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.14 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.16 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.15 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
TIM3.17 QLQLQESGPGLVKPSETLSLTCTVSGGSISSRSYYWGWIRQPPGKGLEWIGSIYYSGFTY
***iviiv-kiv*i-Jziv*******ivi:~k******+********~k*~k*************+******
TIM3.5 YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVT
TIM3.11 YSPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVT
TIM3.12 YAPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVT
TIM3.13 YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVT
TIM3.10 YQPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDPWGQGTLVT
TIM3.18 YQPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFEPWGQGTLVT
TIM3.14 SRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDVWGQGTLVT
TIM3.16 YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDLWGQGTLVT
TIM3.15 YNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVT
TIM3.17 YQPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCATGGPYGDYAHWFDYWGQGTLVT
~k *Jz************************+**************~k******z ********
TIM3.5 M§§ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.11 Y§§ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.12 KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.13 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.10 <SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.18 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
4 <SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.16 <SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.15 <SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.17 <SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
******************inki-**************************1l-************
TIM3.5 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.11 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
2 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.13 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.10 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.18 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.14 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.16 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.15 SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.17 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
************************************************************
TIM3.5 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.11 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.12 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.13 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.10 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.18 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
4 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.16 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.15 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.17 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
**3k*iviv***~k*3?***3\vi-‘k*1?***iv****i-ii:*3?i-*************************~k
27/78
(Cont)
TIM3.5 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.11 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.12 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.13 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.10 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.18 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.14 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.16 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.15 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.17 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
************************************************************
TIM3.5 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
1 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.12 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.13 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.10 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.18 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.14 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
6 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.15 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.17 RBEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
******************************************+***+*************
TIM3.5 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.11 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.12 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.13 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.10 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.18 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.14 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.16 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.17 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
******************~k**************
28/78
Sequence alignment of the heavy chain of 9F6.IgG1.3f and variant (A108T)
9F6 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYY
TIM3.7 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSFISGGGSTIYY
************************************************************
9F6 ADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTAVT
TIM3.7 ADSVKGRFTISRDNAKNSLFLQMNSLRVEDTAVYYCARDGYSSGWYYYGMDVWGQGTTVT
*****************1'***************************************:**
9F6 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
TIM3.7 VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
**********~k********~k******************~k*******~k~k************
9F6 QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
TIM3.7 SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEA
************************************************************
9F6 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
TIM3.7 EGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
************************************************************
9F6 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
TIM3.7 QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
****************************+*******************************
9F6 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
TIM3.7 REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
ink****iriv***iv******ink-ki-***~k*******~k***-k*~k***********~k********
9F6 NVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.7 SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
*****************************Vk***
29/78
ce alignment of the heavy chain of 889.1gG1.3f and variant (S61P)
8B9 QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYN
TIM3.8 QVQLQESGPGLVKPSETLSLTCTVSGGSISRHYWNWIRQPPGKGLEWIGYIHYSGSTNYN
**~k******************~k************~k**********~k**************
8B9 SSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSAST
TIM3.8 PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDTGYYGMDIWGQGTTVTVSSAST
*1:i-*****************~k*************************************~k
8B9 KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
TIM3.8 KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
**********+***************+***+******+***+***********+******
8B9 SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSV
TIM3.8 SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSV
***3“********************************************************
8B9 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
TIM3.8 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
*********ink**~k*~k+‘k*~k*******~k********~k**********~k************
8B9 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK
TIM3.8 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTK
*sl-**********************************************************
8B9 CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
TIM3.8 NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
*********************‘1‘*******************************~k******
8B9 NVFSCSVMHEALHNHYTQKSLSLSPGK
TIM3.8 NVFSCSVMHEALHNHYTQKSLSLSPGK
*i-iri-***********************
WO 13818 PCT/U52017/041946
/78
»: :3». 3409 :39 3.89 “.39 :3». #283 say :39 5.8! $09 :3». 3:8! $6» :89 $.39 new» :40! 5.89 acom :3! 3409
.Ufm —-
Nom vom mom mom on Nam Sum mam
i Nw NoH mm moH 3w «3 mm m8 8 m3 mm 50H ww mg
40m 00
H NNfiH .mom \Nn Na dom «K \mm Rom .3. 6m .mom ~mh .3 43 an dm ‘mam Kn Km swam \wn dm
:.Gm_-m.ms_: :4 23
3-95 @9553g 369.3%: 882-:> 382-..; 282-; $83.; 988-..; £88-; 382;;
.22. “3.89-3.3: : 389.392: .23 Edoyfiazfi aqoyfimz: 3.89.3.3: 23 5.69.2.3: aqom_.~fi.m_2: 389.33: 22. 3.89-2.3: $09-33: H.Gm_-3.m_2: gm: 5.89-3.3:é :.Hom_.mfi.ms_: 9;: 3.39.3.3: $3.33; $89.33: 23 3.89.8.3:
31/78
NH. Hm.
358 logHlyHm log 8'lacyEH.logHmlog|.HHog'59 Hmlog'39“no! NH. logIgloyHm 89
523:8: EHIEHI IEEEQEHIEEEE! EllNH”-NNH
H mm 0m
Iwmm 8H mm E «Nm mNm 2m
mm I:N'ImHmm9% I3.». mmm Ha 2.3 .MNm .mNm 0H
8 iHH8H 5 m NINNH
Elfi- A>NoHadomzi> aHoHo 388 388
QEEHE: :AOMTDdEF EH3
m<m$ 5.39-2.3: $094.35.: HH.Hom_-wH.m_2: domz-_._>-m<m: Nm.Hom_-wH.m.2: dooz-:>-m<m: 309-355.: dSz-:>-m<mH. I% HH.Hom_-mmw HmHoyémm aeoyamw MEF x>mag Hm.Huw_-w.m_2: aeom_.m.m_2: II HH.Hom_.m.m_2: :03 Hm.Hom_-m.ms_: $9-992:
32/78
358 leloyhml0! :89 3.89 “3%. :89 5.89 259 «Soy :3! #289 “8%.
2 -
523:8: IIEII IEEEQEHIEEEE!
3; mNdH ‘mmm HNHla8 EEgm .EE
Elfi- :.Gw_.~.m2: 5.8». C82i>
.83 um.._”0m_-~.m.>=h EF 389$; 3.69-32: 05
$2 3.89-2.2: $3-522: I €89.13: 389-com wmaoyimz: avowgazi
33/78
3.58 :39 3.82 “=69
>>mu1 EHIEII IEEEQEEIEHMWEQ!
a: 5%
22: A83 “maoyéaz: avom_-m.ms_:
34/78
A
Binding of TIM-3 antibodies to CHO-huTIM3 transfectant
12000
o 13A3
I 17C3
> 17C8
Geo-MFI 4 3G4
6000 o 889
o 9F6
b hIgG1
o 0 hIgGZ
-6 44 -2 o 2
Cone (uglmL) hlgG4
006358
007208
005160
009602
003371
007401
39740
42256
29319
WO 13818 PCT/U82017/0419-I6
/78
8
Binding ofanti-TlM-3 to activated human T cells
o 364
2000 I 889
A A 8C4
a 1500 v 9F6
E o 13A3
51°” 0 17C3
u 17C8
X A hG1
0 v hG2
-6 2 0 hG4
0.05043
0.02392
0.1149
0.02660
0.04274
0.03621
0.02083
36/78
A
CHO-cynoTlM3 ectant
25000
20000 I 13A3
A 1703
E 15000 v 1708
8 o 304
10000
0 O 869
D 9F6
0 0 111 G1
-6 4 -2 o 2
a: mngg
Conc(ug/mL)
* hlgG4
0.07486
0.2159
4.709
0.1952
~ 2.532
~ 7.465
'75731
’44504
54134
37/78
FIG. lSB
activated cyno T cells
I 13A3-biotin
A lsotype-biotin
200 A
—4 -2 0 2
Concentration )
—13A3-biotin
EC50 0.06018
WO 13818 PCT/U52017/041946
38/78
70000
60000
(pglmL) 50000
IFN-g
40000
30000
13A3 364 17C3 17C8 889 9F6 Isotype
39/78
A
Ab Conc
(ug/mL)
0.625
12000 0.156
0.039
0.0097
(Pg/mL)
'FN-g
13A3 364 controls
40/78
13
Ab treatment
Isotype staining KLH-2F5-g4p Anti—TIM3: 3G4
‘ 0.3‘
6 ”In-l
e lFN-g a IFN~g 3 . A.
:: ::
Comp-APc-A 1 A..All
E’ .t’
a ‘03 \
8 "
a ,. CompAPc-A 3 U
o 3 0
‘03 LWWW fimw—rmmwfiA5.25 85.1 6|
3 _hullnA‘Au-lnu.l
403 0 I03 10‘ 105 .103 o 103 10‘ 105
Corm-PE-A :: lsolype
o. o 55 8u-
.441ka o 3 I‘lnnlt
lsolype 5 . .3? t.
. lFN~g 6
:: nunflunuuL_.._uJ 4i :: A.AII
Comp-APC-A 6 u U -
U ComAPC-A a
o 0 0 l
3 a 96.9 3.09 86.0
.10 403 $.17 3 j o. 24
'llvulvvvmvivuu , ~-v-r-vynul -r r qm1~ H ~—,....,....,"v..... - ». rm... .-......,---. Lirmvvvmrvvynv vvaWV’fvfuwrfi'
403 3 :I I s
0 103 10‘ 105 403 0 103 10‘ [05 -| o o :0 IO 10
Comp-PE-A :: Isotype Comp-PE-A 2: TIM3 (839) Comp-PE-A :: TIM3 (839)
41/78
. Isotype
fl Anti-TIM3
$>o 65:8
$855 >uo£E<
28 .
oz aW ua ma u u un . g * ~ ~~ .a *~~ «
O ‘
<i’o 6‘6
Cross-blocking of TIM-3 antibodies 1703 biotin
on activated human T cells
-889 biolin
13A3 biotin
E20 20oo
1 0 oo
V \
m 3 m R §§§
com mmm 3: vow XYNOAOL can man mum mu: mu: vow <0 «cm mmw Rm S: ”on" vuw
N0; voéoému:
42/78
om >mo<0x030> mo >mo >mo ONH QZZmeHOHm D 2 omfi ovm oom
m fldBmHOBQZH quAZOHMMM wqm0m
om m>Azwm¢¢mH q OHH oowHomo<qe Ora 0mm 0mm
M Q Q Q BOBm mHQ< moommm>wow
0v whomqwdzaw OOH >2mHqu>ow 00H flmwmmeBQE ONN OMHA¢A<AQ< OwN
an WMmem>mw>
.0; om >m¢mwm>mmm om xmmowzqzwm m omH OHN Ohm
m mmm¢<emom0 UHOfiUHWHwH meHHWHme
ON mHAqngqqq om mezwz>ommo m 3 ova OON omm
£895 mBmfimB>M<m mHaflwQOqo mmem<><Z<
22:. OH or OMH oma omN
.5 >Uommqmmm2 qu>>zoomm MH>AMQZme Z<qmmomqmz 40mmqu<qm
8:38.. van 0mm 00mm
2.33m MZHB m<ma vwm Mona mmm MZHB m<mH vwm mohfl mmm MZHB m<ma vwm moha mmm MEHB MEHH
43/78
A
mAb saturating
hTIM3 47
hTimB-ch ed
on antimch tip
44/78
.8525
.v:.A .u.nv”Amm. T. 362:8
..... :
mavwvfigwxw . mxfimgm 9:25
....................... fig
.. mflfimgw .958
ram. .33 N..
. 6ch
. n<
.0: Dumufluwm ................................ .mg .é 9:528
wm¢ . mwkawmwm
UkEM§_h£wmu.mWC_Uc.£§coma x\\xxx\txxtx}4x\\vxxx?xkxx)«lkkxxkt2t>3XttX\x‘kkktxitxxtt.xxt«xx{xkhtxkxxtxxxxtkX\..\»\§§\~tttt\\§\\xtxxxxkktkxxlxxtxxtxttxtxftktktxkxk\\xKx§§§§vttthttk\\\\kkkxfttxxkttxl‘x‘t‘§s§§§ . mm
\ AvwwmM Ai..~...
vAo »Au .NwAu »N mag»
VVVVVVVV mummwfimm»; \\\\\\\\\ chmm .8538
................. fag .
g“33am fledgmzfig
fag ..\\\\\\\.x\\\\\\\\\\. 8 {mm
..H 83$ AEREH
UmowumflutgmmOuU .
AvA avaAMH\.*Mw.. ..‘ A.v ..§. .3
.......... u.A. ~Nu...“u .. .é 53,
1§§§§§§§§§§§§§ . ...§ “$an i
mafiwUSgwxw In
n mm:
\§\\\\$ am
\ nmwwwn A.~.wn...“v.5 é
0&szm .. V.
H “ I . ..a . .. . :H .mfiwwmwwp
. 5:
.sWfiw . x. . .
mm; .
).)\xmmu 83¢ .
. 5nyu33 uis» Q ~38
. .
45/78
«525 2.65.. mm; oz oz oz mm; 8>
mo oz mw> oz oz oz mm;
“$5 .85
3:89. mafimuuu #86 .886. wmaod- Nomad- vand mm:
030%.. .0
m...— woman» mood mwhvd moood whood 950.0. momm .9...
3.88 < m 5.: n< mmw vow mum
22 m<ma mu: mu: xcmE xcmE
vwm n< n<
. Go:
¢ 099
. ‘\.\\\.\\.\\.¢Vx\w\\\\\
:3§\\\\\\\\\\
\\§ \\\\\\\\\\\\\\§§.\\\\\\\\\\ :.:..\.\::$.\.:.t.>.E . 009.
2:33 \\\\\\\\\\\\ .
T Do:
S. $0.8.v.\\. v
\\ .3.
\ com: 2:83 .\‘\\.\..\A\\ o
mo. >\:\‘.,:..::.$:...:..§:\.::t \\\\\ §\\\\\\\\, 00.2 Z.
\§\\.\\\\\ mm .
\\ 00.04
\\\\ . 00»; u
.. . 00:.
. H . H . H H comp : 7 z 7WHH.W‘ w, md md .V M O M‘
- .
O 2 O to 3. No. n.0- Nd 3 v.0 8 o F coo?
. “F
. .
o o O-
1Wmsm“m
(wu) asuodsa:
46/78
Summary of Functional Activity of Anti-TIM3 Antibodies
Binding Assay (ECSO nM)
PS-TIM3
HumanT CynoT CHO-huTlM T'LAssaY
Blocking
cells (nM) cells (nM) (nM)
47/78
Description of Sequences Represented by the SEQ ID N05
-I———
HIE—_-
-!———
-I———
48/78
(Cont).
.5———
-E_——
13A3, including the
following 13A3
ts: N600; N605;
N60A; D101E; P102V;
P102Y; P102L; N600
and P102Y; N600 and
01016 CDR1 (VH) Amino Acid
889, including the 889
42 ($61P) variant CDR1(VH) Amino Acid
m—CDR1 (VH)
.2! ms conuvH)
9F6, including the 9F6
(A108T) variant; 3G4;
17C8 CDR1 (VH) Amino Acid
13A3, including the
following 13A3
variants: D101E,
P102V, P102Y, and
P102L CDR2 (VH) Amino Acid
CDRZiVH)
m—coazivm
.5 ms CDRZlVH)
9F6, including the 9F6
50 (A108T) variant CDRZ (VH) Amino Acid
__CDRZlVH)
17C8 CDRZiVH)
13A3, including the
following 13A3
variants: N600, N605,
CDR3 (VH) Amino Acid
m_—-($61P)variant CDR3 (VH) Amino Acid
m—conswm
17c3 H)
9F6, including the 9F6
57 (A108T) variant CDR3 (VH) Amino Acid
”53—comm
49/78
(Cont).
61 889, 8C4, 17C8 9F6 VL Amino Acid
(VK3)
memvw
13A3, 889, 8C4, 17C3, CDRl (VL) Amino Acid
9F6 (VK2, VK3), 3G4,
mawn cow
13A3, 889, 8C4, 17C3, CDRZ (VL) Amino Acid
9F6 (VKZ, VK3), 364,
96w com
889, 8C4, 9F6 (VK3), CDR3 (VL) Amino Acid
13A3 (N600, 0101s) fHC(no C—terminal K)
50/78
(Cont).
.m———
.21———
“M‘N‘mmm”
mwosn
WO 13818 PCT/USZOl7/04l946
51/78
(Cont).
122 13A3 (N600); 13A3 CDRZ (VH) Amino Acid
(N600, P102Y); 13A3
(N60Q, DlOlE)
13mm, comm
889w comm
126 13A3(0101E); 13A3 CDR3 (VH) Amino Acid
(N60Q, DlOlE)
mm comm
(N60Q, P102Y)
52/78
.
174 13A3, including the CDR1 (VH) Nucleotide
following 13A3
variants: N60Q; N605;
N60A; DlOlE,‘ P102V;
P102Y; P102L; N600
and P102Y; 13A3
(N60Q, DlOlE)
175 889, including the 889 CDR1(VH) Nucleotide
($61P) variant
CDR1(VH)
CDR1(VH)
178 9F6, including the 9F6 CDR1 (VH) Nucleotide
(A108T) variant; 3G4;
13A3, including the CDR2 (VH) Nucleotide
following 13A3
variants: DlOlE,
P102V, P102Y, and
P102L
CDR2 (VH) Nucleotide
183 9F6, ing the 9F6 CDR2 (VH) Nucleotide
(A108T) variant
53/78
(Cont).
comvvm
186 13A3, including the CDR3 (VH) Nucleotide
following 13A3
variants: N600, N605,
($61P) variant
CCCCWC,
CCCCMC
190 9F6, including the 9F6 CDR3 (VH) Nucleotide
(A108T) variant
CCCCVCC
194 889, 8C4, 17C8 9F6 VL Nucleotide
(VK3)
esvvvn
197 13A3, 8B9, 8C4, 17C3, CDR1 (VL) Nucleotide
9F6 (VKZ, VK3), 3G4,
ssvvvn com
199 13A3, 889, 8C4, 17C3, CDR2 (VL) Nucleotide
9F6 (VKZ, VK3), 364,
n cmwu
WK” ”“3“”
13A3(N60C1, 0101s) lgGl.1fHC
54/78
(Cont).
13A3 (N600, DlOlE) lgGl.3f HC (no C—terminal K)
374 13A3 (N6OQ, 0101E) IgGl.3f HC (no inal K) Nucleotide
(TIM3.18 ) (T168C)
889 (S61P) lgGl.3fHC (no C-terminal K)
9F6 (A108T) lgGl.3fHC (no C-terminal K)
55/78
(Cont).
“New“
ooooooo
255 13A3 (N600); 13A3 CDRZ (VH) Nucleotide
(N60Q, P102Y); 13A3
(NBOQ, DlOlE)
oooomooo cocoon)
oooomooo cococvo)
coococo coczcvoo
mocoooco cococvoo
ooooooozw co
(N600, P102Y); 13A3
(N60Q, DlOlE)
.aI———
56/78
(Cont).
--_—degenerate)
--_—X17X18(VHCDR3degenerate)
mil—_—
13A3 hlgG4 HC (without C~terminal K)
T|M3.5 — 13A3 lgG4P Hc (without C—terminal K)
305 TIM3.10 - 13A3 IgG4P HC Amino Acid
(N600)
T|M3.10 — 13A3 IgG4P HC (without C—terminal K) Amino Acid
(N600)
T|M3,11 — 13A3 (N605) lgG4P HC
57/78
(Cont).
TIM3.11 — 13A3 (N605) IgG4P HC (without C—terminal K)
T|M3.12 — 13A3 (N60A) lgG4P HC
T|M3.12 — 13A3 (N60A) lgG4P Hc ut C-terminal K)
(DlOlE)
(DlOlE)
(P102V)
(P102V)
(P102Y)
(P102Y)
(P102L)
(P102L)
(N600, P102Y)
(N600, P102Y)
(N600, DlOlE)
(N600, DlOlE)
58/78
(Cont).
ma———
(N60Q, DlOlE)
--——Domain
fl_—-Domain
fl——-Domain
--——Domain
--_—Domain
-_Residues 119—127 of Mature Human TIM3 Extracellular Domain
——bums-m
(N600, DlOlE)
(N60Q, DlOlE)
fl“—(N60Q,DlOlE)
(N60Q, DlOlE)
(N60Q, DlOlE)
59/78
(Cont).
383 TIM3.18 — 13A3 f HC (T168C) (no C-terminal K) with signal Nucleotide
(N600, DlOlE) sequence
(N60Q, DlOlE)
(N600, DlOlE)
60/78
A
Centre; :96 S anti-TEN
E 0:10 Tumor Free
0.510 Tumor Free
(mm3’S (mmg’ ‘S’
volume E volume N§
Tulnor 4§
§ Tumor
Days Post Implantation Days Post lmptmtation
RMP? 4 4 anti-PDT Anti-PD“! + anti-Timis
E 2
2'10 Tamar Fme am Tumr Free
1mm”3 (mma)§0
volume S voiume M80
Tumor g Tumor M‘8O
8 20 40 60 o 20 46 60
Days Post impiantation Days Past implantation
61/78
B
2 ”86%“:
_ RMT3-23 (anti-TlMrlgGZa)
fi «
“ AbM TIM-B-mlgG 0265A)
"g “3509 RMP1-14(anti-PD-1)
g m RMT3-23 + RMP1-14
g “330 M AbM+ RMP1-14
“““ Isotype control (anti-DT)
g 5&0
62/78
mm :8. .33; €on Wm
mm 353303 B.
ii. iii u¢umwwdfi.uw mm ii ii €913th Auwtoaob
3 ”Mm 236 5.5380292
a; mum
mp we” 0%33 coumamookmé £83382me
i mm Summmwgzo - -
max mvC N32
mm mm
O - -
mm »:wmm«nmmm wfi
mN m»
.0; u,wmwwwm»mmwwwwmuawxw$mmmm.mxwawwmmwywwmwmwv iii; it; ii swans;
n» iii; m3 .
«:»m R inn-ii
:w :vmmmmmmmmuwmwmmjum®wa
wwmmm R
mww»..:«~.,w
63/78
snagging.“ a \ E
s“.333éfifimgggx M.“
«m §§§s ‘wxqzmxgmmfim
-\\\\\\\\ Vxw.\\\\ Munxuxwmmfimmvgfiwmfl a...
.3. Mmmofigm
.OE $93 mg.“ nmaxxwmwxagmm
«awuxfi txfikkmawn
\\\ p1»
. \\i}w§\,
{'3 a.
dwxw (wiéxu
ha?» Euflmwxmw~»¢w>&?«
:¢dw&m§.5«.§u3m
r3: i‘( am (‘N‘ m:
{ea} ”<33.st (am amine-«333
n43. van
64/78
A
125I-TIM3 Ab Standard Curve
2000000
1500000
0. 9935
0. 1000000
500000
0 5 10 15 20 25
125l-11M3 Ab (nM)
Y=mX+b
Y = 80220(1nM) + 899.3
Y = 81119.3
1nM125l-Ab = 3 cpm
Slope 80220 i 1526
Y-intercept when X=0.0 899.3 i 11140
65/78
”59.5
.80... mmz 9%me m2?
a... gr x:
mN o.c.>u.
£8 x ii ON €8.24. ‘3.{t\‘xtz‘tsqktétx .2.
w vmmxw..um.\. WAX
05 me ma 3:33:2 ummmwaxw8>o
:0 m2: .9 308.88
$5 056019 \\§\§§\\\\\§§\x\\x\ g§§§§§$§§i§ wxxxx§§§§§§§§§¥§§§x§§§ OH m._>_:._§w._m~H 5...: Q”3%; mm“
* m
85 5.:
03$,“ 9mm... 3m.mm~
. \ \xl‘tx\t‘§2:w§§§t§\¥$<t§ ..o0 o
MEN ON.O mac OH.° mod CO
.0 EEE<
.0:— Punoq qv s-wu—nue-Im salowu
mEuEm
.80... mmz 9...“.me \
x! x?
m__8 §\\\\“§“§\ u §§§é§W§§§§§§V§§§K§ >uo£E< ..xxww‘“ vii::\\tt2n§@3\r$\WA.ww\.\\‘\
\ En
010 me v N\\\...\« «Key.
c0 m2... w-2_b:cm-_m= \t3»thE\u.t:$.$\$\w\.. 92.... 3‘“ 20589.
3£OIU \Xx‘firtm N ..>.¢ .°\
. . N
cmEs... 2: ttozzuu$§$wvxx owfiiv
NmNO WONOWWmmoaodm o
mo CO
Ho .
. .0 0
D.u n oq qV CL.wmlU e.l S3 0|W U
.33 32 2:0me
6. + L1 mgngwm
mé ucfimka
>8£E< . g 03.4»
V53 % Ozn g
@2529? a 4N :8
8:8 . Eu
22: 28331
wood 8
o 80.0 Sod 80.0
Wnw. W. 9Wwu.ue_Ig SmOw
.23 mmz 2:88
.0. .i. .a. rte
xomH <
N owmdfi
Locoo m-§:.._Em-_§ n
m-_>:._. H $53 Eu
o 2058mm
67/78
:59: v09:
.wH.m_>_: 85:8 ._o:coo
$.29 cm
0: 830$ 8302
I UIEB
«SN 42338.0 Agmaow
.0: A- as
£98 man ”Ba cozmbcoocoo
528:: 29.5
0008 ooocv cocoa
WO 13818 PCT/U52017/041946
68/78
amm-m.HOm_.wH.m$_F 8w
0: 0.6
UH. I I
MEN 455385 45538
.0: A- pm
42333 mam
”as”: 559.2858
.5385 .2me
oooov oooom oooow 082‘
W.d2)
69/78
meOm—r—
JOSCOU
£02 — waywamz:
,5. :\\\§ é:
cm oH
.07.—
H :Ema
ad ameaozz
70/78
«09; 69;
m.H0m_.wH.m—>:._. ”6:28 “wozcoo
on 830% $309
_\_.» “xxx vx“
7c. 455385 4Exmaom
.0: A- um
453:8 mam
”Ba COSEucoucoo
523:: macaw
ooow O 0 o
E .3. 8
flux/5d) 5N5!
71/78
T|M3.18.|gGl.3 NoAb lsotype
m [:1 m
////////A
*7///////////////////////A
J 7////////////////////////A
3000 2000 1000
(1w/5d) 5'N:ll
72/78
TIM-3 Coma-PFMn
1..,..,.“Fwy".,.,.,..‘...:.Y.r,.,..,.
m a: a: c: c> c:
2 as (0 v m
span a; 932$me
C0206 3
’36 513mm
437342492 31:
. ..“»«w-»
"\m“."MW
‘v.‘si\-
.v.‘\
..~.““»..\.~“»n.
\....\~~~..‘“_‘
Em$~8¢.33: 0
995% Q1. 9345815“de
CD163 N3
3‘32;
N ..“N...~.\.~w~\
“www - .“WNW.
mam““mu. . .. . q\\\\\s~\\v~\
. . .w\\\\. . .u.
\\\\c “h
waw o; pszggmum
73/78
oz 330m. m.H0m_.wH.m_>:._.
a D \\\\\\\\\
mwmvfim
.oooo~ Hooomfi woooofi
W0 13818 PCT/U$2017/041946
74/78
WO 13818 PCT/U52017/041946
75/78
76/78
coamNmaEwE. §
«3:3» an
mcwwwzofio yfificfiw 333$: Eammfificm
§ a x
‘ \\ K \ \
-~--‘
u§mm\u\w\w‘vv~uummmwwv §»\\§\\\“~ A“
wwmfifi gmznwvwfifi
«w\no.w.H.
77/78
wwvuéomz Dmsocm35-wwvm<-Oo©Z
LY hr
com oov can D
nu; 15 mean:
.07.— cw
8E<m35 Ecoconc-mmi<-m§o E :E?
. m vmcocmsa-wm§<-m<m
3.9 F‘—
i. § 32.
con con 93
'30! '15 UESW mu! 1:! ueam
78/78
RXGSV
393 0F
FIG. “WLRTUERQWY” RYWHKE "’WQWGMNOEKFNLKLW
Hum-Kw”,N»,.
39A 3A3
“’RffiiFGiMHQEKFflLKL‘
SEQUENCE LISTING
<110> BRISTOL-MYERS SQUIBB COMPANY
<120> ANTIBODIES AGAINST TIM3 AND USES THEREOF
<130> 3338.052PC02/ELE/C-K/DKC
<150> US 62/459,499
<151> 201715
<150> US 62/362,541
<151> 201614
<160> 385
<170> PatentIn version 3.5
<210> 1
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 IgG1.1f HC
<400> 1
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 2
<211> 447
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8B9 IgG1.1f HC
<400> 2
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 3
<211> 447
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 8C4 IgG1.1f HC
<400> 3
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 4
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> dy 17C3 IgG1.1f HC
<400> 4
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 5
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 IgG1.1f HC
<400> 5
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 6
<211> 454
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 3G4 IgG1.1f HC
<400> 6
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly Lys
<210> 7
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 17C8 IgG1.1f HC
<400> 7
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 8
<211> 452
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 f HC (no C-terminal K)
<400> 8
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 9
<211> 446
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8B9 IgG1.1f HC (no C-terminal K)
<400> 9
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 10
<211> 446
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8C4 f HC (no C-terminal K)
<400> 10
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 11
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 17C3 IgG1.1f HC (no C-terminal K)
<400> 11
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 12
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 IgG1.1f HC (no C-terminal K)
<400> 12
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 13
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 3G4 IgG1.1f HC (no C-terminal K)
<400> 13
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly
<210> 14
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 17C8 IgG1.1f HC (no C-terminal K)
<400> 14
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 15
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 IgG1.3f HC
<400> 15
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 16
<211> 447
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8B9 IgG1.3f HC
<400> 16
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 17
<211> 447
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8C4 IgG1.3f HC
<400> 17
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 18
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 17C3 IgG1.3f HC
<400> 18
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 19
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 IgG1.3f HC
<400> 19
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 20
<211> 454
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 3G4 IgG1.3f HC
<400> 20
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly Lys
<210> 21
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> dy 17C8 IgG1.3f HC
<400> 21
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 22
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 IgG1.3f HC (no C-terminal K)
<400> 22
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 23
<211> 446
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9 f HC (no C-terminal K)
<400> 23
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 24
<211> 446
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 8C4 IgG1.3f HC (no C-terminal K)
<400> 24
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 25
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 17C3 IgG1.3f HC (no C-terminal K)
<400> 25
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 26
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 9F6 IgG1.3f HC (no C-terminal K)
<400> 26
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 27
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 3G4 IgG1.3f HC (no C-terminal K)
<400> 27
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly
<210> 28
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 17C8 IgG1.3f HC (no C-terminal K)
<400> 28
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 29
<211> 215
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3, 17C3, 3G4 LC
<400> 29
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala
100 105 110
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
115 120 125
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
130 135 140
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145 150 155 160
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
165 170 175
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
180 185 190
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
195 200 205
Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 30
<211> 215
<212> PRT
<213> cial Sequence
<220>
<223> dy 8B9, 8C4, 17C8 LC
<400> 30
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
100 105 110
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
115 120 125
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
130 135 140
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145 150 155 160
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
165 170 175
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
180 185 190
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
195 200 205
Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 31
<211> 215
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 (VK3) LC
<400> 31
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala
100 105 110
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
115 120 125
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
130 135 140
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145 150 155 160
Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
165 170 175
Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
180 185 190
Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
195 200 205
Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 32
<211> 214
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 (VK1) LC
<400> 32
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
<210> 33
<211> 214
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 (VK2) LC
<400> 33
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
<210> 34
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 VH
<400> 34
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 35
<211> 117
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8B9 VH
<400> 35
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
<210> 36
<211> 117
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8C4 VH
<400> 36
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
<210> 37
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 17C3 VH
<400> 37
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 38
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 VH
<400> 38
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser
115 120
<210> 39
<211> 124
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 3G4 VH
<400> 39
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 40
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 17C8 VH
<400> 40
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 41
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 CDR1 (VH)
<400> 41
Ser Arg Ser Tyr Tyr Trp Gly
1 5
<210> 42
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9 CDR1 (VH)
<400> 42
Arg His Tyr Trp Asn
1 5
<210> 43
<211> 5
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8C4 CDR1 (VH)
<400> 43
Arg Tyr Tyr Trp Ser
1 5
<210> 44
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 17C3 CDR1 (VH)
<400> 44
Ser Tyr Tyr Met His
1 5
<210> 45
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 CDR1 (VH)
<400> 45
Asp Tyr Tyr Met Ser
1 5
<210> 46
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 CDR2 (VH)
<400> 46
Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 47
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9 CDR2 (VH)
<400> 47
Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys Ser
1 5 10 15
<210> 48
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8C4 CDR2 (VH)
<400> 48
Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 49
<211> 17
<212> PRT
<213> cial Sequence
<220>
<223> dy 17C3 CDR2 (VH)
<400> 49
Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe Gln
1 5 10 15
<210> 50
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 CDR2 (VH)
<400> 50
Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
<210> 51
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 3G4 CDR2 (VH)
<400> 51
Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
<210> 52
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 17C8 CDR2 (VH)
<400> 52
Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15
<210> 53
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 CDR3 (VH)
<400> 53
Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
1 5 10
<210> 54
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9 CDR3 (VH)
<400> 54
Asp Thr Gly Tyr Tyr Gly Met Asp Ile
1 5
<210> 55
<211> 9
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8C4 CDR3 (VH)
<400> 55
Asp Thr Gly Tyr Tyr Gly Met Asp Val
1 5
<210> 56
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 17C3 CDR3 (VH)
<400> 56
Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 57
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 CDR3 (VH)
<400> 57
Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
1 5 10
<210> 58
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 3G4 CDR3 (VH)
<400> 58
Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp Val
1 5 10 15
<210> 59
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 17C8 CDR3 (VH)
<400> 59
Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
1 5 10
<210> 60
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3, 17C3, 3G4 VL
<400> 60
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105
<210> 61
<211> 108
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9, 8C4, 17C8 , 9F6 (VK3) VL
<400> 61
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 62
<211> 107
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 (VK1) VL
<400> 62
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala
25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
40 45
Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 63
<211> 107
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 (VK2) VL
<400> 63
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
40 45
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 64
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3, 8B9, 8C4, 17C3, 9F6 (VK2, VK3), 3G4, 17C8 CDR1
<400> 64
Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10
<210> 65
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 9F6 (VK1) CDR1 (VL)
<400> 65
Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala
1 5 10
<210> 66
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3, 8B9, 8C4, 17C3, 9F6 (VK2, VK3), 3G4, 17C8 CDR2
<400> 66
Gly Ala Ser Ser Arg Ala Thr
1 5
<210> 67
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK1) CDR2 (VL)
<400> 67
Asp Ala Ser Ser Leu Glu Ser
1 5
<210> 68
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3, 17C3, 3G4 CDR3 (VL)
<400> 68
Gln Gln Tyr Gly Ser Ser Pro Ile Thr
1 5
<210> 69
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9, 8C4, 9F6 (VK3), 17C8 CDR3 (VL)
<400> 69
Gln Gln Tyr Gly Ser Ser Pro Leu Thr
1 5
<210> 70
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK1) CDR3 (VL)
<400> 70
Gln Gln Phe Asn Ser Tyr Pro Arg Thr
1 5
<210> 71
<211> 8
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 (VK2) CDR3 (VL)
<400> 71
Gln Gln Tyr Gly Ser Ser Leu Thr
1 5
<210> 72
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q) IgG1.1f HC
<400> 72
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 73
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> dy 13A3 (N60S) IgG1.1f HC
<400> 73
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 74
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60A) IgG1.1f HC
<400> 74
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 75
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.1f HC
<400> 75
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 76
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.1f HC
<400> 76
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 77
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 ) IgG1.1f HC
<400> 77
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 78
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (P102L) IgG1.1f HC
<400> 78
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 79
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.1f HC
<400> 79
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 80
<211> 447
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 8B9 (S61P) IgG1.1f HC
<400> 80
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 81
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 9F6 (A108T) IgG1.1f HC
<400> 81
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 82
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60Q) IgG1.1f HC (no C-terminal K)
<400> 82
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 83
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60S) IgG1.1f HC (no C-terminal K)
<400> 83
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 84
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60A) IgG1.1f HC (no C-terminal K)
<400> 84
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 85
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (D101E) IgG1.1f HC (no C-terminal K)
<400> 85
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 86
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (P102V) IgG1.1f HC (no C-terminal K)
<400> 86
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 87
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.1f HC (no C-terminal K)
<400> 87
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 88
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.1f HC (no C-terminal K)
<400> 88
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 89
<211> 452
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.1f HC (no C-terminal K)
<400> 89
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 90
<211> 446
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 8B9 (S61P) IgG1.1f HC (no C-terminal K)
<400> 90
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 91
<211> 452
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 (A108T) IgG1.1f HC (no C-terminal K)
<400> 91
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 92
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (N60Q) IgG1.3f HC
<400> 92
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 93
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60S) IgG1.3f HC
<400> 93
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 94
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60A) IgG1.3f HC
<400> 94
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 95
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (D101E) IgG1.3f HC
<400> 95
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 96
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (P102V) IgG1.3f HC
<400> 96
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 97
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.3f HC
<400> 97
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 98
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.3f HC
<400> 98
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 99
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.3f HC
<400> 99
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 100
<211> 447
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8B9 (S61P) IgG1.3f HC
<400> 100
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 101
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 ) IgG1.3f HC
<400> 101
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 102
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q) f HC (no C-terminal K)
<400> 102
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 103
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60S) IgG1.3f HC (no C-terminal K)
<400> 103
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 104
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60A) IgG1.3f HC (no C-terminal K)
<400> 104
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 105
<211> 452
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (D101E) IgG1.3f HC (no C-terminal K)
<400> 105
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 106
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (P102V) IgG1.3f HC (no C-terminal K)
<400> 106
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 107
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102Y) f HC (no C-terminal K)
<400> 107
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 108
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102L) f HC (no C-terminal K)
<400> 108
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 109
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.3f HC (no C-terminal K)
<400> 109
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 110
<211> 446
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8B9 (S61P) IgG1.3f HC (no C-terminal K)
<400> 110
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 111
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 9F6 ) IgG1.3f HC (no C-terminal K)
<400> 111
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 112
<211> 123
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60Q) VH
<400> 112
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 113
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60S) VH
<400> 113
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 114
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60A) VH
<400> 114
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 115
<211> 123
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (D101E) VH
<400> 115
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 116
<211> 123
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 13A3 (P102V) VH
<400> 116
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 117
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (P102Y) VH
<400> 117
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 118
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (P102L) VH
<400> 118
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 119
<211> 123
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, P102Y) VH
<400> 119
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 120
<211> 117
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8B9 (S61P) VH
<400> 120
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
<210> 121
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 (A108T) VH
<400> 121
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 122
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q); 13A3 (N60Q, P102Y); 13A3 (N60Q, D101E) CDR2
<400> 122
Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser Leu Lys Ser
1 5 10 15
<210> 123
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60S) CDR2 (VH)
<400> 123
Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser Leu Lys Ser
1 5 10 15
<210> 124
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60A) CDR2 (VH)
<400> 124
Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser Leu Lys Ser
1 5 10 15
<210> 125
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) CDR2 (VH)
<400> 125
Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15
<210> 126
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (D101E); 13A3 (N60Q, D101E) CDR3 (VH)
<400> 126
Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
1 5 10
<210> 127
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102V) CDR3 (VH)
<400> 127
Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
1 5 10
<210> 128
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102Y); 13A3 (N60Q, P102Y) CDR3 (VH)
<400> 128
Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
1 5 10
<210> 129
<211> 13
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (P102L) CDR3 (VH)
<400> 129
Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
1 5 10
<210> 130
<211> 330
<212> PRT
<213> Artificial Sequence
<220>
<223> All antibodies HC nt Domain (IgG1.1f)
<400> 130
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 131
<211> 329
<212> PRT
<213> Artificial Sequence
<220>
<223> All dies HC Constant Domain (IgG1.1f) (no C-terminal K)
<400> 131
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly
<210> 132
<211> 330
<212> PRT
<213> Artificial ce
<220>
<223> All antibodies HC Constant Domain (IgG1.3f)
<400> 132
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 133
<211> 329
<212> PRT
<213> Artificial Sequence
<220>
<223> All antibodies HC Constant Domain 3f) (no C-terminal K)
<400> 133
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly
<210> 134
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 IgG1.1f HC
<400> 134
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt agag tcgagtcacc atatccgttg ccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc gttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
gggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt cagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct gcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac ccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg gcca agacaaagcc gcgggaggag
aaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg ccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg tccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 135
<211> 1344
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 IgG1.1f HC
<400> 135
caggtgcagc agtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggaactggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca gcac caactacaat
tcctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agatactggg
tactacggta tggacatctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
agca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt
actc acacatgccc accgtgccca gcacctgaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
gtgg tggacgtgag ccacgaagac gtca agttcaactg ggac
ggcgtggagg tgcataatgc aaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat agga gatgaccaag
gtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc
gacggctcct tcttcctcta tagcaagctc accgtggaca ggtg gcagcagggg
ttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
ctctccctgt ccccgggtaa atga
<210> 136
<211> 1344
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 f HC
<400> 136
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg cagt cgttactact ggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca ctgggagcac caactacaac
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgac gggc
tactacggta tggacgtctg gggccaaggg accacggtca cctc agctagcacc
aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg
ggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac ctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
tgcgtggtgg tggacgtgag agac cctgaggtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga caag
gtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca agcc caac tacaagacca cgcctcccgt gctggactcc
gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
ctctccctgt gtaa atga
<210> 137
<211> 1362
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 17C3 IgG1.1f HC
<400> 137
caggtgcagt tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg catctggata cacc agctactata tgcactgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggaata atcaacccta ggggtgatag cataatctac
gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatttc
tatggttcgg gaaactacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc aagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga tcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg agcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc ggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga cagg ccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg agtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa ctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 138
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 IgG1.1f HC
<400> 138
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ggct
ccagggaagg ggctggagtg attc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcgctgttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt attactgtgc tggc
tatagcagtg gctggtacta ctacggtatg gacgtctggg gccaagggac cgcggtcacc
tcag ccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
tcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc gcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg tccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta cacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 139
<211> 1365
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 3G4 IgG1.1f HC
<400> 139
caggtgcagc tggtggagtc aggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtacta gtggtagtat catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat
ctgcaaatga acagcctgag agccgaggac acggctgtgt gtgc gagagaaggg
tatagcagca gctggtccta ctactacggt atggacgtct ggggccaagg gaccacggtc
accgtctcct cagctagcac caagggccca tcggtcttcc ccctggcacc ctcctccaag
agcacctctg cagc ggccctgggc tgcctggtca aggactactt ccccgaaccg
gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc
ctacagtcct caggactcta ctccctcagc gtga ccgtgccctc cagcagcttg
caga cctacatctg caacgtgaat ccca gcaacaccaa ggtggacaag
agagttgagc cttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa
gccgaagggg ccccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc
tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg
ctgaatggca aggagtacaa gtgcaaggtc aaag ccctcccaag cgag
aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca
tcccgggagg agatgaccaa gaaccaggtc acct gcctggtcaa aggcttctat
cccagcgaca tgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc ttcttcctct atagcaagct caccgtggac
aagagcaggt aggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac
aaccactaca cgcagaagag cctctccctg ggta aatga
<210> 140
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C8 IgG1.1f HC
<400> 140
cagc tggtggagtc tgggggaggc ttggtcaagc ggtc cctgagactc
tcctgtgcag gatt caccttcagt gactactaca tgagctggat ccgccaggct
aagg ggctggagtg ggtttcattc attagtagta gtggtagtat catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggg
tatagcagtg gctgggagta tatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga tcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca gctg
aagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg ccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta cacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac caag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc aaat ga
<210> 141
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3 IgG1.1f HC (no C-terminal K)
<400> 141
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg ccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg attg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc ctgc ctggtcaagg actacttccc ggtg
acggtgtcgt ggaactcagg cgccctgacc gtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg catg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga agaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
tggc agcaggggaa cgtcttctca gtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 142
<211> 1341
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 IgG1.1f HC (no inal K)
<400> 142
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca gtggaagcac caactacaat
tcctccctca gagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agatactggg
tactacggta tggacatctg gggccaaggg accacggtca ccgtctcctc cacc
aagggcccat cggtcttccc cctggcaccc aaga ctgg gggcacagcg
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aatc acaagcccag caacaccaag gtggacaaga gagttgagcc ttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc caca
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca agcc ggagaacaac acca cgcctcccgt gctggactcc
tcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
ctctccctgt ccccgggttg a
<210> 143
<211> 1341
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 IgG1.1f HC (no inal K)
<400> 143
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
actg tctctggtgg ctccatcagt cgttactact ggagctggat ccggcagccc
ccagggaagg agtg gattgggtat atccattaca gcac caactacaac
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca cctg
aagctgagct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgac agatacgggc
tactacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc accc tcctccaaga gcacctctgg gggcacagcg
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg agac ctacatctgc
aacgtgaatc acaagcccag caacaccaag aaga gagttgagcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc agtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg acaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc gcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc
gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
ttct ccgt gatgcatgag gctctgcaca accactacac gcagaagagc
ctgt ccccgggttg a
<210> 144
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 17C3 IgG1.1f HC (no C-terminal K)
<400> 144
caggtgcagt tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg catctggata cacc tata tgcactgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggaata ccta ggggtgatag cataatctac
gcacagaagt tccagggcag agtcaccatg accagggaca cgag cacagtctac
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc tttc
tatggttcgg gaaactacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct gcaa tcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
tggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc tgcc tggtcaaagg cttctatccc
atcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa ctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc gcct gtcc ccgggttga
<210> 145
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 IgG1.1f HC (no C-terminal K)
<400> 145
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg catc tccagggaca acgccaagaa ctcgctgttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt gtgc gagagatggc
tatagcagtg gctggtacta ctacggtatg tggg gccaagggac cgcggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt cagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg agcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtg ctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
gaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc tga
<210> 146
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 3G4 IgG1.1f HC (no C-terminal K)
<400> 146
cagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtacta gtggtagtat catatactac
gcagactctg tgaagggccg catc tccagggaca acgccaagaa ctcactgtat
ctgcaaatga tgag agccgaggac acggctgtgt attactgtgc gagagaaggg
tatagcagca ccta ctactacggt atggacgtct ggggccaagg gaccacggtc
accgtctcct cagctagcac caagggccca tcggtcttcc ccctggcacc caag
agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccg
gtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc
ctacagtcct caggactcta ctccctcagc gtga ccgtgccctc cagcagcttg
ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag
gagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa
gccgaagggg ccccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc
tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca cgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg
ctgaatggca aggagtacaa ggtc tccaacaaag ccctcccaag cagcatcgag
aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca
tcccgggagg agatgaccaa gaaccaggtc agcctgacct tcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc ttcttcctct agct caccgtggac
aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac
aaccactaca cgcagaagag cctctccctg tccccgggtt ga
<210> 147
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C8 IgG1.1f HC (no C-terminal K)
<400> 147
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
gcag gatt caccttcagt taca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtagta gtggtagtat catatactac
tctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggg
tatagcagtg gctgggagta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca gctg
aatggcaagg agtacaagtg ctcc aacaaagccc tcccaagcag gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca gtga tgcatgaggc tctgcacaac
cactacacgc gcct ctccctgtcc ccgggttga
<210> 148
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 IgG1.3f HC
<400> 148
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg ccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc accg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt gaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc accc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
gaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg agtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc gcct ctccctgtcc aaat ga
<210> 149
<211> 1343
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 8B9 IgG1.3f HC
<400> 149
aggtgcagct gcaggagtcg ggcccaggac tggtgaagcc ttcggagacc ctca
cctgcactgt ctctggtggc tccatcagtc actg gaactggatc cggcagcccc
cagggaaggg gtgg attgggtata tccattacag tggaagcacc aactacaatt
cctccctcaa gagtcgagtc tcag tagacacgtc caagaaccag ttctccctga
agctgagctc tgtgaccgct gcggacacgg ccgtgtatta ctgtgcgaga gggt
actacggtat ggacatctgg ggccaaggga ccacggtcac cgtctcctca gctagcacca
agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg
ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg tggaactcag
gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact
ccctcagcag cgtggtgacc gtgccctcca tggg gacc tacatctgca
acgtgaatca caagcccagc aacaccaagg tggacaagag agttgagccc aaatcttgtg
acaaaactca cacatgccca ccgtgcccag cacctgaagc cgaaggggcc ccgtcagtct
tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat
gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg
gcgtggaggt gcataatgcc aagc cgcgggagga gcagtacaac agcacgtacc
gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt
gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag
ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag atgaccaaga
accaggtcag cctgacctgc ctggtcaaag atcc catc gccgtggagt
gggagagcaa gccg gagaacaact acaagaccac gcctcccgtg ctggactccg
acggctcctt ctat agcaagctca ccgtggacaa gagcaggtgg cagcagggga
acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc
tctccctgtc cccgggtaaa tga
<210> 150
<211> 1344
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 IgG1.3f HC
<400> 150
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgttactact ggagctggat ccggcagccc
aagg gactggagtg gattgggtat atccattaca ctgggagcac caactacaac
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc agcggacacg tatt actgtgcgac agatacgggc
tactacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc accc tcctccaaga gcacctctgg agcg
ggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc ttgt
gacaaaactc acacatgccc accgtgccca gaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccc tgaggtcaca
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa
cccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa tatc ccagcgacat cgccgtggag
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt ctcc
gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt tgag gctctgcaca acac gcagaagagc
ctctccctgt gtaa atga
<210> 151
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C3 IgG1.3f HC
<400> 151
caggtgcagt tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg catctggata cactttcacc agctactata tgcactgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggaata atcaacccta atag cataatctac
gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac
atggagctga gcagcctgag atctgaggac acggccgtgt gtgc gagagatttc
tatggttcgg gaaactacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc ggtg
acggtgtcgt ggaactcagg gacc agcggcgtgc tccc ggctgtccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca accg tgtggtcagc gtcctcaccg tcctgcacca gctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
gaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 152
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 IgG1.3f HC
<400> 152
caggtgcagc tggtggagtc aggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg agtg ggtttcattc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg catc tccagggaca agaa ctcgctgttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt attactgtgc gagagatggc
tatagcagtg acta ctacggtatg gacgtctggg gccaagggac cgcggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc gagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg agaacaacta caagaccacg
cctcccgtgc ccga cggctccttc ttcctctata gcaagctcac caag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 153
<211> 1365
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 3G4 IgG1.3f HC
<400> 153
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag gatt caccttcagt gactactaca tgagctggat ggct
ccagggaagg ggctggagtg ggtttcattc attagtacta gtggtagtat catatactac
gcagactctg tgaagggccg catc gaca acgccaagaa ctcactgtat
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagaaggg
tatagcagca gctggtccta ctactacggt atggacgtct ggggccaagg gaccacggtc
accgtctcct cagctagcac ccca tcggtcttcc cacc ctcctccaag
agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccg
gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc
tcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg
caga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag
agagttgagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa
gccgaagggg ccccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc
tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga aaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ggtc agcgtcctca ccgtcctgca ccaggactgg
ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag cagc ccccatcgag
aaaaccatct ccaaagccaa gccc cgagaaccac aggtgtacac cctgccccca
tcccgggagg agatgaccaa gaaccaggtc agcctgacct tcaa aggcttctat
gaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc ttcttcctct atagcaagct caccgtggac
aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac
aaccactaca cgcagaagag cctctccctg tccccgggta aatga
<210> 154
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C8 IgG1.3f HC
<400> 154
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc actc
tcctgtgcag cctctggatt cagt taca ggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtagta gtggtagtat catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat
atga acagcctgag agccgaggac acggctgtgt attactgtgc tggg
agtg gctgggagta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg acca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc cccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
atcg agtg ggagagcaat gggcagccgg acta caagaccacg
cctcccgtgc tggactccga cggctccttc tata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 155
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 IgG1.3f HC (no C-terminal K)
<400> 155
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
actg tctctggtgg ctccatcagc agtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
tacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt cagg cgccctgacc agcggcgtgc tccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag gggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt gaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cctg aggtcacatg cgtggtggtg agcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
aaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 156
<211> 1340
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 8B9 IgG1.3f HC (no C-terminal K)
<400> 156
aggtgcagct gcaggagtcg ggcccaggac tggtgaagcc ttcggagacc ctgtccctca
cctgcactgt ctctggtggc tccatcagtc gtcactactg gatc cggcagcccc
cagggaaggg actggagtgg attgggtata acag tggaagcacc aactacaatt
cctccctcaa gagtcgagtc accatatcag tagacacgtc caagaaccag ttctccctga
agctgagctc tgtgaccgct gcggacacgg ccgtgtatta ctgtgcgaga gatactgggt
actacggtat ggacatctgg ggccaaggga ccacggtcac cgtctcctca gctagcacca
catc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg
ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg tggaactcag
gcgccctgac cagcggcgtg ttcc cggctgtcct acagtcctca ggactctact
ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tgca
acgtgaatca caagcccagc aacaccaagg tggacaagag agttgagccc aaatcttgtg
acaaaactca cacatgccca ccag cacctgaagc cgaaggggcc ccgtcagtct
tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat
gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg
gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac tacc
tcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt
gcaaggtctc caacaaagcc ctcccagccc agaa aaccatctcc aaagccaaag
ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag atgaccaaga
accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt
gggagagcaa tgggcagccg gagaacaact acaagaccac cgtg ctggactccg
acggctcctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg cagcagggga
acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc
tctccctgtc cccgggttga
<210> 157
<211> 1341
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 IgG1.3f HC (no C-terminal K)
<400> 157
caggtgcagc agtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgttactact ggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca ctgggagcac caactacaac
ccctccctca agagtcgagt caccatatca acgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgac agatacgggc
tactacggta tctg gggccaaggg accacggtca ccgtctcctc agctagcacc
ccat tccc accc tcctccaaga gcacctctgg gggcacagcg
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga gcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc ccag caacaccaag gtggacaaga gagttgagcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc caca
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaa
cccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca cctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc
tcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt gatgcatgag gctctgcaca acac gcagaagagc
ctctccctgt ccccgggttg a
<210> 158
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C3 f HC (no C-terminal K)
<400> 158
cagt tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
tcctgcaagg catctggata cactttcacc agctactata tgcactgggt gcgacaggcc
cctggacaag ggcttgagtg aata atcaacccta atag cataatctac
gcacagaagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatttc
tatggttcgg gaaactacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg ggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca accg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg ccct gcccccatcc
cgggaggaga tgaccaagaa cagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg acta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
tggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 159
<211> 1359
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 9F6 IgG1.3f HC (no C-terminal K)
<400> 159
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg attcaccatc gaca acgccaagaa ctcgctgttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt attactgtgc gagagatggc
tatagcagtg gctggtacta ctacggtatg tggg gccaagggac cgcggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc ggtg
tcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
ccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa cagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg caat ccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc tga
<210> 160
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 3G4 IgG1.3f HC (no C-terminal K)
<400> 160
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt taca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtacta gtggtagtat catatactac
tctg tgaagggccg catc tccagggaca acgccaagaa ctcactgtat
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagaaggg
tatagcagca gctggtccta ctactacggt atggacgtct ggggccaagg gaccacggtc
accgtctcct cagctagcac caagggccca tcggtcttcc ccctggcacc ctcctccaag
agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccg
gtgacggtgt cgtggaactc aggcgccctg ggcg tgcacacctt cccggctgtc
tcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg
ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag
agagttgagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa
gggg ccccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc
tcccggaccc ctgaggtcac ggtg gtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag
taca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg
ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc cgag
aaaaccatct ccaaagccaa agggcagccc cgagaaccac acac cctgccccca
tcccgggagg agatgaccaa gaaccaggtc agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc ttcttcctct atagcaagct caccgtggac
aagagcaggt ggcagcaggg cttc tcatgctccg tgatgcatga ggctctgcac
aaccactaca agag cctctccctg tccccgggtt ga
<210> 161
<211> 1359
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 17C8 IgG1.3f HC (no C-terminal K)
<400> 161
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtagta gtggtagtat catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat
ctgcaaatga tgag agccgaggac acggctgtgt attactgtgc gagagatggg
tatagcagtg gctgggagta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ccaa atcg gtcttccccc tggcaccctc ctccaagagc
gggg gcacagcggc ctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg gacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
ccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc cccc catcgagaaa
accatctcca aagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 162
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3, 17C3, 3G4 LC
<400> 162
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
ttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
cctgaagatt tgta ttactgtcag cagtatggta gctcaccgat caccttcggc
caagggacac gactggagat taaacgtacg gtggctgcac catctgtctt catcttcccg
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc
agag aggccaaagt gaag gtggataacg aatc gggtaactcc
caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg
agca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag
ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag
<210> 163
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9, 8C4, 17C8 LC
<400> 163
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
ttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcacctct cactttcggc
ggagggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc
tatcccagag aggccaaagt acagtggaag aacg ccctccaatc gggtaactcc
agtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag
agct tcac cttc ggag agtgttag
<210> 164
<211> 648
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK3) LC
<400> 164
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ggga cacc
ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
ttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcaccgct cactttcggc
ggagggacca aggtggagat caaacgtacg gtggctgcac catctgtctt catcttcccg
ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc
tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc
caggagagtg tcacagagca ggacagcaag gacagcacct tcag cagcaccctg
acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag
ggcctgagct cgcccgtcac cttc aacaggggag agtgttag
<210> 165
<211> 645
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 9F6 (VK1) LC
<400> 165
gccatccagt agtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
tgcc gggcaagtca gggcattagc agtgctttag cctggtatca gcagaaacca
gggaaagctc tcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag gcct
gaagattttg caacttatta ctgtcaacag tttaatagtt accctcggac gttcggccaa
gggaccaagg tggaaatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca
tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc
ctgagctcgc ccgtcacaaa gagcttcaac gagt gttag
<210> 166
<211> 645
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 9F6 (VK2) LC
<400> 166
gaaattgtgt tgacgcagtc tccaggcacc ttgt ctccagggga cacc
ctctcctgca gggccagtca gagtgttagc agcagctact ggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat tcca gcagggccac tggcatccca
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcactcac tttcggcgga
gggaccaagg tggagatcaa acgtacggtg gctgcaccat tcat cttcccgcca
tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag
gtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag
<210> 167
<211> 369
<212> DNA
<213> cial ce
<220>
<223> Antibody 13A3 VH
<400> 167
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
ccgt ccctcaagag tcgagtcacc gttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg attg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctca
<210> 168
<211> 351
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 VH
<400> 168
caggtgcagc tgcaggagtc agga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggaactggat ccggcagccc
ccagggaagg gactggagtg gtat atccattaca gtggaagcac caat
tcctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agatactggg
tactacggta tggacatctg gggccaaggg accacggtca cctc a
<210> 169
<211> 351
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 8C4 VH
<400> 169
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgttactact ggagctggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca ctgggagcac caactacaac
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca cctg
aagctgagct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgac agatacgggc
tactacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc a
<210> 170
<211> 369
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 17C3 VH
<400> 170
caggtgcagt tggtgcagtc tggggctgag gtgaagaagc cctc agtgaaggtc
tcctgcaagg catctggata cactttcacc tata tgcactgggt gcgacaggcc
cctggacaag ggcttgagtg gatgggaata atcaacccta atag cataatctac
aagt tccagggcag agtcaccatg accagggaca cgtccacgag cacagtctac
ctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagatttc
tatggttcgg gaaactacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctca
<210> 171
<211> 375
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 VH
<400> 171
cagtgtcagg tgcagctggt ggagtctggg ggaggcttgg tcaagcctgg agggtccctg
agactctcct gtgcagcctc tggattcacc gact actacatgag ctggatccgc
caggctccag ggaaggggct ggagtgggtt tcattcatta gtggtggtgg tagtaccata
tactacgcag actctgtgaa gggccgattc accatctcca gggacaacgc caagaactcg
ctgtttctgc aaatgaacag cctgagagtc gaggacacgg ctgtgtatta gaga
gatggctata gcagtggctg gtactactac ggtatggacg tctggggcca agggaccgcg
gtcaccgtct cctca
<210> 172
<211> 378
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 3G4 VH
<400> 172
cagtgtcagg tgcagctggt ggagtctggg ggaggcttgg ctgg agggtccctg
agactctcct gtgcagcctc tggattcacc ttcagtgact actacatgag ctggatccgc
ccag ggaaggggct ggagtgggtt tcattcatta gtactagtgg tagtatcata
tactacgcag actctgtgaa gggccgattc accatctcca gggacaacgc caagaactca
ctgtatctgc aaatgaacag cctgagagcc gaggacacgg ctgtgtatta ctgtgcgaga
gaagggtata gcagcagctg gtcctactac tacggtatgg acgtctgggg ccaagggacc
acggtcaccg tctcctca
<210> 173
<211> 375
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C8 VH
<400> 173
cagtgtcagg tggt ggagtctggg ggaggcttgg ctgg agggtccctg
agactctcct gtgcagcctc tggattcacc ttcagtgact actacatgag ccgc
caggctccag ggaaggggct ggagtgggtt tcattcatta gtgg tagtatcata
tactacgcag actctgtgaa gggccgattc accatctcca acgc caagaactca
ctgtatctgc acag cctgagagcc gaggacacgg ctgtgtatta ctgtgcgaga
gatgggtata gcagtggctg ggagtactac ggtatggacg tctggggcca agggaccacg
gtcaccgtct cctca
<210> 174
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 CDR1 (VH) and variants (N60Q; N60S; N60A; D101E;
P102V; P102Y; P102L; N60Q and P102Y; 13A3 (N60Q, D101E))
<400> 174
agtagaagtt gggg c
<210> 175
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 CDR1 (VH) and 8B9 (S61P) variant
<400> 175
cgtcactact ggaac
<210> 176
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 CDR1 (VH)
<400> 176
cgttactact ggagc
<210> 177
<211> 15
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 17C3 CDR1 (VH)
<400> 177
agctactata tgcac
<210> 178
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 CDR1 (VH), 9F6 (A108T) variant, 3G4 and 17C8
<400> 178
gactactaca tgagc
<210> 179
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 CDR2 (VH) and variants (D101E, P102V, P102Y, and
P102L)
<400> 179
agtatctatt ggtt cacctactac aacccgtccc gt
<210> 180
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 CDR2 (VH)
<400> 180
tatatccatt gaag caccaactac aattcctccc tcaagagt
<210> 181
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 CDR2 (VH)
<400> 181
tatatccatt acactgggag caccaactac aacccctccc tcaagagt
<210> 182
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C3 CDR2 (VH)
<400> 182
ataatcaacc gtga tagcataatc tacgcacaga agttccaggg c
<210> 183
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 CDR2 (VH) and 9F6 (A108T) variant
<400> 183
ttcattagtg gtag taccatatac gact ctgtgaaggg c
<210> 184
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 3G4 CDR2 (VH)
<400> 184
ttcattagta ctagtggtag tatcatatac tacgcagact ctgtgaaggg c
<210> 185
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C8 CDR2 (VH)
<400> 185
ttcattagta gtagtggtag tatcatatac tacgcagact ctgtgaaggg c
<210> 186
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 CDR3 (VH) and ts (N60Q, N60S, N60A)
<400> 186
ggggggccct acta cgcccactgg ttcgacccc
<210> 187
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 CDR3 (VH) and 8B9 (S61P) variant
<400> 187
gatactgggt actacggtat ggacatc
<210> 188
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8C4 CDR3 (VH)
<400> 188
gatacgggct actacggtat ggacgtc
<210> 189
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C3 CDR3 (VH)
<400> 189
gatttctatg gttcgggaaa ctactactac ggtatggacg tc
<210> 190
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 CDR3 (VH) and 9F6 (A108T) variant
<400> 190
gatggctata gcagtggctg gtactactac ggtatggacg tc
<210> 191
<211> 45
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 3G4 CDR3 (VH)
<400> 191
gaagggtata gcagcagctg gtcctactac tacggtatgg acgtc
<210> 192
<211> 42
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 17C8 CDR3 (VH)
<400> 192
gatgggtata gcagtggctg ggagtactac ggtatggacg tc
<210> 193
<211> 324
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3, 17C3, 3G4 VL
<400> 193
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga cacc
ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
cagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcag cagactggag
cctgaagatt ttgcagtgta ttactgtcag ggta gctcaccgat caccttcggc
caagggacac gactggagat taaa
<210> 194
<211> 324
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9, 8C4, 17C8 , 9F6 (VK3) VL
<400> 194
gaaattgtgt tgacgcagtc tccaggcacc ttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat tcca gcagggccac tggcatccca
ttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag
cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcaccgct cactttcggc
acca aggtggagat caaa
<210> 195
<211> 321
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK1) VL
<400> 195
gccatccagt agtc tccatcctcc gcat ctgtaggaga cagagtcacc
atcacttgcc gggcaagtca gggcattagc agtgctttag cctggtatca gcagaaacca
gggaaagctc ctaagctcct tgat gcctccagtt tggaaagtgg ggtcccatca
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct
gaagattttg caacttatta ctgtcaacag tttaatagtt accctcggac gttcggccaa
gggaccaagg tggaaatcaa a
<210> 196
<211> 321
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK2) VL
<400> 196
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc
ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
gacaggttca gtgg gtctgggaca gacttcactc tcaccatcag ggag
gatt ttgcagtgta ttactgtcag cagtatggta gctcactcac tttcggcgga
gggaccaagg tggagatcaa a
<210> 197
<211> 36
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3, 8B9, 8C4, 17C3, 9F6 (VK2, VK3), 3G4, 17C8 CDR1
<400> 197
agggccagtc agagtgttag cagcagctac ttagcc
<210> 198
<211> 33
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 9F6 (VK1) CDR1 (VL)
<400> 198
cgggcaagtc agggcattag cagtgcttta gcc
<210> 199
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3, 8B9, 8C4, 17C3, 9F6 (VK2, VK3), 3G4, 17C8 CDR2
<400> 199
ggtgcatcca ccac t
<210> 200
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK1) CDR2 (VL)
<400> 200
gatgcctcca gtttggaaag t
<210> 201
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3, 17C3, 3G4 CDR3 (VL)
<400> 201
cagcagtatg gtagctcacc gatcacc
<210> 202
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9, 8C4, 9F6 (VK3), 17C8 CDR3 (VL)
<400> 202
cagcagtatg gtagctcacc gctcact
<210> 203
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK1) CDR3 (VL)
<400> 203
caacagttta atagttaccc tcggacg
<210> 204
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (VK2) CDR3 (VL)
<400> 204
cagcagtatg gtagctcact cact
<210> 205
<211> 1362
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 13A3 (N60Q) IgG1.1f HC
<400> 205
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
ccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg attg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc gtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg agcc acgaagaccc tgaggtcaag
ttcaactggt acgg ggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg ccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
acgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 206
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60S) IgG1.1f HC
<400> 206
cagctgcagc agtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tactcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gaac cctggtcacc
gtctcctcag ctagcaccaa atcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga agaa cagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
tggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 207
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60A) IgG1.1f HC
<400> 207
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacgcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ccta
cagtcctcag gactctactc cagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca accg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc tgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa ctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 208
<211> 1362
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 13A3 (D101E) IgG1.1f HC
<400> 208
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cagc accg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt gaga
gttgagccca aatcttgtga caaaactcac acatgcccac cagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct atcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg acta caagaccacg
cctcccgtgc tggactccga cttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 209
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102V) IgG1.1f HC
<400> 209
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
actg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacgtatggg gaac cacc
gtctcctcag ccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc ggtg
tcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac ccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct atcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc ccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 210
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102Y) IgG1.1f HC
<400> 210
cagctgcagc agtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct gatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt cgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc gtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca gtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca accg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
tcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa ctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 211
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102L) IgG1.1f HC
<400> 211
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt atct attatagtgg gttcacctac
ccgt ccctcaagag tcgagtcacc atatccgttg ccaa gttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacctatggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg gacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc accg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
tggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg acca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
gaga tgaccaagaa ccaggtcagc tgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 212
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.1f HC
<400> 212
cagctgcagc tgcaggagtc gggcccagga aagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc gttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg attg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc cctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
tcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg acca ggactggctg
aagg agtacaagtg caaggtctcc aacaaagccc gcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga agaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg caat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc ggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 213
<211> 1344
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) IgG1.1f HC
<400> 213
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca gcac caat
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agatactggg
tactacggta tggacatctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aatc acaagcccag caag gtggacaaga gagttgagcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
tgcgtggtgg tggacgtgag agac cctgaggtca agttcaactg ggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
agca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc
gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt tgag gctctgcaca accactacac gcagaagagc
ctctccctgt ccccgggtaa atga
<210> 214
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (A108T) IgG1.1f HC
<400> 214
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcgctgttt
ctgcaaatga acagcctgag ggac gtgt attactgtgc gagagatggc
tatagcagtg gctggtacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc cctc ctccaagagc
gggg gcacagcggc ctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc gtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa tcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc tctt cctcttcccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc accg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagg ccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg caat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 215
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q) IgG1.1f HC (no C-terminal K)
<400> 215
cagctgcagc tgcaggagtc agga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct gcaa cgtgaatcac agca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg gcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg cagc accg acca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
acgc agaagagcct ctccctgtcc ccgggttga
<210> 216
<211> 1359
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60S) IgG1.1f HC (no C-terminal K)
<400> 216
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg cagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tactcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
gggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg gacc gtgc acaccttccc ccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg cagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg ccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg tccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc tata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 217
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60a) IgG1.1f HC (no C-terminal K)
<400> 217
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg cagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt atct attatagtgg gttcacctac
tacgcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg acgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac ccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct atcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg acta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc ggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 218
<211> 1359
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 13A3 (D101E) f HC (no C-terminal K)
<400> 218
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag cacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag actc cctcagcagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa tcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
tggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg ccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
acgc agaagagcct gtcc ccgggttga
<210> 219
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102V) IgG1.1f HC (no C-terminal K)
<400> 219
cagctgcagc tgcaggagtc gggcccagga aagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
ccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacgtatggg gccagggaac cctggtcacc
gtctcctcag ccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc gtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc ggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
tcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc tgcc tggtcaaagg tccc
agcgacatcg ccgtggagtg caat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc gcct ctccctgtcc ccgggttga
<210> 220
<211> 1359
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 13A3 (P102Y) IgG1.1f HC (no C-terminal K)
<400> 220
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc agac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg ctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gccc cgtcagtctt cctcttcccc ccca aggacaccct catgatctcc
cggacccctg catg cgtggtggtg gacgtgagcc acgaagaccc caag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc gcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct atcc
cgggaggaga tgaccaagaa cagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg agaacaacta caagaccacg
cctcccgtgc ccga cggctccttc ttcctctata gcaagctcac cgtggacaag
tggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct gtcc ccgggttga
<210> 221
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102L) IgG1.1f HC (no C-terminal K)
<400> 221
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt cgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc tggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
gggg gcacagcggc cctgggctgc aagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag actc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg catg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc ggaa cgtcttctca gtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct gtcc ccgggttga
<210> 222
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.1f HC (no C-terminal K)
<400> 222
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt gggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
aagc tgagctctgt cgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc tccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac agca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg ggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
aaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg ctcc gccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa ctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 223
<211> 1341
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) IgG1.1f HC (no C-terminal K)
<400> 223
caggtgcagc agtc agga ctggtgaagc agac cctgtccctc
acctgcactg tctctggtgg ctccatcagt tact ggaactggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca gtggaagcac caactacaat
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag tggg
tactacggta tggacatctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg
ggct gcctggtcaa ggactacttc ccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca tgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc agtc
ttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat ggag
agca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc
gacggctcct tcttcctcta tagcaagctc accgtggaca ggtg gcagcagggg
aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
ctgt ccccgggttg a
<210> 224
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 ) IgG1.1f HC (no C-terminal K)
<400> 224
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt taca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtggtg gtggtagtac catatactac
tctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcgctgttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt attactgtgc gagagatggc
tatagcagtg acta ctacggtatg gacgtctggg ggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa tcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc tggactccga cttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc tga
<210> 225
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q) IgG1.3f HC
<400> 225
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg cagc agtagaagtt actactgggg ccgc
ccag ggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc ctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc gagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
tcgt ggaactcagg gacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc cccc gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc tata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc aaat ga
<210> 226
<211> 1362
<212> DNA
<213> Artificial ce
<220>
<223> Antibody 13A3 (N60S) IgG1.3f HC
<400> 226
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tactcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg cccc tggcaccctc ctccaagagc
gggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc cgtcagtctt cccc ccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc gcgggaggag
aaca gcacgtaccg tgtggtcagc gtcctcaccg acca ggactggctg
aatggcaagg agtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg caat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 227
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60A) IgG1.3f HC
<400> 227
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacgcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc ctgt gaccgccgca gacacggctg attg tgcgacaggg
gggccctacg acgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc aagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg gacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt gaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc accg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
gaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg tccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata tcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 228
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (D101E) IgG1.3f HC
<400> 228
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt gggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc gttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc aagg actacttccc ggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa tcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga cagg tgtacaccct gcccccatcc
gaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 229
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102V) IgG1.3f HC
<400> 229
cagctgcagc tgcaggagtc gggcccagga aagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt agag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc ctgt cgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacgtatggg gaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc cctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
tcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct gcaa cgtgaatcac aagcccagca acaccaaggt gaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
tcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 230
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102Y) IgG1.3f HC
<400> 230
cagctgcagc tgcaggagtc agga ctggtgaagc cttcggagac cctgtccctc
actg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc gttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc gttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct gcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc accg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga aggc tctgcacaac
cactacacgc gcct ctccctgtcc aaat ga
<210> 231
<211> 1362
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 13A3 (P102L) IgG1.3f HC
<400> 231
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt gggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacctatggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc gagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag actc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
ccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccca aggacaccct catgatctcc
cggacccctg aggtcacatg ggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg gcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
atcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
acgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 232
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.3f HC
<400> 232
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag cacc atatccgttg ccaa gaaccagttc
aagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg cccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
tcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
aaca accg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac caag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga aggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 233
<211> 1344
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) IgG1.3f HC
<400> 233
caggtgcagc agtc agga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggaactggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca gtggaagcac caactacaat
ctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
agct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agatactggg
tactacggta tggacatctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc accc tcctccaaga gcacctctgg gggcacagcg
gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca
ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc acaagcccag caacaccaag aaga agcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
tgcgtggtgg tggacgtgag ccacgaagac gtca agttcaactg gtacgtggac
gagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac gcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa
cccc gagaaccaca ggtgtacacc ccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca atgggcagcc caac tacaagacca cgcctcccgt gctggactcc
gacggctcct tcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
ctctccctgt ccccgggtaa atga
<210> 234
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 9F6 ) IgG1.3f HC
<400> 234
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
ccagggaagg ggctggagtg ggtttcattc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcgctgttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt attactgtgc gagagatggc
tatagcagtg acta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa tcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga caaaactcac acatgcccac cgtgcccagc agcc
gaaggggccc cgtcagtctt cccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc accc caag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta cacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 235
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q) f HC (no C-terminal K)
<400> 235
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct gatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg tgcgacaggg
tacg gtgactacgc ccactggttc tggg gccagggaac cacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
ccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca accg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc ccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 236
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60S) IgG1.3f HC (no C-terminal K)
<400> 236
cagctgcagc tgcaggagtc agga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tactcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg acgc ccactggttc gacccctggg gccagggaac cctggtcacc
tcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc ggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc accc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc ggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg agtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc ggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
acgc agaagagcct ctccctgtcc ccgggttga
<210> 237
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60A) IgG1.3f HC (no C-terminal K)
<400> 237
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct gtgg gttcacctac
tacgcaccgt ccctcaagag tcgagtcacc atatccgttg ccaa gaaccagttc
tccctgaagc ctgt cgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc cctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc tccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt gaga
ccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa cagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
gtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
acgc agaagagcct ctccctgtcc ccgggttga
<210> 238
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 ) IgG1.3f HC (no C-terminal K)
<400> 238
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtt actactgggg ccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct gtgg gttcacctac
tacaacccgt agag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgg cgtggaggtg cataatgcca agacaaagcc ggag
cagtacaaca gcacgtaccg tgtggtcagc accg acca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc cccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat ccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 239
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102V) IgG1.3f HC (no inal K)
<400> 239
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg tgcgacaggg
tacg gtgactacgc ccactggttc gacgtatggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc ctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag actc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca ccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc accc tgaggtcaag
ttcaactggt acgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
tcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga agaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg caat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca gtga tgcatgaggc tctgcacaac
acgc agaagagcct ctccctgtcc ccgggttga
<210> 240
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102Y) IgG1.3f HC (no C-terminal K)
<400> 240
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt atct attatagtgg gttcacctac
ccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga caaaactcac ccac cgtgcccagc acctgaagcc
gccc cgtcagtctt cctcttcccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc caag
ttcaactggt acgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg ctcc aacaaagccc cccc catcgagaaa
accatctcca aagccaaagg ccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cttc ttcctctata gcaagctcac caag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 241
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102L) f HC (no C-terminal K)
<400> 241
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
ccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacctatggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa atcg gtcttccccc cctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cagc acctgaagcc
gaaggggccc tctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg acca ggactggctg
aatggcaagg agtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 242
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, P102Y) IgG1.3f HC (no inal K)
<400> 242
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg aggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
gggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac ccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc gcgggaggag
aaca accg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 243
<211> 1341
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) IgG1.3f HC (no C-terminal K)
<400> 243
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggaactggat gccc
ccagggaagg agtg gattgggtat atccattaca gtggaagcac caat
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
agct ctgtgaccgc cacg gccgtgtatt cgag agatactggg
tactacggta tggacatctg gggccaaggg accacggtca ccgtctcctc agctagcacc
aagggcccat cggtcttccc accc tcctccaaga gcacctctgg gggcacagcg
gccctgggct gcctggtcaa cttc ccgg tgacggtgtc gtggaactca
ctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac
tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc
aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc caaatcttgt
gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc cccgtcagtc
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
tgcgtggtgg tggacgtgag ccacgaagac gtca agttcaactg gtacgtggac
ggcgtggagg tgcataatgc caagacaaag gagg agcagtacaa cagcacgtac
cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa
gggcagcccc caca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
tgggagagca atgggcagcc caac acca cgcctcccgt gctggactcc
gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg gcagcagggg
aacgtcttct catgctccgt gatgcatgag gctctgcaca acac gcagaagagc
ctgt ccccgggttg a
<210> 244
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 9F6 (A108T) f HC (no C-terminal K)
<400> 244
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc
tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct
aagg ggctggagtg ggtttcattc attagtggtg gtggtagtac catatactac
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa gttt
ctgcaaatga acagcctgag agtcgaggac acggctgtgt attactgtgc gagagatggc
tatagcagtg gctggtacta ctacggtatg gacgtctggg gccaagggac cacggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac ccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc accc caag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca gctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc cccc catcgagaaa
accatctcca aagg gcagccccga gaaccacagg tgtacaccct atcc
cgggaggaga agaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca gtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 245
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q) VH
<400> 245
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt atct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gttc
tccctgaagc tgagctctgt cgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctca
<210> 246
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60S) VH
<400> 246
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg cagc agtagaagtt actactgggg ccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tactcaccgt ccctcaagag tcgagtcacc atatccgttg ccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctca
<210> 247
<211> 369
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 13A3 (N60A) VH
<400> 247
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc agac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct gtgg gttcacctac
tacgcaccgt ccctcaagag tcgagtcacc atatccgttg ccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctca
<210> 248
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (D101E) VH
<400> 248
cagctgcagc tgcaggagtc agga ctggtgaagc cttcggagac cctc
acctgcactg tctctggtgg ctccatcagc agtt gggg ctggatccgc
ccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg aggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctca
<210> 249
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102V) VH
<400> 249
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg aggg
gggccctacg gtgactacgc ccactggttc gacgtatggg gccagggaac cctggtcacc
gtctcctca
<210> 250
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3 (P102Y) VH
<400> 250
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
actg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg aggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctca
<210> 251
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102L) VH
<400> 251
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc agac cctgtccctc
actg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tacaacccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gacctatggg gccagggaac cctggtcacc
gtctcctca
<210> 252
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60Q, P102Y) VH
<400> 252
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggct ggagtggatt gggagtatct attatagtgg ctac
taccaaccgt agag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc ctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gactactggg gccagggaac cctggtcacc
gtctcctca
<210> 253
<211> 351
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) VH
<400> 253
caggtgcagc tgcaggagtc agga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagt cgtcactact ggaactggat ccggcagccc
ccagggaagg gactggagtg gattgggtat atccattaca gtggaagcac caactacaat
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agatactggg
ggta tggacatctg gggccaaggg accacggtca ccgtctcctc a
<210> 254
<211> 369
<212> DNA
<213> cial Sequence
<220>
<223> Antibody 9F6 (A108T) VH
<400> 254
cagctgcagc tgcaggagtc agga aagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
tactcaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg aggg
gggccctacg gtgactacgc ccactggttc gacccctggg gccagggaac cctggtcacc
gtctcctca
<210> 255
<211> 48
<212> DNA
<213> Artificial ce
<220>
<223> Antibodies 13A3 (N60Q), 13A3 (N60Q, P102Y), 13A3 (N60Q, D101E)
CDR2 (VH)
<400> 255
agtatctatt atagtgggtt cacctactac caaccgtccc tcaagagt
<210> 256
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60S) CDR2 (VH)
<400> 256
agtatctatt atagtgggtt cacctactac tccc tcaagagt
<210> 257
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60A) CDR2 (VH)
<400> 257
agtatctatt ggtt cacctactac gcaccgtccc tcaagagt
<210> 258
<211> 48
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 8B9 (S61P) CDR2 (VH)
<400> 258
tatatccatt acagtggaag caccaactac aatccctccc tcaagagt
<210> 259
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (D101E) CDR3 (VH)
<400> 259
ggggggccct acggtgacta cgcccactgg ttcgaaccc
<210> 260
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3 (P102V) CDR3 (VH)
<400> 260
ggggggccct acggtgacta cgcccactgg gta
<210> 261
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibodies 13A3 (P102Y), 13A3 (N60Q, P102Y), 13A3 (N60Q, D101E)
CDR3 (VH)
<400> 261
ggggggccct acggtgacta cgcccactgg ttcgactac
<210> 262
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (P102L) CDR3 (VH)
<400> 262
ggggggccct acta cgcccactgg ttcgaccta
<210> 263
<211> 994
<212> DNA
<213> Artificial Sequence
<220>
<223> All antibodies HC Constant Domain (IgG1.1f)
<400> 263
agctagcacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg
agcg gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc
gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc
aggactctac tccctcagca gcgtggtgac cgtgccctcc ttgg gcacccagac
ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga agcc
caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc
cccgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc
caca tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca actg
gtacgtggac ggcgtggagg tgcataatgc caagacaaag gagg acaa
cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa
ggagtacaag gtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc
caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga
gatgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat
cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gctggactcc gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg
gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
gcagaagagc ctctccctgt ccccgggtaa atga
<210> 264
<211> 991
<212> DNA
<213> Artificial Sequence
<220>
<223> All antibodies HC Constant Domain (IgG1.1f) (no C-terminal K)
<400> 264
agctagcacc aagggcccat cggtcttccc cctggcaccc tcctccaaga ctgg
gggcacagcg gccctgggct tcaa ggactacttc ccgg tgacggtgtc
gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc
aggactctac tccctcagca gcgtggtgac cgtgccctcc ttgg gcacccagac
ctacatctgc aatc acaagcccag caacaccaag gtggacaaga gagttgagcc
caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc
cccgtcagtc ttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc
caca gtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg
gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa
cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac tggc tgaatggcaa
ggagtacaag tgcaaggtct ccaacaaagc cctcccaagc agcatcgaga aaaccatctc
caaagccaaa cccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga
gatgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat
cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gctggactcc tcct tcttcctcta tagcaagctc accgtggaca agagcaggtg
gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
gcagaagagc ctctccctgt gttg a
<210> 265
<211> 994
<212> DNA
<213> Artificial Sequence
<220>
<223> All antibodies HC Constant Domain (IgG1.3f)
<400> 265
agctagcacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg
gggcacagcg gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc
gtggaactca ctga ccagcggcgt gcacaccttc gtcc tacagtcctc
aggactctac tccctcagca gcgtggtgac ctcc agcagcttgg gcacccagac
ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga gagttgagcc
caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc
cccgtcagtc ttcctcttcc aacc caaggacacc ctcatgatct cccggacccc
tgaggtcaca tgcgtggtgg tggacgtgag agac gtca agttcaactg
gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa
cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa
ggagtacaag tgcaaggtct aagc cctcccagcc cccatcgaga aaaccatctc
caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga
gatgaccaag aaccaggtca gcctgacctg cctggtcaaa tatc ccagcgacat
cgccgtggag tgggagagca atgggcagcc caac tacaagacca cgcctcccgt
gctggactcc gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg
gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
gcagaagagc ctgt ccccgggtaa atga
<210> 266
<211> 991
<212> DNA
<213> Artificial Sequence
<220>
<223> All antibodies HC Constant Domain (IgG1.3f) (no C-terminal K)
<400> 266
agctagcacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg
gggcacagcg ggct gcctggtcaa ggactacttc cccgaaccgg tgtc
gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc cctc
aggactctac tccctcagca tgac cgtgccctcc agcagcttgg gcacccagac
ctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga agcc
caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaag ccgaaggggc
cccgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc
caca tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg
gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa
cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc gcaa
ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc
caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga
gatgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat
cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gctggactcc gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg
gggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
gcagaagagc ctctccctgt ccccgggttg a
<210> 267
<211> 19
<212> PRT
<213> cial Sequence
<220>
<223> Signal Peptide
<400> 267
Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala Val Ala Pro Gly
1 5 10 15
Ala His Ser
<210> 268
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 268
Met Glu Thr Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro
1 5 10 15
Asp Thr Thr Gly
<210> 269
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 269
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp
1 5 10 15
Val Leu Ser
<210> 270
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 270
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Ile Lys Gly
1 5 10 15
Val Gln Cys
<210> 271
<211> 21
<212> PRT
<213> Artificial Sequence
<220>
<223> Signal e
<400> 271
Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Trp Leu
1 5 10 15
Pro Gly Ala Arg Cys
<210> 272
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 272
atggactgga cctggagggt cttctgcttg ctggctgtag ctc
<210> 273
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 273
atggaaaccc cagcgcagct tctcttcctc ctgctactct ggctcccaga taccaccgga
<210> 274
<211> 57
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal e
<400> 274
atgaagcacc tgtggttctt cctcctgctg gtggcggctc ccagatgggt cctgtcc
<210> 275
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 275
atggagtttg ggctgagctg cctt gttgctatta taaaaggtgt c
<210> 276
<211> 66
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal Peptide
<400> 276
atggacatga gggtccccgc tcagctcctg gggcttctgc tgctctggct tgcc
agatgt
<210> 277
<211> 330
<212> PRT
<213> Artificial Sequence
<220>
<223> human IgG1 (allotypic variant)
<400> 277
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 278
<211> 107
<212> PRT
<213> Homo s
<400> 278
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210> 279
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> C-terminal end of heavy chain
<400> 279
Leu Ser Pro Gly Lys
1 5
<210> 280
<211> 4
<212> PRT
<213> cial Sequence
<220>
<223> C-terminal end of heavy chain
<400> 280
Leu Ser Pro Gly
<210> 281
<211> 3
<212> PRT
<213> Artificial Sequence
<220>
<223> C-terminal end of heavy chain
<400> 281
Leu Ser Pro
<210> 282
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> VH CDR1 degenerate
<220>
<221> MISC_FEATURE
<222> 4)
<223> Xaa is any amino acid
<220>
<221> MISC_FEATURE
<222> (6)..(7)
<223> Xaa is any amino acid
<400> 282
Xaa Xaa Xaa Xaa Tyr Xaa Xaa
1 5
<210> 283
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<223> VH CDR2 degenerate
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is any amino acid
<220>
<221> MISC_FEATURE
<222> (3)..(5)
<223> Xaa is any amino acid
<220>
<221> MISC_FEATURE
<222> (7)..(10)
<223> Xaa is any amino acid
<220>
<221> MISC_FEATURE
<222> (12)..(17)
<223> Xaa is any amino acid
<400> 283
Xaa Ile Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa
1 5 10 15
<210> 284
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> VH CDR3 degenerate
<220>
<221> MISC_FEATURE
<222> (1)..(10)
<223> Xaa is any amino acid
<220>
<221> MISC_FEATURE
<222> (13)..(20)
<223> Xaa is any amino acid
<400> 284
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Gly Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
<210> 285
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> VL CDR1 rate
<220>
<221> MISC_FEATURE
<222> (3)..(4)
<223> Xaa is any amino acid
<220>
<221> MISC_FEATURE
<222> (6)..(8)
<223> Xaa is any amino acid
<400> 285
Gln Gln Xaa Xaa Ser Xaa Xaa Xaa Thr
1 5
<210> 286
<211> 300
<212> PRT
<213> Homo s
<400> 286
Met Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu
1 5 10 15
Leu Leu Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln
25 30
Asn Ala Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu
40 45
Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly
50 55 60
Asn Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser
65 70 75 80
Arg Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr
85 90 95
Ile Glu Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile
100 105 110
Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val
115 120 125
Ile Lys Pro Ala Lys Val Thr Pro Ala Pro Thr Arg Gln Arg Asp Phe
130 135 140
Thr Ala Ala Phe Pro Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala
145 150 155 160
Glu Thr Gln Thr Leu Gly Ser Leu Pro Asp Ile Asn Leu Thr Gln Ile
165 170 175
Ser Thr Leu Ala Asn Glu Leu Arg Asp Ser Arg Leu Ala Asn Asp Leu
180 185 190
Arg Asp Ser Gly Ala Thr Ile Arg Ile Gly Ile Tyr Ile Gly Ala Gly
195 200 205
Ile Cys Ala Gly Leu Ala Leu Ala Leu Ile Phe Gly Ala Leu Ile Phe
210 215 220
Lys Trp Tyr Ser His Ser Lys Glu Lys Ile Gln Asn Leu Ser Leu Ile
225 230 235 240
Ser Leu Ala Asn Leu Pro Pro Ser Gly Leu Ala Asn Ala Val Ala Glu
245 250 255
Gly Ile Arg Ser Glu Glu Asn Ile Tyr Thr Ile Glu Glu Asn Val Tyr
260 265 270
Glu Val Glu Glu Pro Asn Glu Tyr Tyr Cys Tyr Val Ser Ser Arg Gln
275 280 285
Gln Pro Ser Gln Pro Leu Gly Cys Arg Phe Ala Met
290 295 300
<210> 287
<211> 142
<212> PRT
<213> Homo s
<400> 287
Met Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu
1 5 10 15
Leu Leu Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln
25 30
Asn Ala Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu
40 45
Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly
50 55 60
Asn Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser
65 70 75 80
Arg Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr
85 90 95
Ile Glu Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile
100 105 110
Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val
115 120 125
Ile Lys Pro Gly Glu Trp Thr Phe Ala Cys His Leu Tyr Glu
130 135 140
<210> 288
<211> 2448
<212> DNA
<213> Homo sapiens
<400> 288
agaacactta caggatgtgt gtagtgtggc atgacagaga actttggttt cctttaatgt
gactgtagac ctggcagtgt tactataaga ggca atcagacacc cgggtgtgct
gagctagcac tcagtggggg cggctactgc tcatgtgatt gtggagtaga cagttggaag
aagtacccag tccatttgga gagttaaaac tgtgcctaac agaggtgtcc tctgactttt
caag ctccatgttt tcacatcttc cctttgactg tgtcctgctg ctgctgctgc
tactacttac aaggtcctca gaagtggaat acagagcgga tcag aatgcctatc
tgccctgctt ctacacccca gccgccccag ggaacctcgt ctgc tggggcaaag
gagcctgtcc tgtgtttgaa aacg tggtgctcag gactgatgaa agggatgtga
attattggac atccagatac tggctaaatg tccg caaaggagat ctga
ccatagagaa tgtgactcta gcagacagtg ggatctactg ctgccggatc caaatcccag
gcataatgaa tgatgaaaaa tttaacctga agttggtcat caaaccagcc aaggtcaccc
ctgcaccgac tcggcagaga gacttcactg cagcctttcc aaggatgctt accaccaggg
gacatggccc agcagagaca cagacactgg ggagcctccc tgatataaat ctaacacaaa
tatccacatt ggccaatgag ttacgggact ctagattggc caatgactta cgggactctg
gagcaaccat cagaataggc atctacatcg gagcagggat ctgtgctggg ctggctctgg
ctcttatctt cggcgcttta aaat ggtattctca tagcaaagag aagatacaga
atttaagcct catctctttg gccaacctcc ctccctcagg aaat gcagtagcag
agggaattcg ctcagaagaa aacatctata ccattgaaga gaacgtatat gagg
agcccaatga gtattattgc tatgtcagca gcaggcagca accctcacaa cctttgggtt
gtcgctttgc aatgccatag atccaaccac cttatttttg agcttggtgt tttt
tcagaaacta tgagctgtgt cacctgactg gttttggagg ttctgtccac ggag
cagagttttc tcag aagataatga ctcacatggg aattgaactg ggacctgcac
tgaacttaaa caggcatgtc attgcctctg tatttaagcc aacagagtta cccaacccag
agactgttaa tcatggatgt tagagctcaa tttt atatacacta ggaattcttg
acgtggggtc gctc caggaaattc gggcacatca tatgtccatg aaacttcaga
taaactaggg aaaactgggt gtga aagcataact tttttggcac agaaagtcta
aaggggccac tgattttcaa agagatctgt gatccctttt ttgt ttttgagatg
gagtcttgct ctgttgccca ggctggagtg caatggcaca atctcggctc actgcaagct
ccgcctcctg ggttcaagcg attctcctgc ctcagcctcc tgagtggctg ggattacagg
catgcaccac catgcccagc taatttgttg tatttttagt agagacaggg tttcaccatg
ttggccagtg tggtctcaaa acct catgatttgc ctgcctcggc ctcccaaagc
actgggatta caggcgtgag ccaccacatc cagccagtga tccttaaaag attaagagat
gactggacca ggtctacctt gatcttgaag attcccttgg aatgttgaga tttaggctta
tttgagcact ccaa ctgtcagtgc cagtgcatag cccttctttt ctta
tgaagactgc cctgcagggc tgagatgtgg caggagctcc cagggaaaaa cgaagtgcat
ttgattggtg tgtattggcc aagttttgct tgttgtgtgc ttgaaagaaa atatctctga
tctg tattcgtgga ccaaactgaa gctatatttt tcacagaaga agaagcagtg
acggggacac aaattctgtt gcctggtgga aagaaggcaa aggccttcag atat
taccagcgct ggatcctttg acagagagtg gtccctaaac ttaaatttca tata
ggcttgatct gtcttgctta ttgttgcccc ctgcgcctag cacaattctg acacacaatt
ggaacttact aaaaattttt tgtt aaaaaaaaaa aaaaaaaa
<210> 289
<211> 1012
<212> DNA
<213> Homo sapiens
<400> 289
actgctcatg tgattgtgga gtagacagtt ggaagaagta cccagtccat ttggagagtt
aaaactgtgc ctaacagagg tgtcctctga cttttcttct gcaagctcca tgttttcaca
tcttcccttt gtcc tgctgctgct gctgctacta cttacaaggt cctcagaagt
ggaatacaga gcggaggtcg gtcagaatgc ctatctgccc tgcttctaca ccccagccgc
cccagggaac ctcgtgcccg tctgctgggg caaaggagcc tgtcctgtgt ttgaatgtgg
caacgtggtg ctcaggactg atgaaaggga tgtgaattat tggacatcca gatactggct
aaatggggat ttccgcaaag gagatgtgtc cctgaccata gagaatgtga ctctagcaga
cagtgggatc tactgctgcc ggatccaaat cccaggcata atgaatgatg aaaaatttaa
cctgaagttg gtcatcaaac caggtgagtg gacatttgca tgccatcttt atgaataaga
tttatctgtg gatcatatta aaggtactga ttgttctcat ctctgacttc cctaattata
gccctggagg agggccacta agacctaaag tttaacaggc ggtg agtg
atatttaaca ccttctctct gttttaaaac gtgt gcctgggcgt ggtggctcgc
gcctctggtc ccagcacttt gggaggctga ggccggtgga tcatgaggtc aggaattcga
gaccagcctg atgg taaaaccttg tctccactaa aaatacaaaa aattagccag
ttac gggagcctgt aattctagct acttgggggg cagg agaatcactt
gaacctggaa gtcggaggtt gcggtaagcc aagatctcgc cattgtactc cagcctggct
gacaagagtg aaactctgtc ccaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa
<210> 290
<211> 179
<212> PRT
<213> Homo sapiens
<400> 290
Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr Leu Pro
1 5 10 15
Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp
25 30
Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val Leu Arg
40 45
Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp Leu Asn
50 55 60
Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn Val Thr
65 70 75 80
Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro Gly Ile
85 90 95
Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys Pro Ala Lys
100 105 110
Val Thr Pro Ala Pro Thr Arg Gln Arg Asp Phe Thr Ala Ala Phe Pro
115 120 125
Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala Glu Thr Gln Thr Leu
130 135 140
Gly Ser Leu Pro Asp Ile Asn Leu Thr Gln Ile Ser Thr Leu Ala Asn
145 150 155 160
Glu Leu Arg Asp Ser Arg Leu Ala Asn Asp Leu Arg Asp Ser Gly Ala
165 170 175
Thr Ile Arg
<210> 291
<211> 330
<212> PRT
<213> Homo s
<400> 291
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 292
<211> 327
<212> PRT
<213> Homo s
<400> 292
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
100 105 110
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
180 185 190
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
210 215 220
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
305 310 315 320
Leu Ser Leu Ser Leu Gly Lys
<210> 293
<211> 107
<212> PRT
<213> cial Sequence
<220>
<223> 9F6 VK2 IgG1 light chain
<400> 293
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210> 294
<211> 330
<212> PRT
<213> Artificial ce
<220>
<223> IgG1.1 constant domain (used in anti-TIM3 antibodies)
<400> 294
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 295
<211> 330
<212> PRT
<213> Artificial ce
<220>
<223> IgG1.3 constant domain (used in anti-TIM3 antibodies)
<400> 295
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 296
<211> 7
<212> PRT
<213> Homo s
<400> 296
Cys Pro Val Phe Glu Cys Gly
1 5
<210> 297
<211> 12
<212> PRT
<213> Homo sapiens
<400> 297
Trp Thr Ser Arg Tyr Trp Leu Asn Gly Asp Phe Arg
1 5 10
<210> 298
<211> 10
<212> PRT
<213> Homo s
<400> 298
Arg Ile Gln Ile Pro Gly Ile Met Asn Asp
1 5 10
<210> 299
<211> 99
<212> PRT
<213> Homo sapiens
<400> 299
Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr Leu Pro
1 5 10 15
Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp
25 30
Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val Leu Arg
40 45
Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp Leu Asn
50 55 60
Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn Val Thr
65 70 75 80
Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro Gly Ile
85 90 95
Met Asn Asp
<210> 300
<211> 5
<212> PRT
<213> Artificial Sequence
<220>
<223> Linker
<400> 300
Pro Val Gly Val Val
1 5
<210> 301
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> 13A3 hIgG4 HC
<400> 301
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 302
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> 13A3 hIgG4 HC ut C-terminal K)
<400> 302
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 303
<211> 450
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.5 13A3 IgG4P HC
<400> 303
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 304
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> dy TIM3.5 13A3 IgG4P HC (without C-terminal K)
<400> 304
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 305
<211> 450
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.10 13A3 (N60Q) IgG4P HC
<400> 305
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 306
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody TIM3.10 13A3 (N60Q) IgG4P HC ut C-terminal K)
<400> 306
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 307
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.11 13A3 (N60S) IgG4P HC
<400> 307
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 308
<211> 449
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.11 13A3 (N60S) IgG4P HC (without C-terminal K)
<400> 308
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ser Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 309
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.12 13A3 (N60A) IgG4P HC
<400> 309
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 310
<211> 449
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.12 13A3 (N60A) IgG4P HC (without C-terminal K)
<400> 310
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Ala Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 311
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.13 13A3 (D101E) IgG4P HC
<400> 311
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 312
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 3 13A3 (D101E) IgG4P HC (without C-terminal K)
<400> 312
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 313
<211> 450
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 4 13A3 (P102V) IgG4P HC
<400> 313
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 314
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody TIM3.14 13A3 (P102V) IgG4P HC ut C-terminal K)
<400> 314
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 315
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.15 13A3 (P102Y) IgG4P HC
<400> 315
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 316
<211> 449
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.15 13A3 (P102Y) IgG4P HC (without C-terminal K)
<400> 316
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 317
<211> 450
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.16 13A3 (P102L) IgG4P HC
<400> 317
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 318
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> dy TIM3.16 13A3 (P102L) IgG4P HC (without C-terminal K)
<400> 318
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Leu
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 319
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.17 13A3 (N60Q, P102Y) IgG4P HC
<400> 319
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 320
<211> 449
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.17 13A3 (N60Q, P102Y) IgG4P HC (without C-terminal
<400> 320
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Tyr
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 321
<211> 447
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8B9 IgG1za HC
<400> 321
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 322
<211> 446
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 8B9 IgG1za HC ut C-terminal K)
<400> 322
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 323
<211> 444
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8B9 IgG4P HC
<400> 323
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220
Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe
260 265 270
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln
340 345 350
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440
<210> 324
<211> 443
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8B9 IgG4P HC ut C-terminal K)
<400> 324
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Ser Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220
Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe
260 265 270
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln
340 345 350
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
435 440
<210> 325
<211> 444
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.8 8B9 (S61P) IgG4P HC
<400> 325
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220
Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe
260 265 270
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln
340 345 350
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440
<210> 326
<211> 443
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.8 8B9 (S61P) IgG4P HC (without C-terminal K)
<400> 326
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg His
25 30
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Thr Gly Tyr Tyr Gly Met Asp Ile Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220
Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe
260 265 270
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln
340 345 350
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
435 440
<210> 327
<211> 447
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 8C4 IgG1za HC
<400> 327
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 328
<211> 446
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 8C4 IgG1za HC (without C-terminal K)
<400> 328
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
<210> 329
<211> 367
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.6 8C4 IgG4P HC
<400> 329
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
115 120 125
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
130 135 140
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
145 150 155 160
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
165 170 175
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
180 185 190
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
195 200 205
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
210 215 220
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
225 230 235 240
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
245 250 255
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
260 265 270
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
275 280 285
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
290 295 300
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
305 310 315 320
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
325 330 335
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
340 345 350
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
355 360 365
<210> 330
<211> 366
<212> PRT
<213> Artificial Sequence
<220>
<223> dy TIM3.6 8C4 IgG4P HC (without C-terminal K)
<400> 330
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Tyr
25 30
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
40 45
Gly Tyr Ile His Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Thr Asp Thr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
115 120 125
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
130 135 140
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
145 150 155 160
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
165 170 175
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
180 185 190
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
195 200 205
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
210 215 220
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
225 230 235 240
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
245 250 255
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
260 265 270
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
275 280 285
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
290 295 300
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
305 310 315 320
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
325 330 335
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
340 345 350
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
355 360 365
<210> 331
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 17C3 IgG1za HC
<400> 331
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 332
<211> 452
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 17C3 IgG1za HC (without C-terminal K)
<400> 332
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 333
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> dy TIM3.2 17C3 IgG4P HC
<400> 333
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 334
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody TIM3.2 17C3 IgG4P HC ut C-terminal K)
<400> 334
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
40 45
Gly Ile Ile Asn Pro Arg Gly Asp Ser Ile Ile Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Phe Tyr Gly Ser Gly Asn Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 335
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 IgG1za HC
<400> 335
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 336
<211> 452
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 9F6 IgG1za HC (without C-terminal K)
<400> 336
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
225 230 235 240
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 337
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> dy 9F6 IgG4P HC
<400> 337
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 338
<211> 449
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 9F6 IgG4P HC (without C-terminal K)
<400> 338
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Ala Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 339
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.7 9F6 (A108T) IgG4P HC
<400> 339
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 340
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> dy TIM3.7 9F6 (A108T) IgG4P HC (without C-terminal K)
<400> 340
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Gly Gly Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Tyr Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 341
<211> 454
<212> PRT
<213> cial Sequence
<220>
<223> dy 3G4 IgG1za HC
<400> 341
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly Lys
<210> 342
<211> 453
<212> PRT
<213> Artificial ce
<220>
<223> Antibody 3G4 IgG1za HC (without C-terminal K)
<400> 342
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130 135 140
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
195 200 205
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
210 215 220
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
225 230 235 240
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
245 250 255
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
260 265 270
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
275 280 285
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
290 295 300
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
305 310 315 320
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
325 330 335
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
340 345 350
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
355 360 365
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
370 375 380
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
385 390 395 400
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
405 410 415
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
420 425 430
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
435 440 445
Ser Leu Ser Pro Gly
<210> 343
<211> 451
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.4 3G4 IgG4P HC
<400> 343
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
130 135 140
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn
195 200 205
Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser
210 215 220
Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln
260 265 270
Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Leu Gly Lys
<210> 344
<211> 450
<212> PRT
<213> Artificial ce
<220>
<223> Antibody TIM3.4 3G4 IgG4P HC (without C-terminal K)
<400> 344
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Thr Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Glu Gly Tyr Ser Ser Ser Trp Ser Tyr Tyr Tyr Gly Met Asp
100 105 110
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
115 120 125
Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu
130 135 140
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
145 150 155 160
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
165 170 175
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
180 185 190
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn
195 200 205
Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser
210 215 220
Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly
225 230 235 240
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln
260 265 270
Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr
290 295 300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile
325 330 335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350
Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser
355 360 365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val
405 410 415
Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445
Leu Gly
<210> 345
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> dy 17C8 IgG4 HC
<400> 345
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 346
<211> 449
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 17C8 IgG4 HC (without C-terminal K)
<400> 346
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 347
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> Antibody TIM3.9 17C8 IgG4P HC
<400> 347
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 348
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody TIM3.9 17C8 IgG4P HC ut C-terminal K)
<400> 348
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
25 30
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
40 45
Ser Phe Ile Ser Ser Ser Gly Ser Ile Ile Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Gly Tyr Ser Ser Gly Trp Glu Tyr Tyr Gly Met Asp Val
100 105 110
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 349
<211> 453
<212> PRT
<213> cial Sequence
<220>
<223> dy 13A3 (N60Q, D101E) IgG1.1f HC
<400> 349
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 350
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) f HC (no C-terminal K)
<400> 350
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ser
325 330 335
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 351
<211> 453
<212> PRT
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60Q, D101E) IgG1.3f HC
<400> 351
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly Lys
<210> 352
<211> 452
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) f HC (no C-terminal K)
<400> 352
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala
225 230 235 240
Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
245 250 255
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
260 265 270
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
275 280 285
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
290 295 300
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
305 310 315 320
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
325 330 335
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
340 345 350
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln
355 360 365
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
370 375 380
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
385 390 395 400
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
405 410 415
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
420 425 430
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
435 440 445
Leu Ser Pro Gly
<210> 353
<211> 450
<212> PRT
<213> cial Sequence
<220>
<223> dy TIM3.18 13A3 (N60Q, D101E) IgG4P HC
<400> 353
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
Gly Lys
<210> 354
<211> 449
<212> PRT
<213> Artificial Sequence
<220>
<223> Antibody TIM3.18 13A3 (N60Q, D101E) IgG4P HC ut C-terminal
<400> 354
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val
195 200 205
Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys
210 215 220
Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu
260 265 270
Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu
435 440 445
<210> 355
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) IgG1.1f HC
<400> 355
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
tacg acgc ccactggttc gaaccctggg gccagggaac cctggtcacc
tcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
gggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
tcag gactctactc cctcagcagc gtggtgaccg ccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca aggt ggacaagaga
gttgagccca aatcttgtga caaaactcac ccac cgtgcccagc acctgaagcc
gccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga cagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg caat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc caac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 356
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) IgG1.1f HC (no C-terminal K)
<400> 356
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg gtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct gtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa atcg gtcttccccc tggcaccctc gagc
acctctgggg gcacagcggc ctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag actc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt gaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc
cggacccctg catg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccaagcag catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc tgcc aagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta cacg
gtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
acgc gcct ctccctgtcc ccgggttga
<210> 357
<211> 1362
<212> DNA
<213> Artificial Sequence
<220>
<223> dy 13A3 (N60Q, D101E) IgG1.3f HC
<400> 357
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg tgcgacaggg
tacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca gtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc caag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg
aatggcaagg agtacaagtg ctcc aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct atcc
cgggaggaga tgaccaagaa cagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga
<210> 358
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) IgG1.3f HC (no C-terminal K)
<400> 358
cagctgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt gggg ctggatccgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag cacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc ctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg gcacagcggc cctgggctgc ctggtcaagg tccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca ccct catgatctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg ggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca gcacgtaccg cagc gtcctcaccg tcctgcacca gctg
aagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc gaaa
accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc ggaa ctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 359
<211> 369
<212> DNA
<213> Artificial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) VH
<400> 359
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggatccgc
ccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag tcgagtcacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc gaaccctggg gccagggaac cctggtcacc
gtctcctca
<210> 360
<211> 294
<212> PRT
<213> Macaca fascicularis
<400> 360
Met Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu
1 5 10 15
Leu Leu Thr Arg Ser Ser Glu Val Glu Tyr Ile Ala Glu Val Gly Gln
25 30
Asn Ala Tyr Leu Pro Cys Ser Tyr Thr Pro Ala Pro Pro Gly Asn Leu
40 45
Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Asp Cys Ser
50 55 60
Asn Val Val Leu Arg Thr Glu Asn Arg Asp Val Asn Asp Arg Thr Ser
65 70 75 80
Gly Arg Tyr Trp Leu Lys Gly Asp Phe His Lys Gly Asp Val Ser Leu
85 90 95
Thr Ile Glu Asn Val Thr Leu Ala Asp Ser Gly Val Tyr Cys Cys Arg
100 105 110
Ile Gln Ile Pro Gly Ile Met Asn Asp Glu Lys His Asn Leu Lys Leu
115 120 125
Val Val Ile Lys Pro Ala Lys Val Thr Pro Ala Pro Thr Leu Gln Arg
130 135 140
Asp Leu Thr Ser Ala Phe Pro Arg Met Leu Thr Thr Gly Glu His Gly
145 150 155 160
Pro Ala Glu Thr Gln Thr Pro Gly Ser Leu Pro Asp Val Asn Leu Thr
165 170 175
Gln Ile Phe Thr Leu Thr Asn Glu Leu Arg Asp Ser Gly Ala Thr Ile
180 185 190
Arg Thr Ala Ile Tyr Ile Ala Ala Gly Ile Ser Ala Gly Leu Ala Leu
195 200 205
Ala Leu Ile Phe Gly Ala Leu Ile Phe Lys Trp Tyr Ser His Ser Lys
210 215 220
Glu Lys Thr Gln Asn Leu Ser Leu Ile Ser Leu Ala Asn Ile Pro Pro
225 230 235 240
Ser Gly Leu Ala Asn Ala Val Ala Glu Gly Ile Arg Ser Glu Glu Asn
245 250 255
Ile Tyr Thr Ile Glu Glu Asp Val Tyr Glu Val Glu Glu Pro Asn Glu
260 265 270
Tyr Tyr Cys Tyr Val Ser Ser Gly Gln Gln Pro Ser Gln Pro Leu Gly
275 280 285
Cys Arg Phe Ala Met Pro
<210> 361
<211> 17
<212> PRT
<213> cial Sequence
<220>
<223> Signal Peptide (TIM3.2-TIM3.18)
<400> 361
Met Arg Ala Trp Ile Phe Phe Leu Leu Cys Leu Ala Gly Arg Ala Leu
1 5 10 15
<210> 362
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal Peptide (TIM3.2-TIM3.18 HC)
<400> 362
atgagggctt ggatcttctt tctgctctgc ggga gagcgctcgc a
<210> 363
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<223> Signal Peptide (TIM3.2-TIM3.18 LC)
<400> 363
atgagggctt ggatcttctt tctgctctgc ctggccgggc gcgccttggc c
<210> 364
<211> 123
<212> PRT
<213> cial Sequence
<220>
<223> Antibody 13A3 (N60Q, D101E) VH
<400> 364
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 365
<211> 234
<212> PRT
<213> Artificial Sequence
<220>
<223> 13A3 HC Fab 6x His
<400> 365
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Asp Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Gly Gly His His His His His His
225 230
<210> 366
<211> 234
<212> PRT
<213> cial Sequence
<220>
<223> 13A3 (N60Q, D101E) HC Fab 6x His
<400> 366
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Arg
25 30
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
40 45
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro Ser
50 55 60
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu Pro
100 105 110
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160
Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys
210 215 220
Ser Cys Gly Gly His His His His His His
225 230
<210> 367
<211> 14
<212> PRT
<213> Homo s
<400> 367
Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu
1 5 10
<210> 368
<211> 17
<212> PRT
<213> Homo sapiens
<400> 368
Arg Ile Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys
1 5 10 15
<210> 369
<211> 23
<212> PRT
<213> Homo sapiens
<400> 369
Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp Gly Lys
1 5 10 15
Gly Ala Cys Pro Val Phe Glu
<210> 370
<211> 12
<212> PRT
<213> Homo sapiens
<400> 370
Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr
1 5 10
<210> 371
<211> 18
<212> PRT
<213> Homo sapiens
<400> 371
Trp Thr Ser Arg Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val
1 5 10 15
Ser Leu
<210> 372
<211> 18
<212> PRT
<213> Homo sapiens
<400> 372
Cys Arg Ile Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu
1 5 10 15
Lys Leu
<210> 373
<211> 9
<212> PRT
<213> Homo sapiens
<400> 373
Asn Asp Glu Lys Phe Asn Leu Lys Leu
1 5
<210> 374
<211> 1359
<212> DNA
<213> Artificial Sequence
<220>
<223> TIM3.18 (13A3) f (T168C)
<400> 374
cagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
acctgcactg tctctggtgg ctccatcagc agtagaagtt actactgggg ctggattcgc
cagcccccag ggaaggggct ggagtggatt gggagtatct attatagtgg gttcacctac
taccaaccgt ccctcaagag cacc atatccgttg acacgtccaa gaaccagttc
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattattg tgcgacaggg
gggccctacg gtgactacgc ccactggttc tggg gccagggaac cctggtcacc
gtctcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc
acctctgggg cggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg
acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta
cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc
acct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga
gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaagcc
gaaggggccc cgtcagtctt cctcttcccc ccaaaaccca aggacaccct ctcc
cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt acgtggacgg cgtggaggtg cataatgcca agcc gcgggaggag
cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg acca ggactggctg
aatggcaagg agtacaagtg caaggtctcc aacaaagccc cccc catcgagaaa
accatctcca aagg gcagccccga gaaccacagg tgtacaccct gcccccatcc
cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg agtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc ccga cggctccttc ttcctctata gcaagctcac cgtggacaag
agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtcc ccgggttga
<210> 375
<211> 410
<212> PRT
<213> Artificial ce
<220>
<223> hTIM3-mFc
<400> 375
Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr Leu Pro
1 5 10 15
Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp
25 30
Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val Leu Arg
40 45
Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp Leu Asn
50 55 60
Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn Val Thr
65 70 75 80
Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro Gly Ile
85 90 95
Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys Pro Ala Lys
100 105 110
Val Thr Pro Ala Pro Thr Arg Gln Arg Asp Phe Thr Ala Ala Phe Pro
115 120 125
Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala Glu Thr Gln Thr Leu
130 135 140
Gly Ser Leu Pro Asp Ile Asn Leu Thr Gln Ile Ser Thr Leu Ala Asn
145 150 155 160
Glu Leu Arg Asp Ser Arg Leu Ala Asn Asp Leu Arg Asp Ser Gly Ala
165 170 175
Thr Ile Arg Ile Gly Ala Ser Val Pro Arg Asp Cys Gly Cys Lys Pro
180 185 190
Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro
195 200 205
Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys
210 215 220
Val Val Val Ala Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp
225 230 235 240
Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu
245 250 255
Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met
260 265 270
His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser
275 280 285
Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly
290 295 300
Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln
305 310 315 320
Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe
325 330 335
Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu
340 345 350
Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe
355 360 365
Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn
370 375 380
Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr
385 390 395 400
Glu Lys Ser Leu Ser His Ser Pro Gly Lys
405 410
<210> 376
<211> 154
<212> PRT
<213> cial Sequence
<220>
<223> cynoTIM3-MycHisAvi
<400> 376
Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr Leu Pro
1 5 10 15
Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val Cys Trp
25 30
Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val Leu Arg
40 45
Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp Leu Asn
50 55 60
Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn Val Thr
65 70 75 80
Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro Gly Ile
85 90 95
Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys Pro Ala Lys
100 105 110
Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Glu Gln Lys Leu Ile Ser
115 120 125
Glu Glu Asp Leu Gly His His His His His His Gly Leu Asn Asp Ile
130 135 140
Phe Glu Ala Gln Lys Ile Glu Trp His Glu
145 150
<210> 377
<211> 129
<212> PRT
<213> Artificial ce
<220>
<223> hTIM3_IgV
<400> 377
His His His His His His Ser Ala Ala Leu Glu Val Leu Phe Gln Gly
1 5 10 15
Pro Gly Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln Asn Ala Tyr
25 30
Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val Pro Val
40 45
Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn Val Val
50 55 60
Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg Tyr Trp
65 70 75 80
Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile Glu Asn
85 90 95
Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln Ile Pro
100 105 110
Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile Lys Pro
115 120 125
<210> 378
<211> 470
<212> PRT
<213> cial Sequence
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) IgG1.3f HC with signal peptide
<220>
<221> SIGNAL
<222> (1)..(17)
<400> 378
Met Arg Ala Trp Ile Phe Phe Leu Leu Cys Leu Ala Gly Arg Ala Leu
1 5 10 15
Ala Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser
25 30
Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser
40 45
Arg Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
50 55 60
Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro
65 70 75 80
Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
85 90 95
Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
100 105 110
Tyr Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu
115 120 125
Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
210 215 220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
225 230 235 240
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255
Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
260 265 270
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
370 375 380
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460
Ser Leu Ser Pro Gly Lys
465 470
<210> 379
<211> 469
<212> PRT
<213> Artificial Sequence
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) f HC (no C-terminal K) with
signal peptide
<220>
<221> SIGNAL
<222> (1)..(17)
<400> 379
Met Arg Ala Trp Ile Phe Phe Leu Leu Cys Leu Ala Gly Arg Ala Leu
1 5 10 15
Ala Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser
25 30
Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser
40 45
Arg Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
50 55 60
Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Phe Thr Tyr Tyr Gln Pro
65 70 75 80
Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
85 90 95
Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr
100 105 110
Tyr Cys Ala Thr Gly Gly Pro Tyr Gly Asp Tyr Ala His Trp Phe Glu
115 120 125
Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
210 215 220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro
225 230 235 240
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255
Ala Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
260 265 270
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
370 375 380
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460
Ser Leu Ser Pro Gly
<210> 380
<211> 1413
<212> DNA
<213> Artificial Sequence
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) f HC with signal peptide
<220>
<221> sig_peptide
<222> (1)..(51)
<400> 380
atgagggctt ggatcttctt tctgctctgc ctggccggga gagcgctcgc acagctgcag
ctgcaggagt cgggcccagg actggtgaag gaga ccctgtccct cacctgcact
gtctctggtg gctccatcag cagtagaagt tactactggg gctggatccg ccca
gggaaggggc tggagtggat tgggagtatc tattatagtg ggttcaccta ctaccaaccg
tccctcaaga gtcgagtcac catatccgtt gacacgtcca agaaccagtt ctccctgaag
ctgagctctg tgaccgccgc agacacggct gtgtattatt gtgcgacagg ggggccctac
ggtgactacg cccactggtt cgaaccctgg ggccagggaa ccctggtcac cgtctcctca
gctagcacca agggcccatc ggtcttcccc ccct cctccaagag cacctctggg
ggcacagcgg ccctgggctg cctggtcaag gactacttcc cggt gacggtgtcg
tcag gcgccctgac cgtg cacaccttcc cggctgtcct acagtcctca
ggactctact ccctcagcag gacc gtgccctcca gcagcttggg cacccagacc
tacatctgca acgtgaatca cagc aagg tggacaagag agttgagccc
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaagc cgaaggggcc
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac
agcacgtacc gtgtggtcag cgtcctcacc cacc aggactggct gaatggcaag
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc
aaagccaaag cccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag
atgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
gccgtggagt gggagagcaa tgggcagccg gagaacaact ccac gcctcccgtg
ctggactccg acggctcctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg
ggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg
cagaagagcc tctccctgtc taaa tga
<210> 381
<211> 1410
<212> DNA
<213> Artificial Sequence
<220>
<223> 8 (13A3) (N60Q, D101E) IgG1.3f HC (no C-terminal K) with
signal peptide
<220>
<221> sig_peptide
<222> 51)
<400> 381
atgagggctt ggatcttctt tctgctctgc ctggccggga gagcgctcgc acagctgcag
ctgcaggagt cgggcccagg actggtgaag ccttcggaga ccctgtccct cacctgcact
gtctctggtg gctccatcag cagtagaagt tactactggg gctggatccg ccagccccca
gggaaggggc tggagtggat tgggagtatc agtg ggttcaccta ctaccaaccg
tccctcaaga gtcgagtcac catatccgtt gacacgtcca agaaccagtt ctccctgaag
ctgagctctg tgaccgccgc agacacggct tatt gtgcgacagg ggggccctac
ggtgactacg cccactggtt cgaaccctgg ggccagggaa ccctggtcac cgtctcctca
gctagcacca agggcccatc ggtcttcccc ctggcaccct agag cacctctggg
ggcacagcgg ccctgggctg cctggtcaag ttcc ccgaaccggt gacggtgtcg
tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca
ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc
tacatctgca acgtgaatca caagcccagc aagg tggacaagag agttgagccc
tgtg acaaaactca cacatgccca ccgtgcccag cacctgaagc cgaaggggcc
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg
tacgtggacg aggt gcataatgcc aagacaaagc agga gcagtacaac
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc
aaagccaaag ggcagccccg agaaccacag accc tgcccccatc ccgggaggag
atgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
gccgtggagt gcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg
ctggactccg acggctcctt cttcctctat agcaagctca ccgtggacaa gtgg
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg
agcc tctccctgtc cccgggttga
<210> 382
<211> 1413
<212> DNA
<213> Artificial ce
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) IgG1.3f HC (T168C) with signal
sequence
<220>
<221> sig_peptide
<222> (1)..(51)
<400> 382
gctt tctt tctgctctgc ctggccggga gagcgctcgc acagctgcag
ctgcaggagt cgggcccagg actggtgaag ccttcggaga ccctgtccct cacctgcact
gtctctggtg gctccatcag cagtagaagt tactactggg gctggattcg ccagccccca
gggaaggggc tggagtggat tgggagtatc tattatagtg ggttcaccta ctaccaaccg
aaga gtcgagtcac catatccgtt gacacgtcca agaaccagtt ctccctgaag
ctgagctctg tgaccgccgc agacacggct gtgtattatt gtgcgacagg ggggccctac
ggtgactacg cccactggtt ctgg ggccagggaa ccctggtcac cgtctcctca
gctagcacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg
ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg
tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca
ggactctact ccctcagcag cgtggtgacc tcca gcagcttggg cacccagacc
tacatctgca acgtgaatca cagc aagg tggacaagag agttgagccc
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaagc cgaaggggcc
ccgtcagtct tcctcttccc cccaaaaccc accc tcatgatctc ccggacccct
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc agga gcagtacaac
agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc
aaagccaaag ggcagccccg acag gtgtacaccc tgcccccatc ccgggaggag
atgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg
ctggactccg acggctcctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg
ggga acgtcttctc atgctccgtg gagg ctctgcacaa ccactacacg
agcc tctccctgtc cccgggtaaa tga
<210> 383
<211> 1410
<212> DNA
<213> cial Sequence
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) IgG1.3f HC (T168C) (no C-terminal K)
with signal sequence
<220>
<221> sig_peptide
<222> (1)..(51)
<400> 383
atgagggctt ggatcttctt tctgctctgc ctggccggga gagcgctcgc acagctgcag
gagt cgggcccagg actggtgaag ccttcggaga ccctgtccct cacctgcact
gtctctggtg gctccatcag cagtagaagt tggg gctggattcg ccca
gggc tggagtggat tgggagtatc tattatagtg ggttcaccta ctaccaaccg
tccctcaaga gtcgagtcac catatccgtt gacacgtcca agaaccagtt ctccctgaag
ctgagctctg tgaccgccgc agacacggct gtgtattatt gtgcgacagg ggggccctac
ggtgactacg cccactggtt cgaaccctgg ggccagggaa ccctggtcac cgtctcctca
gctagcacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg
ggcacagcgg gctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg
tggaactcag gcgccctgac cagcggcgtg ttcc cggctgtcct acagtcctca
ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc
tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagag agttgagccc
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaagc cgaaggggcc
ccgtcagtct tcctcttccc cccaaaaccc accc tcatgatctc ccggacccct
gaggtcacat tggt ggacgtgagc cacgaagacc tcaa gttcaactgg
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac
agcacgtacc gtgtggtcag cgtcctcacc cacc aggactggct gaatggcaag
gagtacaagt gcaaggtctc caacaaagcc gccc ccatcgagaa aaccatctcc
aaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag
atgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg
ctggactccg cctt cttcctctat agcaagctca ccgtggacaa gagcaggtgg
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg
cagaagagcc tctccctgtc cccgggttga
<210> 384
<211> 232
<212> PRT
<213> Artificial Sequence
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) LC with signal ce
<220>
<221> SIGNAL
<222> (1)..(17)
<400> 384
Met Arg Ala Trp Ile Phe Phe Leu Leu Cys Leu Ala Gly Arg Ala Leu
1 5 10 15
Ala Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro
25 30
Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser
40 45
Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
50 55 60
Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe
65 70 75 80
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu
85 90 95
Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser
100 105 110
Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val
115 120 125
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
130 135 140
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
145 150 155 160
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
165 170 175
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
180 185 190
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
195 200 205
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
210 215 220
Lys Ser Phe Asn Arg Gly Glu Cys
225 230
<210> 385
<211> 699
<212> DNA
<213> Artificial Sequence
<220>
<223> TIM3.18 (13A3) (N60Q, D101E) LC with signal sequence
<220>
<221> sig_peptide
<222> (1)..(51)
<400> 385
atgagggctt tctt tctgctctgc ctggccgggc gcgccttggc cgaaattgtg
ttgacgcagt ctccaggcac cctgtctttg tctccagggg ccac cctctcctgc
agggccagtc agagtgttag cagcagctac ttagcctggt accagcagaa acctggccag
gctcccaggc tcctcatcta tggtgcatcc agcagggcca tccc agacaggttc
agtggcagtg ggtctgggac agacttcact ctcaccatca gcagactgga gcctgaagat
tttgcagtgt attactgtca tggt agctcaccga tcgg ccaagggaca
cgactggaga ttaaacgtac ggtggctgca ccatctgtct tcatcttccc gccatctgat
gagcagttga aatctggaac tgcctctgtt gtgtgcctgc tgaataactt ctatcccaga
gaggccaaag tacagtggaa ggtggataac gccctccaat actc ccaggagagt
gtcacagagc aggacagcaa ggacagcacc ctca gcagcaccct gacgctgagc
aaagcagact acgagaaaca caaagtctac gcctgcgaag tcacccatca gggcctgagc
tcgcccgtca caaagagctt caacagggga gagtgttag
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/362,541 | 2016-07-14 | ||
US62/459,499 | 2017-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ789986A true NZ789986A (en) | 2022-07-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102493282B1 (en) | Antibodies to TIM3 and uses thereof | |
US11084881B2 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof | |
US20220175921A1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
KR102641640B1 (en) | Anti-ICOS agonist antibodies and uses thereof | |
CN108137687B (en) | anti-OX 40 antibodies and uses thereof | |
KR20200108870A (en) | Antibodies to TIM3 and uses thereof | |
US11306149B2 (en) | Anti-CD40 antibodies and uses thereof | |
NZ789986A (en) | Antibodies against tim3 and uses thereof |